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Vascular remodelling in arterial disease is characterised by vascular smooth muscle cell 
and adventitial fibroblast (AF) proliferation and migration due to mechanical and 
oxidative stresses within the vessel wall, leading to enhanced growth factor signalling. 
Transforming growth factor -1 (TGF-β1) is a pleiotropic growth factor that mediates 
vascular remodelling through eliciting phenotypic changes in AF, which may result 
from the generation of reactive oxygen species (ROS). Nrf2 is a key transcription factor 
that co-ordinates expression of endogenous antioxidant defense genes such as heme 
oxygenase-1 (HO-1) and plays an important role in cellular defense against the 
deleterious effects of ROS. This thesis has investigated whether TGF-β1 modulates 
redox-related signalling pathways, gene expression, cell phenotype and motility in AF 
derived from human aortas. 
 
Results from this study have demonstrated that TGF-β1 treatment resulted in an 
increase in HO-1 protein expression in AF, an effect that was partially diminished in 
cells where Nrf2 had been knocked-down using siRNA. In addition, TGF-β1 also 
enhanced AF migration, measured using time-lapse video microscopy. In the presence 
of superoxide dismutase (SOD), migration of AF was significantly abrogated 
suggesting that TGF-β1-mediated AF migration may be mediated by the generation of 
superoxide. Measurement of ROS generation revealed an increase in AF treated with 
TGF-β1, an effect that was partially attenuated in the presence of a NAD(P)H oxidase 
inhibitor  or SOD.  
  
The ability of the dietary isothiocyanate, sulforaphane (SFN) to activate the Nrf2 
pathway in AF was also investigated. Results revealed that SFN treatment increased 
HO-1 protein expression which was diminished in cells where Nrf2 had been silenced 
using siRNA, suggesting that HO-1 induction was Nrf2-dependent. SFN also caused 
increased nuclear accumulation of Nrf2 and binding to the antioxidant response element 
(ARE), suggesting the involvement of Nrf2 in ARE-mediated antioxidant gene 
expression. The ability of SFN to activate endogenous antioxidant defenses may be a 
potential therapeutic strategy to counteract pathophysiological processes following 
vascular injury and in the pathogenesis of atherosclerosis. 
  
 
  Abstract 
 
 3 
Findings from this study provide novel insights in to the mechanisms underlying the 
contribution of redox signaling in AF that lead to vascular diseases and for interventions 
to modulate TGF-β1-induced adventitial oxidative stress.  
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CHAPTER 1: Introduction 
 
1.1 Atherosclerosis 
Cardiovascular disease (CVD) is the leading cause of death in the world, accounting for 
29% of all deaths globally in 2012 (World Health Organisation, 2012). Atherosclerosis, 
a progressive disease of the medium and large-size arteries is one of the most prevalent 
CVDs and a leading cause of mortality globally, with populations of middle to low 
income countries being most at risk (World Health Organisation, 2012). Despite 
advances in the knowledge about the pathogenesis of atherosclerosis, current therapies, 
although have helped to treat millions of patients, are unable to curb the rising numbers 
of individuals predisposed to this disease. Novel approaches to studying atherosclerosis 
from an alternative perspective may help to tackle this disease more effectively through 
better understanding of the mechanisms involved in its progression. 
 
1.1.1 The ‘inside-out’ hypothesis of atherosclerosis 
Cardiovascular disease and in particular, atherosclerosis, has traditionally been 
associated with the concept that the primary and predominant response to injury in a 
blood vessel is initiated in the lumen and the ensuing events occur in the sub-endothelial 
space (Lusis, 2000; Diaz et al., 1997; Quinn et al., 1987; see Fig 1.1). This well-
established ‘inside-out’ hypothesis postulates that the endothelium plays a central role 
in mediating the inflammatory response by modulating monocyte adhesion and playing 
a pivotal role in the infiltration of oxidized lipids and the consequent formation and 
activation of atherosclerotic lesions (Diaz et al., 1997).  
 
According to the “inside-out” hypothesis, cardiovascular risk factors, including those 
with a strong genetic component such as familial hypercholoesterolaemia, hypertension, 
diabetes and elevated levels of haemostatic factors as well as environmental factors 
such as a high-fat diet, lack of excercise and smoking, are thought to adversely alter the 
vascular endothelium and trigger a  cascade of events (Hansson,  2005; Dzau et al., 
2002; Lusis, 2000). Alterations in blood flow play a critical role in endothelial 
dysfunction which is central to this paradigm (Lovett and Rothwell, 2003; Ross, 1999; 
Nakashima et al., 1998; Gotlieb et al.,1996; MacMillan, 1985). Endothelial cells in the 
straight areas of arteries where flow is uniform and laminar are aligned in the direction 
of flow, however endothelial cells in and around areas of arterial branching where blood 
flow is disturbed and oscillatory, such as the aortic arch and bifurcations,  have no 










   
 
 
Figure 1.1  The structure of a normal large artery.  
Atherosclerosis is a disease of large and medium-sized arteries. The normal morphological 
structure of a large artery consists of three layers (the intima, the media and the adventital layer)  
The luminal facing surface of the vessel consists of a monolayer of endothelial cells which rests 
on an internal elastic lamina. The intima which consists of extracellular connective tissue 
matrix, is a very thin layer and is mainly made up of proteoglycans and collagen. The media 
consists of smooth muscle cells and the outer layer, the adventitia, is mainly made up of 
connective tissue, some SMC, with the majority cell-type being fibroblasts. Adapted from Hu 
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particular orientation and are likely to be more vulnerable to oxidarive and mechanical 
stresses, making them more permeable to macromolecules such as low density 
lipoprotein (LDL) and hence, lesion formation (Lusis 2000; Gimbrone, 1999). 
 
Dysfunctional endothelium is an early manifestation of cardiovascular disease and in 
this context is usually characterised by impaired flow-mediated dilatation throughout 
the arterial tree due to the reduced bioactivity of nitric oxide (NO) (Forstermann, 2008; 
Davies, 2009). Under normal physiological conditions, NO biosynthesis from the 
endothelium is catalysed by the action of endothelial nitric oxide synthase (eNOS) 
which transfers electrons from NAD(P)H in its reductase domain to heme in its oxidase 
domain where the substrate, L-arginine is oxidized to L-citrulline and NO. This 
sequence of events is disturbed when the essential eNOS co-factor, tetrahydrobiopterin 
(BH4) is depleted. Reactive oxygen species (ROS), likely to be generated via NAD(P)H 
oxidase (Landmesser et al., 2003), a hallmark of atherosclerosis, is thought to increase 
the degradation of NO by its reaction with superoxide leading to the formation of the 
peroxynitrite anion (ONOO.) which oxidizes BH4 to the trihydrobioterin radical cation, 
BH3 (Davies, 2009). BH3 can be recycled to BH4 by eNOS or by L-ascorbic acid, 
however increased levels of ONOO., as a result of oxidation of BH4 to biologically 
inactive products, overwhelm the cell’s ability to perform this reduction resulting in 
eNOS uncoupling, that reduces oxygen to superoxide but no longer synthesises NO 
(Davis, 2008).  
 
In addition to reduced bioavailability of NO during atherogenesis, another manifestation 
of altered redox state is the expression of genes that may directly or indirectly regulated 
by ROS (Kunsch and Medford, 1999). These adhesion molecules expressed by the 
dysfunctional endothelium such as intercellular adhesion molecule (ICAM-1) and 
vascular cell adhesion molecule (VCAM-1), increasing its adhesiveness and allowing 
the attachment and infiltration of inflammatory cells such as leukocytes and monocytes 
(Ross, 1999). Accumulation of oxidized LDL in the extracellular sub-endothelial matrix 
occurs passively through endothelial cell junctions and its retention in the vessel wall is 
thought to involve interactions between its protein constituent, apolipoprotein B and 
matrix proteaglycans (Boren et al., 1998). This causes endothelial cells to release 
proinflammatory molecules such as monocyte chemotactic protein-1 (MCP-1) and 
granulocyte colony stimulating factor (GCSF), consequently resulting in the recruitment  
 













Figure 1.2 Endothelial nitric oxide-mediated vasodilation. In response to chemical and 
haemodynamic forces at the luminal surface of the blood vessel, eNOS production is stimulated. 
eNOS transfers electrons from NAD(P)H to the substrate, L-arginine which is then oxidized to 
L-citrulline and NO. NO diffuses into vascular smooth muscle cells in the media of the blood 
vessel and activates soluble guanylyl cyclase (sGC) which catalyses the production of cyclic 
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of monocytes to the arterial wall and their subsequent differentiation into macrophages 
(Diaz et al., 1997; Navab et al., 1996). 
 
Further peroxidation of mildly oxidized LDL to highly oxidized LDL by monocytes and 
macrophages causes the modified apolipoprotein B component of LDL to become more 
negatively charged and allows scavenger receptors on macrophages to phagocytose 
accumulated LDL (Ross, 1999; Raines and Ross, 1993;. Goldstein et al., 1979).  
 
The build-up of this oxidized LDL within the macrophage results in the formation of 
cytosolic lipid droplets and ultimately leads to the transformation of the macrophage 
into a foam cell (Hansson, 2005; Quinn et al., 1987). Activated macrophages also 
release pro-inflammatory cytokines and growth factors, including platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF-2) and transforming growth factor 
β1 (TGF-β1; Ross, 1999) which exacerbate the inflammatory response, causing the 
migration and proliferation of smooth muscle cells (SMC) and the synthesis of 
extracellular matrix (Hansson; 2005; Lusis, 2000), and results in the formation of a 
fibrous cap which covers a necrotic core consisiting of extracellular lipid, cholesterol 
crytstals and necrotic debris (Spagnoli et al., 2007; Hansson, 2005; Ross, 1999). For a 
time, the vessel may be able to compensate for this focal thickening by initiating 
outward remodelling in order to try and counteract the decrease in lumen size (Ward et 
al., 2000), however over time and due to a sustained inflammatory response 
accompanied by smooth muscle cell migration, proliferation and intimal thickening, the 
lumen of the vessel becomes occluded causing stenosis and restricting blood flow 
(Glagov et al., 1987), increasing haemodynamic forces acting on the vessel wall and 
further exacerbating endothelial dysfunction (Davies, 2009). Vascular smooth muscle 
cell (VSMC) migration is an essential element in the process of intimal hyperplasia and 
migration of VSMC from the media to the intima and their secretion of extracellular 
matrix (ECM) proteins is a major component of advanced complicated lesions (Willis et 


















Figure 1.3 The progression of atherosclerosis from the ‘inside-out’. (A) Endothelial 
dysfunction. The earliest hallmark of atherosclerosis is increased endothelial permeabilty, 
expression of adhesion molecules on the surface of endothelial cells and leukocyte adhesion (B) 
Fatty streak formation. Infiltration of monocytes, their transdifferentiation to macrophages 
within the vessel wall and their uptake of lipids results in fatty streak formation. (C) Formation 
of an advanced complicated lesion. A fibrous cap forms over the lesion, walling it off from the 
lumen of the vessel. (D) An unstable fibrous cap. Rupture or ulceration of the fibrous cap can 
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Although coronary artery stenosis contributes to localised ischemia and potentially 
myocardial infarction, it, in itself is not thought  to precipitate these clinical events; 
most cases of infarction are preceded by the formation of an occluding thrombus on the 
surface of the plaque which consists of platelets and activated monocytes (Hansson, 
2005; Zarifis, 2005). Thrombosis may be caused by plaque rupture, an event which can 
result in  the seeping of the contents of the atheromatous plaque into the lumen of the 
blood vessel and consequent exposure of the thrombogenic core of the plaque to the 
blood (Hansson, 2005). The inflammatory response which is a result of the 
accumulation of mast cells, macrophages, platelets and T-cells at the site of the plaque, 
release molecules including inflammatory cytokines, proteases, coagulation factors, 
vasoactive molecules and radicals which contribute to plaque rupture; in particular two 
types of proteases, matrix metalloproteinases and cysteine proteases. Members of these 
families of enzymes, such as MMP-2, MMP-3 and MMP-9 affect the composition of 
the matrix and can lead to hemorrhage from the vasa vasorum or from the lumen of the 
artery with the final result often being acute coronary syndrome, and in most cases 
myocardial infarction (Hansson, 2005; Jones et al., 2003; Dzau et al., 2002; Ross, 
1999). 
 
The importance of looking at new strategies investigating other sites within the vessel 
wall, such as the adventitia, which is likely to play a role in atherogenesis, is apparent. 
Current therapeutic intervention such as aspirin, statins, calcium channel blockers 
(Willis et al., 2004) and sublingual nitroglycerine administration, though largely 
effective, cannot counteract the prevalence of this disease. Targeting other sites of 
inflammation may offer new insights into atherosclerosis as well as the opportunity for 
novel therapeutic intervention 
 
1.1.2 The ‘outside-in’ hypothesis of atherosclerosis 
The majority of evidence implicates the luminal surface as being the main site of the 
inflammatory response where atherosclerosis is initiated, however, there is a growing 
body of evidence which points to the previously ignored, outermost adventital layer of 
the blood vessel (Fig 1.4), which is composed mainly of fibroblasts (Maiellaro and 
Taylor, 2007). The ‘outside-in’ hypothesis postulates that the inflammatory reaction, 
involving complex interactions between an increased number of fibroblasts and 
myofibroblasts and inflammatory cells is one of the early hallmarks  of vascular 
inflammation.  
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A key characteristic of the ‘outside-in’ hypothesis postulates that a denser vasa vasorum 
is thought to be implicated in the progression of the atherosclerotic plaque and eventual 
rupture by nourishing the plaque and potentially playing a role in the maintenance of 
vessel homeostasis during vascular remodelling in hypertensive arteries (Kuwahara et 
al., 2002). In addition to providing essential oxygen and nutrients to the media 
(Crawford et al., 1998), the vasa vasorum is associated with increased expression of 
adhesion molecules by the endothelial cells that line this network of microvessels, 
resulting in a high adventitial infiltration of various classes of leukocytes (Csanyi et al., 
2009). Another characteristic of this hypothesis is an increased production of ROS 
(Maillero and Taylor, 2007; Pagano et al., 1997, see Fig. 1.4), which in turn further 
exacerbates the infiltration of inflammatory cells in the adventitial layer (Csanyi et al., 
2009). Although the exact mechanisms underlying the early inflammatory response 
inititated in the adventitia are not clear, there is some evidence to suggest that ROS 
upregulate the transcription factor, NFκB, which causes the release of several pro-
inflammatory cytokines, which contribute to adhesion molecule expression (Sarada et 
al., 2008). 
 
Fibroblasts from different tissue beds display the same heterogeneous  phenotype, and 
are morphologically characterised as adherent, flat, spindle-shaped cells with flat, oval 
nuclei (Enzerink and Vaheri., 2011). The origins of fibroblasts are thought to be of 
mesenchymal or neural crest origin, however little is known about their differentation 
into specific subsets during pathological processes (Enzerink and Vaheri., 2011). The 
adventitial fibroblast is a central tenet to the ‘outside-in’ hypothesis of atherosclerosis 
and its phenotypic switch to a myofibroblast within the vessel wall is a pivotal event 
(van den Borne et al., 2009; Powell, 2000). The phenotypic switch from a fibroblast to a 
myofibroblast during disease has been widely reported as being TGF-β1-dependent in 
several different types of fibroblast (Wang et al., 2010; van den Borne et al., 2009; 
Powell, 2000; Desmouliere, 1995; Desmouliere et al., 1993). When treated with TGF-
β1, fibroblasts become ‘activated’ and express several proteins which give them the 

















Figure 1.4 The mechanisms leading to the initiation and progression of vascular disease 
from the ‘outside-in’. According to the ‘outside-in’ hypothesis, the adventitia plays a pivotal 
role in the initiation of the inflammatory response seen in atherosclerosis. Inflammatory cues 
such as cytokines signal  adventitial fibrobolasts to undergo a phenotypic switch to a migratory 
myofibroblast. These myofibroblasts migrate to the medial and intimal layers and contribute to 
neointimal hyperplasia. The myofibroblast transforms into a contractile myofibroblast and 
generates cytokines, eventually undergoing apoptosis. Cytokine release causes a massive influx 
of exogenous leukocytes from the vasa vasorum and the subsequent production of superoxide 
which is enzymatically dismuted to H2O2 which may act as a paracrine mediator across the 
vessel wall. Under pathophysiological conditions, NO is rapidly inactivated by NAD(P)H-
derived ROS and results in the highly reactive ROS, peroxynitrite (ONOO-). VSMC 
proliferation and migration lead to further hypertrophy and constrictive medial remodelling 
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Fully differentiated myofibroblasts are characterised by the expression of several 
smooth muscle cell proteins including α-smooth muscle actin, the actin polymerising 
protein, desmin as well as metavinculin and vimentin (Ehler et al., 1996; Powell, 2000; 
Zargham, 2008). Although they express many SMC proteins, myofibroblasts differ 
from smooth muscle cells in that they express very low levels of smooth muscle myosin 
heavy chain (SM-MHC) (Ehler et al., 1996; van den Borne et al., 2009). The contractile 
characteristic of a myofibroblast is mainly owing to the expression of α-smooth muscle 
actin and this cell type displays a secretory phenotype and produces an array of 
proinflammatory chemokines and prostaglandins (Eyden, 2001). It has been reported 
that at least three local events are required to generate α-smooth muscle actin-positive 
differentiated myofibroblasts; the accumulation of biologically active TGF-β1, the 
presence of certain ECM proteins such as the ED-A splice variant of fibronectin, and 
thirdly high extracellular stress arising from the mechanical properties of the ECM and 
cell remodelling activity (Hinz et al., 2007; Desmouliere et al., 2005; Tomasek et al., 
2000; Fig 1.5).  
 
During the progression of atherosclerosis, smooth muscle cells and adventitial 
fibroblasts proliferate and migrate into the intima and where adventitial fibroblasts 
secrete excess extracellular matrix proteins and contribute to neointima formation, 
constrictive remodelling and restenosis. Evidence of this adventital cell migration was 
seen in a model of transluminal coronary angioplasty where vascular lesion formation 
was assessed following balloon overstretch in porcine coronary arteries after days 1, 3, 
7 and 14. It was found that BrdU-labelled adventitial cells had migrated into the intima 
of the injured vessel from 3 days after injury and after fourteen days, the majority of 
BrdU-labelled adventitial cells had migrated into the neointima suggesting that these 
cells contributed to vascular lesion formation in this disease model (Scott et al., 1996). 
The same study also detected an increase in the levels of α-smooth muscle actin in these 
cells after arterial injury, indicating that in addition to migration, the myofibroblasts had 
undergone differentiation and subsequently contributed to arterial remodelling and 
luminal occlusion (Scott et al., 1996).  Further evidence of adventitial fibroblast 
migration into the neointima comes from a rat model of balloon injury, where 
adventitial fibroblasts transfected with beta-galactosidase (LacZ) were introduced into 
the adventita immediately after balloon injury. 
 
 












Figure 1.5 The process of fibroblast differentiation. Under mechanical stress, fibroblasts 
differentiate into proto-myofibroblasts which exhibit actin-containing stress fibres. In the 
presence of TGF-β1 and ED-A fibronectin, proto-myofibroblasts differentiate further into 
myofibroblasts. Myofibroblasts are characterised by the de novo expression of α-smooth muscle 
actin and vimentin as well as the presence of focal adhesions and fibronectin which aid cell 
migration and are responsible for the contractile nature of this cell type. Differentiated 
fibroblasts express many proteins also expressed by smooth muscle cells, however they differ 
from SMC in that they express very low levels of smooth muscle myosin heavy chain (SM-
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Five days post-injury, LacZ-transfected cells were detected in the media and neointima 
at days 7, 10 and 14 (Li et al., 2000). In a similar study investigating arterial injury in 
rat carotid artery, TGF-β1 mRNA levels were increased fivefold after 14 days, during 
which there was significant neointimal formation indicating the importance of TGF-β1 
in the process of adventitial cell-dependent neointimal thickening after injury (Majesky 
et al., 1991). Antagonism of TGF-β1 with the overexpression of inhibitory Smad7 in the 
adventitial layer of carotid artery exposed to balloon injury resulted in the attenuation of 
adventitial cells expressing β-galactosidase contributing to neointima formation 
(Mallawaarachchi et al., 2005) suggesting that neointimal formation is partly mediated 
by this growth factor. 
 
Another growth factor released by platelets, mononuclear cells, endothelial cells and 
SMC in and in the surrounding area of vascular injury that has also been linked to 
enhancing vascular disease progression in concert with TGF-β1 during atherogenesis, is 
platelet-derived growth factor (PDGF; Levitzki, 2004). In vitro, PDGF has been found 
to increase the proliferation of VSMC, as well as increasing their migration; cells 
stimulated with this growth factor exhibited increased expression of actin filaments 
conducive to enhanced cell migration (Engel and Ryan, 1997). A possible mechanism 
by which PDGF may exert its effects on VSMC has been postulated by Sundaresan and 
colleagues who suggest that PDGF transiently increases intracellular levels of H2O2, 
which in-turn may act as a signalling molecule, causing tyrosine phosphorylation, 
mitogen-activated protein kinase activation and cell migration (Sundaresan et al., 1995). 
Furthermore, in a hamster vascular stenosis model in hypercholesterolemic hamsters, 
binding of PDGF to VSMC was higher than that seen in control animals and was 
associated with increased cell proliferation and increased neointima formation when 
compared to control animals (Matsuno et al., 2001). Due to its effect on VSMC 
proliferation in atherosclerotic disease, it is thought that PDGF targets the cyclin-
dependent kinases 2 and 4 (Cdk2/Cdk4) in order to promote cell cycle progression and 
that targeting these may somewhat attenuate neointima formation (Chang et al., 1995; 
Abe et al., 1994).  
  
In addition to adventitial cells contributing to neointimal formation; there is also recent 
evidence to suggest that progenitor cells arising from the adventitial layer may also play 
a role in luminal occlusion following injury. In order to investigate the possibility of 
vascular progenitor cells contributing to the atherosclerotic disease process, Hu and 
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colleagues examined tissue from  ApoE-deficient mice (Hu et al., 2004). 
Immunohistochemical analysis of the adventitial layer from aortic roots revealed that 
large amounts of cell expressed stem cell markers, including Sca-1+, c-kit+, CD34+ and 
Flk1+ (Hu et al., 2004). Furthermore, the same study reported that when Sca-1+ cells 
carrying the LacZ gene were transfected were transferred to the adventitial side of the 
vein grafts in these mice, β-gal+ cells were found in the atherosclerotic lesion of the 
intima suggesting that progenitor cells do indeed contribute to atherosclerotic lesion 
formation (Hu et al., 2004). Interestingly, in vitro, in response to treatment with PDGF-
BB, isolated Sca-1+ cells were able to differentiate into SMC, suggesting that this 
growth factor may contribute to progenitor cell differentiation (Hu et al., 2004). 
Conversley, a study in mouse embryonic stem cells has shown that use of a PDGF 
inhibitor or TGF-β1-neutralizing antibodies did not prevent these cells from 
differentiating into SMC (Lindskog et al., 2006). 
 
A more recent study has also reported similar findings; in injured femoral arteries in a 
mouse model, the number of cells expressing mesenchymal-stem cell markers were 
markedly higher when compared to uninjured control and originated from the adventitia 
(Tigges et al., 2013). In addition, this population of cells was found to contribute to 
neointimal formation (Tigges et al., 2013). Passman and colleagues have also postulated 
that the adventitia is the source of progenitor cells; immunohistochemical analysis 
revealed that Sca-1+, c-kit+, CD34+, CD140+ and Flk1+ expressing cells clustered in a 
domain of sonic hedgehog signnalling  (Shh) that was restricted solely to the adventitial 
layer (Passman et al., 2008). The above studies suggest that the adventitia is a possible 
source of progenitor cells which may act in concert with adventitia-derived fibroblasts 
and contribute to neointimal formation during atherosclerotic disease.  
 
There is increasing evidence to support the hypothesis that the adventitia may be the 
‘first responder’  and initiator of vascular remodelling in large and small arteries during 
atherogenesis, neointima formation following balloon injury and in restenosis. In 
addition to this, TGF-β1 seems to contribute to the activation, phenotypic switch and 
migration of adventital fibroblasts during these disease prosesses. Interactions between 
the outer layer of the blood vessel and this growth factor offer opportunity for novel 
therapeutic intervention from the outside-in (Siow and Churchman, 2007). 
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1.2 Reactive oxygen species in vascular disease 
The term, ROS, refers to a group of biological molecules that are formed upon the 
incomplete reduction of oxygen making them highly reactive (D’Autreaux and 
Toledano, 2007). They include the superoxide anion (O2
-.), hydrogen peroxide (H2O2) 
and the hydroxyl radical (OH.) with each of these having distinct biological activities 
including lipid solubility, half-life and chemical reactivity (D’Autreaux and Toledano, 
2007). Originally hypothesized to be the by-products of enzymatic reactions, and 
considered biological hazards, which caused gross cellular damage, mutagenesis, cancer 
and aging (Ray and Shah, 2005; Droge, 2002; Harman, 1956), upon closer observation 
it was revealed that ROS played complex roles in normal and pathophysiology.  The 
balance between ROS generating systems and antioxidant defence systems is disturbed 
and results in oxidative stress where ROS generation overcomes the cells antioxidant 
defence system (Fig 1.6. B) and antioxidant enzymes (Fig 1.6. C).  
 
Various enzyme systems have been implicated in the production of ROS in the 
cardiovascular system, including NAD(P)H oxidases, xanthine oxidase (XO), 
uncoupled eNOS as well as the leakage of activated oxygen from mitochondria during 
oxidative respiration (Forstermann, 2008). O2
-. is one of the ROS implicated in the 
pathogenesis of vascular disorders and targets Fe-S clusters due to its high electrostatic 
attraction to them. However, due to its charge and its relatively short half-life 
(Paravicini and Touyz, 2006), this radical is unable to cross biological membranes 
making it a poor signalling molecule. O2
-. is spontaneously dismuted to H2O2 by 
superoxide-dismutase (SOD; D’Autreaux and Toledano, 2007).  
 
H2O2 is a milder oxidant in comparison to O2
- and reacts with [Fe-S] and very slowly 
with glutathione and cysteine residues (D’Autreaux and Toledano, 2007). It has a longer 
half-life and is able to diffuse across lipid bilayers, making it an ideal candidate for 
signalling. H2O2 can undergo spontaneous conversion to the hydroxyl radical (OH
.), the 
three-electron reduction state of molecular oxygen, via the Fenton reaction 
(Forstermann, 2008). This ROS is highly reactive and indiscriminate in its targets, 
however due to its extremely short half-life it is unlikely to mediate its effects distant 
from where it is produced (Paravicini and Touyz, 2006). These three main oxygen 
species are derived from various cellular enzyme systems, however those that are most 
relevant to vascular disease appear to be XO, uncoupled eNOS, the mitochondrial 
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1.2.1 ROS-generating enzyme systems 
1.2.1(a) Xanthine oxidase 
Xanthine oxidase (XO) is a metalloenzyme that catalyses the oxidation of hypoxanthine 
and xanthine to form O2
-.. Its ability to readily donate electrons to molecular oxygen to 
produce O2
- has implicated it in vascular disease, in particular it is known to be present 
within the vascular endothelium and may play a role in endothelial dysfunction.  
 
Several studies have shown that XO-generated O2
-. plays a role in hypertension and 
perhaps atherosclerosis. In vivo evidence of XO involvement in atherosclerosis has been 
observed in spontaneously hypertensive rats (SHR) where the activity of the oxyradical 
producing form of XO was seen to be three-fold higher in comparison to the control 
group, with an associated increase in vascular tone in these animals. Administration of a 
tungsten-rich diet containing an inhibitor of XO eliminated detectable levels of enzyme 
activity, suggesting that this enzyme is responsible for oxyradical generation associated 
with increased vascular tone and may contribute to hypertension (Suzuki et al., 1998). 
In contrast to this, Laaksa and colleagues found that long-term treatment of SHR with 
the XO inhibitor, allopurinol reduced XO activity in a salt-induced hypertension model 
but did not reduce overall blood pressure, suggesting that in this case, XO–mediated 











Figure 1.7 The XO reaction. Xanthine oxidase catalyses the oxidation of hypoxanthine and 
xanthine to form highly reactive O2_. .  
 
 
The source of XO in the plasma is unclear, but it is thought that increased levels of 
plasma cholesterol, as seen in atherosclerosis cause the release of this enzyme from the 
liver and into the circulation, whereupon it is able to bind to glycosaminoglycans on 
                    
                                           Xanthine oxidase (XO) 
 
          Hypoxanthine + H2O + 2O2    Xanthine + 2O2-. + 2H. 
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endothelial cells which may be overexpressed as a result of hyperlipidemia (White et 
al., 1996). There is also evidence to suggest that endothelial cells may express xanthine 
dehydrogenase which is converted to XO (Forstermann, 2008), and that XO activity 
may depend upon the activity of NAD(P)H oxidase; endothelial cells lacking the 
p47phox subunit of NAD(P)H oxidase exhibited a markedly reduced production of O2
_.  
and had minimal XO protein and activity (McNally et al., 2003). 
 
Although there is some evidence to suggest that XO contributes significantly to vascular 
disease and to a certain extent, endothelial dysfunction, as demonstrated by studies 
where XO inhibitors caused an overall decrease in O2
_. and an apparent restoration of 
endothelial cell function (Suzuki et al., 1998; Ohara et al., 1993), its role as a causative 
factor in vascular disease rather than a consequence (Laaksa et al., 1998) is still 
somewhat controversial. However, it is clear that XO-derived O2
-.   plays an important 
role in vascular pathophysiology. 
 
1.2.1(b) Endothelial nitric oxide synthase  
Nitric oxide (NO)-mediated vasodilatation is an important regulator of vascular 
homeostasis (Levy et al., 2009). Under normal physiological conditions, and in response 
to chemical and haemodynamic forces at the luminal surface of the blood vessel, 
endothelial nitric oxide synthase (eNOS) generates NO, which in-turn indices 
vasodilation, inhibits platelet aggregation and prevents oxidative modification of LDL 
cholesterol (Forstermann, 2008). 
 
eNOS is a homodimeric enzyme with each subunit consisting of a reductase and 
oxygenase domain (Forstermann, 2008). Between these two domains is a zinc-thiolate 
cluster where the co-factor tetrahydrobiopterin  (BH4) and the substrate L-arginine bind 
(Forstermann, 2008). Electron transfer from the reductase domain enables ferric heme 
to bind to oxygen and form a ferrous dioxy-species, which can receive a second electron 
from either BH4 or from the reductase domain.  This reduction allows the oxidation of 
the substrate, L-arginine to L-citrulline and NO. NO is then able to diffuse from the 
endothelium into the adjacent SMC layer and cause vasodilatation via the activation of 
NO causes the elevation of cyclic-GMP and vasorelaxation via the activation of soluble 
guanylate cyclase (sGC) in the SMC layer.  
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Under pathophysiological conditions, such as hypertension and atherosclerosis, 
increased oxidative stress enhances the degradation of NO by its reaction with O2
-. 
leading to the formation of the peroxynitrite anion (ONOO-), which is able to oxidize 
BH4  to form the radical BH3  and  results in the uncoupling of eNOS (Forstermann, 
2008). This dysfunctional eNOS is no longer able to synthesize NO, and reduces 
oxygen to O2
-. (Forstermann, 2008; Paravicini and Touyz, 2006). Endothelial 
dysfunction is the first step towards progressive atherogenesis (Ross, 1999; Lusis, 
2000). Either the depletion of the co-factor BH4, or decreased availability of L-arginine 
can contribute to eNOS uncoupling; however BH4 supplementation can attenuate this 
process.  In one study administration of BH4 to normotensive and hypertensive patients 
resulted in augmentation of endothelium-dependent vasodilatation in both groups 
(Higashi et al., 2002). Uncoupled eNOS been implicated in many vascular diseases, in 
particular during the pathogenesis of diabetes, hypertension (Forstermann, 2008) and 
atherogenesis (Lusis, 2000), and its role in these diseases points to the pivotal role it 
may play in pathophysiology. 
 
1.2.1(c) Mitochondria-derived ROS 
Mitochondria are constant sources of superoxide, with NADH dehydrogenase (complex 
I) and ubiquinone-cytochrome b-c1 (complex III) being the primary sources of O2
- 
production (Madamanchi and Runge, 2007). The amount of superoxide released from 
the mitochondria is dependent upon the activity of the antioxidant, manganese-
containing superoxide dismutase 2 (SOD2) located in the mitochondrial matrix which 
protects against oxidative damage. Overexpression of SOD2 in a mouse model limited 
the infarct size following coronary artery ligation as well as rendering the heart more 
resistant to ischemia and reperfusion injury (Chen et al., 1998). 
 
There is some evidence to suggest a link between atherosclerotic lesion development 
and mitochondrial dysfunction. Assessment of mitochondrial oxidant generation and 
DNA damage in human specimens showed that the degree of mitochondrial oxidant 
production corresponded with the degree of atherosclerotic lesion development. The 
same study found that in ApoE -/- mice, deficient in mitochondrial SOD2 exhibited 
early increases in mitochondrial DNA damage and a phenotype of accelerated 
atherosclerosis (Ballinger et al., 2002). 
 
 













Figure 1.8 Uncoupling of endothelial nitric oxide synthase. Enhanced production of 
peroxynitrite as a result of oxidative stress causes the oxidation of BH4 to biologically inactive 
products and overwhelms the cells capacity to re-reduce these back to BH4, leading to an 
‘uncoupled’ enzyme that reduces oxygen to superoxide but is no longer able to synthesize NO. 
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A recent study has implicated mitochondrial-derived ROS in the profibrotic effects of 
TGF-β1 in normal human lung fibroblasts; genetic disruption of mitochondrial complex 
III-generated ROS production was seen to attenuate TGF-β1-mediated profibrotic gene 
expression as well as attenuating myofibroblast dedifferentiation (Jain et al., 2013). 
Findings from this study highlight one of the potential sources of ROS which are 
thought to augment TGF-β1-driven vascular remodelling as seen during arterial repair 
(Shi et al. 1996). 
Although direct evidence for the causal role of mitochondrial-derived ROS in vascular 
disease is yet to be elucidated, there is mounting evidence that mitochondrial 
dysfunction and consequent superoxide generation play a part in the development of 
vascular dysfunction, particularly in advanced atherosclerosis (Madamanchi and Runge, 
2007). 
 
1.2.1(d) NAD(P)H oxidase 
NAD(P)H oxidases are multicomponent enzymes, originally found and characterised in 
phagocytes (Ray and Shah, 2005), are functional in membranes of vascular endothelial 
cells, SMCs and fibroblasts (Forstermann, 2008) and are thought to be the major source 
of ROS in the vascular wall (Birukov, 2009). There are seven different homologues; 
Nox1, Nox2, Nox3, Nox4, Nox5 as well as larger and more complex homologues, 
Duox1 and Duox2 (Ray and Shah, 2005). The NAD(P)H oxidase enzyme system 
reduces molecular oxygen to produce O2
- by utilising NADH/NAD(P)H as an electron 
donor. Activation of NAD(P)H oxidases requires the assembly of several membrane-
bound (gp91phox, Nox1/Nox4 and p22phox) and cytosolic subunits (p47phox and 
p67phox; see Fig 1.9). Vascular NAD(P)H oxidases produce constant low-levels of 
ROS under normal physiological conditions and are regulated by various vasoactive 
cytokines and growth factors as well as by physical factors such as shear stress, pulsatile 
strain and stretch (Birukov 2009; Haurani and Pagano, 2007).  
 
In animal models of hypertension, NAD(P)H oxidase activation in the vasculature is 
apparent. In a rat model of angiotensin II (Ang II) -induced hypertrophy and subsequent 
measurement of the mRNA of the membrane bound subunit, p22phox showed that 
expression of this subunit increased three days following infusion (Fukui et al., 1997). 
Administration of SOD decreased both blood pressure and p22phox mRNA expression, 
suggesting that the NAD(P)H oxidase system is involved in the pathology of 
hypertension in vivo (Fukui et al., 1997). Interestingly, in situ hybridisation of aortic 
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tissue from these animals showed an increase in p22phox expression not only in the 
medial smooth muscle but also in the adventitia (Fukui et al., 1997). Further evidence in 
a Nox1 -/- murine model found that infusion of Ang II failed to increase blood pressure 
(Matsuno et al., 2005), suggesting a pivotal role for NAD(P)H oxidase-derived ROS in 
hypertension. 
 
Though much evidence implicates Nox proteins in the development of atherosclerosis, 
recent evidence suggests that their role may be more complex than previously 
envisioned. Genetic deletion of p47phox in a model of diet-induced atherosclerosis in 
ApoE-/- mice found only a partial attenuation in the development of this disease 
(Martino et al., 2008) and a similar study found that p47phox deletion did little to stop 
the progression of atherosclerosis (Yang et al., 2004). Although the role of Nox proteins 
in atherosclerosis is contentious, their role in neointima formation and vascular 
remodelling seems to be more evident. Nox1 knockout mice displayed a significant 
reduction in neointima formation after wire-induced injury (Thomas et al., 2006) with a 
reduction in SMC migration and consequent neointima formation (Looi et al., 2008).  
 
NAD(P)H-derived ROS production is clearly involved in atherosclerosis, but whether 
they are involved in promoting pro-atherosclerotic markers of this disease or play a 
greater role in the later stages including restenosis, neointima formation and vascular 



























Figure 1.9  Spatial and molecular organization of vascular Nox enzymes. Nox 1, 2 
and 5 are represented here in different cellular compartments but can be located either 
within cells or at the plasma membrane, thus releasing O2
.- inside vesicles or 
extracellularly after activation of receptor (R) by ligand (L). O2
.- may affect cytosolic 
signalling after crossing membranes via anion channels, reversible protonation, or 
conversion to H2O2. In contrast Nox4 is always intracellular and constitutively produces 
a higher proportion of membrane-permeable H2O2 than other oxidases. All oxidases, 
except Nox5, form a membrane complex with p22phox. Cytosolic activators vary with 
oxidase subtype: Rac, p47phox and Noxa1 for Nox1 in VSMC; Rac, p47phox and 
p67phox for Nox2; Poldip2 for Nox4; and Ca++ for Nox5. All vascular cells express 
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1.2.2. Mechanical stretch and ROS 
Exposure of blood vessels to cyclic stretch is essential in maintaining vascular 
homeostasis under normal physiological conditions as well as playing a significant role 
in vascular remodelling and maintenance of vascular cell phenotype, regulation of 
vascular tone and expression of vascular wall extracellular matrix constituents (Birukov, 
2009). However, under pathophysiological conditions, such as hypertension, 
atherosclerosis and diabetes, cyclic stretch plays a detrimental role and contributes to 
disease progression (Birukov, 2009). 
 
Chronic increases in cyclic stretch result in hypertension-induced vascular remodelling 
because of vascular cell proliferation and excess collagen synthesis. Ultimately, this 
remodelling leads to a decrease in luminal diameter and increased vascular resistance 
characteristic of clinical hypertension (Ali and Schumacker, 2002). Cell membranes and 
attachment sites are thought to serve as mechanosensors (Davies, 1995) which mediate 
mechanical signals via activation of signalling molecules such as tyrosine (focal 
adhesion kinase) kinases, growth factor receptors and via ion channels (Birukov, 2009).  
 
Recent evidence has shown that ROS generated by stretch may act as signalling 
molecules to regulate gene expression. Endothelial cells exposed to cyclic stretch have 
been shown to generate ROS production which is attenuated by the use of the 
mitochondrial inhibitors diphenylene iodonium (DPI) or rotenone, indicating that the 
mitochondria may be the source of ROS during stretch. In addition to this, the same 
study has shown increased NFκB activation and VCAM-1 mRNA expression, which is 
absent in the presence of antioxidants (Ali et al., 2004). Similarly, in fibroblasts, cyclic 
stretch induced NFκB activation and translocation to the nucleus, which was abrogated 
in the presence of antioxidants suggesting the stretch caused ROS production and as a 
result, the translocation of this transcription factor to the nucleus and potential gene 
transcription of various antioxidant genes (Amma et al., 2005). 
 
This stretch-mediated ROS production and consequent antioxidant gene expression is 
also seen in acute respiratory distress syndrome, where Nrf2/ARE pathway is activated 
resulting in the upregulation of several antioxidant enzymes, including HO-1 (Cho et 
al., 2006). In vitro investigation of the effect of cyclic stretch on Nrf2-dependent ARE-
mediated transcriptional response in pulmonary epithelial and endothelial cells revealed 
that actin remodelling along with epidermal growth factor receptor (EGFR)-activated 
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PI3K-Akt signalling were necessary for the regulation of the Nrf2-regulated antioxidant 
genes, GCLM and GPx1 (Papaiahgari et al., 2007). Previously, actin remodelling has 
been postulated in playing a key role in the modulation of transcription factor activation 
and subsequent gene transcription in epithelial and endothelial cells (Birukova et al., 
2005). As Keap1 is an actin binding protein and involved in the regulation of Nrf2, 
mechanosensing during stretch may be pivotal in activating the induction of antioxidant 
enzymes. There is much evidence for the stretch-induced activation signal transduction 
and gene expression in the vasculature (see Table 1.1). Stretch is particularly important 
in modulating changes in the outer layer of the blood vessel, the adventitia and may 
play a pivotal role in the generation of ROS. These ROS are likely to act as signalling 
molecules and cause changes in cellular differentiation, proliferation and migration and 
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1.2.3. Adventitia-derived ROS  
Fibroblast NAD(P)H oxidase production has received increasing attention in recent 
years, and there is controversy surrounding the location of NAD(P)H oxidases in the 
vascular wall. However, a large body of evidence in favour of NAD(P)H oxidases being 
the main culprits of ROS production in the vasculature has led to the idea that 
adventitial NAD(P)H oxidase is a harbinger and initiator of vascular disease. 
Interestingly, the ROS-generating system in adventitial fibroblasts shares a degree of 
homology to the phagocytic NAD(P)H oxidases, which surpasses that of any other 
vascular oxidase (Haurani and Pagano, 2007).  
 
Several studies have implicated NAD(P)H oxidase-derived superoxide within the 
adventitia as being an important and pivotal event in the development of diabetes 
mellitus, hypertension, atherosclerosis and vascular injury (Chan ett al., 2007; Zhang et 
al., 2003; Azumi et al., 2002; Sorescu et al., 2002; Paravicini et al., 2000; Cifuentes et 
al., 1999; Wang et al., 1999). In a porcine model of stretozotocin-induced diabetes, 
increased NAD(P)H oxidase activity was observed in the coronary media and adventitia 
and was accompanied by an increased inflammatory response in the adventitia (Zhang 
et al., 2003). The NAD(P)H oxidase-dependent inflammatory response has also been 
reported by others; increased expression of adhesion molecules on the endothelial 
surface of the vasa vasorum was seen to lead to the subsequent infiltration of leukocytes 
into the adventitia (Li and Shah, 2004; Libby et al., 2002) leading to a proposal by 
Stenmark and colleagues that ROS-mediated cross-talk between adventitial fibroblasts 
and NFκB-dependent inflammatory processes may be a critical event during 
atherosclerotic disease (Stenmark et al., 2006).  
 
In vivo it has been shown that delivery of the NAD(P)H oxidase inhibitor, gp91ds-tat 
(decoy peptide for cytosolic oxidase component p47phox) to the left carotid adventitia 
specifically blocked Ang-II-induced aortic NAD(P)H oxidase activity, as well as 
reducing Ang-II-induced medial hypertrophy, suggesting this process is mediated by 
adventitial fibroblast-derived ROS (Liu et al., 2004). In addition, Szöcs and colleagues 
have reported an increase in superoxide production 3 days after balloon injury in the 
adventitial and medial layer of coronary arteries (Szöcs et al., 2002), an event also 
reported in response to hypoxia in pulmonary artery adventitial fibroblasts, and 
postulated to be Nox4 dependent (Li et al., 2008). 
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Although there are a plethora of studies suggesting an important role of NAD(P)H 
oxidase-derived ROS in the adventitia, there is contention over the exact isoform that is 
predominantly expressed in the adventitia and several studies suggest that the isoform 
responsible for adventitia-derived ROS is Nox2; a study in Nox2-deficient mice found 
that AngII infusion for six days caused aortic superoxide production and an increase in 
the size of the medial layer in the wild-type (WT) animals that was absent in the 
knockout animals (Wang et al., 2001), with the aortic media increasing in size in the 
WT animals suggesting a role for Nox2–mediated SMC hyperplasia. Histological 
analysis of aortic sections from WT mice infused with Ang II revealed that the majority 
of Nox2 was located in the endothelium and adventitia (Wang et al., 2001). Abundant 
colocalization of Nox2, p22phox, p47phox and p67phox has been observed in cultured 
adventitial fibroblasts of rabbit aorta (Pagano et al., 1998; Pagano et al., 1997). In 
addition, fluorescent immunohistochemistry has demonstrated that Nox2 was highly 
expressed in the adventitial layer of human coronary arteries whereas Nox4 was barely 
detectable (Sorescu et al., 2002). In contrast, in a separate study, qRT-PCR analysis of 
human cardiac fibroblasts has shown that Nox4 and Nox5 were abundantly expressed in 
cardiac fibroblasts whereas levels of Nox1 and Nox2 were barely detectable (Cucoranu 
et al., 2005).  
 
Even under basal conditions, various findings have shown that the vascular adventitia is 
a major source of ROS (Wang et al, 2001; Pagano et al., 1995). Dihydroethidium 
(DHE) fluorescence in situ has shown that superoxide levels are greater in adventitial 
fibroblasts than in SMC (Chamseddine and Miller, 2003). It is thought that the 
predominant Nox isoform in the adventitia is Nox4 (Sorescu et al., 2002) and that in 
general, adventitial fibroblasts possess high specific activity of NAD(P)H oxidase 
relative to other vascular segments (Haurani and Pagano, 2007).  
 
These recent investigations have shown that the adventitia, along with the media, is a 
potential source of ROS, which is likely to contribute to vascular remodelling, 
neointima formation and restenosis (see Table 1.1). Targeting ROS from these layers 
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1.3 Transforming Growth Factor- β 
The transforming growth factor β (TGF-β) family is responsible for eliciting a plethora 
of cellular processes including cell proliferation, differentiation, extracellular matrix 
synthesis and apoptosis (Wrighton et al., 2009; Zhang, 2009; Pardali and Moustakas, 
2007; Bierie and Moses, 2006), as well as important signalling during embryonic 
development (Shi and Massagué, 2003). Conservation of this superfamily across species 
indicates the intrinsic role it plays in biological processes and consequently, 
perturbation of TGF-β signalling can play a significant role in cancer metastasis, 
fibrotic, cardiovascular and autoimmune disease (Goumans et al., 2009; Padua and 
Massagué, 2009; Watabe and Miyazono, 2009; Grainger, 2007; Zhiang et al., 2007). Its 
synthesis and activation are dependent upon various extracellular factors which regulate 
its transcription and consequent expression. 
 
1.3.1 TGF-β1 activation 
The TGF-β family of cytokines contains two subfamilies; the TGF-β/Activin Nodal 
subfamily and the BMP (Bone morphogenic protein) subfamily (Shi and Massagué, 
2003). Members of this superfamily elicit distinct cellular responses, are structurally 
similar and all signal through the activation of heteromeric receptor complexes of type 
II and type I transmembrane threonine/serine kinases (Wrighton et al., 2009). 
 
TGF-β1 mRNA expression is increased in response to various extracellular factors, 
including Ang II, mechanical stress, high glucose concentration or ET-1 (Ruiz Ortega et 
al., 2007) and as a result there is an increase in the production of TGF-β1 protein.  TGF-
β1 is produced as a large latent complex (Annes et al., 2003) which is inactive and 
consists of a main region and a latency associated peptide (LAP). This inactive form is 
anchored in  the extracellular matrix by latent TGF-β binding proteins (Ruiz-Ortega et 
al., 2007) and can be activated by proteolytic cleavage by matrix metalloproteinases 
(MMP-2 and 9) and acidic microenvironments (Ruiz-Ortega et al., 2007). In addition, 
ROS have also been implicated in the activation of latent TGF-β; Baricellos-Hoff and 
colleagues showed that ROS generated by irradiation caused oxidation of several amino 
acids in the latency conferring peptide leading to a conformational change in the latent 
complex, allowing release of TGF-β (Barricellos-Hoff and Dix, 1996). Integrin-
mediated physical forces can also activate TGF-β1; it has been shown that distorting the 
large latent complex via single-molecule force spectroscopy resulted in the release of 
active TGF-β1 (Hubmacher and Apte, 2013). This release is as a result of the cells 
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pulling at the LAP within the large latent complex/latent TGF-β1 binding proteins, 
‘squeezing’ out the active TGF-β1 (Humacher and Apte, 2013). This suggests that 
movement of the cell can augment the release of further TGF-β1, which is of particular 
relevance during vascular remodelling. During the pathophysiology of atherosclerosis, 
fibroblasts and SMC become activated and move from the adventitial and medial layer 
toward the lumen of the vessel, partly due to the chemotactic effect of TGF-β1 and 
other growth factors released from platelets and endothelial cells at the lumen of the 
vessel (Grainger, 2007; Silverstein and Rifkin, 1987) and from macrophages and T-cells 
recruited from the circulation into the intima, forming the beginnings of a plaque (Gong 
et al., 2012; Grainger, 2007). The high levels of activated TGF-β1 at the site of vascular 
injury accelerate the inflammatory disease process (Stenmark et al., 2012). Interestingly, 
several studies into serum levels of TGF-β1 have reported an increase in the levels of 
latent TGF-β1 and a marked decrease in active TGF-β1 levels amongst patients with 
severe atherosclerosis (Grainger, 2007; Grainger et al., 1995) although other studies 
have reported that serum levels of active TGF-β1 are actually increased in these 
individuals (Wang et al., 1997). This is in contrast to the high concentration of active 
TGF-β1 within the neointima, released from platelets, endothelial cells, inflammatory 
cells, as well as from migrating fibroblasts and SMC (Stenmark et al., 2012; Grainger, 
2007, Grainger et al., 1995).  
 
The active form of TGF-β is a 25 kDa dimer, with the two polypeptides interacting via a 
disulphide bond and hydrophobic links.  Once active TGF-β is released, it binds to the 
TGF-βII receptor (TβRII) resulting in activation of TGF-β signalling cascades. 
There are seven known mammalian type I receptors termed ALK1-7 (activin receptor 
like-kinase and five type II receptors (Rahimi and Leof, 2007) in the vast majority of 
cell types. The receptor serine/threonine kinase family is made up of seven type I 
(TβRI) and five type II (TβRII) receptors (Manning et al., 2002) both types of which 
consist of approximately 500 amino acids organised into an N-terminal extracellular 
ligand binding domain, a transmembrane region and a C-terminal serine/threonine 
kinase domain (Shi and Massagué, 2003; Huse et al., 1999). The receptor complex 
usually comprises of two type II receptors and two type I receptors. Upon ligand 
binding, the two receptor types are brought together, and the type II receptor 
transphosphorylates the GS region of the type I receptor, causing its activation and 
allowing it to catalyse the phosphorylation of receptor-regulated SMADs (R-Smads). 
Phosphorylated R-Smads form complexes involving two R-Smads and one Co-smad, in 
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the cytoplasm and these complexes translocate to the nucleus to regulate gene 
transcription (Lonn et al., 2009). 
 
1.3.2 The Smad family of proteins               
The first intracellular mediator of TGF-β signalling, mothers against decapentplegic 
(MAD; Sekelsky et al., 1995) was identified in Drosophila and consequent studies 
revealed orthologs in C.elegans and vertebrates (Derynck et al., 1996) that were given 
the name ‘SMA’ from gene sma for small body size. Smad is a portmanteau of the two.  
 
The Smad family comprises of eight Smad proteins, which can be classified into three 
functional groups. The first group are the receptor-activated Smads (R-Smads; Smad 
1/2/3/5/8), which are phosphorylated by the type I receptor kinases on the Ser-Ser-X-
Ser (SSXS) motif at their extreme C-termini (Hill, 2009). This phosphorylation is 
facilitated by auxillary proteins including SARA (Smad anchor for receptor activation) 
and HRS/HGS (hepatocyte growth factor-regulated tyrosine kinase substrate; Miura et 
al., 2000; Tsukkazaki et al., 1998). 
 
Both SARA and HRS/HGS contain the phospholipid binding FYVE domainand 
function as adaptors to aid recruitment of the receptor activated Smads, Smads2 and 3 to 
the TGF-β receptor complex (Rahimi and Leof., 2007). In particular SARA immobilizes 
Smad2 and 3 near the cell surface in order to aid phosphorylation of these proteins by 
the type I receptor (Tsukazaki et al., 1998). In the basal state, the R-Smads are 
associated with SARA in the cytoplasm, however phosphorylation of Smad2/3 by type I 
receptors on C-terminal residues is thought to decrease their affinity for the binding site 
on SARA (Xu et al., 2000; Tsukazaki et al., 1998). As a result, Smads2/3 dissociate 
from SARA (Tsukazaki et al., 1998) and associate with co-Smad4. The need for adaptor 
proteins to generate the active receptor complex is also coupled to receptor endocytic 
activity, which directly impacts on downstream TGF-β signalling (Hayes et al., 2002; 
Peinheiter et al., 2002). Smad anchor for receptor activation (SARA) is thought to be an 
important accessory protein in the facilitation of Smad signalling, however there is 
evidence to suggest that this protein is not an essential requirement for Smad3 activation 
(Goto et al., 2001).  COS7 cells transfected with mutant Smad3 which lacked the 
binding site for SARA was phosphorylated by TβRI in a similar manner to the wild type 
Smad3. In addition, mutant Smad3 was also able to form complexes with Smad4 and 
translocate to the nucleus in the absence of its SARA binding site (Goto et al., 2001). 













Figure 1.10 TGF-β synthesis and signalling. Several extracellular stimuli increase TGF-β 
mRNA expression, leading to synthesis of this protein. TGF-β is synthesized as an inactive pro-
peptide consisting of a main region and a latency associated peptide (LAP), which is targeted to 
the ECM. TGF-β is activated upon cleavage and binds to the TβR II which inturn 
transphosphorylates TβRI leading to downstream TGF-β signalling-mediated target gene 
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Furthermore, mutant and wild-type Smad3 equally enhanced TGF-β-induced 
transcription (Goto et al., 2001), indicating that in contrast to SARA/Smad2 interaction, 
SARA/Smad3 interaction is not essential for TGF-β/Smad3-mediated signalling (Goto 
et al., 2001). 
 
Once phosphorylated, the R-Smads dissociate from the receptor/SARA complex and 
form either homomeric or heteromeric complexes with Smad4, which makes up the 
second functional group of Smad proteins, known as the common or co-Smad (Hill, 
2009, Wrighton et al., 2009). This R-Smad/Co-Smad complex translocates to the 
nucleus and interacts with Smad-binding elements (SBE: GTCT) or GC-rich sequences 
present in certain promoters (Shi et al., 1998; Zawel et al., 1998). Due to the close 
proximity of SBEs to other transcription factors, Smad proteins have often been found 
to cooperate with a wide variety of transcription factors to regulate gene expression 
such as the members of the forkhead box O family (FoxO1, FoxO3, and FoxO4) 
(Gomis et al., 2006; Massague et al., 2005).  
 
Interestingly the differential functional roles of Smad have also been demonstrated. In a 
pancreatic ductal adenocarcinoma cell line (PDAC), siRNA-mediated silencing of 
Smad3 induces growth inhibition but increases migratory response. Conversely, 
silencing of Smad2 enhanced enhances growth inhibition but decreases migratory 
response (Ungfroroen et al., 2011). This balance between the different R-Smads and 
their consequent responses is obviously a critical factor in the downstream effects on 
gene expression.  
There is increasing evidence to suggest nucleocytoplasmic shuttling of Smad proteins 
(Hill 2009). Studies in mouse oocytes revealed that treatment of cells with leptomycin 
B, a specific inhibitor of CRM1 or Exportin 1 led to the rapid nuclear accumulation of 
Smad4 suggesting that CRM1 was required for the nuclear export of Smad4 (Pierreux et 
al., 2000; Watanabe et al., 2000; Fonerod et al., 1997). This inhibition did not affect 
Smad2/3 shuttling, however later studies in zebrafish embryos using GFP-tagged 
Smad2/3 have provided visual evidence of the continuous shuttling of the R-Smads 
from the cytoplasm to the nucleus (Batut et al., 2007; Schmierer et al., 2005; Nicolas et 
al., 2004). Smad2/3 and Smad4 nuclear accumulation of a relatively slow process which 
reaches maximum response 45 min following ligand stimulation by TGF-β1 (Pierreux et 
al.. 2000) and the majority have been reported to remain in the nucleus for 4-5 h after 
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which they begin to be exported back to the cytoplasm (Inman et al., 2002). In addition 
it is thought that Smad2/3 and Smad4 complexes dissociate in the nucleus as a result of 
Smad2/3 dephosphorylation and are then exported out of the nucleus separately by 
distinct mechanisms (Chen et al., 2005). Thus continuous Smad4 shuttling requires the 
activity requires the activation of nuclear export proteins, whilst Smad2/3 require low 
level dephosphorylation (Hill, 2009).  
The third functional group of Smad proteins comprises of the inhibitory Smads (I-
Smads), Smad6 and Smad7 (Wrighton et al., 2009). These proteins negatively regulate 
the TGF-β pathway by mediating receptor inactivation through recruiting the E3 
ubiquitin ligases; Smurf1/2 (Smad ubiquitination regulatory factor-1) or recruiting the 
catalytic subunit of protein phosphatase-1 to the receptors (Shi et al., 2004) which lack 
the C-terminal sites for phosphorylation by TβRI (Rahimi et al., 2007). Smad6 and 7 
inhibit TGF-β signalling via different mechanisms; Smad6 appears to only inhibit the 
BMP pathway whereas Smad7 inhibits the TGF-β/activin and BMP pathways (Hayashi 
et al., 1997; Imamura et al. 1997). Smad6 competes with Smad4 for receptor 
phosphorylated Smad1 binding whereas Smad7 competes with R-Smads for interacting 
with TβRI (Hayashi et al., 1997) as well as directly mediating TGF-β receptor 
ubiquitination by recruiting Smurf ubiquitin ligases (Kavsak et al., 2000). The 
transcription of inhibitory Smad mRNA is induced by TGF-β and therefore it is likely 
that they act as part of an autoregulatory negative-feedback mechanism during TGF-β 
signal transduction (Heldin et al., 1997). 
 
The importance of the regulation of the TGF-β signalling pathway is evident where 
dysregulation of signalling results in metastatic cancers, fibrotic and cardiovascular 
disease including hypertension, restenosis, atherosclerosis, cardiac hypertrophy, and 
heart failure (Ruiz-Ortega et al., 2007). As a result, various regulatory processes are set 
in place, which, under normal conditions police this pathway.  
 
1.3.3 Non-Smad pathways in TGF-β signalling               
Although it is well established that canonical TGF-β signalling occurs downstream via 
Smad proteins, it is becoming increasingly evident that TGF-β also signals via Smad-
independent pathways that are activated by the TGF- β receptors through either 
phosphorylation or direct interaction. These pathways include branches of MAP kinase 
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(MAPK) pathways, Rho-like GTPase signalling pathways, and phosphatidylinositol-3-
kinase (PI3K)/Akt pathways (Zhang. 2009).  
 
TGF- β mediated Erk-pathway activation was first identified in rat intestine and mink 
lung epithelial cells (Mulder et al. 1992; Yan et al., 1994). The kinetics of Erk activation 
in response to TGF-β stimulation is an entirely cell and culture dependent event; rapid 
activation has been observed in epithelial cells (Hartsough and Mulder., 1995) breast 
cancer cells (Frey and Mulder., 1996) and fibroblasts (Musci et al., 1996) whereas more 
delayed activation has been observed in pancreatic acinar cells (Simeone et al., 2001).  
 
Recent discovery of the dual specificity of TβRs acting as both tyrosine and 
serine/threonine kinases resulted in the elucidation of the mechanism whereby TGF-β 
activates the Ras-Erk-MAPK pathway (Zhang, 2009). Phosphorylation of both serine 
and threonine residues as well as at tyrosine residues has been shown to be an initial 
event which results in the recruitment of several adaptor proteins that leads to the 
activation of the Erk-MAPK signalling pathway in response to TGF-β stimulation. 
Tyrosine autophosphorylation on three sites of the cytoplasmic domain of TβRII 
(Lawler et al., 1997) can result in the recruitment of Src homology domain 2-containing 
protein (Shc) and consequent phosphorylation of TβRII Ty284 and recruitment of the 
Shc domain of growth factor binding protein 2 (Grb2) and p38 MAPK activation 
(Galliher and Schiemann, 2007). The tyrosine kinase activity of TβRII suggests that it 
could promote non-Smad signalling pathways, further supported by the finding that 
selective activation of the Erk 1/2 in dermal cells has been attributed to the high 
expression of TβRII, whereas in contrast, in epidermal cells, canonical TβRI-Smad 
signalling is dominant and Erk activation is non-existent due to the high expression of 
TβRI (Bandyopadhay et al., 2011). 
 
Activated TβRI uses its intrinsic tyrosine kinase activity to phosphorylate Shc directly 
on its tyrosine kinase and serine residues (Mu et al., 2012). Phosphorylated Shc then 
associates with TβRI and recruits Grb2 and SOS, and in the process, activates Erk-
MAPK (Lee et al., 2007). Dephosphorylation of TβRI by PP2a results in the inhibition 
of further signalling downstream of this receptor, indicating that its activity is highly 
dependent upon its phosphorylation status; decreased recruitment of PP2a to TβRI 
results in increased TβRI signalling in a manner dependent on Erk-MAPK (Yu et al., 
2010).  
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In addition to Erk-MAPK activation, TGF-β has also been demonstrated to activate the 
JNK/p38 pathway, which is perhaps the best characterised Smad-independent pathway. 
JNK and p38 are activated by MAP kinase kinases (MKK); TGF-β is able to activate 
JNK and p38 through MKK4 and MKK3/6 respectively (Engel et al., 1999; Hocever et 
al. 1999; Frey and Mulder, 1997) and p38 MAPK in the C2C12 fibroblast cell line 
(Hanausa et al., 1999), in HEK293 cells (Sano et al., 1999), and in murine epithelial 
cells (Bhowmick et al., 2001). The Smad proteins have been shown to be dispensable in 
the TGF-β-induced activation of JNK; experiments carried out using a dominant-
negative form of Smad3 or use of cells deficient in Smad3 or Smad4 have demonstrated 
the induction of genes downstream of TGF-β as a result of activation of JNK signalling 
(Hocevar et al., 1999; Engle et al., 1997). Furthermore, use of a mutant TβRI with a 
mutation in the L45 loop rendering it defective in Smad binding and activation but 
without the loss of its kinase activity, demonstrated activation of the JNK and p38 
MAPK pathways in response to TGF-β ligand binding (Itoh et al., 2003; Yu et al., 
2002). 
 
One component that is important in the upstream activation of p38-MAPK is TGF-β-
activated kinase 1 (TAK1) (Yamaguchi et al., 1995). TAK1 has been postulated as 
being indispensible for TGF-β-induced activation of JNK; deletion of the Tak1 gene in 
mice led to earlt embryonic lethality and impaired JNK activation (Shim et al., 2005). 
Recently, it has been reported that TGF-β activates TAK-1 through the catalytic 
activation of the ubiquitin ligase TNF-receptor-associated factor 6 (TRAF6, Landstrom 
et al., 2010). TRAF6 was found to be a crucial component in the activation of TAK1-
KNK/p38 pathways; phosphorylation of p38 by TβRI was severely curtailed by a 
TRAF6 deletion mutant (Yu et al., 2002). In a mouse hepatocyte cell line, knockdown 
of TRAF6 using siRNA resulted in the inhibition of TGF-β activation of JNK and p38, 
however upon reintroduction of TRAF6 into these cells using TRAF6 cDNA restored 
the activation of these kinase pathways in response to TGF-β (Yamashita et al., 2008). 
 
The TRAF6-TAK1-JNK/p38 cascade occurs in conjunction with the Smad-dependent 
pathway to regulate cellular responses downstream of TGF-β such as the induction of 
apoptosis, during which TRAF6-TAK1-JNK/p38 pathway is essential; knockdown of 
TRAF6 or using a p38 inhibitor resulted in the abrogation of TGF-β-mediated apoptosis 
in mouse hepatocytes and mouse epithelial cells (Yu et al., 2002; Yamashita et al., 
2008). Furthermore, using a dominant negative form of MKK3 or p38 blocked TGF-β-
Chapter 1                                                                                                                                      Introduction 
 
 57 
induced changes in the cytoskeleton and EMT (Yu et al., 2002). Similarly, knockdown 
of TRAF6 resulted in inhibition of TGF-β-mediated EMT (Yamashita et al., 2008). 
 
Another pathway implicated in the TGF-β signalling pathway is PI3K which has been 
shown to rapidly activate PI3K by phosphorylating its downstream effector, Akt. In 
mouse mammary epithelial cells, treatment with exogenous TGF-β1 resulted in the 
phosphorylation of Akt at Ser-473 and consequent changes in cell morphology, 
including the acquisition of spindle cell morphology, an effect which was inhibited in 
the presence of the Akt inhibitor, LY294002 (Bakin et al 2000). The ability of TGF-β1 
to induce cell survival and induce angiogenesis is also PI3K/Akt dependent; inhibition 
of this pathway resulted in decreased cell survival and impairment of angiogensis in 
mouse capillary endothelial cells (Vinals and Pouyssegur, 2001). 
 
There is much evidence in the literature to demonstrate the importance of Smad-
independent pathways in TGF-β1-mediated cell responses in a wide range of cell types. 
It is important to note that these pathways often work in conjunction with the Smad 
proteins to elicit various cellular mechanisms and also highlights the complexity of 
TGF-β1-mediated signalling, the regulation of which is extremely important and 
perturbation of which can result in pathological conditions.  
 
1.3.4 Regulation of TGF-β receptors 
An early step in TGF-β signalling is the ligand-induced formation of a tetrameric 
receptor complex comprising of two TβRII and TβRI units (Lonn et al., 2009). This 
activated tetrameric receptor complex is internalized via either clathrin-coated pits or 
clathrin-independent caveolin-1-positive lipid rafts (Guglielmo et al., 2003). The 
mechanism of endocytosis at the cell membrane can have direct downstream effects on 
signal transduction. Clathrin-mediated endocytosis results in receptor re-cycling back to 
the cell surface subsequent to transportation of receptors to early endosomes. 
Conversely caveolae-dependent internalisation results in receptor ubiquitination and 
lysosomal degradation (Lonn et al., 2009). Receptor endocytosis via these two pathways 
is at equilibrium; TGF-β mediated receptor activation is not thought to favour one of 
these pathways of internalisation over the other (Lonn et al., 2009). Receptor 
endocytosis is still a poorly understood phenomenon and specific factors, which result 
in either of these two pathways of receptor internalisation have not been determined.  
Furthermore, It has been proposed that in the serine-threonine kinase system, ligands do 
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not regulate trafficking but rather act to recruit the type I receptor and stabilize the 
heterotetrameric receptor complexes during constitutive trafficking (Guglielmo et al., 
2003).  
 
In broad terms, clathrin-mediated endocytosis increases TGF-β signalling by carrying 
the receptor complex to early endosomes where sustained signalling may take place 
after which the receptors are recycled back to the cell surface (McClean amd 
Guglielmo, 2010; Guglielmo et al., 2003). In this pathway, the Smad2 anchoring 
protein, SARA is bound to receptors at the plasma membrane but it is also highly 
enriched in early endosomes (Guglielmo et al., 2003). Although it was previously 
thought that the clathrin-mediated pathway was responsible for bringing the receptor to 
SARA-bound Smad2 and therefore resulting in receptor-mediated Smad2 
phosphorylation, it is now believed that this pathway functions to sequester receptors 
away from the caveolin-1-positive lipid rafts, which can inhibit TβRI and its 
downstream signalling (Guglielmo et al., 2003). 
 
Caveolin-1-positive lipid rafts are involved in the negative feedback of TGF-β 
signalling as internalisation via caveolae results in the association of Smurf2 with the 
recepors and consequent ubiquitination of the receptor complex and lysosomal 
degradation (McClean and Guglielmo, 2010; Lonn et al., 2009). Whereas SARA-bound 
Smad2 localises to early endosomes rich in phosphatidyl inositol 3 phosphate 
(PtdIns(3)P), the inhibitory Smad7 and the E3 Ubiquitin ligase, Smurf1/2 prefer 
association with the cholesterol and sphingolipid-rich composition of lipid rafts which 
aid inhibition of downstream signalling (Guglielmo et al., 2003). It has been proposed 
that the Smurf proteins enhance the interaction of inhibitory Smad7 with the TGF-β 
receptor complex, allowing Smad7 to compete with R-Smads for receptor activation 
before it begins to degrade the receptor complex (Suzuki et al., 2002). Various proteins, 
including heat shock protein 90, the adaptor serine-threonine kinase receptor-associated 
protein (STRAP) and several E2 and E3 ubiquitin ligases control the overall process of 
receptor downregulation (Lonn et al., 2009). 
 
Equilibrium between each of these receptor-regulatory pathways determines whether 
the pathway results in Smad activation and gene transcription (clathrin-dependent 
pathway) or receptor degradation (raft-caveolin route) and therefore inhibition of TGF-β 
signalling. The endocytic mechanism of TβRs can therefore have profound effects on 
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TGF-β signalling and a number of pathologies, including metastatic cancers and fibrotic 
diseases show aberrant TGF-β signalling indicating the importance of receptor 
endocytosis as a method by which downstream TGF-β signalling is regulated.  
 
 
1.3.5 Dysegulation of TGF-β signalling 
Due to the wide-ranging effects of TGF-β1 on cellular processes, its signalling is a 
tightly regulated process which, when it becomes dysregulated, can result in 
pathophysiological situations. Notably, dysregulation is often associated with epithelial-
mesenchymal transition (EMT) and myofibroblastic differentiation, where excess 
production of TGF-β1 can result in a pathological cell type that can compound and 
accelerate vascular disease (Bobik, 2006). These initial local changes can have far-
reaching implications during disease development with excessive fibrocellular 
proliferation and inward arterial remodelling, which can eventually result in a clinical 
event (Davies et al., 2003; Wu et al., 2003; Ward et al., 1997).   
 
1.3.5a TGF-β1 and vascular disease 
TGF-β has a multitude of effects on the different cell types that make up the vessel wall 
(Grainger, 2007). In culture, TGF-β1 stimulates ECM production and the expression of 
contractile proteins and in endothelial cells it inhibits cell proliferation, migration and 
the expression of adhesion molecules (Grainger et al., 2000). Dysregulation of TGF-β1 
signalling ultimately results in pro-atherogenic changes in the blood vessel (Ruiz-
Ortega et al., 2007).  
 
Several animal models have highlighted the importance of TGF-β1 in the maintenance 
of normal vessel physiology; deletion of a single allele of the tgfb1 gene caused a 50% 
reduction in TGF-β1 protein in the vessel media in mice. A high-fat diet caused these 
mice to express high levels of ICAM-1 and VCAM-1 on their vascular endothelium, 
which was accompanied by the infiltration of macrophages and fatty streak formation in 
the aortic wall, characteristic of early inflammatory changes in lesion formation in 
human atherosclerotic disease (Grainger et al., 2000). TGF-β1 is thought to be involved 
in plaque stability by promoting the secretion of ECM proteins such as collagen. In 
order to investigate this further, Mallat and colleagues used a neutralizing TGF-β 
antibody in ApoE-/- mice which led to the acceleration of lesion formation. These 
lesions contained more inflammatory components and a decreased collagen content, 
making them more prone to rupture (Mallat et al., 2001). This is supported by findings 
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from human coronary arteries in which there was a decreased expression of TGF-β1 in 
unstable plaques when compared to TGF-β1 expression in stable plaques, where its 
expression was invariably higher (Jiang et al., 2004; Reckless et al., 2001). mRNA 
expression analysis of human aortas found that in branch-points of the aorta that were 
more likely to develop atherosclerotic plaques, TGF-β1 mRNA expression was very 
low, whereas in straight parts of the aorta where the probability of plaque development 
was low, higher levels of TGF-β1 mRNA expression were detected (Borkowski et al., 
1995). In spite of the body of evidence which suggests that impaired TGF-β1 signalling 
accelerates atherosclerosis, it is not clear whether increased expression of TGF-β1 
protects against atherosclerosis. However, one study has reported that the 
overexpression of TGF-β1 in the aortae of ApoE-/- hyperlipidemic mice resulted in 
fewer T-lymphocytes, more collagen, less lipid and lower expression of inflammatory 
cytokines which may offer possible therapeutic potential (Frutkin et al., 2009).  
 
Further animal studies have yielded similar results; in mice, in areas of arterial injury 
following surgery, the expression of active TGF-β1 was lower in the medial layer than 
that seen in non-injured arteries, with expression of SM-MHC and type IV collagen also 
significantly depressed in the media, suggesting that TGF-β1 modulates arterial 
remodelling by causing the differentiation of cells in the medial layer (Grainger et al., 
1998).  
 
Initial studies looking at the role of TGF-β1 in arterial injury produced by balloon 
angioplasty revealed that mRNA levels of TGF-β1 were significantly increased within 6 
h of carotid injury (Majeskt et al., 1991). Furthermore, immunohistochemical studies 
showed that the majority of SMC in the neointima stained for TGF-β1 and was related 
to neointima formation implicating it in neointima thickening following balloon 
angioplasty (Majesky et al., 1991). More recently, study into LTBPs which govern 
TGF-β1 release has shown that LTBP-1 and 2 are detected in the neointima and 
neoadventitia of a porcine model of coronary angioplasty, in a similar fashion to TGF-
β1 (Sinha et al., 2001). The same study demonstrated a higher level of LTBP proteolysis 
that correlated with increased active and latent levels of TGF-β1 and increased arterial 
injury response suggesting a pivotal role for TGF-β1 during angioplasty-induced injury 
(Sinha et al., 2001). Results in neoadventital cells from this study  are supported by 
those in a balloon catheter denudation model in which rats were treated with vehicle or 
TGF-β1 inhibitor (Ryan et al., 2003). Inhibition of TGF-β1 was seen to promote vessel 
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enlargement, however lumen size remained unchanged, despite neointima formation 
suggesting a role for TGF-β1 in injury-induced reduction of lumen area since its 
inhibition prevented this (Ryan et al., 2003). Intra-arterial infection of adenovirus-
expressing Smad3 (AdSmad3) in Sprague-Dawley rats that had undergone left carotid 
balloon injury found that contribution of TGF-β1 to neointima formation may be via the 
proliferation of vascular SMC resulting in intimal hyperplasia, an event that was found 
to be dependent upon the phosphorylation of the cyclin-dependent kinase inhibitor p27 
by Smad3 (Tsai et al., 2009). This critical role for Smad3 in remodelling has been 
further compounded by its medial gene transfer in a rat carotid angioplasty model in 
which it caused adventitial changes including myofibroblast transformation, 
proliferation and collagen production, which are all hallmarks of adaptive remodelling 
(Kundi et al., 2009). In light of these findings that implicate TGF-β1, it is not surprising 
that antagonising its actions has proven to be beneficial in preventing fibrosis and 
scarring.  The use of locally administered TGF-β1 receptor antagonists following 
angioplasty/stenting are therefore a promising therapeutic avenue for the prevention of 
restenosis following angioplasty-induced injury (Agrotis et al., 2005).  
 
Although the majority of data on the biological role of TGF-β in the vascular wall 
shows that it is protective against disease by promoting plaque stability, there is some 
data that contends this (Grainger, 2007). A number of studies have shown that TGF-β1 
is implicated in disease pathogenesis (Table 1.3). In the intima of normal human non-
atherosclerotic aortic segments there was very little expression of TGF-β1, however 
fibro-fatty/fatty streak lesions a high expression of TGF-β1 was detected, indicating that 
TGF-β1 could contribute to lesion formation (Grainger, 2007). In particular, in smooth 
muscle cells in vitro, TGF-β1 stimulates the production of the ECM proteins, 
fibronectin and type I collagen (Pennttnen et al., 1988; Ignotz et al., 1987), 
characteristics of adverse vessel remodelling that is associated with coronary artery 
occlusion (Ross, 1999). Transfection of the human tgf-β1 gene into porcine arteries in 
vivo demonstrated that this increased TGF-β1 expression was associated with ECM 
synthesis accompanied by intimal hyperplasia, implicating TGF-β1 in the development 
of vascular lesions (Nabel et al. 1993). A more recent study has also reported similar 
findings; delivery of a TGF-β1 antisense-expressing construct prevented TGF-β1 
expression in a rat model of intimal hyperplasia, and consequently also significantly 
decreased intimal thickness when compared to saline-treated control animals (Sun et al., 
2012).  
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The regulation of gene expression in cardiovascular disease by microRNAs (miRNAs), 
and in particular, those that regulate the downstream actions of the TGF-β1 signalling 
pathway are a highly topical area of research. miRNAs are strands of short non-coding 
RNAs that regulate gene expression by modulating the translation and/or ability of 
target mRNAs (Boyd, 2008). Primary transcripts of miRNAs are transcribed by RNA 
polymerase II, subsequently processed within the nucleus by the RNaseIII 
endonuclease, Drosha into approximately 70 nt hairpin intermediates known as pre-
miRNAs. These are subsequently cleaved by the cytoplasmic RNaseIII, Dicer to release 
a double-stranded duplex comprising the mature miRNA and its antisense complement. 
miRNAs are incorporated  into the RNA-induced silencing complex (RISC) which 
recognises its target genes by partial sequence complementarity between the miRNA 
and motifs typically within the 3’untranslated regions (UTRs) of its target gene then 
promote mRNA degradation or inhibit translation (Dimmeler and Nicotera, 2012). 
 
Recent investigation into miRNA regulation of TGF-β1 has highlighted several 
miRNAs that are involved in vascular disease progression, including miR-26a, miR-143 
and miR-145 (Hata and Davis, 2009; Thum et al., 2008; see General discussion section 
6.5.1). These miRNAs have been implicated in vascular disease progression in response 
to the production of TGF-β1, though the mechanisms behind this relationship are still to 
be fully elucidated (Thum et al., 2008). Preliminary data regarding the cross-talk 
between TGF-β1 and several miRNAs is displayed in the General Discussion (section 
6.5.1). 
 
The importance of local changes in TGF-β activity at sites of lesion formation and its 
subsequent role in the balance between a stable and unstable plaque phenotype 
ultimately dictates the progression of atherosclerosis and disease outcome. The 
significance of this cytokine in the vessel wall during atherogenesis is evident and its 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sulforaphane (SFN) is one of a large number of naturally occurring isothiocyanates 
(ITC), first identified and isolated from hoary cress (Prochdzka, 1959) and later from 
broccoli florets (Zhang et al., 1992). Its isolation from broccoli was also accompanied 
by the observation that SFN was able to induce both quinine reductase and glutathione-
S-transferase activities in liver, stomach, small intestine and lung tissue derived from 
mice fed SFN extracts (15 μM, 5 days). Later studies showed that it is a potent 
chemopreventative (Keum, 2011; Munday et al., 2008; Traka et al., 2008; Zhang and 
Tang, 2007; Kwak et al., 2002) and is also a known activator of the Nrf2/ARE pathway 
and consequently, the induction of Nrf2-target antioxidant genes (Oh et al., 2012; Chen 
et al., 2011; Chang et al., 2010).  
 
1.4.1 Occurrence/source(s) and isolation 
ITCs are found in cruciferous vegetables such as broccoli florets, cabbage and 
cauliflower. SFN is an ITC and in its natural form, exists as the glucosinolate precursor, 
glucoraphanin. ITC are known to be synthesized and stored as glucosinolates in plants 
and are released when damage to plant tissues occurs (Zhang and Tang, 2007). The 
conversion of glucosinolate to ITC is catalysed by myrosinase, which, in plants, co-
exists with glucosinolates but is stored separately (Fenwick et al., 1983). Glucosinolate 
can be partially hydrolysed in the intestinal tract and local enteric flora is known to 
possess myrosinase activity allowing the coversion of glucosinolates to ITC 
(Bheemreddy and Jeffery, 2007).  
  
1.4.2 Metabolism and excretion  
In vivo, SFN is rapidly metabolized through the mercapturic acid pathway (Zhang and 
Tang, 2007) and conjugated with GSH, a reaction that is catalysed by GST and results 
in a conjugate which undergoes further enzymatic modifications, catalysed by Υ-
glutamyltranspeptidase and results in the formation of a cysteinylglycine-SFN 
conjugate. Following further modification, which is catalysed by cysteinylglycinase, 
results in the formation of a cysteine conjugate. A final modification by N-
acetyltransferase results in a N-acetylcysteine-SFN conjugate (Zhang and Tang, 2007). 
 
SFN is rapidly eliminated and this is correlated with its rapid absorption and short 
plasma half-life; in one human study, plasma concentrations were reported to be in the 
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range of 0.94 – 2.27 μM one hour following consumption of 200 μM ITC extract (Petri 
et al., 2003). Other pharmacokinetic studies in humans have revealed that consumption 
of a single portion of broccoli cress or mature broccoli can generate plasma SFN 
concentrations of approximately 1 μM (Riedl et al., 2009; Ye et al., 2002) and 60 nM 
(Hanlon et al., 2009) respectively. Further studies have gone on to confirm the 
breakdown and excretion of SFN to be mainly via the mercapturic acid pathway (Al 
Janobi et al., 2006; Gasper et al., 2005).  
 
In cell culture, the intracellular accumulation of SFN, particularly in the cytoplasm, is a 
rapid process and has been reported in several different cell types (Callaway et al., 
2004; Zhang and Callaway; 2002; Zhang, 2001). In murine hepatoma cells, treatment 
with SFN (5 μM) resulted in rapid intracellular accumulation after just 30 min of 
exposure which continued to increase for up to 6 h, reaching peak levels of 350 μM and 
decreasing thereafter (Zhang and Talalay, 1998). Similarly in mouse fibroblast cells, 
rapid intracellular accumulation of SFN was observed after 30 min, with intracellular 
concentrations attained being 40 – 180 times higher than the initial extracellular 
concentration (5 μM) (Zhang and Talalay, 1998). The rapid accumulation of SFN is 
thought to be a GSH-driven process where ITC-GSH conjugates accumulate in cells and 
as a result, cause phase II enzyme induction. Therefore this suggests that cells with 
higher GSH concentrations have a higher level of intracellular accumulation of ITC 
(Zhang, 2001; Callaway et al., 2004). ITC that are already conjugated with thiols are 
unable to accumulate in cells with accumulation also being dependent on the continuous 
presence of ITC in the extracellular space (Zhang, 2000). In order to counteract ITC-
GSH build-up inside the cell, conjugates are rapidly exported by a membrane transport 
protein, MRP1. In human leukaemia and human myeloma cells, use of an inhibitor for 
MRP1 resulted in continued intracellular accumulation of SFN-GSH conjugates (Zhang 
and Callaway., 2002). The balance between the accumulation and export of ITC-GSH 
conjugates is an important process, and one which results in the induction of phase II 
detoxifying enzymes, thereby enhancing the cells ability to protect itself against further 
extracellular insults.  
 






Figure 1.11 Cellular accumulation and export of SFN. SFN (R-N=C=S) penetrates the cell 
membrane by diffusion and upon entering the cell is rapidly conjugated with intracellular thiols, 
predominantly GSH. Intracellular accumulation of SFN-GSH conjugates results in the rapid 




1.4.3 SFN and therapeutic benefits 
A number of epidemiological studies have revealed the beneficial effects of diet in 
preventing the pathophysiological events that can lead to cardiovascular disease (CVD) 
(Cornelis et al., 2007; Genkinger et al., 2004; Hung et al., 2004; Yochum et al., 1999) 
and more recently, several studies have reported the beneficial effects of the 
consumption of SFN-rich vegetables in reducing the risk of CVD-related complications. 
Although rapidly cleared from plasma, it is plausible that SFN is able to induce 
antioxidant enzymes for up to at least 24 h in healthy individuals, and levels that have 
been reported in plasma through consumption of Brassica vegetables have been 
demonstrated to influence the physiology of vascular and inflammatory cells (Evans, 
2011). Several studies have investigated the effects of Brassica vegetable consumption 
on vascular physiology and pathophysiology. In one such study, ingestion of 200 
mg/day of broccoli sprouts in a hypertensive-stroke prone rat model resulted in 
significantly lower oxidative stress levels in cardiovascular and kidney tissues as 
demonstrated by increased levels of reduced glutathione (GSH) content and decreased 
oxidized GSH in addition to an increase in endothelial-dependent relaxation of the aorta 
and significantly lower blood pressure, demonstrating the beneficial effects of its 
consumption during hypertension (Wu et al., 2004). Another study investigating the 
effects of SFN on the murine aorta from wild-type and Nrf2- knockout animal found 
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that SFN was able to abrogate the expression of the adhesion molecule VCAM-1 in 
atheroprone sites within the aorta whilst also activating the Nrf2/ARE pathway (Zakkar 
et al., 2009). 
 
Evidence from in vitro studies has also confirmed the beneficial and potentially 
therapeutic effects of SFN on pathophysiology. In rat aortic smooth muscle cells, 
treatment with SFN (0.25 – 5 μM) has been shown to result in a concentration-
dependent induction of GSH, glutathione peroxidase, glutathione S-transferase and 
NQO1 (Zhu et al., 2008). The same study also showed that pre-treatment with SFN 
protected aortic smooth muscle cells from oxidative and electrophilic cytotoxicity 
induced by xanthine oxidase or H2O2, giving cells resistance to extracellular stresses 
(Zhu et al., 2008). These results correlate with those found in a later study in endothelial 
cells where a one hour of pre-treatment with SFN (1 – 4 μM) suppressed TNF-α-
induced monocyte chemotactic protein (MCP-1) and VCAM-1 mRNA and protein 
levels. Expression of dominant negative Nrf2 inhibited SFN-induced ARE-driven 
promoter activity in the same study, though this had no effect on SFN-mediated 
inhibition of VCAM-1 and MCP-1 (Chen et al., 2009). GSH is one of the first lines of 
defence cells employ in order to protect against oxidative insults and measurement of 
intracellular GSH and its associated enzymes is often used as an indicator of a cell’s 
redox status; the oxidation and reduction of proteins which can often occur in a 
complementary fashion in order to maintain cellular homeostasis. In vascular SMC 
from spontaneously-hypertensive rats, basal levels of GSH were significantly lower 
than those observed in normotensive rats. This was accompanied by higher levels of 
oxidative stress that were attenuated by treatment with SFN, which also enhanced HO-1 
protein levels in these animals (Wu and Juurlink, 2001).  
 
As well as being cardio-protective, SFN is also a widely known chemopreventative 
agent and has been demonstrated as being a potent natural inhibitor of the cancer 
disease pathology. In animal models of chemical carcinogenesis, SFN has been shown 
to abrogate, and in some cases, inhibit the disease process. Zhang and colleagues have 
shown that administration of SFN (75 - 150 μM, 5 days) around the time of exposure to 
the carcinogen, 9,10-dimethyl-1,2-benzanthracene, resulted in a significant decrease in 
the incidence, multiplicity and weight of mammary tumours in a Sprague-Dawley 
model of chemical carcinogenesis (Zhang et al., 1994). Similar results have been 
reported in a mouse model of benzo[a]pyrene-induced carcinogenesis formation where 
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SFN (7.5 μmol/day for 20 weeks) blocked tumour formation in the forestomach region 
(Fahey et al., 2002). The same study reported that brief exposure to SFN was shown to 
be bacteriacidal and was reported to eliminate intracellular H- pylori from a human 
epithelial cell line (Fahey et al., 2002). Both the chemopreventative and 
antibacteriacidal effects of SFN in this study have been postulated to be attributed to the 
induction of phase II antioxidant enzymes via the Nrf2/ARE pathway (Fahey et al., 
2002) (see below). The chemopreventative action of SFN has been attributed to its 
ability to inactivate histone deacetylase-6, thereby interfering with the expression of 
androgen receptor genes which are important in facilitating signalling and therefore 
disease progression during cancer (Gibbs et al., 2009).  
 
1.4.4 SFN and the Nrf2/ARE pathway  
The activation of the Nrf2/ARE pathway by SFN has been shown to be as a result of the 
modification of critical cysteine residues on Keap1 (Dinkova-Kostova et al., 2002). One 
study has shown that SFN-mediated ARE-luciferase activation is abrogated when 
NIH3T3 cells are co-transfected with plasmids containing an ARE-luciferase reporter 
gene for Nrf2 and a mutant Keap1 protein containing deletions of several domains 
including C151, suggesting this cysteine is essential for SFN-mediated activation of the 
Nrf2 pathway (Zhang and Hannink, 2003). Work carried out by Hong and colleagues 
has shown that exposure of recombinant Keap1 protein to SFN results in the formation 
of a Keap1-SFN adduct (Hong et al., 2005). Further work by another group has 
confirmed the formation of a Keap1-SFN adduct and have postulated that this interation 
occurs between SFN and the Cys151 residue on Keap1 (Hu et al., 2011). In contrast, 
one study has suggested that the modification of specific cysteine residues on Keap1 
may be insufficient for Nrf2 activation and that this activation may occur through 
alternative mechanisms, possibly via the ubiquitination of Keap1, which is followed by 
the nuclear accumulation of Nrf2 (Eggler et al., 2005). Other studies have postulated the 
importance of the mitogen-activated protein kinase pathway in SFN-mediated Nrf2 
activation; treatment of human hepatoma (HepG2) and murine hepatoma (Hepc1c1c7) 
cells with SFN stimulated the activity of Erk2 and resulted in the induction of NQO1, 
which was abolished after the use of an Erk2 inhibitor (Yu et al., 1999). Furthermore, in 
HepG2 cells, the same treatment stimulated the activity of p38 MAPK, and its 
inhibition using a specific inhibitor resulted in enhanced activity of quinone reductase 
while overexpression of dominant-negative mutant of p38 MAPK potentiated the 
activation of the ARE reporter gene suggesting that p38 MAPK is important in the 
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regulation in ARE-mediated induction of phase II detoxifying enzymes following SFN 
treatment (Yu et al., 2000). 
 
Although the mechanisms behind the activation of Nrf2 by SFN remain to be fully 
elucidated, it is well established that the Nrf2/ARE pathway is an important downstream 
target of SFN and several studies have reported the modulatory effects of SFN on this 
antioxidant defence pathway. Initial in vivo evidence came from a murine Nrf2 
knockout model which concluded that the protective effects of SFN administration 
against tumour formation were abrogated in Nrf2-deficient animals and strongly 
suggested that this protective effect was due to the activation of the Nrf2/ARE pathway 
(Fahey et al., 2002). This led to further studies examining the protective effects of SFN 
as a chemopreventative agent and results from Fahey and colleagues were confirmed in 
a skin tumorigenesis mouse model study. Here, the topical application of SFN (100 
nmol/day for 14 days) prior to exposure to a carcinogen resulted in a decrease incidence 
of skin tumour in the WT animals whilst no chemoprotective effect was observed in 
Nrf2 knockout animals (Xu et al., 2006). Furthermore, microarray analysis of tissue 
samples from the small intestine of wild-type and Nrf2-knockout mice treated with 
SFN, revealed that a number of phase II genes were upregulated, including NQO1, 
GST, GCS, GPx and biosynthetic enzymes of the GSH and glucoronidation conjugation 
pathways as well as the induction of Nrf2 protein in wild-type animals, an effect that 
was abrogated in knockout animals (Thimulappa et al., 2002). Interestingly, the study 
also reported that Nrf2 mRNA levels remained unchanged, confirming previous 
findings that SFN may affect Nrf2 post-translationally by mediating the activity of a 
variety of intracellular kinases pathways and thereby causing its phosphorylation 
(Keum, 2011; Zhang and Hannink, 2003).  
 
Due to its beneficial effects during cancer pathogenesis, there has been growing interest 
in the potential therapeutic benefits of SFN during other disease pathologies. In a study 
in a streptozocin-induced model of diabetic nephropathy, SFN was able to significantly 
attenuate oxidative damage and prevent the fibrotic changes such as hypertrophy and 
extracellular matrix accumulation in the kidney by suppressing the protein expression of 
TGF-β1 in wild-type animals whilst having little or no effect in Nrf2-deficient animals. 
The same study also reported increases in Nrf2 protein levels and an inverse decrease in 
TGF-β1 protein expression in human renal mesangial cells treated with SFN (Zheng et 
al., 2011). The effects and possible cross-talk between SFN and the TGF-β1 signalling 
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pathways has also been demonstrated in a hepatic fibrosis mouse model. SFN was 
reported to prevent hepatic fibrosis in this model, whilst also reducing the expression of 
α-SMA and type I collagen. This effect was postulated to be due to the Nrf2-dependent 
inhibition of TGF-β1 signalling where Nrf2 was thought to prevent the phosphorylation 
of Smad2/3, thereby preventing TGF-β1-mediated gene expression and fibrosis (Oh et 
al., 2012). 
 
The inconclusive evidence from clinical trials looking at the potential therapeutic effects 
of exogenous antioxidant administration has led to the investigation of ways in which 
endogenous antioxidants may be upregulated in order to protect against oxidative stress 
and disease (Kris-Etherton et al., 2004; BiondiS-Zaccai et al., 2002; Steinberg, 2000). 
The dietary intake of SFN may help to protect against disease by activating the 
endogenous antioxidant Nrf2/ARE pathway and therefore may be used as a preventative 
measure against various disease pathologies (Annabi et al., 2008; Noyan-Ashraf et al., 
2006).  
 
1.4.5 SFN and reactive oxygen species  
Several studies have postulated that SFN may cause the activation of endogenous 
antioxidant pathways by increasing the transient generation of intracellular ROS. In 
human bronchial epithelial cells, SFN (10 μM) has been shown to increase ROS levels 
as measured by the DCF-DA assay, 10 min after treatment and these levels continued to 
increase up until 8 h after treatment. This increase in ROS levels was accompanied by 
the activation of the Nrf2/ARE pathway and increased protein expression of HO-1 after 
4 h, an observation that was abrogated in cells transfected with Nrf2 siRNA (Lee and 
Lee, 2011). Although this particular study highlights the possibility that SFN activates 
Nrf2-mediated gene expression through the generation of ROS, it did not investigate the 
potential source of ROS in this cell type (Lee and Lee, 2011), however it has been 
suggested that the source of ROS may be mitochondria-dependent.  
 
Previously, Singh and colleagues have reported that in a human prostate cancer cell 
model, SFN increases intracellular ROS levels by disrupting the mitochondrial 
membrane potential as SFN-induced ROS generation was significantly attenuated on 
pre-treatment with mitochondrial respiratory chain complex 1 inhibitors including 
diphenyleneiodonium and rotenone (Singh et al., 2005). Furthermore, SFN treatment 
also resulted in GSH depletion and a decrease in cell viability which was attenuated in 
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cells pre-treated with N-acetylcysteine in this cell type (Singh et al., 2005). Similar 
results were found in a study where endothelial cells were exposed to SFN (4 μM) in 
culture, resulting in an increase in intracellular ROS levels as assessed by the DCF-DA 
assay, and was accompanied by an increase in the activation of Nrf2 and related ARE-
linked gene expression which protected cells from further oxidative damage and 
cytotoxicity (Xue et al., 2008). A more recent study in human lung cells has also 
reported an increase in Nrf2-regulated gene expression (NQO1, glutmate-cysteine ligase 
and thioredoxin reductase) at 24 h following the nuclear accumulation of Nrf2 in 
response to a rise in intracellular ROS levels follwowing exposure of cells to SFN 
(Poerschke et al., 2012). 
 
The ability of SFN to activate the endogenous antioxidant Nrf2/ARE pathway 
highlights it as an important, possible preventative and therefore therapeutic agent 
during cardiovascular disease. Its ability to rapidly enhance intracellular ROS levels and 
therefore cause an elevated and sustained increase in antioxidant gene expression even 
after its metabolism and excretion may offer it up as a preventative measure to attenuate 
disease progression.   
 
 
1.5 Endogenous antioxidant enzyme systems 
In order to counter-balance oxidative stress, the cell has a number of antioxidant 
defence systems, which protect it against the excess production of ROS and maintain 
cellular homeostasis.  In particular, glutathione, is the first line of defence and is 
responsible for the conjugation, metabolism and excretion of most stress-inducing 
insults facing the cell. Antioxidant genes are also important in providing the cell with 
longer-term defence and these include heme-oxygenase (HO-1) and the phase II 
detoxifying enzyme, NQO1. These cellular defence systems are tightly regulated and 
under the control of Nrf2, a transcription factor that plays an important role in the 
protection of the cell against oxidative stress.  
 
1.5.1 Nrf2-Keap 1 pathway 
The Nrf2-Keap1 pathway regulates the oxidative stress-protective responses in 
mammals (D’Autreaux and Toledano, 2007). Nrf2 (nuclear factor (erythroid-derived-2)-
like2) is a cap’n’collar basic leucine zipper (CNC-bZIP) transcription factor which 
binds to the antioxidant response element (ARE) found in promoter regions of genes 
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encoding phase II detoxification enzymes and antioxidant proteins (Lee and Johnson, 
2004) and which is thought to be ubiquitously expressed. However, despite its 
widespread expression, disrupting the nrf2 gene in mouse embryonic stem cells has 
revealed that it may be dispensable for normal development (Chan et al., 1996). 
Regulation of Nrf2 is via six highly conserved domains known as Nrf2-ECH homology 
(Neh 1-6) domains; the Neh1 domain contains a CNC-type basic leucine zipper domain, 
which allows Nrf2 to heterodimerize with small Maf proteins and is essential for DNA 
binding as well as containing a nuclear localization signal (Motohashi et al., 2004; Itoh 
et al., 1999). The N-terminal Neh2 domain binds to the Kelch domain of the Nrf2-
cytosolic repressor, Keap1 (Itoh et al., 1999) and contains seven lysine residues to allow 
for the negative regulation of Nrf2 via ubiquitin conjugation and subsequent 
proteasome-mediated degradation of Nrf2 (Zhang et al., 2004). The C-terminal Neh3 
domain is essential for the transcriptional activity of Nrf2 Zhang, 2006) whilst Neh4 
and 5 are two independent transactivation domains that interact with CREB-binding 
protein (Katoh et al., 2001). The Neh6 domain contains an abundance of serine residues, 
though the exact function of this domain has not been clearly identified (Zhang, 2006). 
 
The activity of Nrf2 is regulated by its inhibitory protein Keap1 (Zhang, 2006). Its 
discovery was as a result of using the N-terminal Neh2 domain of Nrf2 as bait in a yeast 
two-hybrid assay (Itoh et al., 1999) during which it was found that the C-terminal Kelch 
domain of Keap1 was found to bind to the Neh2 domain of Nrf2 (Li et al., 2004). There 
is much controversy over the exact location of Keap1. Initially described as being 
located primarily in the cytoplasm, bound to the actin cytoskeleton and with its main 
role being to retain Nrf2 in this subcellular compartment until exposure of cells to 
oxidative stress (Kang et al., 2004), there is now evidence to suggest that Keap1 may 
not be as passive a protein as initially thought. Several studies have reported that Keap1 
plays a pivotal role in actively targeting Nrf2 for proteasomal degradation rather than 
passively sequestering it in the cytoplasm (Nguyen et al., 2009; Kobayashi et al., 2004; 
Zhang et al., 2004). It has been suggested that under basal conditions, the constitutive 
activity of Keap1 promotes the ubiquitylation of Nrf2 through the cullin-3-dependent 
pathway (Kobayashi et al., 2004; Zhang et al., 2004), however oxidative stress enables 
Nrf2 escape Keap1-dependent degradation, leading to stabilization of Nrf2, its nuclear 
localization and activation of ARE-driven genes (Zhang and Hannink, 2003). In 
particular, two critical cysteine residues important for Keap1-dependent ubiquitylation 
have been found on Keap1; C273 and C288 and serine substitution at either disables 
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Keap1-dependent ubiquitination of Nrf2 (Zhang and Hannink, 2003). A third cysteine 
residue, C151, located on the BTB domain of Keap1 has been reported to be required 
for the stabilization of Nrf2 and for the activation of Nrf2-regulated gene transcription 
(Tian et al., 2012). It has also been suggested that antioxidant-induced modification of 
Keap1 C151 leads to a conformational change in Keap1, allowing Nrf2 to be 
phosphorylated at Ser40, leading to Nrf2 release from Keap1 (Tian et al., 2012). Other 
studies suggest that due to the constitutive expression of Nrf2-regulated genes, the Nrf2-
Keap1 complex is not localized within the cytoplasm but rather that it shuttles in and 
out of the nucleus to allow for basal expression of genes in order to maintain redox 
homeostasis within the cell (Petri et al., 2012). Many studies report increases in Nrf2 
protein levels but no change in Nrf2 mRNA levels suggesting that some oxidants may 
regulate Nrf2 in a post-translational manner (Purdom-Dickinson et al., 2007).  
 
Several kinases have been reported to directly phosphorylate Nrf2, thereby affecting its 
cellular location and stability (Keum, 2011). Initial studies looking at possible kinases 
identified protein kinase C (PKC) as being a possible candidate responsible for this 
phosphorylation; Huang and colleagues found that exposing HepG2 cells to oxidative 
stress in the form of phorbol 12-myristate 13-acetate (PMA) resulted in the nuclear 
localization of Nrf2, an effect which was abrogated in the presence of a PKC inhibitor 
suggesting PKC-mediated phosphorylation is important in the nuclear translocation of 
this transcription factor (Huang et al., 2000). Further work by the same group revealed 
the phosphorylation site as being Ser40 on Nrf2; Nrf2 bearing a Ser to Ala mutatuion at 
amino acid 40 was not phosphorylated by PKC and partially impaired Nrf2 activation 
og ARE-driven transcription in a reporter gene assay (Huang et al., 2002). However, the 
observation that Nrf2 activation was only partially impaired suggested that there may be 
other factors that may modify Nrf2 and thereby downstream gene transcription.  
Treatment of rat cardiomyocytes with H2O2 showed an increase in Nrf2 protein after 1 h 
as well as increased Nrf2-ARE binding activity, both of which were blocked by 
treatment of cells with the PI3K inhibitor, LY294002 (Purdom-Dickinson et al., 2007). 
To further confirm that the increase in Nrf2 protein was not due to increased levels of 
Nrf2 RNA, cells were treated with the RNA synthesis inhibitor, actinomycin D, which 
failed to block H2O2 from increasing levels of Nrf2 protein (Purdom-Dickinson et al., 
2007). This study demonstrates that in addition to PKC, PI3K may also regulate Nrf2 by 
phosphorylation by increasing its stability and thereby allowing it accumulation in the 
cell.  











Figure 1.12 The Nf2-Keap1 pathway of ARE-driven gene expression. Under normal 
physiological conditions, Nrf2 is sequestered in the nucleus by Keap1 and targeted for 
degradation via the ubiquitin-proteasome pathway. However, in response to oxidative stress, 
cysteine residues on Keap1 become oxidized and Keap1 is no longer able to mediate the 
degradation of  Nrf2. Nrf2 translocates to the nucleus, and along with small Maf protein binds 
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In addition to PKC and PI3K, there is evidence to suggest that p38 MAPK also directly 
phosphorylates Nrf2; in HepG2 cells, p38 MAPK directly phosphorylated the 
recombinant GST-tagged Nrf2 protein and promoted the interaction of this recombinant 
protein with endogenous Keap1 in vitro, preventing Nrf2 nuclear translocation (Keum 
et al., 2006). In the same study, the isothiocyanate, SFN was found to promote the 
nuclear translocation of Nrf2 by blocking the p38 MAPK pathway, suggesting that this 
pathway is involved in the negative regulation of Nrf2 (Keum et al., 2006). A study in a 
hamster cancer cell line treated the isothiocyanate, phenethyl isothiocyanate (PEITC), 
found that this compound increased the phosphorylation of ERK1/2 and JNK1/2, 
causing the release of Nrf2 from Keap1 and its subsequent translocation to the nucleus, 
indicating the importance of these kinases in ARE-driven gene expression (Xu et al., 
2006). The import and export of Nrf2 is pivotal in driving antioxidant gene expression; 
sustained and excessive nuclear accumulation of Nrf2 has been shown to be lethal in 
mice (Wakabayashi et al., 2003) and in vitro has been shown to be lead to apoptotic cell 
death (Strachan et al., 2005) therefore it can be assumed that the regulation of the 
nuclear export of Nrf2 is also tightly regulated. Jain and Jaiswal have proposed that 
Fyn, a tyrosine kinase that phosphorylates Nrf2 at Tyr568, and promotes its nuclear 
export and degradation (Jain and Jaiswal, 2006). Further work by the same group 
proposes that GSK-3β acts as adirect upstream regulatory kinase of Fyn, contributing to 
Nrf2 phosphorylation at Tyr568 (Jain and Jaiswal, 2007). This is further compounded 
by evidence froma study carried out by Rojo and colleagues in which SFN is thought to 
activate ARE-dependent gene expression by regulating Fyn/ GSK-3β activity (Rojo et 
al., 2008).  
 
As well as phosphorylation, the acetylation and deacetylation of Nrf2 has also been 
postulated to play a role in its nuclear localization and transactivation. In HEK293T 
cells exposed to sodium arsenite, Nrf2 was shown to undergo reversible acetylation in a 
number of lysine residues in its Neh1 DNA-binding domain under the action of CREB-
binding protein (CBP). This acetylation was reported to encourage Nrf2 transcriptional 
activity (Sun et al., 2009). Similarly, in another study, in HepG2 cells, CBP induced the 
acetylation of Nrf2, increasing its binding to the ARE and thereby increasing Nrf2-
driven gene transcription (Kawai et al., 2011). Furthermore, the histone deacetylase, 
sirtuin 1 (SIRT1) was shown to decrease acetylation of Nrf2 and subsequent gene 
transcription; briefly the study reported that acetylation of Nrf2 resulted in its increased 
nuclear localization whereas deacetylation conditions favored its cytoplasmic 
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localization (Kawai et al., 2011). It is now widely reported that the post-translational 
modification of Nrf2 is pivotal in determining its sub-cellular localization and 
consequently its ability to induce antioxidant genes. Phosphorylation and acetylation 
events can enhance Nrf2 nuclear localization, however as the above studies have shown, 
these events can change depending on the oxidative stressor or the cell type in question.  
 
ARE-driven enzymes and antioxidants include glutathione peroxidase (GSH), 
NADPH:quinone oxidoreductase-1 (NQO1), heme-oxygenase-1 (HO-1) and 
Peroxiredoxin (Prx). Nrf2-regulated expression of antioxidant enzymes in relation to 
cardiovascular disease has been widely reported. Treating murine aortic smooth muscle 
cells and macrophages with the lipid peroxidation product, 4-hydroxynonenol (4-HNE) 
resulted in the nuclear translocation of Nrf2. Nrf2 also caused the up-regulation of 
CD36 on macrophages, an important scavenger receptor mediating the uptake of 
oxidized LDL (oxLDL) and playing an important role in foam cell formation. This was 
accompanied by Nrf2-mediated HO-1 and Prx protein expression in the macrophage 
(Ishii et al., 2004). The Nrf2-mediated induction of antioxidant enzymes human aortic 
smooth muscle cells in response to oxidized lipids was also seen in another study where 
Nrf2 induced HO-1 protein expression in response to moderately oxidized LDL (Anwar 
et al., 2005). In a similar study, Nrf2-expressing adenovirus was transfected into 
vascular smooth muscle cells (VSMCs) following angioplasty, resulting in an increase 
in the expression of several antioxidant enzymes, including HO-1 (Levonen et al., 2007) 
as well as effectively reducing oxidative stress in response to oxLDL and vascular 
inflammation as assessed by macrophage cell count (Levonen et al., 2007). 
 
The importance of this pathway has also been seen in endothelial cells exposed to shear 
stress. Laminar shear stress is thought to be atheroprotective and exposure of 
endothelial cells to laminar shear stress revealed that Nrf2 was strongly activated and 
mediated downstream antioxidant protein expression, offering some of the first 
evidence that the Nrf2/ARE pathway was key in protecting certain areas of the artery 
from atherosclerotic lesion formation (Dai et al., 2007). Shear stress also caused 
activation of the Nrf2/ARE pathway in human umbilical vein endothelial cells 
(HUVECs) exposed to laminar shear stress. These cells exhibited an upregulation of 
several Nrf2-mediated genes, including HO-1 and NQO1 and inhibition of Nrf2 with 
the antioxidant, N-acetyl cysteine, also caused a downregulation in the expression of 
HO-1 and NQO1 (Warabi et al., 2007). 
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These studies demonstrate the significance of the Nrf2/ARE pathway in protecting 
against oxidative insults and regulating redox balance in the vasculature. 
 
1.5.2 Glutathione  
Glutathione (GSH) is one of the first and most important antioxidant defence systems in 
mammalian cells (Meister, 1983 Meister 1988a & b). An ubiquitous intracellular 
tripeptide, it is composed of glutamate, cysteine and glycine and its synthesis in the 
cytosol is a tightly regulated process (Lu, 2009) and it is also here that the majority of 
cellular GSH is located as well as within several intracellular organelles including the 
mitochondria, which contains a much smaller proportion of cellular GSH, with a small 
percentage located in the endoplasmic reticulum (ER) and the remainder in the nucleus 
(Hwang et al., 1992; Meredith and Reed, 1982). GSH is the thiol-reduced form and 
exists in millimolar concentration in most mammalian cells (fibroblasts 0.5 – 5 mM, 
Zucker et al., 1997, liver 5 – 10 mM, Lu., 2009), with the disulphide-oxidised (GSSG) 
form making up less than 1% of total cellular GSH (Akerboom et al., 1982). The 
importance of this intracellular thiol is demonstrated in the number of vital functions it 
serves within the cell; detoxification of electrophiles; scavenging free radicals; 
maintainence of protein thiol status; acting as a reservoir for cysteine as well as 
modulating critical cellular processes such as DNA synthesis, immune function and cell 
proliferation (Kaplowitz et al., 1985; Meister and Anderson 1983). 
 
The most important and well-known function of GSH is antioxidant defence; GSH can 
detoxify H2O2 and lipid peroxide, reactions which are catalysed by glutathione 
peroxidase (GPx) as well as conjugating with and detoxifying electrophiles through 
glutathione S-transferase-catalysed reactions (Liu and Pravia, 2010). The small redox 
enzymes glutaredoxin (Grx) and sulfiredoxin (Srx) catalyse reactions, which keep 
protein cysteine residues in their reduced form, which when oxidised can be converted 
to the sulfenic (RSOH), sulfinic (RSO2H) or sulfonic (RSO3H) acid (see Fig 1.13). The 
oxidative modification of protein cysteine residues, including those on the cytosolic 
inhibitor of Nrf2, Keap1 (Kobayashi and Yamamoto, 2005) are important in ROS-
mediated regulation of protein function (Lui and Pravi, 2010). The ratio of GSSG:GSH 
is an indicator of a cell’s redox status and maintenance of intracellular GSH 
homeostasis is vital for normal cellular functions; GSH redox cycling, catalysed by 
GSSG reductase prevents loss of GSH in the form of GSSG during various reduction 
reactions with oxidants, however most cells maintain their redox status by de novo 
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synthesis of GSH. This synthesis is a two-step process, catalysed by glutamate-cysteine 
ligase (GCL) and GCL synthetase and is explained further below. 
 
The availability of cysteine, the sulphur amino acid precursor and the activity of the rate 
limiting enzyme, GCL, composed of a  catalytic (GCLC) and modifier (GCLM) 
subunit, are the main determinants of GSH synthesis (Liu and Pravia., 2010; Lu., 2009). 
The rate of GSH synthesis is highly dependent upon the levels of GCL activity; 
oxidative stress caused by a variety of agents can result in increased GCL activity, 
increased GCLC mRNA and GCLC gene transcription and as a consequence, an 
increase in total cellular levels of GSH (Wild et al., 1999; Zipper and Mulcahy 2003; 
Zipper and Mulcahy 2000). TGF-β1 has also been shown to regulate GSH synthesis at 
the level of GCLC; in type II alveolar epithelial cells, TGF-β1 was found to inhibit the 
expression of GCLC whilst having no effect on GCLM (Jardine et al., 2002) and this 
was further confirmed in hepatocytes where TGF-β1-mediated apoptosis resulted in 
decreased GCLC mRNA and cleavage of GCLC protein and consequently a decrease in 
GCL activity but had no effect on GCLM protein levels (Franklin et al., 2003). 
Furthermore, in rat hepatic stellate cells, TGF-β1 lowered levels of GSH, which 
consequently facilitated fibrogenesis (Fu et al., 2008).  
 
The transcriptional regulation of GCLC has been closely studied and consensus NFκB, 
Sp-1, AP-1, metal response and antioxidant response (ARE)/electrophile responsive 
(EpRE) elements have been identified in the human GCLC promoter (Moinova and 
Mulcahy, 1998; Mulcahy et al., 1997; Mulcahy and Gipp,, 1995). In particular, 
identification of ARE led to the finding that Nrf2 plays an important role in the 
regulation of GSH synthesis by transactivating the human GCLC promoter (Mulcahy et 
al., 1997). To further confirm this, transcriptional regulation of rat GCLC using Nrf2 
knockout fibroblasts showed that Nrf2 knockout cells had lower levels of GCLC (Yang 
et al., 2005a). Okouchi and colleagues have also shown that Nrf2 is important for 
GCLC subunit expression; exposure of human brain endothelial cells to chronic 
hyperglycemic stress resulted in apoptosis, increased activation of PI3K/Akt/mTOR 
signalling and increased phosphorylation and nuclear translocation of Nrf2 and 
consequently increased GCLC subunit expression (Okouchi et al., 2006).   
 
Nrf2 is also important for the induction of GCLM; the rat GCLM promoter has a 
functional ARE element (-295 to -285) which is important for the basal promoter 
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activity as well as TNF-α-mediated induction of GCLM (Yang et al., 2005b). Mulcahy 
and colleagues have demonstrated that upregulation of GCLM by beta-naphthoflavone 
involved binding of Nrf2 to a functional ARE/EpRE site located at -302 of human 
GCLM (Moinova and Mulcahy, 1998). However, not all inducers of oxidative stress 
affect levels or induction of GCLM and the discordance between the relative expression 
of GCLC and GCLM may depend upon the expression of the two subunits in different 
cell/tissue types (Lu, 2009). 
 
Increased levels of GSH are associated with an early proliferative response and are 
essential for the cell to enter the S phase (Iwata et al., 1994; Messina and Lawrence, 
1989; Shaw and Chou, 1986). Increased levels of GSH have been reported in rat 
hepatocytes (Huang et al. 2008) and following partial hepatectomy; blocking the 
increase in GSH resulted in impaired liver regeneration (Huang et al., 2001). It is known 
that GSH modulates DNA synthesis by maintaining reduced glutaredoxin or 
thioredoxin, both of which are required for the activity of ribonucleotide reductase, the 
rate-limiting enzyme in DNA synthesis (Holmgren, 1981) and this may be one way by 
which GSH modulates cell proliferation. Changes in the thiol-redox status may also 
affect the expression or activity of factors important for cell cycle progression and can 
also modulate cell death; GSH depletion has been reported during apoptosis secondary 





























Figure 1.13 GSH synthesis and cycling in cells 
GSH reduces hydrogen peroxide (H2O2) and lipid peroxide (LOOH) through glutathione 
peroxidase (GPx) catalysed reactions resulting in oxidised glutathione (GSSG). GSSG is then 
reduced back to GSH in a reaction catalysed by glutathione reductase (GRS) and which requires 
NAD(P)H. GSH is also important in protein redox signalling; depending upon the intensity of 
the oxidative insult, protein cysteine residues can be oxidised to sulfenic (RSOH), sulfinic 
(RSO2H) and sulfonic (RSO3H) acid. Conversion to sulfonic acid form is considered to be 
irreversible, however sulfinic acid can be reduced back to sulfenic acid through an Srx catalyzed 
reaction. Sulfenic acid then reacts with GSH to form protein mixed disulfides 
(glutathionylation), which can be reduced back to free-thiol form (deglutathionylation) through 
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1.5.3. Heme oxygenase-1 
Various risk factors for the development of coronary heart disease and other 
cardiovascular diseases mediate HO-1 gene expression, including increased blood 
pressure, altered laminar flow, advanced glycation end products (AGEs), oxidized lipids 
and a number of inflammatory processes (Stocker and Perella, 2006). HO-1 catalyses 
the first rate-limiting step of heme to its metabolites carbon monoxide (CO), which 
causes mild vasodilation, ferrous iron (Fe3+) which is stored by ferritin and biliverdin 
which is further broken down to bilirubin and which acts as an antioxidant (Fig 1.14).  
 
High levels of bilirubin and biliverdin are thought to be inversely related to the 
progression of atherosclerosis (Idriss et al., 2008). The protective effects of bilirubin 
may be due to its ability to protect plasma lipids, such as LDL from peroxidation by 
strongly inhibiting the formation of hydrogen peroxide (Neuzil and Stocker, 1994). 
Bilirubin has also been shown to be protective, in the post-ischemic myocardium in a 
Langendorff model of ischemia/reperfusion, where exogenously applied bilirubin 
significantly restored myocardial function, limited infarct size and mitochondrial 
damage. This attenuation in myocardial function was completely abolished in the 
presence of a heme-oxygenase inhibitor (Clarke et al., 2000), suggesting that HO-1-
derived bilirubin is involved in cardio-protection against reperfusion injury. Further 
evidence for the protective role of bilirubin in the vasculature comes from studies that 
show that there is an inverse relationship between plasma bilirubin and risk of coronary 
artery disease (Idriss et al, 2008). Evidence for the cardio-protective role of bilirubin in 
the prevention of atherosclerosis is supported  detection of decreased bilirubin activity 
in atherosclerosis (Hopkins et al., 1996). More recent evidence has shown that the 
cardio-protective effects of bilirubin may be due to its ability to directly inhibit 
NAD(P)H oxidase by interrupting the assembly and activation of this enzyme (Jiang et 
al., 2006), thereby attenuating ROS generation.  
 
Another product of HO-1 that is cardio-protective is CO, which has anti-proliferative 
and anti-inflammatory properties (Morita, 2005). Its action as a vasodilator is  due to its 
ability to increase levels of cGMP in VSMCs; inhibition of CO using haemoglobin 
reduced VSMC cGMP (Morita and Kourembanas, 1995). The same study found that the 
additional effects of CO included inhibition of endothelin-1 (ET-1) and platelet-derived 
growth factor (PDGF-B) which in turn abrogated VSMC proliferation. Therefore CO  
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Figure 1.14  The heme-oxygenase enzyme system. Heme oxygenase is the first rate limiting 
enzyme that catalyses the breakdown of heme to CO (mild vasodilator), ferrous iron (which is 
stored by ferritin) and biliverdin which is further broken down to bilirubin by biliverdin 
reductase (antioxidant properties). 
 
 
The third product of heme metabolism, ferrous iron, can act as an electron donor and 
therefore contribute to ROS generation. However, there is some evidence to show that it 
can also be cardioprotective (Idriss et al, 2008). The HO-1-dependent release of ferrous 
iron is thought to increase resistance to oxidative stress (Ossola et al., 2000) by  
enhancing cellular capacity for sequestering iron (Tomaro and Batlle, 2002). In addition 
to this, in endothelial cells, increases in ferritin keep iron pools low and reduce oxidant-
induced lipid peroxidation (Selmeci et al., 2000). This experimental evidence highlights 
the important role of HO-1 and its metabolites in protecting the vasculature against the 
damaging effects of oxidative stress.  
 
1.5.4 NADPH:quinone oxidoreductase 1 
NQO1 is an enzyme belonging to the family of phase II detoxification enzymes, which 
are responsible for the conjugation of xenobiotics into water-soluble compounds, which 
may be excreted in urine or bile. NQO1 is thought to be involved in the cellular defence 
against the electrophilic and oxidizing metabolites of xenobiotic quinones, such as 
vitamin E, which results in the generation of the antioxidant forms of these molecules 
(Ross, 2004). Although initial study revealed that its primary function is 
chemoprotection, recent evidence has shown that it is involved in superoxide 
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scavenging with the cell (Ross, 2004). NQO1 works by mediating the two-electron 
reduction of quinones to hydroquinones, in particular its antioxidant role involves 
reduction of ubiquinone to ubiquinol (Ross, 2004). A two-electron reduction removes a 
reactive electrophilic quinone from a biological system and bypasses one-electron 
reduction reactions that can generate reactive oxygen species (Ross, 2004). NQO1 
knockout mice have revealed the importance of this enzyme against quinone toxicity; 
NQO1 knockout mice administered with the superoxide and quinone generator, 
menadione were more susceptible to oxidative stress and toxicity when compared to 
wild-type animals (Radjendirane et al., 1998). Under levels of high oxidative stress, 
NQO1 is induced  in cells to high levels (Dinkova-Kostova and Talalay, 2010), and 
although the rate of interaction of this enzyme with superoxide is less than a magnitude 
above the rate of chemical dismutation of superoxide (Dinkova-Kostova and Talalay, 
2010), its activity in tissues with decreased activity of SOD could provide an additional 
layer of protection against oxidative stress.  
 
1.5.5. Superoxide dismutase 
As previously mentioned, NO, which has important anti-inflammatory and 
anticoagulant properties as well as its vasodilatory effect, can be rapidly inactivated by 
reacting with O2
- leading to the production of the unstable anion ONOO., a process 
commonly occurring in hypercholesterolemia, hypertension, diabetes and ageing (Fukai 
and Fukai, 2011; Madamanchi and Runge, 2007; Guzik and Harrison, 2006). The main 
cellular defence against this reaction are a group of oxidoreductase enzymes, known as 
superoxide dismutases (SODs). The SOD system is one of the major antioxidant 
systems in the cell, catalysing the dismutation of the highly reactive O2
- to oxygen and 
H2O2. Three forms of the enzyme exist in humans, SOD1 (copper-zinc SOD located in 
the cytoplasm), SOD2 (manganese SOD, found in the mitochondria) and SOD3 (an 
extracellular form of copper-zinc SOD) (Forstermann, 2008) each of which are 
contained in distinct subcellular localisations; SOD1 is localised in the cytosol and 
mitochondria, SOD2 is localised to the mitochondrial matrix and SOD3 is anchored to 
the extracellular matrix (Nguyen et al., 2004; Petersen et al., 2004; Fukai et al., 2002). 
Although their cellular localisations are distinct, all three isoforms exert various 
biological effects through H2O2, which can function as a signalling molecule and 
stimulate cellular responses such as hypertrophy, proliferation and migration via the 
oxidation of Akt, Src, and MAPKs or the inactivation of protein tyrosine kinases (Fukai 
and Fukai, 2011; Rhee, 2006).  
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Due to its localisation in the cytosol, SOD1 plays an important role in protecting NO-
mediated vasorelaxation; SOD1 knockout mice exhibit increased levels of vascular O2
- 
and ONOO., increased myogenic tone and vasoconstrictor responses (Didion et al., 
2002). Furthermore, overexpression of SOD1 in transgenic mice has been shown to 
improve vascular dysfunction in a model of subarachnoid haemorrhage (Kamii et al., 
1999). Adenoviral gene-transfer of SOD1 to the aortas of Watanabe heritable 
hyperlipidemic rabbits resulted in a significant decrease in endothelial O2
- (Miller et al., 
1998). A similar study in diabetic rabbits found that the adenoviral gene-transfer of 
SOD to the aorta significantly reduced O2
- production and thereby improved 
endothelium-dependent relaxation, suggesting that SOD prevented the oxidation of NO 
to ONOO. in this disease model (Zanetti et al., 2001) and mice with a deleted SOD1 
gene were more susceptible to ischemia/reperfusion injury in comparison with wild-
type animals (Forstermann, 2008). Due to the ability of SOD to stimulate cellular 
responses such as migration, several studies have examined the role of SOD in reducing 
neointima formation. Ozumi and colleagues have reported that adenoviral transfer of 
extracellular SOD reduced ROS generation as well as reducing proliferation of VSMC 
and associated neointima formation in a cuff-injury model in rats (Ozumi et al., 2005). 
Similarly, catheter-mediated gene transfer to the arterial wall of balloon-denuded rabbit 
aortas reduced restenosis by decreasing the number of macrophages and enhancing the 
recovery of endothelial layer in this disease model (Laukkanen et al., 2002) whilst 
liposomal SOD delivery reduces redox-dependent expression of TGF-β1 and collagen 
in dermal myofibroblasts (Vozenin-Brotons et al., 2001). This evidence points to the 
critical regulation of O2
-, H2O2, and ONOO
., by SOD as being one of the most 
important defence systems in the vasculature that protects against increased oxidative 
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1.6 Cell migration 
Cell migration is a highly regulated process, involving the spatiotemporal 
reorganization of a number of structural proteins which make up the actin cytoskeleton 
as well as coordinating a myriad of signaling events that come together to mediate 
migration during embryogenesis, wound healing, immune response and tissue 
development (Kole et al., 2005). Due to the diverse role it plays in normal physiological 
processes, its dysregulation can contribute to the development of various pathological 
processes, including cardiovascular disease and cancer (Ridley, 2001).  
 
Depending upon the stimulus, cell migration can be directional or random, however it is 
not entirely clear how the cells basic motility machinery is coupled to a steering 
mechanism that is able to integrate environmental cues with polarized signalling to 
promote persistent migration. Directional cell migration is thought to have two sources: 
intrinsic cell directionality and external regulation. Intrinsic directionality is as a result 
of the cell responding to a non-directional motogenic signal, such as the uniform 
application of PDGF that can trigger the motility machinery in the absence of an 
external guiding factor and is often known as chemokinesis (Giannone et al., 2009; 
Petrie et al., 2009). During chemokinesis, In contrast, chemotaxis occurs when a soluble 
factor, such as TGF-β1 is applied asymmetrically and dictates the direction of cell 
migration. This directional migration is as a result of regulated formation of 
lamellopodia, which are observed as a consequence of external guidance cues, 
topography of the ECM, intracellular polarity machinery and adhesion receptors (Petrie 
et al., 2009). Directional migration is as a result of new protrusions forming at the pre-
existing leading edge, rather than in different directions around the cell periphery 
(Andrew and Insall, 2007). TGF-β1 has been shown to be a chemotactic agent for 
fibroblasts and application of this growth factor can result in the directional movement 
of this cell type toward the increasing gradient of this chemotactic agent (Acharya et al., 
2009; Postlethwaite et al., 1987). In addition to TGF-β1, fibroblasts have also been 
shown to migrate towards chemotactic agents, including PDGF, FGF and epidermal 
growth factor (Archarya et al., 2009; Giannone et al., 2009; Petrie et al., 2009). 
Transwell migration assays have shown that the addition of a PDGF to the lower 
chamber of the well results in the directional migration of fibroblasts, which increases 
with increasing PDGF concentration (Engel and Ryan, 1997). In vivo, growth factors 
that can act as chemotactic agents are numerous, especially during disease, when the 
production of several of these is increased and can work in synergy to cause the 
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directional movement of fibroblasts toward the lumen of the vessel, where they are 
usually concentrated (Stenmark et al., 2012; Grainger et al., 2007). 
An initial event seen during cell migration is the establishment of spatial polarity 
accompanied by the extension of membrane protrusions, known as lamellipodia in the 
direction of movement. In vitro, study of fibroblasts cultured on a 2D matrix has 
revealed that cells exhibit a polarized morphology; the leading edge displays a fan-like 
front called the lamella and a tapered tail end (Suraneni et al., 2012). Observation of the 
leading edge has revealed membrane ruffling, a process that is facilitated by the 
formation of newly polymerized actin filaments which make up the two of the structures 
seen at the leading edge; filopodia and lamellipodia (Ridley, 1994; Fig 1.15). Both 
structures lie on top of the more stable lamellal actin network and probe the cellular 
environment ahead of a migrating cell, detecting the stiffness of the surrounding ECM. 
In particular, the lamellopodia and the lamella are thought to play a pivotal role during 
migration and both of these actin-rich structures are known to work together in order to 
drive the forward movement of the cell (Giannone et al., 2009). Adhesions located at 
the leading edge are transduced by the actin network to the rear of the lamellipodium 
where myosin II-dependent contractile forces are generated, eventually pulling at the 
lamellipodial actin bundles resulting in a variation of migratory behavior dependent 
upon the strength of the adhesions (Burnette et al., 2011). An alternative model of cell 
migration has been postulated where actin filaments that are gathered in the 
lamellipodia as ‘arcs’ are thought to be pulled back into the lamella by myosin II and 
adhesions at the leading edge. In this model, a single arc may contact a number of 
adhesion sites, acting as a break to slow down migration or alternatively, using it as a 
site of future protrusion resulting in a net gain in forward movement of the cell as long 
as adhesions at the leading edge remain strong (Burnette et al., 2011; Giannone et al., 
2007).  
Actin polymerization is a critical event in the initial step of lamellipodial extension 
during cell migration and requires the activity of the small signaling G-protein, Rac. 
Branching of the existing actin filament networks that make up lamellipodial extensions 
is thought to be through the Rac-dependent activation of actin-related proteins 2/3 
(Arp2/3) and this complex acts as a nucleation site for new actin filaments to form at 
70° from existing, ‘mother’ filaments (Lauffenberger and Horwitz, 1996) downstream 
of Rac activation. The Rac-driven interaction of IRSp53, an adaptor protein necessary 
for Rac1-mediated membrane ruffling, with WAVE, a member of Wiskott-Aldrich 
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syndrome family protein (WASP), further drives filament branching as this complex 
binds to the C-terminal acidic domain of the Arp2/3 complex, resulting in its nucleation 
(Ridley, 2001). An additional mechanism by which Rac promotes actin polymerization 
is by ‘uncapping’ actin filaments at their barbed ends or by affecting the rate of actin 
depolymerization by stimulating the activity of LIM-kinase which then phosphorylates 
and inactivates cofilin, a protein that severs actin filaments thereby enhancing actin 
depolymerization by (Pavlov et al., 2007; Stanyon and Bernard, 1999; Arber et al., 
1998). The initial induction of Rac has been reported to be as a result of growth factors, 
including TGF-β1, cytokines as well as extracellular components, and whose activation 
is mediated by tyrosine kinases and G-protein coupled receptors, both of which are 
dependent upon PI3K activity (Ridley, 2001). 
Evidence implicating Rac in the phosphorylation of both myosin heavy chain (MHC) 
and myosin light chain (MLC) via p21-activated kinase (PAK) with one study reporting 
enhanced phosphorylation of MLC in the lamellipodial region of cells (Matsumura et 
al., 1998).  
The attachment of the extending lamellipodia to the extracellular matrix 
(ECM)/substrate is modulated by the small focal complex structures and is thought to 
activate Rac and the small GTPase, Cdc42 (Horwitz and Parsons, 1999). The speed of 
migration and the level of activity of Rac and Cdc42 are dependent upon the 
composition of the surrounding ECM/substrate (Ridley, 2001). In slow moving cells, 
such as fibroblasts, focal complexes can mature into Rho-induced focal adhesions 
(Velichkova and Hasson, 2003). Under normal physiological conditions, the continuous 
assembly and disassembly of focal complexes is an important event during migration, a 
process that is also regulated by Rac, directly through PAK and indirectly by its ability 
to antagonize Rho activation (Sander, 1999). As well as Rac, Src and focal adhesion 
kinase (FAK) have also been reported to induce the disassembly of focal adhesions 
(Ridley, 2001).  
As the cell moves forward, its body contracts in order to facilitate movement, an event 
that is dependent upon actomyosin contractility and can be regulated by Rho. Rho-
activation of Rho-kinases results in the inhibition of phosphorylation of MLC which is 
mediated by MLCK, and is activated by calcium and stimulated by Erk MAPKs (Sander 
1999) (Fig 1.15). Reducing Rho activity can have two converse effects; enhanced 
migration due to reduction in the adhesion of cells to the ECM or alternatively, a 
reduction in cell contractility which inevitably attenuates the process of cell migration 
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(Sander et al., 1999; Arber et al., 1998).  
A fourth and final event during cell migration is tail detachment and is generally 
considered the ‘rate-limiting’ step of cell migration, with the rate of tail detachment 
being dependent upon the type of cell and the number of focal adhesion attachments to 
the ECM (Palecek et al., 1998). In slow moving cells such as fibroblasts, this process is 
regulated by calpain, a cysteine protease responsible for facilitating the degradation of 
focal adhesion complexes at the rear of a moving cell (Palecek et al., 1998). The 
importance of calpain in mediating tail detachment has been demonstrated by the use of 
pharmacological inhibitors of this protease in goldfish fin fibroblasts where it was 
observed that inhibiting it resulted in an inhibition of adhesion complex disassembly, 
suggesting a critical role for it during cell migration (Bhatt et al., 2002). Src and FAK 




























Figure 1.15 Role of Ras and Rho GTPases in cell migration 
The formation of protrusions at the leading edge of a cell requires the activity of the small 
GTPase, Rac whilst Cdc42 induces filopodia formation and provides a polarity signal, ensuring 
that Rac-induced protrusions are restricted to the leading edge. Focal adhesions form at the 
trailing edge of the cell and undergo continuous assembly and disassembly, often occurring as a 
result of Ras-dependent inhibition of Rho. Contraction at the rear of the cell requires the activity 
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1.7 Hypothesis and Aims 
 
TGF-β1 can modulate fibroblast phenotype leading to enhanced expression of 
myofibroblast marker proteins and increased cell motility. Previous studies have also 
reported that TGF-β1 causes the upregulation of antioxidant enzymes, possibly by 
causing the generation of reactive oxygen species (ROS). We hypothesise that TGF-β1 
may cause activation of the Nrf2 signalling pathways and increase the activity and 
protein expression of HO-1 and NQO1 as well as depleting total cellular GSH. 
Therefore the aims of this thesis were to examine whether TGF-β1, a growth factor 
which is involved in atherogenesis, differentially modulates the expression and activity 
of proteins and enzymes downstream of the antioxidant stress pathway, Nrf2, including 
mRNA and protein levels of HO-1 and NQO1 and total intracellular glutathione (GSH) 
in cultured human aortic adventitial fibroblasts (HAoAF).  
 
In addition, the effects of the dietary isothiocyanate, sulforaphane (SFN) were also 
investigated in HAoAF. SFN has been reported as a known activator of the Nrf2/ARE 
pathway and an inducer of phase II enzyme activity and several studies have 
demonstrated its potential therapeutic benefit when administered either prophylactically 
or during cardiovascular disease. We hypothesise that SFN activates the Nrf2 pathway 
and increases the protein expression and activity of HO-1 and NQO1 in HAoAF as well 
as causing the depletion of GSH levels. The current study sought to investigate the 
effect of SFN on the activation of the Nrf2/ARE pathway and its downstream 
transcriptional targets. The effect of SFN on HO-1and NQO1 mRNA and protein levels 
were determined and its effect on total cellular GSH was also measured, the activation 
of which may be of potential therapeutic benefit in this cell type.  
 
TGF-β1 and ROS in the vessel wall may contribute to neointimal hyperplasia in 
atherogenesis, partly by the modulation of vascular remodelling as a result of enhanced 
cell migration from the adventitial and medial layers towards the intima. We 
hypothesise that TGF-β1 casues an increase in HAoAF migration and that this may 
occur in a ROS-dependent manner. The aim of this thesis was to further elucidate the 
effect of TGF-β1 on HAoAF migration and to determine whether this effect was a ROS-
modulated process. Furthermore, investigation into the potential source of ROS was 
also investigated.  The findings from this study may provide novel insights for future 
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therapeutic intervention to modulate antioxidant defence genes with TGF-β1 signalling 
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CHAPTER 2: Materials and Methods 
 
2.1 Human aortic adventitial fibroblasts 
 
2.1.1 Culture of human aortic adventitial fibroblasts 
Cryopreserved human aortic adventitial fibroblasts (HAoAF) were commercially 
obtained (Lonza) at passage 3. Manufacturer’s information indicated that cells had been 
routinely characterized using immunofluorescence staining and stained negative for 
smooth muscle α-actin, a marker used to indicate that HAoAF had not differentiated 
into smooth muscle cells. Quality control information provided by the manufacturer 
stated that all cells were performance assayed for HIV-1, mycoplasma, Hepatitis-B, 
Hepatitis-C, bacteria, yeast and fungi and that cell viability, morphology and 
proliferative capacity were measured after recovery from cryopreservation.  
 
Subsequently, cells were defrosted and cultured in a T25 (25 cm2) flask. Cells were 
cultured in phenol red-free Dulbecco’s modified Eagles medium (DMEM, Sigma-
Aldrich UK) containing 1000 mg/L glucose and supplemented with 10% fetal calf 
serum (FCS), L-glutamine (5 mM), penicillin (100 U/ml) and streptomycin (100 ug/ml). 
Cells were maintained at 37°C in an atmosphere of air and 5% CO2. Experiments were 
conducted with cells from passages 4-9. Once cells had reached confluence in the T25 
flask, they were detached using trypsin/EDTA (0.1% trypsin and 0.02% EDTA) in 
sterile phosphate-buffered saline (PBS). Detachment of cells was checked using an 
inverted light microscope (Nikon, TMS). The trypsin/EDTA was inactivated using 
phenol red-free DMEM supplemented with 10% FCS (37°C). The cells were then 
resuspended and transferred to a T75 (75 cm2) flask. Once confluence was reached, 
cells were further subcultured into T75 flasks or in 6, 24 or 96 well plates for 
experiments (see section 2.1.3). The media was replaced every 2 days until an 80% 
confluent monolayer was observed.  
 
2.1.2 Determination of fibroblast seeding density 
To seed the requisite number of fibroblasts for experiments (Table 2.1), cell density was 
determined using a Neubauer chamber (Fig 2.1). Confluent fibroblasts at passage 4-8 
were trypsinized and resuspended in DMEM supplemented with 10% FCS. For 
counting, 10 μL of cell suspension was transferred onto a haemocytometer chamber. 
The number of cells overlying four 1 mm2 areas of the haemocytometer were counted 
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using an inverted light microscope (4× objective magnification) and the number of cells 
per millilitre of cell suspension determined from average of cell numbers in all four 
areas using the following formula; concentration = number of cells x 10,000/number of 
squares. The media was replaced every other day until the monolayer was confluent. 
 
Culture plate Seeding area (cm2) Working 
volume/well (ml) 
Average cell yield at 
confluency 
6-well plate 9.5 1.9 – 2.9  9.5 x 105 
24-well plate 1.9 0.38 – 0.57 1.9 x 105 
96-well plate 0.32 0.1 – 0.2 0.32 x 104  
 
Table 2.1 Number of fibroblasts seeded per culture plate 
 
 




Figure 2.1 Cell counting using a haemocytometer 
Cells in the corner areas were counted under a microscope. Cell density was calculated from the 
average of the cell numbers in four corner areas using the following formula; concentration = 
number of cells x 10, 000/number of cells. 
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2.1.3 Treatment of human aortic adventitial fibroblasts 
Confluent monolayers of HAoAF were equilibrated in DMEM supplemented with 1% 
FCS, L-glutamine (5 mM), penicillin (100 U/ml) and streptomycin (100 μg/ml) 18-24 h 
prior to incubating with treatments. Treatments (transforming growth factor beta-1 
[TGF-β1, 0-10 ng/ml], sulforaphane [SFN, 0-10 μM] or vehicle [0.01% dimethyl-
sulphoxide, DMSO v/v] were diluted in DMEM supplemented with 1% FCS. Cells 
were incubated with treatments for 0-72 h. In studies investigating migration in HAoAF 
and in studies investigating ROS generation, cells were treated in the absence or 
presence of superoxide dismutase (SOD, 200 U/ml) in addition to treatment with TGF-
β1. Furthermore, in ROS-generation studies, cells were pre-incubated with the   
NAD(P)H oxidase inhibitor, VAS2870 (10 μM) or SOD (200 U/ml) for 30 min and then 
acutely co-treated with TGF-β1 and VAS or SOD for 40 min during measurement of 
ROS generation.  
 
2.2 Determination of protein expression in HAoAF by Western blot          
      analysis 
2.2.1 Extraction of total cellular proteins 
After treatment periods were completed, HAoAF cultured in 6 or 24-well plates were 
gently washed twice with ice cold PBS. Cells were then lysed in 125 μl for 6-well plates 
or 75 μl for 24-well plates of sodium-dodecyl sulphate (SDS) lysis buffer (50 mM Tris 
base pH 6.8, 10% glycerol and 2% SDS and with the addition of 0.02% protease 
inhibitor cocktail [protease inhibitor I and II, see Appendix II]). Lysis buffer used for 
the extraction of phosphorylated proteins contained phosphatase inhibitors I and II (0.1 
% v/v, Sigma-Aldrich, UK, see Appendix II). The cells were incubated on ice for 10 
min and lysates subsequently transferred to microcentrifuge tubes and heated for 5 min 
at 95°C and stored at -20°C until further analysis.  
2.2.2 Extraction of nuclear proteins 
HAoAF were cultured in T75 cm2 flasks until confluent and nuclear protein was 
extracted using a nuclear fraction extraction kit (Active Motif, USA). After treatment 
with TGF-β1 (2.5 or 5 ng/ml), SFN (2.5 or 5 µM) or vehicle control (DMSO 0.01% 
v/v), confluent monolayers were washed with ice cold PBS/phosphatase inhibitor 
solution once and detached by scraping in 3 ml of this buffer. The cell suspension was 
centrifuged at 500 rpm for 5 min and cell pellets were resuspended in 500 µl kit 
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hypotonic buffer and incubated on ice for 15 min in order to rupture cell membranes. 25 
µl of kit detergent was added to the cell pellet and the total solution was vortexed for 10 
s. The cell pellet was centrifuged at 13,000 rpm for 30 s and supernatants containing the 
cytosolic fraction were collected and stored at -80 °C until required for western blot 
analysis. Pellets containing nuclear proteins were resuspended in 50 µl kit complete 
lysis buffer (containing protease inhibitor cocktail, lysis buffer and supplemented with 
10 mM dithiothreitol [DTT]) and subsequently placed on a rotating platform (150 rpm) 
for 30 min. Pellets were then vortexed for 30 s and centrifuged at 13,000 rpm for a 
further 10 min. Nuclear extracts in the supernatant were then collected and stored at -80 
°C until further analysis by western blot or DNA binding ELISA (TransAM, Activ 
Motif, USA). Fractionation of nuclear and cytosolic lysates was confirmed by western 
blot analyses of specific nuclear and cytosolic proteins.  
Protein concentration of nuclear lysates was determined using the BCA protein assay 
(see section 2.2.3).  
 
2.2.3 Determination of protein concentration using the bicinchoninic acid protein  
         assay 
The protein concentration of each sample was determined using the bicinchoninic acid 
(BCA) protein assay as described by Smith et al., 1985. The assay was performed using 
a commercial kit (BCA Protein, Novagen) in a clear 96-well plate. Samples were heated 
at 95 °C for 5 min before being diluted 1:1 with ddH2O. The protein concentration of 
unknown samples was determined by using bovine serum albumin (BSA) protein 
standards (0.15 - 2 mg/ml BSA in distilled water). 5 μl of each standard and 5 μl of SDS 
lysis buffer was added to duplicate wells in order to generate a standard curve. A blank 
duplicate consisted of 5 μl ddH2O and 5 μl SDS lysis buffer.  
200 μl of BCA reagent, made up of reagent A (bicinchoninic acid, sodium carbonate, 
sodium tartrate, and sodium bicarbonate in 0.1 M NaOH, pH 11.25) and reagent B (4% 
cupric sulphate) in a ratio of 50:1 was added to each well. The plate was then covered 
and incubated at 37°C for 30 min before absorbance was measured at 562 nm using a 
plate reader (Spectramax 190, Molecular devices). Data was analysed using the 
SoftMaxPro programme and protein concentrations were calculated based on mean 
absorbance values. In order to ensure an accurate readout was being taken, only 
standard curves with a correlation coefficient of R2 >0.995 were accepted (see Fig. 2.2). 
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Protein concentration of nuclear lysates was determined using the BCA protein assay 
(see above). Due to the high reactivity of reducing agents within the lysis buffer with 
the cupric ions in the BCA reagents, nuclear lysate samples were diluted five-fold in 
ddH2O. Nuclear extracts were then diluted 1:1 with SDS lysis buffer and heated for 5 
min at 95 °C before SDS-PAGE and subsequent assessment of nuclear protein 
expression by western blot analysis.   
 
2.2.4 SDS-PAGE and Western blotting 
Expression of specific proteins in total and nuclear lysates was determined by western 
blot analysis. Samples were separated on either 10% or 12% polyacrylamide minigels 
using the Laemmli SDS-PAGE buffer system (Laemmli, 1970). Polyacrylamide 
minigels were prepared (375 mM Tris, 0.1% SDS at pH 8.8, 0.04% ammonium 
persulphate [APS] and 0.08% N,N,N’,N’-tetramethylethylenediamine [TEMED] ) and 
overlaid with a 3% stacking gel (0.125 M Tris, 0.1% SDS at pH 6.8, 0.05% APS and 
0.2% TEMED). Before loading, all samples were first reduced by the addition of 2-
Mercaptaethanol and 0.2% bromophenol blue and then treated for 5 min at 95°C. 
Samples (10 µg per lane) were loaded onto the stacking gel and a voltage gradient of 
150 volts was applied for 1 h in a mini gel electrophoresis tank (Biorad). Following 
SDS-PAGE, the separated proteins were transferred onto a methanol-activated 
polyvinylidene (PVDF) membrane using a semi-dry electrophoretic transfer cell 
(Biorad) and transfer buffer (25 mM Tris, 192 mM glycine and 10% methanol), as 
described by Towbin et al., 1979, at 20 V for 1.5 h.  
In order to determine whether proteins had been adequately transferred onto 
polyvinylidene difluoride (PVDF) membranes, the membranes were stained using the 
azo dye, Ponceau red (Sigma) and subsequently washed several times in ddH2O in order 
to remove residual staining.  Membranes were then incubated in 5% non-fat dried milk 
in PBS 0.1% Tween for 1 h at room temperature in order to minimise non-specific 
primary antibody binding, followed by washing in PBS 0.1% Tween and incubation 
with appropriate primary antibody diluted in 3% BSA (w/v) in PBS 0.1% Tween (Table 
2.1) for a further hour. After the transfer, the polyacrylamide minigels were stained 
using coomassie blue gel staining solution (50% methanol, 0.05% Coomassie Brilliant  
 
 











Figure 2.2 Protein concentration standard curve 
Bovine serum albumin (BSA) protein standards (0.15-2.0 mg/ml) were added in duplicate to a 
96 well plate. 200 µl of BCA protein assay reagent was added to each well and the plate was 
incubated for 30 min at 37°C. The absorbance read on a plate reader (Spectramax 190, 
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Blue R and 10% acetic acid) overnight at room temperature. The following day, gels 
were destained using destain solution (7% acetic acid and 5% methanol) in order to 
visualise protein bands. 
After primary antibody incubation, membranes were washed in PBS 0.1% Tween for 15 
min and subsequently for 3 x 5 min washes and incubated with appropriate HRP-
conjugated secondary antibody made up in 3% (w/v) non-fat milk (Table 2.2) for 1 h at 
room temperature. Membranes were washed as before and enhanced 
chemiluminescence was performed in order to visualise protein expression (Thorpe and 
Kricka., 1986). 
 
2.2.5 Enhanced Chemiluminescence Detection 
Enhanced chemiluminescence (ECL) was performed after incubation of the PVDF 
membrane with HRP-conjugated secondary antibody using a commercially available 
detection kit (Pierce). The ECL solution was prepared by diluting the reagents provided 
by the manufacturer to a ratio of 1:1. The membrane was placed on saran wrap and the 
protein side was incubated with ECL solution for 1 min at room temperature. Excess 
ECL solution was removed and the protein bands visualised using the G:Box gel 
imaging system from SynGene (Cambridge, UK). Relative band densities were 
quantified using the densitometry software, ImageJ (version 1.42, National Institutes of 
Health) and the ratio of the protein of interest to the loading control, α-tubulin, for 
whole cell extracts or lamin C for nuclear extracts, was determined and expressed a 













Target Protein MW (kDa) Species Dilution Supplier Catalog No. 





NQO1 31 Goat pAb 1:500 Santa Cruz Sc-16464 
Nrf2 (c20) 110 Rabbit pAb 1:500 Santa Cruz Sc-722 







1:1000 Santa Cruz sc-32251 
Vimentin 57 Rabbit 
mAb 
1:1000 Abcam ab15248 
Caldesmon 120-150 Mouse 
mAb 
1:1000 Millipore mab3576 
Calponin 36 Rabbit 
mAb 





1:500 Millipore 04953 
Smad 2/3 50 - 60 Rabbit pAb 1:500 Millipore 07-408 
Phospho-Akt 60 Rabbit 1:500 Cell 
Signalling 
9271S 
pan-Akt 60 Rabbit 1:500 Cell 
Signalling 
4685S 
Phospho-JNK 46, 54 Rabbit 1:500 Cell 
Signalling 
9251L 
pan-JNK 46, 54 Rabbit 1:500 Cell 
Signalling 
9252L 
Phospho-Erk 1/2 44, 42 Rabbit 1:500 Cell 
Signalling 
4370L 
pan-Erk1/2 60 Rabbit 1:500 Cell 
Signalling 
4695 
p38MAPK 43 Rabbit 1:500 Cell 
Signalling 
9212S 
Lamin A/C 69, 62 Goat pAb 1:500 Santa Cruz sc-6254 
α-Tubulin 55 Rat mAb 1:5000 Chemicon mab1864 
 
 
Table 2.2 Primary antibodies used for the determination of specific proteins on 
polyvinylidene membrane. Following semi-dry transfer of proteins onto nitrocellulose 
membrane, the membrane was blocked for 1 h and subsequently incubated with 10 ml of 
appropriate primary antibody, diluted in PBS containing 3% BSA and 0.1% Tween-20, for a 
further hour. The membrane was then washed in PBS 0.1% Tween for 30 min in order to 
remove any non-specific binding and incubated for a further hour with HRP-conjugated 
secondary antibody. Antibodies for phosphorylated proteins were diluted in TBS-T containing 
5% BSA and 0.05% Tween-20. 
 
 




Antibody Dilution Supplier Catalog No. 
Donkey anti-goat 1:2000 Santa Cruz sc-2020 
Goat anti-mouse 1:2000 Autogen abn106 HRP 
Goat anti-rabbit 1:2000 Autogen abn117 HRP 
Goat anti-rat 1:2000 Autogen abn192 HRP 
 
Table 2.3 Secondary antibodies used for the determination of specific proteins on 
polyvinylidene membrane.  Following incubation with primary antibody for 1 h, the 
membrane was washed in PBS 0.1% Tween for 30 min and subsequently incubated for a further 
hour with HRP-conjugated secondary antibody. After incubation with secondary antibody, the 




2.3 Tetrazolium assay to measure HAoAF viability 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used as an index to measure HAoAF viability. Mitochondrial dehydrogenases in viable 
cells reduce the tetrazolium dye, MTT to the water insoluble dark blue/purple formazan 
(Denizot and Lang., 1986). A solubilisation solution, such as dimethyl sulphoxide 
(DMSO) is added to dissolve the insoluble formazan solution to give a visible dark 
purple colour which acts as an indicator of cell viability and which can be quantified by 
measuring the intensity of absorbance and correlating it with the mitochondrial 
dehydrogenase activity and cell viability.  
Confluent cultures of HAoAF were seeded at a density of 1x103 cells per well in a 96 
well plate in DMEM supplemented with 10% FCS. Cells were equilibrated in DMEM 
supplemented with 1 % FCS 18 h prior to treatment with TGF-β1 (0 – 5 ng/ml), SFN 
(2.5 – 10 μM) or H2O2 (50 – 100 μM) for 24 h. Cells were treated in 4 replicate wells in 
each experiment. After this incubation period, the treatment conditions were aspirated 
and 50 μl of 10% MTT solution (made up in DMEM supplemented with 1% FCS) was 
dispensed into each well. The cells were then further incubated at 37°/5% CO2 for 4 h 
after which 200 μl of DMSO was added to each well and left on a rotating platform for 
10-15 min to aid dissolution of the formazan crystals. The absorbance was then 
measured at 562 nm using a spectrophotometer (SpectraMax 190, Molecular Devices) 
and data was expressed as a percentage of the absorbance in untreated control cells. 
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 2.4 Measurement of nuclear Nrf2 accumulation and DNA binding 
To investigate the effect of TGF-β1 on the transcription factor, Nrf2, and its nuclear 
accumulation in HAoAF and the Nrf2 mediated antioxidant gene activation was 
determined by western blotting, immunofluorescence (He et al., 2009; Churchman et 
al., 2009) and a DNA binding ELISA (TransAM, Activ Motif, USA).  
 
2.4.1 DNA binding ELISA for Nrf-2-DNA binding activity 
The capacity of nuclear Nrf2 to bind ARE sequences was quantified using a DNA 
binding ELISA kit (TransAM, Active Motif, USA) in order to detect and quantify Nrf2 
activation. Oligonucleotides containing the ARE consensus binding site (5’-
GTCACAGTGACTCAGCAGAATCTG -3’) immobilized on an ELISA plate bind the 
active form of Nrf2 contained in the nuclear extracts. Following incubation of the 
nuclear extracts with the immobilized oligonucleotide, a primary antibody used to 
detect Nrf2 upon DNA binding is added to the wells followed by the addition of an 
HRP-conjugated secondary antibody. The result is colorimetric change that can be 
quantified by spectrophotometry at 450 nm (Spectramax 190, Molecular devices).  
HAoAF nuclear extracts were thawed at room temperature and subsequently placed on 
ice. As recommended by the manufacturers protocol, 7.5 µg of nuclear extract diluted in 
complete lysis buffer (provided by the kit) to give a total volume of 10 μl was added to 
the ELISA plate in duplicate followed by the addition of 40 µl complete binding buffer. 
In addition, 10 µl complete lysis buffer as blank and 7.5 µg of Nrf2-transfected COS 
(CV-1 (simian) in Origin, and carrying the SV40 genetic material) nuclear extract 
(provided by the kit) and used as a positive control were also assessed in addition to 
HAoAF nuclear extracts.  
After incubation of nuclear extracts with immobilized oligonucleotides at room 
temperature for 1 h with mild agitation, the wells were washed twice with washing 
buffer (provided with the kit) and incubated with Nrf2 specific primary antibody 
(1:1000 diluted in antibody binding buffer, 100 µl/well) at room temperature without 
agitation. HRP-conjugated secondary antibody (1:1000 diluted in antibody binding 
buffer, 100 µl/well) was then added to the wells and incubated for a further 1 h. 
Subsequent to antibody incubations, wells were washed twice using buffer and 
incubated with developing solution (provided with the kit, 100 µl/well) for ~15 min in 
the dark until a colour change from yellow to medium-dark blue was observed. A stop 
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solution (provided with the kit, 100 µl/well) was then immediately added to the wells in 
order to prevent further colour development.  The absorbance was measured at 450 nm 
using a spectrophotometer (Spectramax 190, Molecular devices) within 5 min of the 
addition of the stop solution with a reference reading taken at 655 nm. All readings 
were corrected for background.  
 
2.4.2 Immunofluorescent staining of Nrf2 in HAoAF 
To evaluate Nrf2 nuclear translocation, cells were incubated with TGF-β1 (5 ng/ml) or 
SFN (5 μM) for 1, 2 or 4 h, washed twice with PBS, and fixed with 4% formaldehyde 
for 30 min at room temperature. Cells were left in permeabilization solution (0.1% 
Triton X-100 in PBS) for 10 min followed by antibody blocking solution (3% BSA in 
PBS) for 30 min, and subsequent overnight incubation with primary antibody anti-Nrf2 
(rabbit, 1:400; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) diluted in PBS (1% 
BSA) at 4 °C. After being washed with PBS, the cells were incubated with Alexa 488-
conjugated secondary antibody (goat anti-rabbit IgG–488; 1:200; Invitrogen, Paisley, 
UK) for 2 h at room temperature and then washed twice with PBS. In order to viualise 
F-actin, cells were further incubated with rhodamine phalloidin conjugated to 
tetramethylrhodamine (TRITC, 200 nM) diluted in PBS for 1 h at room temperature. 
Coverslips were mounted upside down onto SuperFrost® microscope slides (Menzel 
Glaser, Braunschweig, Germany) using Vectasheild® Mounting Medium containing 
4',6-Diamidino-2-Phenylindole, Dilactate (DAPI) for nuclear staining. Coverslips were 
viewed using a fluorescent inverted microscope (Nikon Diaphot adapted for 
fluorescence, Japan) fitted with appropriate filters and linked to image processing 



















Figure 2.3 DNA binding ELISA assay for the determination of nuclear Nrf2 activity 
Nuclear lysates containing activated Nrf2 from HAoAF were incubated with the ELISA plate 
coated with immobilized oligonucleotides containing an ARE sequence. Following incubation, 
primary antibody which recognises epitopes on Nrf2 upon DNA binding was added to the wells 
followed by the addition of HRP conjugated secondary antibody. The colorimetric readout was 
detected at 450 nm using a spectrophotometer and indicated the levels of active Nrf2 in the 
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2.5 Expression of marker proteins to characterise HAoAF phenotype 
2.5.1 Immunfluorescent staining of human aortic adventitial fibroblasts 
Cultures of human aortic adventitial fibroblasts were stained for α- smooth muscle actin 
(Santa Cruz) and vimentin (Abcam) in order to determine their phenotype. 
Immunofluorescent staining was performed following treatment of cells with control 
(DMEM supplemented with 1% FCS) or TGF-β1 (2.5 – 5 ng/ml, 0-24 h). Cells were 
cultured on glass coverslips (VWR International) in 6 well plates. Cells were adapted in 
DMEM supplemented with 1% FCS for 18-24 h prior to commencement of 
treatment(s). Following treatment with TGF-β1 for appropriate time period, treatments 
were aspirated and cells were gently washed twice with PBS (37°C) and fixed with 4% 
formaldehyde in PBS (1 ml/well) for 30 min at room temperature. Following 
formaldehyde fixation, cells were gently washed again twice with PBS and 
permeabilised with Triton X-100 (0.1 % in PBS) for 10 min at room temperature. In 
order to minimise non-specific primary antibody binding, cells were incubated with 
blocking buffer containing 3% BSA in PBS for 30 min at room temperature before 
being incubated with appropriate primary antibody in 1% BSA for 4 h at room 
temperature. Following incubation of cells with primary antibody (α- smooth muscle 
actin or vimentin), cells were incubated with an Alexafluor 488 labelled secondary 
antibody (1:400, ex/em 495/519 nm, Invitrogen) for 2 h at room temperature in the dark 
and subsequently washed. To stain for F-actin fibres, cells were stained with rhodamine 
phalloidin conjugated to tetramethylrhodamine (TRITC, 200 nM)  (200 nm, Sigma 
Aldrich) diluted in PBS for 1 h at room temperature. Coverslips were mounted upside 
down onto SuperFrost® microscope slides (Menzel Glaser, Braunschweig, Germany) 
using Vectasheild® Mounting Medium containing 4',6-Diamidino-2-
Phenylindole, Dilactate (DAPI) for nuclear staining. Coverslips were viewed using a 
fluorescent inverted microscope (Nikon Diaphot adapted for fluorescence, Japan) fitted 
with appropriate filters and linked to image processing software (Hamamatsu HC Image 
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2.6 Determination of intracellular glutathione  
2.6.1 Cell extraction for glutathione assay 
After incubation with treatments (see section 2.1.3), medium was aspirated and cells 
were washed twice with ice-cold PBS and incubated with 400 μl/well of 6.5% 
trichloroacetic acid (TCA) to lyse cells. The plates were then left on ice and gently 
agitated occasionally to ensure even coverage of the cells with 6.5% TCA. After 10 
min, supernatant containing GSH was collected and transferred for storage at -80°C for 
further analyses. The remaining cells in the well plate were solubilised by adding 300 μl 
of 0.5 M NaOH to each of the wells and left on the bench for 2-4 h before storage at -
20°C until further required for analysis of protein content. Protein concentrations were 
determined using the BCA assay (Pierce) as previously described in section 2.3.1 to 
correlate with the GSH levels. 
 
2.6.2 Determination of intracellular reduced glutathione by fluorometric assay 
Intracellular glutathione levels were measured as originally described by Hissin & Hilf 
(1976) and as modified by Senft et al., (2000). Samples stored at -80°C, previously 
extracted as described above, were defrosted on ice for determination of glutathione 
(GSH) content using a fluorometric assay. Conjugation of total GSH to a fluorophore 
reagent O-Phthaldialdehyde (OPA) leads to the formation of a highly fluorescent 
isoindole (Senft et al., 2000). 
Microcentrifuge tubes containing the extracted sample in 6.5% TCA or GSH standards 
prepared in 6.5% TCA (0-30 nmol) were vortex mixed and 7.5 μl each added to 277.5 
μl of phosphate-EDTA (0.1 mol-1 KH2PO4, 5 nmol -1 EDTA, pH>8) in triplicate to a 
black 96 well plate. This was followed by the addition of 15 μl of freshly prepared 0.1% 
w/v o-Phthaldialdehyde (OPA, Sigma-Aldrich, UK) in methanol which fluoresces upon 
reacting with the GSH in the cell extracts. The plate was incubated in the dark for 25 
min at room temperature and fluorescence measured at 350 nm excitation and 420 nm 
emission in a microtitre plate reader (Hidex Chameleon V). Glutathione concentrations 
in each sample were determined by correlating with the glutathione standard curve 
obtained (Fig 2.4) and normalised for protein content in each well to express glutathione 
concentration as nmol/mg protein. 
 
 











Figure 2.4 Representative GSH standard curve 
Fluorescence readings of the GSH standards were expressed relative to their known 
concentrations (0-30 μM) to generate a standard curve. The equation obtained from the standard 
curve was then used to calculate the concentration of GSH in samples read on the same plate 
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2.7 Reactive oxygen species detection 
2.7.1 Determination of reactive oxygen species generation using luminescence 
Detection of reactive oxygen species (ROS) generation in live cells was carried out 
using the luminol analogue, LO12 (20 μM, Wako Chemicals, USA), which has been 
shown to detect extracellular superoxide generation (Daiber et al., 2004). Cells were 
seeded in sterile white 96 well plates with a clear-bottomed base and equilibrated in 
phenol red-free DMEM supplemented with 1% FCS 18-24 h prior to treatment. All 
treatments were in quadruplicate and were diluted in Krebs buffer (131 mM NaCl, 5.6 
mM KCl, 25mM NaHCO3, 1mM NaH2PO4.H2O, 2.5mM CaCl2, 1mM MgCl2, 5mM 
HEPES, 5mM  glucose and 100uM L-arginine) and the plate was read in a 
luminescence plate reader (Hidex Chameleon V) for 1 sec/well over 40 min at 37°C. 
For long-term treatments, cells were incubated with treatments diluted in phenol red-
free DMEM supplemented with 1% FCS and after the appropriate incubation times, the 
treatments were removed and replaced with the same treatment conditions diluted in 
Krebs buffer and subsequently luminescence was measured over 40 min. Luminescence 
was determined as mean light units (MLU) and were indicative of superoxide 
generation. After readings were obtained, the Krebs buffer was removed from the plate 
and replaced with 50 µl NaOH (0.5 M) overnight at room temperature for the 
determination of protein (µg) content per well. The BCA protein assay was performed 
(see section 2.3.1) and chemiluminescence readings were corrected for protein content 
of each well.  An average of the MLU for each condition was taken in order to 
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2.8 Transfection of HAoAF with Nrf2 siRNA 
In order to determine whether the transcription factor, Nrf2 is responsible for the 
upregulation of specific antioxidant proteins in response to various treatments, cells 
were transfected with short interfering (siRNA) targeted against Nrf2 (Piao et al., 2012) 
and then challenged with either TGF-β1 or SFN. Short RNAs area group of intracellular 
regulatory RNAs (usually <30 bp) including siRNA, micro interfering (miRNA) and 
repeat associated short interfering (rasiRNA) (Hannon and Rossi, 2004; Meister and 
Tuschl, 2004). The mechanism of small RNA interference is depicted in Fig 2.6. once 
delivered into mammalian cells, double strand short RNA templates undergo several 
maturation steps to form a single strand short RNA. This single strand short RNA is 
complementary to the target mRNA and its binding initiates the degradation of the 
target mRNA, mediated by the RNA-induced silencing complex (RISC) (Meister and 
Hannon, 2004). Specific gene silencing provides an important method to investigate the 
downstream effects of the protein of interest. In the current study, comparison of 
antioxidant responses in HAoAF to TGF-β1 or SFN were determined in cells 
transfected with siRNA targeted against Nrf2. Whole cell protein lysates were then 
collected and protein expression determined using SDS-PAGE and western blot 
analysis. 
Cells were seeded at a density of 50,000 cells per well in a 24-well plate and were 
maintained in phenol red-free DMEM supplemented with 10 % FCS. Cells were 
allowed to adhere for 24 h and were subsequently transfected with siRNA.  2 μl of 
DharmaFECT4® (Dharmacon, Thermo Scientific, UK) was diluted into 498 μl of 
serum-free Optim-MEM® (Roche). Scrambled and Nrf2 siRNA was also prepared by 
diluting 8 μl scrambled siRNA or 8 μl Nrf2 siRNA with 100 μl Optim-MEM® to give a 
final concentration of 4 picomoles/well. The transfection reagent was then added to the 
scrambled and Nrf2 siRNA tubes and incubated for 20 min to allow the siRNA to form 
a complex with the transfection reagent. The siRNA:transfection complex was then 
added drop-wise to wells containing phenol red-free DMEM supplemented with 10% 
FCS and the plate was gently rotated to ensure equal distribution of siRNA over the 
centre surface of the well. Eight hours following transfection, the transfection mixture 
was aspirated from wells and replaced with DMEM supplemented with 1% FCS for 
overnight equilibration. Cells were then treated with TGF-β1 or SFN for 8 h. Control 
wells contained only DMEM supplemented with 1% FCS. Following incubation with 
appropriate treatment, culture medium was aspirated and cells were gently washed twice 
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with ice cold PBS (4°C). Cells were lysed in 75 μl SDS-lysis buffer and the collected 






Figure 2.5 Gene silencing by short RNA in mammalian cells  
Exogenous short RNAs such as dsRNA (siRNA) and short hairpin RNA (shRNA) and 
endogenous miRNA in mammalian cells undergo the same maturation process to a single strand 
small RNAwhich is complementary to the target mRNA. The binding of small RNA to the 
target mRNA initiates its degradation mediated by RNA-induced silencing complex (RISC). 
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2.9 Quantitative reverse transcription polymerase chain reaction  
      (qRT-PCR) for detection of mRNA and miRNA levels in HAoAF 
Levels of messenger RNA and microRNA of genes of interest in HAoAF were 
determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
and mRNA and miRNA was extracted using the Qiagen miRNeasy spin column kit and 
the RNeasy Plus mini kit respectively, following the manufacturer’s protocol. All 
experimental procedures were carried out using DNase and RNase-free consumables.  
 
2.9.1 Extraction and purification of total RNA 
Total RNA was extracted from cells using the miRNeasy spin column kit (Qiagen) 
following the manufacturers protocol. The kit provided all materials required for the 
isolation of total RNA <200 nucleotides using spin columns and their patented phenol-
guanidine-based QIAzol Lysis Reagent. All experimental procedures were carried out 
using DNase and RNase-free consumables. Briefly, after adapting cells to DMEM 
supplemented with 1% FCS for 18-24 h, confluent HAoAF were treated with either 
TGF-β1 (0-5ng/ml) or SFN (0-5 µM) for 4 or 8 h. Following incubation, cells were 
washed with ice-cold PBS twice prior to the addition of QiaZol lysis reagent (300 
µl/well for 6 well plate) and incubated on ice for 10 min before being transferred to 
RNase-free microcentrifuge tubes for homogenizing by vortex-mixing. The homogenate 
was then incubated at room temperature (15-25°C) for 5 min followed by the addition 
of 140 µl chloroform (Sigma) after which it was shaken vigorously for 15 s and 
incubated at room temperature for 2-3 min. The homogenate was then spun down and 
the resulting precipitated RNA was sequentially purified and eluted using the spin 
column procedure where the sample was loaded onto the spin column and spun down 
followed by several wash steps resulting in the adsorption of the RNA onto the silica gel 
membrane. Total RNA was then eluted in nuclease-free water and RNA concentration 
was determined by using a spectrophotometer.  
 
2.9.2 Extraction and purification of microRNA 
Total miRNA was purified from total RNA in cells using the RNeasy Plus mini kit 
(Qiagen) following the manufacturers protocol. The kit provided all materials for the 
isolation of small RNA (containing miRNA, ~22 nucelotides in length) using gDNA 
Eliminator spin columns. All experimental procedures were carried out using DNase 
and RNase-free consumables. Briefly, after adapting cells to DMEM supplemented with 
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1% FCS for 18-24 h, confluent HAoAF were incubated with either DMEM 
supplemented with 1% FCS (control), TGF-β1 (5ng/ml), HNE (10 µM) or glucose 
oxidase (2.5 U/ml), for 6 h. Following incubation, cells were washed with ice-cold PBS 
twice prior to the addition of Buffer RLT Plus (350 µl/well for 6 well plate) before 
disrupting and homogenizing the sample. The homogenate transferred to a gDNA 
Eliminator spin column and centrifuged for 30 s at >10,000 rpm. 1.5 volumes of 70% 
ethanol was added to the flow-through and mixed thoroughly by vortexing. The sample, 
including any precipitate that may have formed, was then transferred to an RNeasy spin 
column and centrifuged for 15 s at >10,000 resulting in the adsorption of the RNA onto 
the silica gel membrane. 0.65 volumes of 100% ethanol was added to the flow-through 
and mixed thoroughly by vortexing before transferring to a RNeasy MiniElute spin 
column and centrifuging for 15 s at >10,000 rpm. Following a wash step, 500 µl of 80% 
ethanol was added to the RNeasy MiniElute spin column and then spun for 15 s at 
>10,000 rpm. The flow-through was discarded and the RNeasy MiniElute spin column 
was placed in a 1.5 ml collection tube. Small RNA (containing miRNA) was then eluted 
in RNase-free water.  
 
2.9.3 Measurement of RNA quality 
RNA concentration in the extract (1 µl) was determined by absorbance read at 260 nm 
(A260) using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, USA). 
Concentrations (ng/µl) were calculated based on the assumption that 1 unit absorbance 
at 260 nm represents 40 ng/µl of mRNA in the sample. RNA purity was checked by the 
ratio of absorbance at 260 nm to 280 nm (A260/A280). A pure RNA extraction with 
minimum genomic DNA contamination is indicated by a ratio of ~2. The ratio of 18S to 
28S (ribosomal peaks) was used as a reference for RNA integrity. Only samples with 
A260/A280 > 2 were used in this study according to recent guidelines (Bustin et al., 
2009). 
 
2.9.4 Reverse Transcription 
In order to perform qRT-PCR, isolated RNA was first transcribed into cDNA using the 
High Capacity RNA-to-cDNA Kit from Applied Biosystems according to the 
manufacturer’s instructions. The kit provides removal of any contaminating genomic 
DNA as well as the achievement of a high yield of cDNA. 500 ng of extracted RNA 
was used for RT and added to 10 µl of RT mix. The total mixture was made up to 20 µl 
with RNase-free water and RT was run using a thermal cycler (Applied Biosystems) 
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pre-set according to manufacturers guidelines. The cycle was as follows; 37°C for 60 
min, 95°C for 5 min and a subsequent hold at 4°C for 5 min. Following RT, stock 
concentration was then diluted 1 in 5 for qRT-PCR.  
 
2.9.5 qRT-PCR 
cDNA in the RT samples was assessed by real time quantitative polymerase chain 
reaction using a SyberGreen-based PCR mix (Sensi-Mix® SYBR-green no ROX, 
Bioline). A master mix containing forward primer, reverse primer, Quantifast SYBR 
green and nuclease free H2O was first prepared on ice (see 2.9.1 composition) and 
added to 100 well gene discs (Qiagen) using an automated robot, CAS-1200  (Corbett 
Life Sciences, Australia) into tubes containing 2 µl of sample cDNA  or of standard 
cDNA (10-1 - 10-9 copies of target genes). On each disc, 2 blank (nuclease free water 
only) and two RT negative samples were also assessed to check contamination of 
genomic DNA. Loaded discs were run for PCR amplification in a Corbett Rotorgene 
which determines copy numbers via relative fluorescence generated by SYBR-green 
following its excitation. The polymerase enzyme in the samples was activated at 95°C 
for 10 min, followed by 45 cycles of 95°C for 10 s (denaturing), 57°C for 15 s (primer 
annealing) and at 72°C for 5 s (amplification). To assess the quality and efficiency of 
the PCR reaction, a melting point analysis was carried out after each run to distinguish 
target amplicons from PCR artefacts such as misprimed products; samples were heated 
from 65°C to 95°C at 1 degree/cycle. Rotorgene PC software (Corbett, UK) was used to 
evaluate PCR efficiency and transform the absorbance values to a logarithmic scale 
which allowed gene copy number in samples to be obtained, relative to the standard 
curve. The copy number of target genes was adjusted relative to the geometric mean of 
3 stably expressed house-keeping genes: ribosomal protein L13a (RPL13A), succinate 
dehydrogenase unit complex A (SDHA) and TATABOX (thymine, adenine, thymine, 
adenine box). The stability of these genes was determined as an M value using GeNorm 
Excel software (http://medgen.ugen.be/ivdesomp/genorm/), which analyses the 
variation in the expression of a reference gene compared with that of other reference 
genes (Vandesomplele et al., 2002). The M value is inversely proportional to the 
variation and any reference gene with an M value < 1.5 was rejected for use for the 
pairing analysis, with the final combination of 3 reference genes having the lowest M 
value indicating their relative stability in this cell system. A normalisation factor for 
each sample was then calculated by the software based on the geometric mean of these 
reference genes, the expression of target genes (copy numbers) in each sample was then 
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corrected by the corresponding normalisation factor using the Rotorgene program to 
minimize non-biological variations between the samples (Vandesompele et al., 2002; 
Dikalov et al., 2007).  
 
Reagent Volume (μl) 
Forward primer 0.4 






Table 2.4 Relative components of mastermix used for RT-qPCR 
 
During PCR, the number of cycles required to enter the exponential phase of the PCR is 
dependent upon the initial amount of target sequence at the beginning of the reaction 
and shifts in PCR curves are expressed as the differences between the crossing 
thresholds (CT) between each sample (Guenin et al., 2008). Following the assessment 
of PCR efficiency (Fig 2.5), which is specific for each primer pair and therefore 
indicative of the suitability of the primers chosen, the difference between the expression 




















Figure 2.6 Representative qPCR standards to determine gene copies in samples 
(A) Logarithmic-transformed amplification profile of a typical standard curve, demonstrating 
that gene copy number is inversely proportional to the point at which the amplification plot 
crosses the cycle number threshold. (B) Logarithmic-transformation of the standard curve 
plotting log concentration against the cycle number in which the amplification plot (A) crosses 
the threshold. Linear regression analysis shows the correlation coefficient (R2) and the 
efficiency of the reaction, which gives a measure of both the accuracy of the qPCR step and the 
suitability of the primers chosen.  
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2.10 Time-lapse Video Microscopy 
Time-lapse video microscopy was performed in cells cultured in 12 well plates. Cells 
were seeded in phenol red-free DMEM supplemented with 10% FCS at a density of 
30,000 cells/well and allowed to adhere for 24 h. Culture media was changed to phenol 
red-free DMEM supplemented with 1% FCS 18 h prior to incubation with the 
treatments (see Methods section 2.1.3) in DMEM supplemented with 1% FCS. Some 
cells were incubated with SOD (200 U/ml) for 30 min prior to the commencement of 
imaging. iMultifield live cell imaging was performed on a Zeiss Axiovert 100 
microscope using an automated scanning stage. Phase contrast images were acquired by 
using a 10x/0.25 N-Achroplan phase contrast objective. Images were collected using a 
Sensicam (PCO Cook) charge coupled device (CCD) camera. A frame was captured 
every 10 min over 8 h using AQM acquisition software (Andor Bioimaging, Belfast, 
U.K.). Nuclei of migrating cells from the time-lapse sequence were tracked using 
ImageJ software. Movement of the nuclei was taken as an indication of the distance 
migrated per cell and the average of the total distance travelled per cell was calculated. 
All cells in a particular field were tracked and the average distance of all cells was 
determined in that particular field of view and taken as the average distance migrated in 
response to the treatment administered. Migration speed and distance was quantified by 
importing cell-tracking data into Excel and calculating the average distance migrated 





















Figure 2.7 Representative image of cell tracking using ImageJ  
Cells migration was analysed using ImageJ. Tracking the movement of nuclei was used as an 
indicator of cell migration and all cells in the field of view were tracked over 8 h. Frame (A) is 
the first frame taken from a single well and (B), (C) and (D) are subsequent frames over an 8 h 
period. Circles indicate the movement of the nucleus of a single cell being tracked. Tracking 
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2.11 Statistical analysis 
All data are expressed as means ± standard error of the mean (SEM) from a minimum of 
at least 3 different experiments, unless stated otherwise. Statistical variance from the 
mean was determined using the normal distribution, tested using a two-tailed students t-
test in Microsoft Excel. Confidence limits were established using an unpaired Student’s 
t-test or one-way analysis of variance (ANOVA) with the Tukey’s post hoc correction 
for multiple comparisons, to give a statistical significance between data sets established 
at p < 0.05 to p < 0.001. All results that are statistically significant are marked, and in 
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The adventitial fibroblast, previously assumed to be an inert cell type, whose main role 
was thought to provide support and contribute to the structure of the outermost layer of 
the blood vessel, is now a known key player in the pathology of vascular diseases. First 
described in experimental wound healing (Gabbiani et al., 1971), fibroblast to 
myofibroblast differentiation is initiated during tissue injury, when the local release of 
cytokines, in particular, TGF-β1 (Eyden, 2004) results in the activation of fibroblasts, 
which, as a consequence, acquire a migrating (Coen et al., 2011) and contractile 
phenotype (Desmouliere et al., 2005), typically seen after stretch injury due to balloon 
angioplasty and during wound healing. This differentiation process is characterised by 
the acquisition of a contractile apparatus (Desmouliere et al., 2005; Gabbiani et al., 
1971) during which the de novo expression of the cytoskeletal proteins, α-smooth 
muscle actin and vimentin, occurs (Enzerink and Vaheri, 2011; Tomasek et al., 2002). 
These series of events eventually lead to the synthesis of several components of ECM 
and the organisation of a mechanically supportive structure, which is able to produce 
significant contractile force (Hinz et al., 2007; Tomasek et al., 2002). 
 
There is much evidence to implicate of TGF-β1 in the pathogenesis of fibrosis during 
disease and wound healing. Release of biologically active TGF-β1 enhances the 
synthesis of extracellular matrix (ECM) proteins, exerting its effects via the intracellular 
Smad proteins, which have been postulated to play an essential role in ECM protein 
gene expression (Dobaczewski et al., 2010) as demonstrated in a mouse model of 
bleomycin-induced pulmonary fibrosis, where Smad3 deficiency attenuated collagen 
deposition (Zhao et al., 2002). Similar results were observed in a murine model of renal 
tubulointerstitial fibrosis induced by unilateral ureteral obstruction  (Sato et a., 2003), 
where the TGF-β1/Smad3 signalling pathway was disrupted resulting in a decrease in 
the levels of renal fibrosis and epithelial to mesenchymal transition.  
 
The incorporation of α-smooth muscle actin into stress fibres augments the contractile 
activity of fibroblastic cells and is a pivotal step in the contraction phase of connective 
tissue remodelling (Hinz et al., 2001); interfering with α- smooth muscle actin 
significantly reduces tension generated by myofibroblasts (Hinz et al., 2002). 
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Furthermore, in the infarct area of post-myocardial infarcted heart, there was an 
upregulation of α-smooth muscle actin protein expression when hearts were subjected to 
pressure or volume overload (Santiago et al., 2010; Borg et al., 1996).  
 
In addition to α-smooth muscle actin, a second cytoskeletal protein is expressed by 
myofibroblasts. Vimentin, first described as being the only intermediate filament 
protein to be expressed by myofibroblasts (Schurch et al., 1984), and initially a widely 
used marker for the identification of myofibroblast phenotype (Coulson-Thomas et al., 
2010; de Matos et al., 2010; Firth et al., 2010; Ji et al., 2010; Touhami et al., 2005; 
Muchaneta-Kubara et al., 1997), is expressed by mesenchymal cells (Shi et al., 1996). 
The primary function of vimentin is to provide structure to cells and is thought to be 
potentially involved in cell movement (Strauss et al., 2000). Several studies have 
reported an increase in the expression of vimentin in myofibroblasts (Ji et al., 2010). In 
tissue from patients with chronic thromboembolic pulmonary hypertension, there was 
an increase in vimentin in areas of fibrotic thrombus formation with resident fibroblasts 
expressing vimentin and exhibiting a myofibroblast phenotype (Firth et al., 2010). In 
addition to this, thoracic aortas transplanted into the abdominal aortas of Wistar rats in 
order to assess the role of adventitial fibroblasts in transplant vasculopathy, revealed 
adventitial fibroblast activation and differentiation into myofibroblasts was 
characterized by immunostaining of vimentin and α-smooth muscle actin (Ji et al., 
2010). Furthermore, the treatment of pulpal fibroblasts with TGF-β1 enhanced the 
expression of vimentin and resulted in a contractile myofibroblast phenotype (Martinez 
et al., 2007). Therefore this chapter aimed to determine the phenotype of HAoAF in 
culture by assessing the expression of these two myofibroblast markers and the response 
of this cell type to exogenous TGF-β1 treatment. 
 
TGF-β1 is known to be promitogenic in several different cell types (Bhowmick et al., 
2003), it is also a potent growth inhibitor in epithelial and hematopoietic cells (Akhurst, 
2002), whilst in fibroblasts it causes proliferation and migration (Strutz et al., 2001). 
The ability of TGF-β1 to cause proliferation and migration in some cell types and 
growth inhibition in others is still only partly understood; its growth arrest properties 
are though to be attributed to its association with a group of proteins known as cdks 
(Strutz et al., 2001) which associate with cell-cycle regulating cyclins. These proteins 
form a dimer which drives cell cycle progression and can be inhibited by the action of 
cdk inhibitors that can be mediated by TGF-β1. In addition to this, TGF-β1 also opposes 
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the effects of genes that affect vascular remodelling (Bobik, 2006), mitogenic growth 
factors and proinflammatory cytokines; the binding of Smad3 to the CCAT/enhancer-
binding protein-β and reducing the expression of CCAT/enhancer-binding protein-δ 
results in the activation of vascular smooth muscle cells (VSMC; Feinberg at el., 2005). 
Despite evidence to suggest that TGF-β1 can act as a growth inhibitor, it is well 
established that its autocrine and paracrine action on VSMC during neointima formation 
results in their activation and proliferation (Kundi et al., 2009). At low concentrations it 
can stimulate proliferation of VSMC by inducing platelet-derived growth factor (PDGF, 
Kundi et al., 2009)  
 
The effects of TGF-β1 on HAoAF are poorly defined in the literature, and due to the 
pleiotropic nature of this growth factor it is important to establish the various actions it 
may have on this cell type in terms of phenotype, proliferation, toxicity and activation 
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3.2 Morphology of HAoAF  
3.2.1 Expression of α-smooth muscle actin in HAoAF 
α-Smooth muscle actin is a widely used marker for the characterisation of fibroblast to 
myofibroblast differentiation, (Hinz et al., 2012; Dabiri et al., 2006; Cucoranu et al., 
2005; Rocic and Lucchesi, 2005). In order to determine whether exposure to TGF-β1 
contributes to HAoAF differentiation, HAoAF were treated with TGF-β1 (0-5 ng/ml, 
12-24 h) and subsequently incubated with a primary antibody against the cytoskeletal 
protein α-smooth muscle actin and a secondary fluorescent antibody (see Methods 
section 2.5). Immunofluorescence analysis revealed that there was basal expression of 
α-smooth muscle actin in untreated cultured HAoAF (Fig 3.1, panel D). This expression 
was not significantly increased following treatment of cells with TGF-β1 for 12 or 24 h 
(Fig 3.1, panel E and F), indicating that these cells had undergone differentiation in 
culture and were exhibiting a myofibroblast phenotype. 
 
In addition to immunofluorescence analysis, to confirm that HAoAF expressed α-
smooth muscle actin, Western blot analysis of protein expression was carried out in 
cells treated with TGF-β1 (0-5 ng/ml,) for 4-72 h to assess the long-term effects of 
TGF-β1 on HAoAF phenotype. Confluent HAoAF were equilibrated in DMEM 
supplemented with 1% FCS 18 h prior to treatment with TGF- β1. Subsequently, cells 
were lysed and total cell protein was extracted and assessed using SDS-PAGE and 
Western blot analysis (see Methods section 2.2). Results revealed that there was a basal 
expression of α-smooth muscle actin in HAoAF and that this expression was not 
significantly augmented following exposure to TGF-β1 (0 – 5 ng/ml) over 72 h (Fig 3.2 
A & B). This finding further confirms the results from immunofluorescence analysis 
and suggests that HAoAF had acquired a myofibroblast phenotype in vitro. In addition, 
cells treated with SFN exhibited no change in the expression of α-smooth muscle actin, 




























































































































































































































































































































































































































































































































                               
 
 
Figure 3.2 α- Smooth muscle actin protein expression in HAoAF after treatment with 
TGF-β1. Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 
1% FCS and subsequently treated with TGF-β1 (0 -10 ng/ml) for 4 - 72 h prior to whole cell 
protein extraction. α-Smooth muscle actin protein expression levels in these samples was 
assessed using SDS-PAGE and Western blot analysis (A and B). Results were analysed by 
densitometry with smooth muscle α-actin corrected for the loading control, α-Tubulin (C). 
Values denote means ± SEM, n = 3 independent experiments.   















Figure 3.3 α-Smooth muscle actin protein expression in HAoAF after treatment with SFN. 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle control (DMSO 0.01%) or SFN (5 μM) for 4 - 72 h prior to 
whole cell protein extraction. α- Smooth muscle actin protein expression levels in these samples 
was assessed using SDS-PAGE and Western blot analysis (A). Results were analysed by 
densitometry with α- smooth muscle actin corrected for the loading control, α-Tubulin (B). 
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3.2.2 Expression of vimentin in HAoAF  
Another molecular marker that is characteristic of the phenotypic switch of a fibroblast 
to a myofibroblast is the intermediate filament protein vimentin, the expression of 
which has been widely used as an index of myofibroblast differentitation (Roelofs et al., 
1998; Sampson et al,. 2011). In order to determine whether exposure to TGF-β1 
contributes to HAoAF differentiation, cells were treated with TGF-β1 (0-5 ng/ml, 12-24 
h) and subsequently incubated with a primary antibody against vimentin and a 
secondary fluorescent antibody (see Methods section 2.5). Basal expression of vimentin 
was observed in untreated cells (Fig 3.4, panel D) and this was comparable to vimentin 
expression exhibited by cells treated with TGF-β1 (5 ng/ml, 12 - 24 h, Fig 3.3, panels E 
and F). This effect was independent of the time period of incubation with the treatment 
conditions, as indicated by the cytoplasmic staining of vimentin in all treatment groups 
(Fig 3.3). This immunofluorescence data suggests that HAoAF exhibit basal expression 
of vimentin and that this expression is not further enhanced or altered by treatment with 
TGF-β1 suggesting that HAoAF exhibited a myofibroblast phenotype at the time of 
experiments. 
 
In addition, vimentin protein expression was also assessed by Western blot analysis. 
Cells were treated with TGF-β1 (0-5 ng/ml,) for 4-72 h to assess the long-term effects 
of TGF-β1 on HAoAF phenotype. Results revealed that there was a basal expression of 
vimentin in HAoAF in untreated control cells and that this expression was not enhanced 
in the presence of TGF-β1.  Treatment of cells with SFN also revealed that SFN did not 
alter the expression of vimentin in HAoAF. These findings confirm results from 
immunofluorescent analysis and further indicate that HAoAF had differentiated into 



















































































































































































































































































































































































































































































































Figure 3.5 Protein expression of vimentin in HAoAF after treatment with TGF-β1  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 -10 ng/ml) for 4 - 72 h prior to whole cell protein 
extraction. Vimentin protein expression levels in these samples was assessed using SDS-PAGE 
and Western blot analysis (A and B). Results were analysed by densitometry with vimentin 
corrected for the loading control, α-Tubulin (C). Values denote means ± SEM, n = 3 
independent experiments.   
 












             
 
 
Figure 3.6 Protein expression of vimentin in HAoAF after treatment with SFN 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle control (DMSO 0.01%) or SFN (5 μM) for 4 - 72 h prior to 
whole cell protein extraction. Vimentin protein expression levels in these samples was assessed 
using SDS-PAGE and Western blot analysis (A). Results were analysed by densitometry with 
vimentin corrected for the loading control, α-Tubulin (B). Values denote means ± SEM, n = 3 












3.3 Effect of SOD on expression of α-smooth muscle actin and vimentin       
      in HAoAF 
In order to determine whether the differentiation of HAoAF was dependent upon ROS, 
in particular, O2
-. (Vozenin-Brotons et al., 2001), HAoAF were treated with TGF-β1 in 
the absence or presence of superoxide dismutase (SOD). Confluent HAoAF were 
equilibrated in DMEM supplemented with 1% FCS 18 h prior to treatment with TGF- 
β1 (0 - 5 ng/ml) in the absence or presence of SOD (200 U/ml), for 4 – 72 h. 
Subsequently, cells were lysed and total cell protein was extracted and assessed using 
SDS-PAGE and Western blot analysis (see Methods section 2.2). 
 
Results revealed that basal expression of vimentin and α-smooth muscle actin in 
HAoAF was not affected in the presence of SOD. Exposure of cells to TGF-β1 (0 - 5 
ng/ml, 4-72 h) did not alter their phenotype and no differences were observed when 
cells were incubated with SOD. These results suggest that the differentiation of HAoAF 
to myofibroblasts may not be altered by scavenging O2
-. which further suggests that 
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Figure 3.7 α- Smooth muscle actin protein expression in HAoAF after treatment with 
TGF-β1 and SOD. Confluent HAoAF were equilibrated in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with TGF-β1 (0 -5 ng/ml) in the absence 
or presence of SOD (200 U/ml) for 4 - 72 h prior to whole cell protein extraction. α- Smooth 
muscle actin protein expression levels in these samples was assessed using SDS-PAGE and 
Western blot analysis (A). Results were analysed by densitometry with α- smooth muscle actin 
corrected for the loading control, α-Tubulin (B and C). Values denote means ± SEM, n= 3 



















Figure 3.8 Vimentin protein expression in HAoAF after treatment with TGF-β1 and SOD 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 -5 ng/ml) in the absence or presence of SOD (200 U/ml) 
for 4 - 72 h prior to whole cell protein extraction. Vimentin expression levels in these samples 
was assessed using SDS-PAGE and Western blot analysis (A). Results were analysed by 
densitometry with α- smooth muscle actin corrected for the loading control, α-Tubulin (B and 











3.4 Effect of TGF-β1 on mitochondrial dehydrogenase activity in  
      HAoAF 
Cell viability was assessed by measuring mitochondrial dehydrogenase activity using 
the MTT assay (see Methods section 2.3), a widely used method to assess cytotoxicity 
in cultured cells (Fotakis & Timbrell, 2006; Bjorkerud & Bjorkerud, 1996). HAoAFs 
were seeded at a density 1x103 cells per well in a 96 well plate in DMEM supplemented 
with 10% FCS. Once confluent and 18 h prior to incubation with treatment conditions, 
cells were equilibrated in DMEM supplemented with 1 % FCS and subsequently treated 
with TGF-β1 (2.5 – 10 ng/ml), vehicle control (DMSO 0.01%), SFN (2.5 -10 μM) or 
H2O2 (50 – 100 μM). Cells treated with TGF-β1 exhibited no significant change in 
mitochondrial dehydrogenase activity when compared to untreated control (Fig 3.7, A), 
indicating that TGF-β1 has no effect on HAoAF mitochondrial dehydrogenase activity. 
H2O2, which was used as a positive index of MTT formazan development; cells treated 
with 50 and 100 μM exhibited a 93% decrease in mitochondrial dehydrogenase activity, 
suggesting that H2O2 caused a significant decrease in the viability of HAoAF.  
 
In addition to TGF-β1, cells were also treated with SFN. Following treatment of 
HAoAF with SFN (2.5 μM), there was a slight decrease in mitochondrial 
dehydrogenase activity when compared to vehicle control and treatment with SFN (10 
μM) also resulted in a decrease in mitochondrial dehydrogenase activity (Fig 3.7, B), 
however this decrease was not statistically significant. These results suggest that SFN 
does not cause a significant decrease in HAoAF viability at the concentrations used in 
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Figure 3.9 Effect of TGF-β1 and SFN on HAoAF viability 
Confluent cultures of HAoAF were seeded at 1x103 cells per well in a 96 well plate in DMEM 
supplemented with 10% FCS. Cells were equilibrated in DMEM supplemented with 1 % FCS 
18 h prior to treatment with (A) TGF-β1 (2.5 – 5 ng/ml), (B) SFN (2.5 – 10 μM) or H2O2 (50 – 
100 μM) for 24 h. Mitochondrial dehydrogenase activity was determined by measuring the 
formation of MTT formazan dye as described in Methods and was used as an indicator of cell 
viability. Values denote mean ± SEM, n = 4 independent experiments. ***p <0.001 vs. control 















































3.5 Effect of TGF-B1 on Smad phosphorylation in HAoAF 
The phosphorylation of Smad2 (pSmad2) investigated in HAoAF to confirm the 
activation of TGF-β1 signalling in these cells. Confluent HAoAF (P6 - P9) were 
equilibrated in DMEM supplemented with 1% FCS 18 h prior to treatment with TGF- 
β1 (0 - 5 ng/ml), for 0.5 – 4 h. Subsequently, cells were lysed and total cell protein was 
extracted and assessed using SDS-PAGE and Western blot analysis (see Methods 
section 2.2). Basal expression of pSmad2 protein was observed in untreated HAoAF 
(0.5 – 4 h). This effect was significantly augmented during the treatment of HAoAF 
with TGF- β1 (2.5 ng/ml, 2 – 4 h, p<0.05), and maximum expression of pSmad2 was 
observed after 2 h (5 ng/ml, p<0.05; Fig 3.8, A). These results corroborate those 
observed during immunofluorescence analysis and suggest that cells are responsive to 










































Figure 3.10 Phosphorylated Smad2 protein expression in HAoAF after treatment with 
TGF-β1. Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 
1% FCS and subsequently treated with TGF-β1 (0 -5 ng/ml) for 30 min – 4 h prior to whole cell 
protein extraction. pSmad2 protein expression levels in these samples was assessed using SDS-
PAGE and Western blot analysis. Results were analysed by densitometry with pSmad2 protein 
levels corrected for the loading control, total Smad2/3. Values denote means ± SEM, *p<0.05 










3.6 Effect of TGF-β1 on pSmad localisation in HAoAF 
Phosphorylation of Smad2 and its nuclear translocation in response to TGF-β1, which 
typically occurs between 30 min - 4 h (Stockwell and Schreiber, 1998; Xu et al., 2000; 
Watkins et al., 2012), is an important and definitive step in the activation of the TGF-β1 
pathway (Guo et al., 2009; Lu et al., 2009) and is often used as an index to assess the 
activation of this pathway (Watkins et al., 2012; Ungefroren et al., 2011; Mavrakis et 
al., 2007; Bitzer et al., 2000). HAoAF were seeded onto glass coverslips in DMEM 
supplemented with 10% FCS. Once appropriate confluence was achieved, cells were 
equilibrated in DMEM supplemented with 1% FCS 18 h prior to incubation with TGF-
β1 (2.5 - 5 ng/ml) for 2 h. Cells were subsequently fixed and stained for pSmad2. 
Immunofluorescence staining of HAoAF revealed that pSmad2 is localized diffusely in 
the cytoplasm as well as the nucleus. However, upon treatment with TGF-β1 (2.5 – 5 
ng/ml) for 2 h, cells exhibit increased fluorescence within the nuclear compartment 
indicating that there is an increase in the levels of pSmad2 in the nuclei of TGF-β1-
treated cells. These results suggest that the TGF-β1 signaling pathway may already be 
acutely activated in HAoAF, perhaps due to the autocrine production of TGF-β1 by 
these cells, however when incubated with exogenous TGF-β1, pSmad2 nuclear 
translocation is enhanced and therefore indicative of the activation of this signaling 























































































































































































































































































































































































































































































































































































3.7 Effect of TGF-β1 on HAoAF proliferation 
TGF-β1 is well known to increase proliferation in mesenchymal cells and in fibroblasts 
(Frolik et al., 1983), whilst in SMC, epithelilal and endothelial cells it acts as a growth 
inhibitor (Chen et al., 2006). To assess the effect of TGF-β1 on HAoAF proliferation, a 
cell proliferation assay was carried out. Cells were seeded at a density of 1 x 104 
cells/well in a 24-well plate in DMEM supplemented with 10% FCS. 18 h prior to 
incubation with treatment conditions, cells were equilibrated in DMEM supplemented 
with 1% FCS and subsequently incubated with either low serum media (DMEM 
supplemented with 1% FCS), high serum media (DMEM supplemented with 10% FCS) 
or with TGF-β1 (5 ng/ml) in DMEM supplemented with 1% FCS for a time period of 0-
4 days. Cell number and protein content was determined every 24 h over this time 
period; Figures 3.10, A and B show the differential increase in protein concentration 
and cell number over time. Cells treated with high serum media, exhibited a significant 
increase in cell number over four days (p<0.001); this was correlated with protein 
concentration, which also increased over four days. Similarly, cells incubated with 
TGF-β1 exhibited a significant increase in cell proliferation as measured by cell number 
and protein after 4 days (p<0.001). In contrast to this, cells in low serum media 
exhibited no change in cell number or in protein concentration. When cell number and 
protein concentration were plotted, data exhibited a positive linear correlation 



































Figure 3.12 HAoAF cell proliferation curve following treatment with TGF-β1 
Cells were seeded in 24 well plates in phenol red-free DMEM supplemented with 10% FCS. 
Cells were adapted to DMEM supplemented with 1% FCS for 18 h, 24 h after seeding. Once 
adapted, cells were treated with either phenol red-free DMEM supplemented with 1% FCS, 
phenol red-free DMEM supplemented with 10% FCS or with TGF-β1 (5 ng/ml) added to 
DMEM supplemented with 1% FCS for four days. The (A) average protein concentration and 
(B) cell number was determined every 24 h over four days. Total protein concentrations were 
determined following lysis of cells with NaOH (0.5 M) using the BCA protein assay.  Values 
denote means ± SEM. *p <0.05 vs. control, **p <0.01 vs. control, ***p <0.001 vs. control using 
unpaired Student’s t-test. n = Representative of 4 independent cell cultures. 




















Figure 3.13 Correlation of cell number with protein concentration in cultured HAoAF  
Cells were seeded in 24-well plates in phenol red-free DMEM supplemented with 10% FCS. 
Cells were adapted in DMEM supplemented with 1% FCS for 18 h, 24 h after seeding. Once 
adapted, cells were treated with either phenol red-free DMEM supplemented with 1% FCS, 
phenol red-free DMEM supplemented with 10% FCS or with TGF-β1 (5 ng/ml) for four days. 
Values represent correlation of mean data shown in Fig 3.10. n = 6 independent experiments, 





















3.8 Effect of TGF-β1 on activation of Smad-independent signalling  
      pathways  
In addition to Smads, TGF-β1 also modulates other downstream cellular signalling 
pathways through either phosphorylation or via direct interaction, including various 
branches of MAP kinase and phosphatidylinositol-3-kinase (PI3K)/Akt pathways 
(Bakin et al., 2000; Simeone et al., 2001; Zhang et al., 2009). It has also been postulated 
that the activation of the Nrf2/ARE signalling pathway may be regulated by several 
kinases including phosphorylation of Erk 1/2  (Cullinan et al., 2003; Araujo et al., 
2010), p38MAPK and Akt/PI3K pathways (Zipper et al., 2000; Zipper et al., 2003; 
Papaiahgari et al., 2006). Therefore, in order to determine whether TGF-β1 activates 
Smad-independent pathways in HAoAF and whether activation of these may lead to 
phosphorylation events that may trigger activation of the Nrf2/ARE pathway, 
phosphorylation of kinases was investigated in HAoAF. Confluent HAoAF (were 
equilibrated in DMEM supplemented with 1% FCS 18 h prior to treatment with TGF- 
β1 (5 ng/ml) or SFN (5 μM) for 1 – 4 h. Subsequently, cells were lysed and total cell 
protein was extracted and assessed using SDS-PAGE and Western blot analysis (see 
Methods section 2.2). 
 
Following treatment of HAoAF with TGF-β1 for 1 – 4 h, there was a significant 
increase in pAkt protein expression when compared to untreated control (p<0.05). This 
increase was observed 1 h after treatment and continued to increase with maximum 
protein expression was observed after 2 h (p<0.01). At 4 h, this decreased slightly, 
however remained significantly upregulated when compared to untreated control 
(p<0.05). There was no increase in pAkt seen in untreated control cells (Fig 3.12). SFN 
(5 μM) also caused an increase in pAkt, (p<0.05) and continued to increase after 4 h 
(p<0.01). This suggests that both TGF- β1 and SFN activate the PI3K/Akt signalling 
pathway in HAoAF.  
 
The protein expression of pErk 1/2 was also investigated. Basal expression of protein 
expression of pErk was observed in HAoAF in untreated control after 30 min. This 
expression decreased over time, and was seen to decrease in a time-dependent manner 
after 1 h. Similarly, after 30 min of TGF- β1 treatment, protein expression of pErk was 
observed after 30 min, an effect which had markedly decreased after 4 h. This response 
to TGF- β1 was not statistically significant when compared to untreated control (Fig 




3.13). HAoAF treated with SFN expressed pErk 30 min after treatment which was 
sustained for 2 h following treatment but which decreased after 4 h, however this 
decrease was not statistically significant.  
 
There was also some basal protein expression of p-p38MAPK in HAoAF that was 
sustained for up to 2 h and had increased after 4 h in untreated control cells. In TGF- β1 
treated cells, there was an increase in p-p38MAPK 30 min following treatment which 
continued to decrease after 2 h, though this decrease was not statistically significant. 
SFN treated cells exhibited an increase in p-p38MAPK after 30 min and this increase was 
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Figure 3.14 Phosphorylated Akt protein expression in HAoAF after treatment with TGF-
β1 or SFN. Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 
1% FCS and subsequently treated with TGF-β1 (0 -5 ng/ml) or SFN (5 μM) for 30 min – 4 h 
prior to whole cell protein extraction. Phospho-Akt protein expression levels in these samples 
was assessed using SDS-PAGE and Western blot analysis (A). Results were analysed by 
densitometry with pAkt protein levels corrected for the loading control, total Akt (B). Values 
denote means ± SEM, *p <0.05 TGF- β1 vs. control, **p <0.01 TGF- β1 vs. control, #p <0.05 
TGF- β1 vs. control, ##p <0.001 SFN vs. control using unpaired Student’s t-test. n= 3 
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Figure 3.15 Phosphorylated Erk protein expression in HAoAF after treatment with TGF-
β1 or SFN. Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 
1% FCS and subsequently treated with TGF-β1 (0 -5 ng/ml) or SFN (5 μM) for 30 min – 4 h 
prior to whole cell protein extraction. Phospho-Erk protein expression levels in these samples 
was assessed using SDS-PAGE and Western blot analysis (A). Results were analysed by 
densitometry with pErk protein levels were corrected for the loading control, total Erk (B). 
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Figure 3.16 Phosphorylated p38 MAPK protein expression in HAoAF after treatment with 
TGF-β1 or SFN. Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented 
with 1% FCS and subsequently treated with TGF-β1 (0 -5 ng/ml) or SFN (5 μM) for 30 min – 4 
h prior to whole cell protein extraction. Phospho-p38 protein expression levels in these samples 
was assessed using SDS-PAGE and Western blot analysis (A). Results were analysed by 
densitometry with P-p38 protein levels corrected for the loading control, total p38 (B). Values 
denote means ± SEM. *p<0.05 TGF-β1-treated vs. control (1 h), #p<0.05 SFN-treated vs. 
control (1 h), ##p<0.001 SFN-treated vs. control (2 h) using unpaired Student’s t-test. n= 3 












Vascular disease is partly characterised with changes in the cellular microenvironment 
that actively promote disease development, one characteristic feature of this process 
being fibroblast differentiation (Sampson et al., 2011). Differentiation of fibroblasts to a 
myofibroblast phenotype is a well established sequence of events (Hu and Xu, 2011) 
and is initiated upon vascular injury, causing the release of cytokines, including TGF-
β1, from resident cells (Werner and Grose, 2003). The process takes place in the arterial 
adventitia and results in myofibroblast formation, a cell type that has migratory and 
contractile properties partly owing to the de novo expression of α-smooth muscle actin 
and vimentin and consequent actin cable formation and the expression of focal 
adhesions, events which, in concert, facilitate the pathophysiological role of this cell 
type (Engel et al., 1997; Stephens et al., 1997). During vascular disease and in response 
to TGF-β1, myofibroblasts migrate towards the neointima and contribute to adverse 
vascular remodelling (Enzerink et al., 2011), therefore in this chapter, HAoAF were 
characterised and the effect of TGF-β1 on HAoAF was investigated. 
 
3.9.1 Expression of α-smooth muscle actin and vimentin in HAoAF 
Fibroblasts acquire contractile stress fibres in response to mechanical challenge, which 
are composed of the cytoplasmic actins, β and γ-actins, a feature that is characteristic of 
the ‘protomyofibroblast’. This phenotype is an intermediate step in in vivo vascular 
models of disease and usually proceeds toward the ‘differentiated myofibroblast’ (Hinz 
et al., 2007). Further differentiation results in a cell type that has migratory and 
contractile properties and is known as the myofibroblast. Several studies have reported 
the myofibroblastic transformation of vascular fibroblasts in vitro (Li et al., 2007; 
Shephard et al., 2004; Masur et al., 1996). Therefore, in order to establish the phenotype 
and morphology of cells being used for this study, the protein expression of α-smooth 
muscle actin and vimentin in HAoAF was investigated using immunofluorescence and 
Western blot analysis. Immunofluorescence analysis revealed the basal expression of 
both of these myofibroblast marker proteins by HAoAF. (Fig 3.1 and 3.4). Similarly, 
Western blot analysis revealed the basal expression of both α-smooth muscle actin and 
vimentin, the expression of which did not change with treatment of cells with 
exogenous TGF-β1 (Fig 3.2 and 3.4). These results suggest that cells had differentiated 
into myofibroblasts, possibly through the process of cell culture (Hinz et al., 2009; 
Wipiff et al., 2007).  




The release of endogenous TGF-β1 by fibroblasts in culture has been widely reported in 
the literature and has been shown to result in fibroblast differentiation (Hinz et al., 
2007; Li et al., 2007; Shephard et al., 2004). Masur and colleagues postulate that 
although the presence of TGF-β1 is necessary for the differentiation of fibroblasts to 
myofibroblasts in culture, it alone is not sufficient since, in addition to the presence of 
this growth factor, the lack of cell-cell contacts is also required for myofibroblastic 
transformation to occur (Masur et al., 1996). Their study in corneal fibroblasts revealed 
that cells seeded at lower density (5 cells per mm2) produced a cell culture population 
consisting of 70-80% myofibroblasts, 5-7 days after seeding however, cells seeded at a 
high density (500 per mm2) produced cultures with only 5-10% myofibroblasts (Masur 
et al., 1996). In the current study, HAoAF were cultured at a sub-confluent density; 
although cells in culture were not completely devoid of cell-cell contact, in comparison 
to in vivo conditions, and coupled with other culture conditions, as discussed below, it 
may, in part, explain the myofibroblast phenotype exhibited under basal conditions by 
these cells.  
 
Other studies have also reported differentiation of cells through the cell culture process. 
Investigation of rat hepatic fibroblasts in culture revealed that this cell type also 
underwent differentiation in vitro, with increased staining of α-smooth muscle actin 
observed on day 4 of culture which progressively increased over time. Further analysis 
using qRT-PCR also demonstrated the development if α-smooth muscle actin 
expression over time in culture (Li et al., 2004). This differentiation was seen to be 
TGF-β1-dependent since use of a TGF-β1 receptor kinase inhibitor which antagonised 
autocrine TGF-β1 signalling, resulted in the attenuation of the differentiation of 
fibroblasts into myofibroblasts, as measured by α-smooth muscle actin expression (Li et 
al., 2007). The same study postulated that this differentiation was a function of 
mechanical stiffness, i.e. the stiffness of the substrate upon which cells were plated. It 
was observed that fibroblasts plated on gels of increasing stiffness underwent 
myofibroblastic differentiation, with α-smooth muscle actin being more readily 
incorporated into stress fibres, accompanied by cell spreading and increased expression 
of pro-collagens I and III (Li et al., 2007). 
 
In culture, fibroblasts may become ‘activated’ by rigid cell culture vessel plastic and 
acquire α-smooth muscle actin-positive stress fibres, an effect which is not exhibited by 




cells cultured on soft culture substrates (Hinz, 2012). The first report of this 
phenomenon came from a study in NIH3T3 fibroblasts that observed that cells detected 
and responded to soft and stiff substrates (Pelham and Wang, 1997) with cells cultured 
on a soft substrate generating well-separated myotubes with actomyosin appearing 
diffuse, however, cells grown on a stiff substrate began to acquire abundant stress fibres 
and strong focal adhesions after only a few days in culture (Discher et al., 2005; Pelham 
and Wang., 1997). Cell shape was also distinctly different; on the more rigid substrate, 
cells were well spread, however, those grown on increasingly flexible substrates were 
less so and displayed an irregular shape, different to the atypical spindle shape 
displayed by undiffentiated fibroblasts (Pelham and Wang, 1997). These studies suggest 
that substrate stiffness may be partly responsible for the cytoskeletal re-organisation 
seen in fibroblasts undergoing differentiation and may be an important factor with 
further implications on cell migration in culture conditions (Buxboim et al., 2010; 
Discher et al., 2005; Engler et al., 2004). These reports partly explain the myofibroblast 
phenotype exhibited by HAoAF observed in the current sudy, a phenomenon which 
may be due to the conditions in which cells were cultured.   
 
In contrast, other studies have reported that in culture, cells remain undifferentiated and 
only differentiate upon exposure to TGF-β1. Results from this study are not consistent 
with those observed in cultured human colon-derived fibroblasts, where untreated cells 
exhibited no myofibroblast markers, however upon treatment of cells with TGF-β1, 
cells underwent myofibroblastic transformation and exhibited an increased expression 
of α-smooth muscle actin and myofibroblast contractility which were accompanied by 
the release of collagen type I when compared to untreated cells (Denys et al., 2008).  
However, other studies have revealed that TGF-β1 may not completely account for the 
process myofibroblastic transformation and that mechanical force generation, culture 
medium containing high levels of serum and other growth factors may also be involved 
as demonstrated by a keratinocyte-fibroblast co-culture model (Shephard et al., 2004). 
In this co-culture model, TGF-β1 alone was insufficient in causing fibroblast 
differentiation, however in the presence of a stiff substrate, and in synergy with 
granulocyte-macrophage colony stimulating factor, fibroblasts began to express α-
smooth muscle actin (Shephard et al., 2004). Results reported in the literature and work 
from the current study suggest that the culture conditions, substrate stiffness and length 




of time in culture may all have played a role in the differentiation of HAoAF into 
myobroblasts in this study.  
 
It must be noted that the origin of the cells used in the current study carries several 
experimental limitations. The manufacturer (Lonza, USA) stated that cells had 
undergone routine characterization and had stained negative for smooth muscle α-actin, 
a common marker used for the identification of a smooth muscle cell morphology 
(Enzerink and Vaheri, 2011; Tomasek et al., 2002; see Chapter 3 discussion). However, 
although this is the case, it was also stated that the cultures generated from these cells 
could be used for the study of disorders of fibrosis, scleroderma, fibrosarcoma, 
xeroderma pigmentosum and histiocytoma. This may indicate that the results reported 
in this study regarding the effects of TGF-β1 may not be HAoAF specific and that TGF-
β1 may have similar effects on non-aortic fibroblasts. Future work in non-aortic 
fibroblasts, such as dermal fibroblasts, in order to determine an experimental 
comparison would need to be carried out.  
 
3.9.2 Effect of TGF-β1 and SFN on mitochondrial dehydrogenase activity in  
         HAoAF  
Studies have previously reported that TGF-β1 is able to increase the proliferation of 
fibroblasts in vitro (Zang et al., 2006) whereas others have reported that TGF-β1 is an 
antiproliferative cytokine (Kim et al., 2002). SFN has also been shown to be 
cytoprotective in mouse embryonic fibroblasts (Akhtar et al., 2012; Higgins et al., 2009) 
whilst also demonstrated as being a cytotoxic agent by other studies (Doudican et al., 
2010; Sestili et al., 2010). Therefore in order to determine the effect of TGF-β1 and 
SFN on HAoAF viability, the colorimetric MTT assay was employed. Cells were 
treated with TGF-β1 (2.5 – 10 ng/ml) or SFN (2.5 – 10 μM) for 24 h and subsequently 
the MTT assay was carried out. Results indicated that treatment with TGF-β1 resulted 
in no changes in mitochondrial dehydrogenase activity when compared to untreated 
control. HAoAF treated with SFN also displayed no significant changes in 
mitochondrial dehydrogenase activity when compared to untreated control.  
 
Previous studies using the MTT assay have also shown that TGF-β1 does not suppress 
cell growth; in nasopharyngeal carcinoma cells treated with TGF-β1, there was no 
effect on growth despite observed nuclear translocation of pSmad2, indicating that 




TGF-β1 signalling pathways were activated in this cell type (Xiao et al., 2010). Similar 
results have been reported in ovarian cancer cells, where cells exhibited no significant 
growth inhibition in response to TGF-β1 (5 ng/ml) as measured by the MTT assay, 
despite activation of the TGF-β1 signalling pathway, as determined by phosphorylation 
of the type I TGF-β1 receptor (Yamada et al., 1999). A more recent study in keloid 
fibroblasts has shown that exposure to TGF-β1 (5 ng/ml) for 24 h resulted in no change 
in cell viability or alteration in proliferation when compared to untreated control (Wu et 
al., 2012). In contrast to these findings, the anti-proliferative activity of TGF-β1 has 
been reported in other cell types. In NRK-49F fibroblasts, a fibroblast cell line derived 
from a mixed population of fibroblasts, TGF-β1 caused a dose-dependent decrease in 
cell number as measured by the MTT assay following exposure to TGF-β1 for 6 – 96 h 
(Weyhe et al., 2007). The authors attributed this phenomenon as being cell type-
dependent as well as being partly due to culture conditions such as substrate material 
and noted that it was in contrast with the existing literature (Weyhe et al., 2007).  
However, the concentration of TGF-β1 that fibroblasts were exposed to in this 
particular study was supra-physiological (25 ng/ml – 50 ng/ml), and similar levels that 
would only be seen in pathophysiological conditions such as in end-stage systemic 
sclerosis or advanced atherosclerotic lesions and may in-part explain these contrasting 
findings (Dziadzio et al., 2005; McCaffery, 2000).  
 
Additionally, in human limbal epithelial cells, TGF-β1 (1 ng/ml) has been shown to 
decrease cell viablility and was thought to do so by antagonising the ability of 
epidermal growth factor to stimulate corneal cell proliferation as well as by 
upregulating the expression of the cyclin-dependent kinase inhibitors, p57 and p15 
(Chen et al., 2006). There is evidence in the literature which points to TGF-β1 being a 
growth suppressor by decreasing cell viability as well as increasing cell growth as 
measured by the MTT assay, however, the effect of TGF-β1 appears to be a cell-type 
and TGF-β1 concentration and time-dependent event. Existing evidence in the literature 
suggests that TGF-β1 is a growth-inhibitor for epithelial cell cultures whilst acting as a 
powerful growth factor for mesenchymal cells (Bhowmick et al., 2003; Wenner and 
Yan, 2003; Moses et al., 1992). In VSMC and endothelial cells, TGF-β1 has been 
reported to inhibit proliferation (Halloran et al., 1995; Kirschenlohr et al., 1995; Mii et 
al., 1993; Bjorkerud, 1991; Takehara et al., 1987; Baird and Durkin et al., 1986). One 
study has postulated that the antiproliferative effects of TGF-β1 in SMC are due to the 




ability of TGF-β1 to prolong the G2 phase during proliferation of SMC in vitro 
(Grainger et al., 1994).  In the current study, it has been found that TGF-β1 (2.5 -5 
ng/ml) does not increase cell proliferation or decrease cell viability in HAoAF over a 24 
h time-period.  
 
SFN has been demonstrated to cause cytotoxicity in several cell types. In B16F-10 cells, 
a melanoma cell line, increasing concentrations of SFN (1 – 50 g/ml) caused a 
concomitant increase in cytotoxicity and significantly reduced the rate of proliferation 
in these cells (Thejass and Kuttan, 2006). Further investigation in mouse embryonic 
fibroblasts from wild-type and Nrf2 -/- animals revealed that SFN caused a significant 
increase in cell death at concentrations above 3 M in cultures from wild-type animals. 
This effect was markedly enhanced in knockout animals where challenge with SFN 
caused a significant decrease in cell viability, suggesting that the activation of the 
Nrf2/ARE is protective against SFN-induced cytotoxicity in this cell type (Higgins et 
al., 2009). A similar study carried out in a pancreatic tumour cell line has also reported 
that treatment of these cells with SFN resulted in an increase in apoptotic cell death, 
thought to be as a result of SFN antagonising the NFκB pathway, downregulating 
apoptotic inhibitors, and thus decreasing cell viability (Kallifatidis et al., 2009). 
Conversely, one study looking at the effect of SFN against the toxic response of copper 
oxide (CuO) nano-particles in mouse embryonic fibroblasts found that in cells exposed 
to these nanoparticles, there was a dose-dependent decrease in cell toxicity in cells 
treated with SFN (Akhtar et al., 2012). The study postulated that the protective effect of 
SFN against CuO nano-particles was due to the ability of SFN to activate the Nrf2/ARE 
pathway and consequently up-regulate levels of glutathione reductase and GSH in this 
cell type (Akhtar et al., 2012). The effect on SFN as a cytotoxic agent may be harnessed 
and its use as a theraputic agent in diseases such as cancer may be of high therapeutic 
value.   
 
Due to its ability to activate phase II enzymes, SFN may be used as a therapeutic agent 
to prevent or attenuate vascular disease processes such as hypertension. Previously, Wu 
and colleagues have reported that treatment of SMC from spontaneously hypertensive 
rats (SHR) displayed higher oxidative stress when compared to wild-type animals, as 
determined by the expression of HO-1 protein (Wu et al., 2001). However, when treated 
with SFN (0.05 – 1 μM) for 24 h, SMC exhibited an increase in cellular GSH levels and 




experienced a decrease in oxidative stress levels (Wu et al., 2001). Recent evidence has 
also reported the ability of SFN to inhibit neointima formation by targeting adhesion 
molecules such as vascular cell adhesion molecule (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1) through the suppression of NFκB and another 
transcription factor, GATA6, the mRNA and protein expression of both of which was 
reduced in SFN-treated injured carotid artery sections (Kwon et al., 2012). SFN 
treatment of SMC from these animals revealed that both proliferation and migration of 
SMC was inhibited by SFN (Kwon et al., 2012). These results were confirmed in a 
separate study that also suggests that SFN may attenuate SMC proliferation and 
therefore neointima formation by suppressing VCAM-1, the increased expression of 
which is associated with increased proliferation of SMC which eventually leads to 
enhanced atherosclerotic lesion formation (Kim et al., 2012). However, in the current 
study, SFN (2.5 – 10 M) did not cause a significant decrease in cell viability following 
exposure of cells for 24 h, but it must be noted that  the ability of SFN to induce 
cytotoxicity may be a function of cell type, concentration and length of time of exposure 
to this isothiocyanate.  
 
 
3.9.3 TGF-β1 elicits Smad phosphorylation and nuclear translocation in HAoAF 
In order to demonstrate that TGF-β1 was able to activate Smad signalling in HAoAF, 
the phosphorylation of Smad2 was investigated using Western blot analysis. Cells were 
treated with TGF-β1 (2.5 – 5 ng/ml) for 0.5 – 4 h and whole cell protein was extracted 
and Western blot analysis was carried out (Massague, 2012; Hill, 2009; Feinberg et al., 
2005, Fig 3.10). Results demonstrated that exposure to TGF-β1 resulted in the 
significant phosphorylation of Smad2 when compared to untreated control, indicating 
that the Smad signalling pathway is activated downstream of TGF-β1 in HAoAF. In 
order to further confirm the activation of this pathway, immunofluorescence analysis 
was carried out in order to determine the nuclear translocation of pSmad2 in HAoAF, an 
event which is required for the induction of genes downstream of TGF-β1 (Fig 3.11). 
Results showed that in response to TGF-β1, there was enhanced nuclear translocation of 
pSmad2, further confirming the activation of the Smad signalling pathway by TGF-β1 
in HAoAF.  
 
The phosphorylation of Smad2 downstream of TGF-β1 is well established  signalling 
event, and in particular, the phosphorylation of two serine residues in the C-terminus of 




Smad2, Ser465 and 467, in an obligate manner, are required for TGF-β1 signalling to 
occur (Souchelnytskyi et al., 1997). A recent study in keloid fibroblasts that were 
exposed to TGF-β1 (5 ng/ml) for 48 h showed that cells exhibited a sustained activation 
of the Smad signalling pathway in response to this growth factor as demonstrated by the 
phosphorylation of Smad2 and 3 (Wu et al., 2012). In nasal polyp-derived fibroblasts, 
the phosphorylation of Smad2/3 has been shown to be a ROS-dependent process as 
exposure of cells to TGF-β1 treatment of cells resulted in the production of ROS as 
measured by 2″,7″-dichlorfluorescein-diacetate (DCF-DA) in addition to the 
phosphorylation of pSmad2/3, however treatment of cells with the flavoprotein inhibitor 
diphenyliodonium, or the antioxidants N-acetylcysteine, and ebselen resulted in the 
abrogation  Smad2/3 phosphorylation, suggesting that the activation of this pathway 
downstream of TGF-β1 may be partly mediated by ROS (Park et al., 2012). In the 
present study, the potential regulation of Smad2 phosphorylation by ROS was not 
investigated, however, further work investigating this possibility of ROS in affecting 
signalling downstream of TGF-β1 would be novel in HAoAF. 
 
In HAoAF, a basal expression and nuclear translocation of pSmad2 was observed in 
untreated control cells. Several studies have proposed that the activation of the Smad 
signalling pathway occurs during myofibroblast differentiation (Usuki et al., 2012; Gu 
et al., 2007; Hu et al., 2003).  In a murine lung fibroblast cell line, exposure to TGF-β1 
for 24 h resulted in an increase in mRNA levels of α-smooth muscle actin and a 
concomitant increase in mRNA levels of type I collagen, which is typically downstream 
of TGF-β1/Smad signalling. Double immunostaining of cells showed phosphorylation 
of Smad2 as well as an increase in α-smooth muscle actin expression suggesting that 
differentiation of this cell type was closely related to Smad2 phosphorylation and its 
nuclear translocation (Usuki et al., 2012). An additional study in human fetal lung 
fibroblasts demonstrated that the overexpression of Smad3 markedly increased TGF-β1-
induced α-smooth muscle actin promoter activity and α-smooth muscle actin expression 
in vitro, an effect that was abrogated in the presence of the overexpression of a 
dominant negative mutant Smad3 or Smad7 (Gu et al., 2007). Gu and colleagues 
postulate the involvement of Smad3 in fibroblast differentiation as cells had undergone 
differentiation and exhibited the expression of myofibroblast markers in culture, as well 
as the basal expression of pSmad2 and its presence in the nucleus in untreated control 




cells which may suggest that these two events may be related (Gu et al., 2007). These 
results are consistent with those reported in the current study. 
 
3.9.4 TGF-β1 results causes HAoAF proliferation 
To determine the effects of TGF-β1 on proliferation in HAoAF, cells were treated with 
TGF-β1 for 1-4 days and cell number was recorded and total cell protein was extracted 
and used as a an indicator of proliferation.  Results showed that TGF-β1 caused a 
significant increase in the average cell protein concentration (p<0.001) and an 
associated increase in average cell number (Fig 3.12) over 4 days when compared to 
untreated control. Since its discovery, TGF-β1 has been widely associated with the 
proliferation of various cell types (Frolik et al., 1983) but in particular, during vascular 
pathophysiology, it is seen as being a key player in the proliferation of fibroblasts. In 
vivo, during transplant vasculopathy performed in rats, qRT-PCR revealed a significant 
upregulation of TGF-β1 and further analysis using immunohistochemistry revealed 
proliferation of fibroblasts and myofibroblasts in the adventitial layer and their 
subsequent migration towards the neointima, an event that was TGF-β1-dependent (Ji et 
al., 2010). Furthermore, in rats, pressure overload induced by a suprarenal aortic 
constriction resulted in the production of myocardial fibrosis as a result of fibroblast 
proliferation in response to increased levels of TGF-β1 mRNA (Kuwahara et al., 2002).  
 
Assessment of myocardial mRNA revealed increased TGF-β1 levels after 3 days, but 
intraperitoneal administration of an anti-TGF-β1 neutralizing antibody subsequently 
prevented myocardial fibrosis, implicating TGF-β1 in driving proliferation in this 
disease model (Kuwahara et al., 2002). In addition to in vivo studies, in vitro studies 
have also confirmed the role of TGF-β1 in enhancing cell proliferation. In fibroblasts 
from a transgenic mouse model in which the TGF-β1 type II receptor is upregulated, it 
was found that exogenous treatment with TGF-β1 resulted in enhanced fibroblast 
proliferation, a finding that was confirmed with immunohistochemistry (Derret-Smith et 
al., 2010). Yijing and colleagues have also demonstrated similar findings in adventitial 
fibroblasts derived from rat aorta where exposure of cells to TGF-β1 for 24 h resulted in 
a two-fold increase in proliferation when compared to untreated control (Yijing et al., 
2012). This increase was coupled with an increase in the protein expression of pErk 1/2, 
known to be upregulated during proliferation of cells (Mebratu and Tesfaigzi, 2009). In 
another study, targeted knockdown of Erk2 using a lentivirus resulted in a marked 




decrease in proliferation in rat joint-adhesion tissue fibroblasts, suggesting that TGF-β1 
activation of Erk1/2 is an important pathway involved in TGF-β1-mediated proliferation 
of fibroblasts  (Li et al., 2009). This is of particular relevance to the current study as 
basal upregulation of pErk was observed in HAoAF and may explain the increase in cell 
proliferation following exposure of cells to TGF-β1. 
 
Although in fibroblasts, TGF-β1 is known to cause cell proliferation, in several different 
other cell types including epithelial, endothelial and hematopoietic cells, it can potently 
inhibit cell proliferation (Elliot and Blobe, 2005). This inhibition of growth, although 
poorly understood, is thought to be due to the ability of TGF-β1 to prevent progression 
through the cell cycle by inducing the expression of cyclin kinase inhibitors p15INK4b 
(Hannon et al., 1994), p21CiP1 (Datto et al., 1995) and p27KIP1 (Polyak et al.,1994) 
which block cyclin and cyclin-dependent kinases from phosphorylating the tumour 
suppressor protein, retinoblastoma protein, allowing the hypophosphorylated form of 
this protein to bind and sequester the E2F transcription factor, as well as directly 
suppressing c-myc expression (Pietenpol et al., 1990).  
 
An increase in oxidative stress can act as a pro-oncogenic-associated stress that 
promotes proliferation and motility (Rachkonda et al., 2010). Loss of MnSOD in mouse 
embryonic fibroblasts increased ROS levels, stimulating cyclins D1 and B1, making 
cells insensitive to antigrowth signals whereas overexpression of MnSOD, resulted in 
the suppression of superoxide levels and facilitated the transition of proliferating cells 
into a quiescent phase (Sarsour et al. 2008). Conversely, in lung fibroblasts, enhanced 
proliferation following exposure to TGF-β1 was not attenuated after treatment with the 
antioxidant N-acetyl-cysteine (Moses et al., 1994). In the current study, cell 
proliferation in the presence of TGF-β1 and an antioxidant was not assessed. Further 
studies looking at the potential of antioxidants to attenuate adventitial fibroblast 
proliferation in the presence of TGF-β1 may offer a window of therapeutic opportunity 
since TGF-β1 has been reported to increase the production of ROS, therefore its 
attenuation may be clinically beneficial (Samson et al., 2011; Sturrock et al., 2006; 








3.9.5 Effect of TGF-β1 on activation of Smad-independent signalling pathways  
It is becoming increasingly evident that in addition to the classical Smad pathway, TGF-
β1 also activates non-Smad signalling pathways including Erk, p38 MAPK and PI3K/Akt, 
which were investigated in this study.  
 
The mechanism by which TGF-β1 causes the activation of the Erk pathway has recently 
been reported as being attributed to the dual specificity of the TGF-β1 type I and II 
receptors that are thought to act as both tyrosine and serine/threonine kinases and 
phosphorylation of tyrosine residues in the activated receptors results in the recruitment 
of several adaptor proteins, possibly Smad7, which have been reported to be involved in 
the Erk signalling pathway (Mu et al., 2012). Erk-MAPKs are thought to interact with 
the canonical Smad signalling pathway by preventing the nuclear translocation of Smad 
proteins which occurs when Erk phosphorylates the linker region in Smads, 
consequently preventing TGF-β1-dependent gene expression (Feng and Derynck, 
2005). In the current study, Erk phosphorylation was observed basally in untreated 
control cells and in TGF-β1 treated cells, it was observed after 30 min of stimulation. 
The kinetics of Erk phosphorylation have been postulated as being cell-type and 
culture-condition dependent with some studies reporting peak Erk phosphorylation 
hours after TGF-β1 stimulation as seen in pancreatic acinar cells (Simeone et al., 2001) 
whilst others have reported phosphorylation after 5-10 min (Olsson et al., 2001; Musci 
et al., 1996). In the current study, Erk phosphorylation was observed basally in 
untreated control cells and in TGF-β1 and SFN-treated groups after 30 min Fig. 3.15). 
A recent study carried out in epithelial and mesenchymal cells and in fibroblasts has 
reported similar findings. Basal phosphorylation of Erk was reported in mesenchymal 
cells, however this activation was not observed in epithelial cells, which required 
exposure to TGF-β1 for it to occur (Hough et al., 2012). The same study reported that 
Erk phosphorylation was necessary for TGF-β1 –dependent fibroblast proliferation 
(Hough et al., 2012). Results from proliferation studies in HAoAF demonstrate that 
proliferation in this cell type is TGF-β1-dependent, and the activation of Erk signalling 
may be a mechanism by which these cells proliferate. These results are supported by 
further evidence in NIH3T3 cells in which fibroblast proliferation and differentiation 
induced by TGF-β1 was an Erk-dependent process as use of an Erk 1/2 inhibitor 
completely abrogated this response in cells (Xiao et al., 2012).  
 




p38MAPK has also been implicated in mediating cell proliferation in conjunction with 
Erk1/2. Airway SMC treated with TGF-β1 (1 ng/ml) exhibited increased [3H]-
thymidine incorporation and cell number over 48 h whilst also exhibiting a significant 
increase in phosphorylated p38 and Erk1/2 after 1 h of treatment. Treatment of cells 
with p38 or Erk1/2 inhibitors significantly abrogated TGF-β1-induced DNA synthesis 
in these cells suggesting p38 and Erk1/2 phosphorylation is necessary for TGF-β1-
dependent proliferation in this cell type (Chen and Kalil, 2006). 
 
There is also a plethora of evidence to suggest a role of PI3K in TGF-β1 signalling. In 
the current study, the downstream effector of PI3K, Akt was observed to be rapidly and 
significantly phosphorylated in HAoAF exposed to TGF-β1 after 1 h of treatment (Fig 
3.12, p<0.05 TGF- β1 vs. control and p<0.01 TGF- β1 vs. control at 2 h). This 
phosphorylation by TGF-β1 has been previously reported as being due to the 
constitutive association of the TGF-β1 type II receptor with p85, a regulatory subunit of 
PI3K (Yi et al., 2005). Upon TGF-β1 binding to the receptor, p85 also associates with 
the TGF-β1 type I receptor and activates PI3K consequently activating a downstream 
signalling cascade (Yi et al., 2005). The downstream PI3K/Akt pathway has been 
implicated in being involved in TGF-β1-induced EMT with one study reporting that it 
was necessary for the TGF-β1-mediated actin filament reorganisation and consequent 
cell migration seen during epithelial-mesenchymal transition (Bakin et al., 2000). As 
well as this, PI3K/Akt activation has also been postulated to play a role in TGF-β1-
mediated fibroblast proliferation as pharmacological inhibition of this kinase results in 
an abrogation in TGF-β1-mediated morphological alterations and cell proliferation in 
fibroblasts (Wang et al., 2005; Daniels et al., 2004). These studies suggest that 
PI3K/Akt activation is an important downstream pathway by which TGF-β1 exerts its 
mitogenic effects in fibroblasts. In the context of the current study, this pathway may be 
involved in the TGF-β1-dependent proliferation of HAoAF, however, further studies 
examining the effects of pharmacological inhibition of PI3K/Akt are required in order 
to confirm this.   
 
A number of studies have reported the ability of SFN to effect the activation of Erk and 
p38 pathways. In the present study, SFN was observed to significantly increase the 
protein levels of phosphorylated Akt (p <0.05 SFN vs. control and p <0.01 SFN vs. 
control) as well as increasing phosphorylated p38 in a time-dependent manner; 




however, Erk phosphorylation was upregulated after 30 min of exposure to SFN (Figs 
3.12 and 3.13). It is apparent from previous studies that the effect of SFN on these 
various kinase pathways is dependent upon several different factors, including cell type, 
period of time of exposure and the concentration of SFN that cells are exposed to. In 
human HepG2 cells, SFN (20 μM) has been reported to activate Erk1/2 phosphorylation 
whilst strongly suppressing phosphorylation of p38 (Keum et al., 2006). The authors 
also postulated that stimulation of p38 in these cells resulted in a greater interaction of 
Nrf2 with its inhibitory protein, Keap1, suggesting that SFN-mediated activation of this 
antioxidant pathway was partly regulated by SFN-mediated suppression of p38 (Keum 
et al., 2006). The ability of SFN to augment antioxidant signalling downstream of Nrf2 
may be of therapeutic relevance as this modulation of an endogenous antioxidant 
pathways can offer increased cytoprotection against oxidative stress, something that 
exogenous antioxidants have not been able to achieve (Kris-Etherton et al., 2004; 
Steinberg 2000). However the disparity of the effects of SFN in different cell types 
highlights the complexity of its actions on cell signalling and must be taken into account 
when considering it for therapeutic use. This disparity is reflected in a study 
investigating its effects on adipocytes exposed to SFN (0 – 20 μM) for up to 48 h where 
SFN was reported to decrease the phosphorylation of Erk 1/2 and Akt, an effect that 
resulted in cell cycle arrest at the G0/G1 phase (Choi et al., 2012). A more recent study 
carried out in VSMC has reported that 2 h pre-treatment of cells with SFN (1-5 μg/ml) 
resulted in a dose-dependent inhibition of TNF-α-induced adhesion of THP-1 
monocytic cells and protein expression of VCAM-1 coupled with an associated 
suppression of TNF-α-induced production of intracellular ROS and suppression of 
phosphorylation of p38, Erk and JNK (Kim et al., 2012). The anti-inflammatory actions 
of SFN observed in this study further point to the potential therapeutic use of this ITC in 
modulating endogenous antioxidants with its use being of particular relevance to 
cardiovascular disease. 
 
Chuang and colleagues have shown that SFN inhibited PI3K signalling in platelets, and 
in culture was able to significantly reduce thrombus formation on a collagen-coated 
surface under flow conditions (Chuang et al., 2013). The underlying mechanism of this 
inhibition was postulated to be the ability of SFN to cause the ubiquitination of the p85 
regulatory subunit of PI3K, thereby preventing its translocation to the membrane for 
signalling events to occur, as well as causing the ubiquitination and degradation of 




phosphoinositide-dependent kinase 1 which is required for Akt activation (Chuang et 
al., 2013). The underlying mechanisms of MAPK activation by SFN were not 
investigated in this study but further work examining these may offer a clearer 
understanding of how SFN modulates the activation of various signalling cascades in 
HAoAF. The increase in pAkt in response to SFN in HAoAF may suggest a possible 
alternative route by which SFN may phosphorylate Nrf2, thereby activating the 
Nrf2/ARE pathway, as has also been reported elsewhere (Zheng et al., 2011). 
 
This chapter has provided evidence of the effects of TGF-β1 on HAoAF in culture 
conditions. Exposure of cells to TGF-β1 results in the activation of the Smad signalling 
pathway in this cell type as well as the activation of several Smad-independent 
signalling pathways. Stimulation of HAoAF with TGF-β1 did not appear to alter the 
phenotype of these cells in culture and it was demonstrated that these cells had fully 
differentiated into a myofibroblast cell type. TGF-β1 has also been shown to increase 
cell proliferation and activate several Smad-independent pathways which were also 












CHAPTER 4:  
Results 
 





CHAPTER 4: Activation of redox signalling in human aortic adventitial 





Adventitial fibroblast (AF) migration and proliferation contributes to medial 
hypertrophy following vascular injury (Siow et al., 2003; Li et al., 2000) and there is 
increasing evidence to suggest that adventitia-derived reactive oxygen species (ROS) 
can act as signalling molecules to enhance this migration (Cascino et al., 2011; Haurani 
and Pagano, 2007). The cytokine, TGF-β1 is a key regulator of remodelling in vascular 
diseases, contributing to AF migration, a process that may occur in concert with 
enhanced ROS generation (Siow and Churchman, 2007). The Nrf2/ARE pathway is one 
of the most important antioxidant pathways within a cell that acts to restore redox 
balance following excess ROS production. Under normal physiological conditions, Nrf2 
is sequestered in the cytoplasm by its inhibitory protein, Keap1 and is subject to 
proteasomal degradation (Itoh et al., 1999; McMahon et al., 2003). However Nrf2 
activation, as a result of disruption of the complex formed between Keap1 and Nrf2 is 
an important mechanism of defence against oxidative and xenobiotic stress (Motahashi 
et al., 2004) and results in the accumulation of Nrf2 in the nucleus, dimerization with 
small Maf protein and its binding to the ARE in the promoter region of target genes and 
their consequent transcriptional activation (Osburn and Kensler, 2008).  
 
Heme oxygenase-1 (HO-1) is one of the many Nrf2-regulated genes and is a rate 
limiting, stress inducible enzyme that has previously been shown to confer protection 
against oxidative injury whilst maintaining tissue homeostasis (Morita, 2005; Ning et 
al., 2002). Its role in catalysing the degradation of heme to yield bilirubin, carbon 
monoxide and free ferrous iron has been reported as being protective in rodent models 
of ischemia reperfusion injury and intimal hyperplasia following balloon injury 
(Otterbein et al., 2003). The importance of this antioxidant enzyme has been exhibited 
in HO-1 knockout mice where absence of HO-1 results in increased cell death and 
accelerated neointima formation due to enhanced vascular smooth muscle cell migration 
(Yet et al., 2003).  
 
The flavoenzyme, NAD(P)H-quinone oxireductase (NQO1) is another Nrf2-regulated 
antioxidant gene and the depletion or knockdown of NQO1 is associated with increased 





oxidative stress and predisposition to disease (Li et al., 2012). In vitro and in vivo 
studies carried out in human and rodent models have consistently reported that NQO1 is 
one of the most robustly inducible genes amongst the battery of Nrf2-regulated 
antioxidant enzymes and a number of pharmacological inducers of the Nrf2/ARE 
pathway have been shown to induce NQO1 mRNA and protein levels (He et al., 2011; 
Higgins et al., 2011; Suh et al., 2004). Recently, a number of studies in animal models 
have reported the potential protective role NQO1 plays in cardiovascular injury and 
atherogenesis, therefore investigating its induction in HAoAF in response to TGF-β1 
and SFN is an important indicator of the induction of the Nrf2/ARE pathway (Zhu and 
Li, 2012). 
 
Glutathione (GSH) is one of the first lines of defence cells employ in order to protect 
against oxidative stress (Lui et al., 2011). This tripeptide is able to prevent damage to 
important cellular components caused by ROS by serving as an electron donor, itself 
becoming reversibly oxidised. Its reversion back to its reduced form is catalysed by 
glutathione reductase (GSR; Englemann et al., 2005). The ratio of reduced to oxidised 
glutathione within cells is often an indicator of cellular toxicity and measurement of 
GSH depletion is widely used method of assessing the degree of oxidative stress that a 
pharmacological compound induces (Chen et al., 2006; Hissin and Hilf, 1976). 
Glutamate cysteine ligase (GCL) is a heterodimeric enzyme critical in the first step of 
glutathione synthesis and is composed of two proteins; glutamate cysteine ligase 
catalytic subunit (GCLC) and glutamate cysteine ligase modifier subunit (GCLM), both 
of which are transcriptionally regulated by Nrf2 (Yang et al., 2005). The levels of GSH 
and the expression of the component parts of its pathway are accurate indicators of 
levels of stress in a cell or tissue and are a routine measure of cellular toxicity (Hissin 
and Hilf, 1976).    
 
Due to its inducible nature and its biological effects, the Nrf2/ARE pathway plays a 
protective role in the vascular wall against atherogenesis (Morita, 2005) and 
interventions aimed at modulating the activation of this pathway in the vascular wall 
may therefore provide a novel way in which to treat or prevent vascular injury or 
disease.  Previously it has been shown that TGF-β1 activates the Nrf2 antioxidant 
pathway in human aortic smooth muscle cells, resulting in HO-1 protein expression 
(Churchman et al., 2009) as well as causing the depletion of GSH during fibrosis in 





various disease models (Kang et al., 20011; Lui et al., 2004). SFN is a known phase II 
enzyme inducer, as well as causing glutathione depletion in various cell culture and 
animal models and in the current study it was used to activate the Nrf2/ARE pathway 
(Krehl et al., 2012; Oh et al., 2012; Vomhof-Dekrey et al., 2012; McMahon et al., 
2001). Therefore, following the characterisation of HAoAF, as described in Chapter 3, 
this chapter sought to explore the effect of TGF-β1 and SFN on the transcriptional 

































4.2 Nrf2 expression in HAoAF treated with TGF-β1 or SFN 
Total protein and mRNA levels of Nrf2 in whole cell lysates from HAoAF treated with 
TGF- β1 (0-5 ng/ml, 4-8 h) were determined by Western blot analyses and qRT-PCR 
respectively. HAoAF lysates were probed with a Nrf2 specific antibody (Spring 
Bioscience, USA, see Methods section 2.2 and 2.9) which detected two bands at 110 
kDa and 66 kDa. There is evidence to suggest that the mobility of the Nrf2 protein on 
denaturing Tris/glycine buffered SDS gels does not correspond directly to its molecular 
mass of approximately 66 kDa (Nguyen et al., 2009; Li et al., 2005) and may be due to 
an abundance of acidic residues found in Nrf2, causing it to migrate anomalously (Moi 
et al., 1994) to give a band at 110 kDa. Furthermore, in siRNA knockdown experiments 
carried out in this study, a decrease in Nrf2 expression detected at the 66 kDa band has 
been observed. Therefore, all western blot analysis of Nrf2 in HAoAF was based on the 
densitometry of the 66 kDa band (Nguyen et al., 2009). 
 
4.2.1 Nrf2 mRNA levels in HAoAF following treatment with TGF- β1 or SFN 
For the determination of Nrf2 mRNA levels following treatment of HAoAF with TGF- 
β1 (0-5 ng/ml, 4-8 h), confluent HAoAF were equilibrated in DMEM supplemented 
with 1% fetal calf serum (FCS) 18 h prior to treatment for 4 and 8 h, mRNA was 
extracted  (see Methods section 2.9) at two different time-points and qRT-PCR was 
performed. After treatment with TGF- β1 (2.5 ng/ml) for 4 h, there was no change in 
Nrf2 mRNA levels when compared to untreated control. Treatment with TGF-β1 (5 
ng/ml) resulted in a slight decrease in Nrf2 mRNA levels, however this decrease was 
not significant (Fig 4.1) After 8 h of treatment with TGF- β1 (2.5 and 5 ng/ml) there 
was also little change in Nrf2 mRNA levels when compared to untreated control (Fig 
4.1.1b).  
 
As there was little or no significant change in Nrf2 mRNA levels following treatment of 
HAoAF with TGF- β1, suggesting it is a very mild insult in this cell type, HAoAF were 
also treated with the dietary isothiocyanate, sulforaphane (SFN), as a positive control 
and Nrf2 mRNA levels were examined. At 4 h of treatment with SFN, there was a slight 
but not significant increase in Nrf2 mRNA levels when compared to vehicle treated 
cells (DMSO 0.01 %, Fig 4.2).  Interestingly, at 8 h, vehicle treated cells had higher 
Nrf2 mRNA levels when compared to SFN-treated (2.5 – 5 μM) cells (Fig 4.2) and 
levels were lower than those observed at 4 h.  

















Figure 4.1 Effect of TGF-β1 on Nrf2 mRNA levels in HAoAF  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 – 5 ng/ml) for 4 or 8 h. Levels of Nrf2 mRNA in the 
samples were quantified by qRT-PCR and expressed relative to 3 housekeeping genes 
































Figure 4.2 Effect of SFN on Nrf2 mRNA levels in HAoAF  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle control (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4 or 8 h. 
Levels of Nrf2 mRNA in the samples were quantified by qRT-PCR and expressed relative to 3 
housekeeping genes (RPL13A, SDHA and TATABOX). Values denote means ± SEM. n = 6 



















4.2.2 Protein expression of total Nrf2 in HAoAF following treatment with TGF- β1  
         or SFN 
To determine whether treatment of HAoAF with TGF- β1 or SFN elicited changes in 
the levels of Nrf2 protein in cells, confluent HAoAF were equilibrated in DMEM 
supplemented with 1% FCS 18 h prior to treatment with TGF- β1 (0 - 5 ng/ml), vehicle 
control (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4 – 24 h. Subsequently, cells were 
lysed and total cell protein was extracted and assessed using SDS-PAGE and Western 
blot analysis (see Methods section 2.2). In untreated cells, there was basal Nrf2 protein 
expression (Fig 4.3a) at 4 – 24 h. Interestingly, treatment with TGF- β1 (2.5 ng/ml) 
resulted in a decrease in total Nrf2 protein expression when compared with control, with 
total Nrf2 declining after 8 h and then gradually increasing, but remaining below the 
levels observed in untreated control cells. Cells treated with TGF- β1 (5 ng/ml) 
exhibited a further decrease in Nrf2 protein expression at 24 h (Fig 4.1.3b). These 
immunoblot results indicate that TGF- β1 does not significantly alter total Nrf2 protein 
levels in HAoAF when compared with untreated control. 
  
Treatment of cells with SFN (2.5 μM) did not appear to result in an increased protein 
expression of Nrf2 when compared with vehicle control. When treated with a higher 
concentration of SFN (5 μM), cells exhibited increased Nrf2 protein expression after 12 
h which appeared to plateau after 12 h (Fig 4.1.4b). Although protein expression in 
response to SFN (5 μM) was higher than that seen in untreated control, it was not a 































Figure 4.3 Nrf2 protein expression in HAoAF after treatment with TGF-β1  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 – 5 ng/ml) for 4 - 24 h prior to whole cell protein 
extraction. Total Nrf2 protein levels in these samples were assessed using SDS-PAGE and 
Western blot analysis. Results were analysed by densitometry with Nrf2 corrected for the 
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Figure 4.4 Nrf2 protein expression in HAoAF after treatment with SFN  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle control (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4 - 24 h prior 
to whole cell protein extraction. Total Nrf2 protein levels in these samples were assessed using 
SDS-PAGE and Western blot analysis. Results were analysed by densitometry with Nrf2 
corrected for the loading control, α-Tubulin. Values denote means ± SEM, n= 3-5 independent 















4.3 HO-1 expression in HAoAF treated with TGF-β1 or SFN 
4.3.1 HO-1 mRNA levels in HAoAF following treatment with TGF- β1 or SFN 
As HO-1 is an antioxidant enzyme and is transcriptionally regulated by Nrf2, amongst 
other transcription factors (Jadhav et al., 2008; Lin et al., 2007; Morita, 2005), the levels 
of HO-1 mRNA following treatment of HAoAF with TGF- β1 (0 – 5 ng/ml) for 4 and 8 
h were examined. After 4 h of treatment with TGF- β1 (2.5 and 5 ng/ml) there was no 
change in HO-1 mRNA levels when compared to untreated control (Fig 4.5). Similar 
observations were made following exposure of HAoAF to TGF- β1 (2.5 and 5 ng/ml) 
for 8 h, however, interestingly, there was a decrease in HO-1 mRNA levels across all 
treatments after 8 h of treatment (Fig 4.5), although this was not significant. 
 
In cells treated with SFN (2.5 and 5 μM), a dose dependent increase in HO-1 mRNA 
levels was observed when compared with vehicle control (DMSO 0.01%), however this 
increase was non-significant (Fig 4.6). After 8 h, HAoAF treated with vehicle (DMSO 
0.01%) or SFN (2.5 μM) exhibited increased HO-1 mRNA levels when compared to 
cells treated with the same treatments for 4 h. Conversely, treatment of HAoAF with 
SFN (5 μM) for 8 h resulted in a decrease in HO-1 mRNA levels when compared to 4 h 









































Figure 4.5 HO-1 mRNA levels in HAoAF after treatment with TGF-β1 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS for 
18 h and subsequently treated with TGF-β1 (0 – 5 ng/ml) for 4 or 8 h. Levels of HO-1 mRNA in 
the samples were quantified by qRT-PCR and expressed relative to 3 housekeeping genes 
































Figure 4.6 HO-1 mRNA levels in HAoAF after treatment with SFN 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4 or 8 h. Levels of 
HO-1 mRNA in the samples were quantified by qRT-PCR and expressed relative to 3 
























4.3.2 Protein expression of HO-1 in HAoAF following treatment with TGF- β1 or     
         SFN 
In addition to assessing the changes in mRNA levels of HO-1 in response to TGF- β1 or 
SFN, HO-1 protein levels were determined in HAoAF cell lysates treated with TGF- β1 
or SFN. Confluent HAoAF were equilibrated in DMEM supplemented with 1% FCS 18 
h prior to treatment with TGF- β1 (0 - 5 ng/ml), vehicle control (DMSO 0.01%) or SFN 
(2.5 – 5 μM) for 4 – 24 h. Subsequently, cells were lysed and total cell protein was 
extracted and assessed using SDS-PAGE and Western blot analysis. Lysates were 
probed for a HO-1 specific antibody (see Methods section 2.2) and expressed relative to 
α-tubulin. 
 
As shown in Fig 4.7, treatment with three different concentrations of TGF- β1 (2.5 - 10 
ng/ml) resulted in the increased protein expression of HO-1 after 8 h when compared 
with untreated control. Results indicate that 4 h following treatment TGF- β1 there was 
little or no increase in HO-1 protein expression when compared with untreated control. 
After 8 h there was a significant increase in HO-1 protein expression (p<0.05) when 
compared with untreated control and this decreased after 24 h. When the three different 
concentrations of TGF- β1 are compared, 5 ng/ml was the concentration at which there 
was the highest induction of HO-1 protein expression (Fig 4.7B), with 8 h being the 
timepoint at which this induction was statistically significant. These results suggest that 
TGF- β1 (5 ng/ml) caused a significant increase in HO-1 protein expression after 8 h in 
HAoAF. 
 
Treatment with three different concentrations of SFN (2.5 – 10 μM) resulted After 8 h 
there was a significant increase in HO-1 protein expression (p<0.05) when compared 
with untreated control and this decreased after 24 h. Peak induction of HO-1 protein 
expression occurred at 8 h for all concentrations of SFN used to treat cells. These results 
suggest that SFN (5 and 10 μM, 8 h) caused a significant increase in HO-1 protein 
















    A  
                   
 
 





Figure 4.7 HO-1 protein expression in HAoAF after treatment with TGF-β1  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 – 10 ng/ml) for 4 - 24 h prior to whole cell protein 
extraction. Total HO-1 protein levels in these samples were assessed using SDS-PAGE and 
Western blot analysis. Results were analysed by densitometry with HO-1 corrected for the 
loading control, α-Tubulin. Values denote means ± SEM, *p<0.05 TGF- β1 (5 ng/ml) vs. 
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Figure 4.8 HO-1 protein expression in HAoAF after treatment with SFN  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle (DMSO, 0.01%) or SFN (2.5 μM – 10 μM) for 4 - 24 h prior 
to whole cell protein extraction. Total HO-1 protein levels in these samples were assessed using 
SDS-PAGE and western blot analysis. Results were analysed by densitometry with HO-1 
corrected for the loading control, α-Tubulin. Values denote means ± SEM, *p<0.05 SFN (5 and 











4.4 NQO1 expression in HAoAF treated with TGF-β1 or SFN 
4.4.1 NQO1 mRNA levels in HAoAF following treatment with TGF- β1 or SFN 
The transcriptional activation of NQO1 is regulated by Nrf2 (Miller et al., 2012; Oh et 
al., 2012), therefore levels of NQO1 mRNA in HAoAF in response to treatment with 
TGF- β1 (0 – 5 ng/ml) and SFN (2.5 and 5 μM) were determined. The same samples 
that were used to determine Nrf2 and HO-1 mRNA levels were also used to determine 
NQO1 mRNA levels. Following treatment with TGF-β1 (2.5 and 5 ng/ml) for 4 h, there 
was no change in levels of NQO1 mRNA when compared to untreated control (Fig 4.9). 
After 8 h, similar observations were made, however treatment with TGF- β1 (2.5 ng/ml) 
resulted in a decrease in NQO1 mRNA levels, although this was not significant (Fig 
4.9). 
 
NQO1 mRNA levels in cells treated with SFN (2.5 and 5 μM) did not change after 4 h 
in comparison with vehicle control (DMSO 0.01%). This was also observed in cells 
treated for 8 h; although all treatment groups displayed a slight increase in NQO1 levels 
after 8 h of exposure to either vehicle control or SFN when compared to 4 h, this 
increase was not statistically significant. Treatment with SFN (2.5 and 5 μM) for 8 h did 
not increase NQO1 mRNA levels in HAoAF in comparison to vehicle control (DMSO 













































Figure 4.9 NQO1 mRNA levels in HAoAF after treatment with TGF-β1 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 – 5 ng/ml) for 4 or 8 h. Levels of NQO1 mRNA in the 
samples were quantified by qRT-PCR and expressed relative to 3 housekeeping genes 

































Figure 4.10 NQO1 mRNA levels in HAoAF after treatment with SFN 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with vehicle (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4 or 8 h. Levels of 
NQO1 mRNA in the samples were quantified by qRT-PCR and expressed relative to 3 

























4.4.2 Protein expression of NQO1 in HAoAF following treatment with TGF- β1 or  
         SFN 
Expression of NQO1 protein was also determined in HAoAF treated with TGF-β1. 
After 4 and 8 h, treatment of HAoAF with TGF-β1 (2.5 and 5 ng/ml) resulted in a slight 
increase in NQO1 protein expression when compared with untreated control, and these 
levels appeared to decrease after 12 h of treatment (TGF-β1 5 ng/ml). After 24 h, levels 
of NQO1 protein in TGF-β1-treated cells was below that observed in untreated cells 
(Fig 4.11). Changes in NQO1 protein expression in cells following exposure to TGF-β1 
were not statistically significant.  
 
Cells treated with SFN exhibited lower levels of NQO1 protein expression than vehicle 
control (DMSO 0.01%) after 4 and 8 h of treatment (Fig 4.3.4a). This increased after 8 
h and continued to rise after 12 h. After 24 h, SFN-treated cells had higher levels of 
NQO1 protein expression than vehicle control, though this was not statistically 






























        
 
 





Figure 4.11 NQO1 protein expression in HAoAF after treatment with TGF-β1  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 – 5 ng/ml) for 4, 8, 12 or 24 h prior to whole cell protein 
extraction. Total NQO1 protein levels in these samples were assessed using SDS-PAGE and 
Western blot analysis. Results were analysed by densitometry with NQO1 corrected for the 















       
 
 





Figure 4.12 NQO1 protein expression in HAoAF after treatment with SFN  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with either vehicle control (DMSO 0.01%) or SFN (2.5 – 5 μM) for 4, 8, 
12 or 24 h prior to whole cell protein extraction. Total NQO1 protein levels in these samples 
were assessed using SDS-PAGE and Western blot analysis. Results were analysed by 
densitometry with NQO1 corrected for the loading control, α-Tubulin. Values denote means ± 










4.5 Levels of intracellular GSH in HAoAF treated with TGF-β1 or  
SFN 
Intracellular GSH levels are an important indicator of a cell’s redox status and are often 
used as a determinant of whether the cell/tissue has been exposed to oxidative stress. 
Several studies have reported that that TGF-β1 causes a depletion in intracellular GSH 
levels and as a consequence, induces oxidative stress during tissue remodelling or 
fibrotic processes observed in bronchial asthma, chronic pulmonary disease, idiopathic 
pulmonary fibrosis and vascular remodelling (Liu et al., 2012; Sugiura et al., 2009; 
Bakin et al., 2005; White et al., 1992). However, others have reported that TGF-β1 
attenuates glutathione depletion and protects against oxidative stress (Pauly et al., 
2011). Similarly, SFN has also been shown to deplete intracellular GSH levels by 
initially and rapidly conjugating with glutathione-S-transferases (GST; Munday et al., 
2008; Dinkova-Kostova et al., 2007). SFN has also been observed as increasing the 
expression of glutathione reductase by activating the Nrf2/ARE pathway (Xue et al., 
2008) and when administered in the diet, it has been associated with a lower risk of 
myocardial infarction (Cornelis et al., 2007). In order to elucidate the effects of TGF-β1 
and SFN on intracellular GSH levels in HAoAF, cells were treated with TGF-β1 or SFN 
and intracellular GSH levels were measured.  
 
Confluent cultures of HAoAF were equilibrated in DMEM supplemented with 1% FCS 
18 -24 h prior to incubating with TGF-β1 (5 ng/ml), vehicle control (DMSO 0.01%) or 
SFN (5 μM) for a further 0 – 24 h. Intracellular reduced GSH was analysed using a 
fluorescence assay as described in Methods (see Methods section 2.6.1 and 2.6.2). GSH 
levels in cells treated with TGF-β1 remained unchanged when compared to untreated 
control (Fig 4.13).  After 8 h, there was an increase in intracellular GSH levels in both 
untreated control and TGF-β1 treated cells, which returned to baseline after 24 h.  
 
When treated with SFN, there was an initial and significant depletion in intracellular 
GSH levels in SFN-treated cells after 2 – 4 h (p<0.05 SFN vs. control, 2 and 4 h) of 
when compared to control. This initial depletion recovered after 8 h and returned to just 




















Figure 4.13 Glutathione levels in HAoAF treated with TGF-β1 
Cells were treated with TGF-β1 (5 ng/ml) for 2, 4, 8, 24 and subsequently incubated with 6.5% 
TCA. Following incubation, the supernatant was removed from cells and total glutathione levels 
were determined using the opthalaldehyde assay. Glutathione was expressed relative to cellular 















































Figure 4.14 Glutathione levels in HAoAF treated with SFN 
Cells were treated with vehicle (DMSO 0.01%), SFN (5 μM) for 2, 4, 8, 24 and subsequently 
incubated with 6.5% TCA. Following incubation the supernatant was removed from cells and 
total glutathione levels were determined using the opthalaldehyde assay. Glutathione was 
expressed relative to cellular protein content. Values denote means ± SEM, *p<0.05 SFN vs. 



































4.6 Nuclear levels of Nrf2 in HAoAF treated with TGF- β1 or SFN 
Activation of the Nrf2 pathway by oxidants and the consequent downstream 
transcription of antioxidant enzymes is a process that is largely dependent on the 
translocation of Nrf2 to the nucleus and its subsequent binding to the ARE in the 
promoter region of target genes. Therefore, changes in the levels of Nrf2 protein in the 
nucleus can be indicative of activation of the Nrf2/ARE signalling pathway.  The 
following set of experiments sought to determine whether treatment of HAoAF with 
either TGF- β1 or SFN resulted in Nrf2/ARE activation and were assessed using 
Western blot and an ELISA-based binding activity assay (TransAM) of nuclear extracts 
from treated HAoAF. Nrf2-specific immunofluorescence was also carried out in order 
to determine Nrf2 subcellular localisation. It has been reported that nuclear import of 
Nrf2 following stimulation with a biological challenge is a rapid process and can occur 
within 15 min of exposure (Kaspar and Jaiswal., 2010). Furthermore, there is evidence 
to suggest that this initial nuclear import of Nrf2 begins to decline 4 hours after 
exposure to the challenge (He at al., 2011). Therefore, nuclear levels of Nrf2 were 
assessed between 1 – 4 hours of exposure to either TGF- β1 or SFN.  
 
4.6.1 Expression of nuclear Nrf2 in HAoAF following treatment with TGF- β1 or  
         SFN 
To determine whether TGF- β1 or SFN elicited an increase in the translocation of Nrf2 
to the nucleus in HAoAF, confluent HAoAF were equilibrated in DMEM supplemented 
with 1% FCS 18 h prior to treatment for 1 – 4 h. Subsequently cells were lysed and cell 
fractionation was carried out using a commercially available kit in order to obtain 
nuclear extracts (see Methods section 2.4) which were then analysed using SDS-PAGE 
and Western blot. Nuclear Nrf2 levels were expressed relative to lamin C. After 1 h, 
there was no increase in the protein expression of nuclear Nrf2 with either TGF- β1 or 
SFN treatment. There was basal protein expression of Nrf2 in the cytoplasm at 1 h and 
this was significantly higher than Nrf2 protein observed in the nucleus (Fig 4.15; 
p<0.05, untreated control, nuclear vs. cytoplasmic fraction; p<0.05, TGF- β1-treated, 
nuclear vs. cytoplasmic fraction; p<0.01, SFN-treated, nuclear vs. cytoplasmic fraction). 
At 2 h, there was an increase in nuclear Nrf2 levels with both TGF- β1 and SFN treated 
cells when compared to cytosolic levels; an effect that was statistically significant (Fig 
4.16; p<0.05, untreated control, nuclear vs. cytoplasmic fraction; p<0.01, TGF- β1-
treated, nuclear vs. cytoplasmic fraction; p<0.001, SFN-treated, nuclear vs. cytoplasmic 





fraction) as analysed by densitometry. Levels of cytoplasmic Nrf2 appeared to decrease 
when compared to those seen at the 1 h timepoint. After 4 h, levels of nuclear Nrf2 had 
returned to baseline in all groups treated, whilst levels in the cytosol increased 
significantly when compared to nuclear levels (Fig 4.17; p<0.01, untreated control, 
nuclear vs. cytoplasmic fraction; p<0.01, TGF-β1-treated, nuclear vs. cytoplasmic 
fraction; p<0.001, SFN-treated, nuclear vs. cytoplasmic fraction) suggesting that Nrf2 












































Figure 4.15 Nuclear and cytosolic Nrf2 levels in HAoAF following TGF-β1 or SFN 
treatment for 1 h. Confluent HAoAF were equilibrated in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with either TGF-β1 (5 ng/ml) or SFN (5 
μM) for 1 h. Levels of Nrf2 (66 kDa) in (B) nuclear and (C) cytosolic extracts was determined 
by Western blotting. Results were analysed by densitometric analysis and nuclear Nrf2 was 
corrected for the nuclear reference protein, lamin C (62 kDa). Cytosolic Nrf2 levels were 
corrected for α-Tubulin (52 kDa). Values denote means ± SEM. No significant changes were 
observed in Nrf2 levels in treatment vs. control.  
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Figure 4.16 Nuclear and cytosolic Nrf2 levels in HAoAF following TGF-β1 or SFN 
treatment for 2 h. Confluent HAoAF were equilibrated in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with either TGF-β1 (5 ng/ml) or SFN (5 
μM) for 1 h. Levels of Nrf2 (66 kDa) in (B) nuclear and (C) cytosolic extracts was determined 
by Western blotting. Results were analysed by densitometric analysis and nuclear Nrf2 was 
corrected for the nuclear reference protein, lamin C (62 kDa). Cytosolic Nrf2 levels were 
corrected for α-Tubulin (52 kDa). Values denote means ± SEM. *p<0.05, TGF-β1-treated 
nuclear fraction vs. control-treated nuclear fraction; **p<0.01, SFN-treated nuclear fraction vs. 
control-treated nuclear fraction using unpaired Student's t-test. n = 3-5 independent 
experiments. 














Figure 4.17 Nuclear and cytosolic Nrf2 levels in HAoAF following TGF-β1 or SFN 
treatment for 4 h. Confluent HAoAF were equilibrated in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with either TGF-β1 (5 ng/ml) or SFN (5 
μM) for 1 h. Levels of Nrf2 (66 kDa) in (B) nuclear and (C) cytosolic extracts was determined 
by Western blotting. Results were analysed by densitometric analysis and nuclear Nrf2 was 
corrected for the nuclear reference protein, lamin C (62 kDa). Cytosolic Nrf2 levels were 
corrected for α-Tubulin (52 kDa). Values denote means ± SEM. No significant changes were 
observed in Nrf2 levels in treatment vs. control. n = 3-5 independent experiments. 
 
 





4.6.2 Nrf2 immunofluorescence in HAoAF treated with TGF-β1 or SFN 
In addition to Western blot analysis, immunofluorescent staining of Nrf2 was performed 
in HAoAF in order to assess Nrf2 subcellular localisation in response to TGF-β1 (5 
ng/ml) or SFN (5 μM). Immunofluorescence is a widely used technique to determine 
the subcellular localisation of Nrf2 in various cell types (Zhang et al., 2012; Tanaka et 
al., 2011; Papaiahgari et al., 2006; Papaiahgari et al. 2004), which allows the 
simultaneous visualisation of changes within the cytosol and nuclei of cells that have 
been treated with different stimuli. Sub-confluent HAoAF were equilibrated in DMEM 
supplemented with 1% FCS 18 h prior to treatment with TGF-β1 (5 ng/ml) or SFN (5 
μM) for 1, 2 or 4 h and subsequently fixed and incubated with an Nrf2-specific antibody 
(see Methods section 2.4.2). Nuclei were stained with DAPI and F-actin was stained 
with rhodamine-conjugated phalloidin. Nrf2 was localised primarily in the cytosol of 
cells treated with either TGF-β1 (5 ng/ml) or SFN (5 μM) for 1 h and was comparable 
to untreated control (Fig 4.18A, panels G-I). After 2 h of treatment with TGF-β1 (5 
ng/ml), there was an increase in nuclear Nrf2 (Fig 4.4.2b, panel H) when compared to 
that seen in the nuclei of untreated control cells (Fig 4.18B panel G). SFN (5 μM) also 
caused an increase in the nuclear accumulation of Nrf2 after 2 h. After 4 h, in TGF-β1 
(5 ng/ml) treated cells, Nrf2 had moved out of the nucleus and was primarily located in 
the cytosol (Fig 4.18C, panel H); SFN (5 μM) treated cells displayed more diffuse 
staining with Nrf2 located in the cytosol with some remaining in the nucleus (Fig 
4.18C, panel I). This immunofluorescence data is consistent with Western blot analysis 
(Figs. 4.13-4.15) and indicates that Nrf2 nuclear translocation occurs 2 h following 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.6.3 Nuclear Nrf2-ARE binding activity in HAoAF treated with TGF-β1 or SFN 
Although nuclear translocation of Nrf2 is associated with the induction of downstream 
antioxidant enzymes, it does not necessarily directly correlate with Nrf2-mediated gene 
transcription (Kratschmar et al., 2012). Activation of the Nrf2 pathway requires the 
binding of Nrf2 to the ARE in the promoter region of antioxidant genes in order to elicit  
gene transcription. Nrf2 nuclear accumulation occurs 2 h after treatment with TGF-β1 
or SFN; therefore, the binding of Nrf2 in nuclear lysates obtained from cells treated 
with TGF-β1 (5 ng/ml) or SFN (5 μM) for 2 h was investigated using a commercially 
available ELISA assay (Active Motif, see Methods section 2.4). The kit allows 
measurement of binding of the transcription factor in the nuclear extracts to consensus 
ARE oligonucleotides (Afonyushkin et al., 2010). In nuclear extracts from cells treated 
with TGF-β1 (2.5 ng/ml and 5 ng/ml), there was no significant change in nuclear 
binding of Nrf2 to the ARE when compared to untreated control (Fig 4.19A). In SFN 
(2.5 – 5 μM) treated cells appeared to be an increase in Nrf2 binding activity in a dose 
dependent manner. SFN-treated extracts had a significantly increased Nrf2 binding 
activity (Fig 4.19B; p<0.05, SFN (2.5 μM) vs. vehicle control (DMSO 0.01%), p<0.05, 
SFN (5 μM) vs. vehicle control (DMSO 0.01%)). These results indicate that although 
TGF-β1 may cause an accumulation of Nrf2 in the nuclei of HAoAF, this may not be 
indicative of Nrf2-ARE binding and therefore activation of the Nrf2 signalling pathway, 
however SFN treatment results in the binding of Nrf2 to the ARE and is therefore 
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Figure 4.19 ARE-binding activity of nuclear Nrf2 in HAoAF treated with TGF-β1 or SFN  
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (2.5 - 5 ng/ml) or SFN (2.5 – 5 μM) for 2 h. Nuclear extracts 
containing active Nrf2 were then collected using the TransAM nuclear extraction kit and 
binding activity of Nrf2 was investigated using an ELISA based assay for duplicate samples. 
Nrf2 that was bound to the immobilized ARE on the ELISA plate was expressed as absorbance 
values read at 450 nm. Values denote means ± SEM. *p<0.05, SFN (2.5 μM) vs. vehicle and 





















































4.7 Induction of HO-1 in HAoAF transfected with Nrf2 siRNA 
In order to determine whether TGF-β1-mediated HO-1 protein expression was as a 
result of the activation of the Nrf2/ARE signalling pathway, siRNA was performed. 
Cells were seeded and maintained in DMEM supplemented with 10 % FCS. Cells were 
allowed to adhere for 24 h and were subsequently transfected with siRNA. Eight hours 
following transfection, the transfection mixture was aspirated from wells and replaced 
with DMEM supplemented with 1% FCS for overnight equilibration. Cells were then 
treated with TGF-β1 (5 ng/ml) or SFN (5 μM) for 8 hours. HAoAF transfected with 
scramble siRNA and then treated with TGF-β1 or SFN, exhibited an increase in Nrf2 
and HO-1 protein expression when compared to untreated control, however this 
increase was not significant. In cells transfected with Nrf2 siRNA and subsequently 
treated with TGF-β1, there was a significant decrease in Nrf2 and HO-1 protein 
expression (p<0.05) when compared to those cells transfected with scramble siRNA 
(Fig 4.20 B and C). A significant decrease in Nrf2 and HO-1 protein expression was 
also observed in cells transfected with Nrf2 siRNA and subsequently treated with SFN 
(p<0.05 vs. scramble and p<0.01 vs. scramble respectively, Fig 4.20 A, B and C). 
Although cells exhibited a significant decrease in HO-1 protein expression, it was not 
completely abrogated suggesting that TGF-β1 and SFN-induced HO-1 protein 




























Figure 4.20 Effect of Nrf2 siRNA knockdown on TGF-β1 and SFN-mediated HO-1 protein 
expression. HAoAF transfected with Nrf2 or scrambled siRNA were seeded and maintained in 
10% FCS. 24 h after seeding, cells were transfected for 8 h, then equilibrated in 1% FCS for 18 
h prior to treatment with either TGF-β1 (5 ng/ml) and SFN (5 μM) for 8 h. Nrf2 and HO-1 
protein expression levels in whole cell lysates were determined by western blot analysis, (A). 
Representative western blot and quantification of (B) Nrf2 and (C) HO-1 levels were 
determined by densitometry and expressed relative to α-tubulin. Values denote ± SEM, 
$$<p0.01 SFN-treated scramble vs. control-treated scramble, *p<0.05 TGF-β1-treated scramble 
vs. TGF-β1-treated Nrf2 transfected, #p<0.05 SFN-treated scramble vs. SFN-treated Nrf2-
transfected, ##p<0.01 SFN-treated scramble vs. SFN-treated Nrf2-transfected using ANOVA. n 
= 7 independent experiments.  
 






Recent investigations into the pathophysiology of atherosclerosis and restenosis have 
revealed that the previous understanding of the disease processes involved was 
incomplete (Haurani and Pagano, 2007). Early evidence in this area of research 
suggested that the intimal layer and smooth muscle cell (SMC) layer was the main site 
where the inflammatory process was initiated (Schwartz et al., 1997; Ross, 1999; Lusis, 
2000); however, later studies have revealed that the adventitia may in fact be one of the 
sites of the initiation of diseases of the medium and large arteries (Liu et al., 2010; 
Lusis, 2000). The role of growth factors, in particular of TGF-β1 in SMC migration and 
proliferation have been reported in the literature over the past two decades. In particular, 
TGF-β1 has been reported to play a pivotal role in atherogenesis and vascular 
remodelling following angioplasty in humans and models of arterial injury in animals 
(Khan et al., 2007; Chung et al., 2002; Schulick et al., 1998; Nabel et al. 1993) and in 
mediating fibrotic kidney disease as seen during diabetic nephropathy and hypertension 
(Lan and Chung, 2012; Zarjou and Agarwal, 2012). Interestingly, dietary 
supplementation of the isothiocyanate, SFN has been shown to be beneficial in 
increasing basal levels of GSH, glutathione peroxidase (GPx) and glutathione reductase 
(GSR) as well as increasing the protein levels of these Nrf2–regulated antioxidant 
enzymes in vascular SMC (VSMC) from spontaneously hypertensive rats (Juurlink et 
al., 2001). Therefore, this study sought to investigate the effect(s) of both TGF-β1 and 
SFN on HAoAF and the possible role they may play in mediating cellular redox status 
in this cell type.  Results from this study provide novel evidence that TGF-β1 and SFN 
cause the induction of the cytoprotective antioxidant enzyme, HO-1 and nuclear 
translocation of the transcription factor Nrf2 in HAoAF. Furthermore, SFN causes a 
significant increase in Nrf2-ARE binding in HAoAF implicating it in the activation of 
this redox-sensitive antioxidant pathway in this cell type.  
 
4.8.1 Effects of TGF-β1 and SFN on HO-1 and NQO1 induction in HAoAF 
The upregulation of TGF-β1 in atherosclerotic disease has been widely reported with 
the adventitia being implicated as one of the sites of disease initiation (Haurani and 
Pagano, 2007). Dietary SFN has been reported as being beneficial during cardiovascular 
disease, owing to its ability to upregulate several Nrf2-regulated phase II antioxidant 
enzymes. A hallmark of atherosclerotic disease is oxidative stress therefore the purpose 
of this study was to investigate the effect of TGF-β1 and SFN on the redox status of 





HAoAF. Recently, it has been postulated that ROS are released during the phenotypic 
transformation of fibroblasts to myofibroblasts and are important mediating collagen 
deposition that is widely associated with vascular remodelling following injury (Rocic 
and Lucchesi, 2005). TGF-β1 mediates myofibroblastic transformation but it is not 
known whether induction of antioxidant genes, such as HO-1 and NQO1 via Nrf2 is 
involved in this process. 
 
TGF-β1 is widely implicated in a variety of cardiovascular diseases and is secreted by 
all vascular cell types, including endothelial cells, VSMC, macrophages and 
myofibroblasts (Ruiz-Ortega et al., 2007). In culture, VSMC have been reported to 
produce TGF-β1 for their own growth and proliferation (Majesky et al., 1991) and in 
aortic tissue of hypertensive rats, TGF-β1 mRNA levels have been reported to be 
threefold higher than those seen in normotensive animals (Sarzani et al., 1989). Similar 
observations have been made in a model of carotid artery injury where mRNA levels of 
TGF-β1 increased six hours after injury and remained elevated for two weeks following 
injury. This observation was coupled by an increased production of TGF-β1 by SMC 
found in the neointima (Majesky et al., 1991). 
 
Thus this study provides an important insight into the mechanisms underlying adaptive 
responses to TGF-β1 in HAoAF, a cell type of direct relevance to atherogenesis (Liu 
and Kong, 2010; Haurani and Pagano, 2007). When treated with TGF-β1, HAoAF did 
not exhibit an increase in NQO1 mRNA or protein levels (Fig 4.9) and there was also 
no change in HO-1 mRNA levels after 4 h when compared to untreated control, though 
interestingly, levels decreased after 8 h (Fig 4.5). Despite these observations, a time-
dependent increase in HO-1 protein expression was seen in response to TGF-β1 (5 
ng/ml), which peaked after 8 h and which was a statistically significant effect (p<0.05); 
levels returned to slightly below baseline after 24 h (Fig 4.7). Although these results are 
not entirely consistent with evidence in the literature, similar findings have been 
reported in a study in airway SMC, where cells treated with TGF-β1 (1 ng/ml) exhibited 
significant increases in HO-1 protein expression but with no change in NQO1 protein 
levels and little change in HO-1 and NQO1 mRNA levels at 4 and 8 h (Michaeloudes et 
al., 2011).  
 





The underlying mechanisms responsible for the increase in HO-1 protein induction are 
likely to vary between cell-types.  Kutty and colleagues first reported the alteration of 
HO-1 mRNA and protein by TGF-β1 (5 ng/ml) in four different cell types; HeLa cells, 
bovine choroid fibroblasts, bovine corneal fibroblasts and human retinal pigment 
epithelial cells.  A maximal increase in HO-1 protein expression was observed after 8 h 
of treatment in bovine choroid fibroblasts, a finding that is consistent with the present 
study, but which was absent in HELA, bovine corneal fibroblasts and human retinal 
pigment epithelial cells in the same study (Kutty et al., 1994). Other studies have also 
reported a peak increase in HO-1 protein levels after 8 h in response to TGF-β1, for 
example in lung epithelial cells, HO-1 induction in response to a range of TGF-β1 (0-30 
ng/ml) concentrations, peaked at 8 h and was attributed to the activation of the 
transcription factor, NFkB via the PI3K/Akt pathway (Lin et al., 2007).  
 
Although the present study did not observe any significant changes in mRNA levels of 
HO-1, others have shown increases in HO-1 mRNA levels that correlate with a 
concomitant increase in protein. Kapturczak and colleagues have reported that treatment 
with TGF-β1 (2 ng/ml) led to a significant increase in HO-1 mRNA levels after 4 h 
which peaked at 8 h and returned to baseline after 48 h and was accompanied by an 
increase in HO-1 protein expression (Hill-Kapturczak et al., 2000). Although TGF-β1 
elicited increases in HO-1 protein in HAoAF, in contrast to the findings of Hill-
Kapturczak and colleagues, TGF-β1 had no significant effect on HO-1 mRNA levels in 
this present study.  
 
In addition, a study carried out in human aortic smooth muscle cells (HAoSMC), 
Churchman and colleagues reported that in response to treatment with TGF-β1 (2.5 and 
5 ng/ml), there was a significant increase in HO-1 protein expression after 4 h which 
remained elevated for up to 12 h following treatment (Churchman et al., 2009). It was 
also observed that TGF-β1-mediated HO-1 induction was in-part regulated by the Erk 
1/2 and JNK signalling pathways in addition to the classical Smad signalling pathway in 
this cell type. Interestingly, antagonism of TGF-β1 signalling by adenoviral over-
expression of Smad7 (Nakao et al., 1997) resulted in a downregulation of HO-1 protein 
expression, strongly suggesting that there is possible cross-talk between the TGF-β1 
signalling pathway and the induction of HO-1 in HAoSMC (Churchman et al., 2009).  
Similar results have been observed in human proximal tubule cells, where the use of an 





anti-TGF-β1 antibody resulted in a marked decrease in HO-1 mRNA levels when 
compared to cells treated with TGF-β1 alone (1 ng/ml, 8 h) further suggesting that these 
two signalling pathways may interact (Hill-Kapturczak et al., 2000).  
 
Although the majority of studies investigating the effect of TGF-β1 on HO-1 levels are 
consistent with the results reported here in HAoAF, it has also been reported that TGF-
β1 can decrease levels of HO-1 mRNA and protein. In a rat model of endotoxemia, 
LPS-induced HO-1 mRNA and protein were suppressed after the administration of 
TGF-β1 (Pellacani et al., 1998). The same study also reported that rat aortic SMC 
stimulated with IL-1β and then treated with TGF-β1, exhibited a downregulation of IL-
1β-mediated HO-1 mRNA and protein levels as well as a decrease in HO-1 enzymatic 
activity (Pellacani et al., 1998). The present study in HAoAF has found that although 
TGF-β1 treatment results in an increase in HO-1 protein levels, it had no effect on 
mRNA levels. This may be due to the time-point at which these measurements were 
made as other studies have shown changes in HO-1 mRNA levels after treatment with 
TGF-β1 over 2 – 48 h (Hill-Kapturczak et al., 2000; Kutty et al., 1994). The underlying 
mechanism by which TGF-β1 induces HO-1 protein expression is unclear, however 
measuring the enzymatic activity of HO-1 (Moterlini et al., 1996) in response to TGF-
β1 could provide further useful information and allow elucidation of the pathway and 
mechanism by which this induction occurs. 
  
In this study, use of the isothiocyanate, SFN was used as a positive control as its role as 
an Nrf2-inducer has been characterised in several different cell types (Keum et al., 
2006; Keum et al., 2011; Michaeloudes et al., 2011). However, emerging evidence 
recently reported in the literature highlights the possible effects of SFN on the Smad 
signalling pathways (Oh et al., 2012; Chin et al., 2011) highlighting the potential role of 
SFN as an important therapeutic agent in fibrosis, diabetes, chemoprevention and 
vascular disease (Kaminski et al., 2010, Negi et al., 2011; Oh et al., 2012; Keum et al., 
2011). Therefore, induction of antioxidant enzymes by SFN in myofibroblasts may be a 
way of conferring protection from further and on-going oxidative stress in vascular 
diseases and may even be used as a clinically beneficial means of intervention against 
vascular remodelling. In this study, HAoAF were treated with SFN and HO-1 and 
NQO1 mRNA levels and protein expression were analysed.  
 





Observation of NQO1 mRNA (2.5 – 5 µM, 4 – 8 h) and protein (2.5 – 5 µM, 4 – 24 h) 
levels revealed that these did not change in response to SFN in HAoAF (Figs. 4.10 and 
4.12). This finding is in contrast to results previously reported in other cell types, in 
particular, in airway SMC and mouse embryonic fibroblasts where SFN increased 
NQO1 mRNA levels and protein expression (Michaeloudes et al., 2011; Keum et al., 
2006). Analysis of SFN treatment on HO-1 mRNA levels in HAoAF revealed that it 
had no significant effect on these levels (Fig 4.6), however cells exhibited a dose and 
time-dependent increase in HO-1 protein expression, with the highest significant 
increase observed at 8 h after SFN treatment, which returned to basal levels after 24 h 
(Fig 4.8). Similar observations have been made by Keum and colleagues, who reported 
that exposure of mouse embryonic fibroblasts to SFN (5 µM) resulted in an induction of 
HO-1 protein levels 12 h after treatment, which decreased after 24 h. The same study 
showed that treatment of mouse embryonic fibroblasts with SFN was accompanied by a 
significant increase in Nrf2 protein levels and increased ARE-luciferase activity, 
suggesting that HO-1 induction was mediated by the Nrf2-ARE pathway in this cell 
type (Michaeloudes et al., 2011; Keum et al., 2006).  
 
In both TGF-β1 and SFN-treated cells, there was little change in Nrf2 mRNA levels and 
basal expression of Nrf2 protein was unaltered (Figs. 4.1-4.4). This is in-keeping with 
some reports which suggest that Nrf2 is constitutively expressed and whole cell protein 
levels remain unaltered in some cell types (Nguyen et al., 2005). Although this was the 
case, several factors are able to affect the activity of proteins. The quantity of an 
mRNA, its stability or degradation and rates of ribosome initiation all directly impact on 
protein output; degradation of mRNA results in the steady state decrease in the 
expression of the protein (Hargrove and Schmidt, 1989). Without changes at the 
transcription level, mRNA steady-state levels can vary dramatically by small changes in 
mRNA stability, which has recently been shown to be prone to regulation by 
microRNA, which can repress or target degradation resulting in gene silencing (Eades et 
al., 2011). mRNA stability may be a reason for the unchanged levels of Nrf2 in 
response to TGF-β1 and SFN treatment in this study. Other possible post-translational 
modifications include hypermethylation of proteins; hypermethylation of the Keap1 
promoter has been shown to result in Keap1 protein expression and the accumulation of 
nuclear Nrf2 (Kansanen et al., 2013). In addition, the acetylation of Nrf2 by the 
transcription factor CREB, has been observed as increasing it’s binding to its cognate 





response element in a target gene promoter and increasing Nrf2-dependent transcription 
from target gene promoters (Kawai et al., 2011). Post-translational modifications of 
proteins were not investigated in the current study, however future work regarding these 
may shed further light on the levels of protein expression observed here.    
 
Results from other studies suggest that alternatively, the transcription factor, NFκB, 
may regulate HO-1 protein as opposed to Nrf2, as was reported in a study where human 
gingival fibroblasts were stimulated with cyclosporine A (Chin et al., 2011). Analysis of 
alternative transcription factors was not investigated in the present study, however 
future work focusing on other potential transcription factors that regulate HO-1, and that 
have been reported as being activated by TGF-β1 and SFN, including AP-1 and CREB 
(Kawal et al., 2011; Zhang et al., 2006; Sano et al., 1999) would shed further light on 



























4.8.2 Effect of TGF-β1 and SFN on intracellular GSH levels in HAoAF 
The dysregulation of GSH has been reported in aging (Lui et al., 2004) and various 
disease models including diabetes mellitus (Okouchi et al., 2006), cholestasis 
(Serviddio et al., 2004), cancer, drug-resistant tumours (Huang et al., 2001) and fibrosis 
amongst others (Roum et al., 2003; Rahman et al., 1999; Beeh et al., 2002). TGF-β1 has 
been implicated in as being involved in these disease processes and has been found to 
reduce intracellular GSH (Lui et al., 2004) in various cell types, including epithelial 
cells (Bakin et al., 2005), hepatocytes (Fu et al, 2008), endothelial cells (White et al., 
1992) and fibroblasts (Lui et al., 2004) in vitro. Therefore, in order to assess the effects 
of TGF-β1 on GSH levels in HAoAF, a fluorometric assay was performed (Hissin and 
Hilf, 1976). It was found that treatment of cells with TGF-β1 did not elicit any changes 
in intracellular GSH in HAoAF over 24 h. 
 
Previous studies have indicated that TGF-β1 elicits GSH depletion. In NIH3T3, a 
murine embryonic fibroblast cell line, depletion of intracellular GSH as a result of TGF-
β1 exposure was accompanied by an increase in collagen accumulation, an effect which 
was blocked following replenishment of intracellular GSH with exogenous GSH or N-
acetyl cysteine (NAC), indicating that GSH plays a pivotal role in TGF-β1-mediated 
fibrogenesis (Sanchez et al., 1997). A more recent study has postulated a possible cross-
talk between the mechanisms involved in TGF-β1-induced profibrotic responses and 
GSH where treatment of human fetal lung fibroblasts with TGF-β1 resulted in the 
transformation of cells to a pro-fibrotic phenotype whilst also augmenting fibronectin 
production and enhancing gel contraction (Sugiura et al., 2009). However, when co-
treated with NAC, these effects were significantly attenuated suggesting that NAC 
inhibited not only TGF-β1 signalling but also the TGF-β1-mediated wound healing 
process and fibroblast differentiation (Liu et al., 2004). They have also suggested that 
NAC is able to modify TGF-β1, rendering it inactive as well as inhibiting its binding to 
its receptor (Sugiura et al., 2009). This finding suggests a possible mechanism by which 
ROS are involved in TGF-β1-mediated effects in fibroblasts and that use of an 
antioxidant such as NAC may abrogate these effects. Such changes may include the 
activation of certain MAPK phosphatases, leading to the sustained activation of various 
MAPK pathways and subsequent activation of downstream signalling pathways, 
including antioxidant pathways such as Nrf2 and NFκB (Liu and Pravia, 2010).  
 





It has been postulated that the mechanism by which TGF-β1 causes the depletion of 
intracellular GSH is via the inhibition of glutamate cysteine ligase catalytic subunit 
(GCLC) gene transcription and the suppression of GCLC promoter activity, with many 
studies suggesting that this may be the process by which TGF-β1 causes intracellular 
GSH depletion in fibrotic diseases. (Jardine et al., 2002). Jardine and colleagues have 
reported this observation as being due to the TGF-β1-mediated activation of the 
activator protein (AP-1) pathway; their study in alveolar epithelial cells has reported an 
increase in the DNA binding activity of both AP-1 and ARE in TGF-β1-treated 
epithelial cells (Jardine et al., 2002). This finding has been further confirmed by a more 
recent one in mammary epithelial cells, which has found that TGF-β1 suppresses of the 
activity of the human GCLC proximal promoter which bears an ARE (Bakin et al., 
2005). Others studies have suggested TGF-β1 is able to cleave the catalytic subunit of 
GCLC and downregulate GCLC gene expression resulting in a reduction in the activity 
of GCL and consequent depletion of intracellular GSH (Franklin et al., 2003). Findings 
from these studies suggest that TGF-β1 may elicit an increase in oxidative stress by 
depleting the antioxidant protection afforded by GSH which plays an important role in 
ROS detoxification. However, in the present study, and in contrast to findings from the 
literature, TGF-β1 treatment did not affect intracellular GSH levels in HAoAF, which 
may indicate a possible adaptive response in cells, similar to that observed by Pauly and 
colleagues who found that TGF-β1 stimulates cysteine uptake leading to the 
maintenance of cellular glutathione (Pauly et al., 2011). This study may also potentially 
explain the increase in intracellular GSH seen 8 h after treatment, and may be indicative 
of normal redox cycling events during GSH synthesis.  
 
Animal studies and several epidemiological studies suggest that regular consumption of 
cruciferous vegetables lower the risk and incidence of diseases including cancer of the 
prostate, lung, breast and colon (Liu et al., 2008; Juge et al., 2007) as well as conferring 
protection against hyperglycaemia, hypertension and myocardial infarction (Xue et al., 
2008; Cornelis et al., 2007; Noyan-Ashraf et al., 2006; Wu et al., 2001). Therefore, in 
order to determine the potential beneficial effects that SFN could confer to the 
adventitial layer, which is known to be involved in atherosclerotic disease progression 
(Ruiz-Ortega et al., 2007), HAoAF were treated with SFN and intracellular GSH levels 
measured. Results revealed that SFN causes an initial depletion in GSH levels after 4 h 
of treatment (see Fig 4.14), which recovered after 8 h and returned to just above 
baseline after 24 h. Several studies have also reported the depletion of GSH in cells 





treated with SFN. Similar findings in endothelial cells were observed where treatment 
with SFN resulted in a transient depletion of GSH which recovered over 12 h of 
treatment and which was abrogated when cells were pre-incubated with NAC (Liu et al., 
2008). In a study in VSMC from spontaneously hypertensive rats, cells treated with 
SFN (0 – 0.5 μM) displayed an initial decrease in intracellular levels, however cells 
recovered over time and levels of GSH returned to baseline (Wu and Juurlink et al., 
2001). A more recent study carried out in a bronchial epithelial cell line demonstrated 
similar findings to the current study where SFN treatment resulted in the depletion of 
intracellular GSH after 2 h followed by a GSH rebound and elevation of GCL owing to 
an increase in the levels of nuclear Nrf2 after 4 h of SFN treatment (Poerschke et al., 
2012).  
 
The recovery of intracellular GSH levels has been attributed to the ability of SFN to 
induce the expression of the Nrf2/ARE-regulated genes GCLC/GCLM; initial exposure 
to SFN results in the conjugation of SFN with GST resulting in the observed GSH 
depletion, however SFN has also been reported as modifying cysteine residues on 
Keap1, allowing the release of Nrf2, its translocation to the nucleus and consequently 
the increased expression of GST and glutamate cysteine ligase (GCL) which in turn 
results in the synthesis of newly formed GSH, replenishing intracellular levels and 
returning them to baseline (Xue et al., 2008). Interestingly, vehicle-treated cells 
displayed higher levels of GSH than those treated with SFN. NMR studies have 
revealed that GSH is highly flexible in an aqueous solutions and is able to transition to 
the extended, semi-folded and folded states. However, in DMSO, the stronger hydrogen 
bonds and the hydrophobic interactions make GSH stable in the folded state, allowing it 
to accumulate in high levels. In the absence of an agent which causes its depletion, GSH 
may continue to accumulate in the cells in a time-dependent manner, as observed here 
(Fig. 4.14; Zhang et al., 2011). A more accurate gauge of cellular redox state could be 
ascertained with the use of an enzymatic or HPLC assay which would give the 
GSH:GSSG ratio (Rousar et al., 2012). In addition, due to the commencement of 
measurement at 2 h following treatment, measurements were not obtained at time zero 
and so conclusions pertaining to an increase or decrease in the levels of GSH in either 
treatment group, from time zero cannot be drawn. The current study has found that SFN 
treatment results in the initial depletion of intracellular GSH, however this later recovers 





and returns to baseline at 24 h and may offer potential of SFN as prophylaxis, affording 
protection to cells from ongoing oxidative stress during disease.  
 
The method used to analyse cellular GSH levels in the present study was the 
fluorometric method, first proposed by Hissin and Hilf, 1976 which measures reduced 
glutathione (GSH). However, it has been suggested that this is not an accurate measure 
of the redox state of the cell, especially when the cell is under oxidative stress and that 
the ration of reduced to oxidized glutathione (GSH:GSSG) is a more accurate gauge of 
cellular stress (Floreani et al., 1997). Furthermore, when compared to a variety of other 
glutathione assays, levels measured by the fluorometric method were not comparable 
with those measured by the other assays (Floreani et al., 1997).   
 
Work into the methodology of the original protocol (Hissin and Hilf, 1976) has allowed 
the optimisation of this method to produce a more accurate readout of GSH (Rousar et 
al., 2012). Rousar and colleagues found that adjusting the original wavelengths used for 
excitation from 350 to 340 nm enhanced the intensity of fluorescence by 20% as did 
decreasing the temperature during measurement (Rousar et al., 2012). In the current 
study, the excitation wavelength used was 350 nm and the samples were incubated at 
room temperature before fluorometric reading was commenced, both of which may 
have affected the values obtained of the levels of GSH in HAoAF.     
 
Irrespective of these factors, measurement of the ratio of GSH:GSSG remains a more 
accurate measure of cellular oxidative stress, which is not taken into account when 
using the fluorometric method. Although this method is easy to perform and with the 
potential of a high throughput of samples, it is limited by its inability to determine the 
GSH:GSSG ratio which is important when investigating oxidative stress in a cell 
system. Future work using an enzymatic method or HPLC may provide a more accurate 












4.8.3 Effect of TGF-β1 and SFN on Nrf2 nuclear accumulation  
As activation of the Nrf2 pathway requires its translocation to the nucleus and 
subsequent binding to the ARE, the effect of TGF-β1 and SFN treatment on the cellular 
localisation of Nrf2 in HAoAF was investigated. Nrf2 heterodimerizes with Jun and 
small Maf proteins in the nucleus and binds to the ARE in the promoter region of 
antioxidant enzymes to regulate their expression; including the cytoprotective enzyme, 
HO-1 and the phase-II detoxification enzyme NQO1 (Jaiswal, 2004; Jain et al., 2005).  
The distribution and activity of Nrf2 in response to chemical/electrophillic stress is 
variable between different cell types (Nguyen et al., 2009; Watai et al., 2007; Jain et al., 
2005; Velichkova and Hasson, 2005), however in all cell types, its nuclear translocation 
is associated with the transcription of antioxidant genes following binding to the ARE 
of antioxidant genes (Keum, 2011), therefore HAoAF were treated with TGF-β1 (5 
ng/ml) or SFN (5 μM) and nuclear fractions extracted. Immunofluorescence analysis 
revealed that in response to TGF-β1 (5 ng/ml), there was enhanced nuclear 
accumulation of Nrf2, which was also seen in response to SFN (5 μM) after 2 h of 
treatment (Fig. 4.18 B). These results are in agreement with previous data from 
HAoSMC where Nrf2 nuclear accumulation was seen after 2 h of TGF-β1 (5 ng/ml) 
treatment; an accumulation that increased in a dose-dependent manner (Churchman et 
al., 2009). Initially, these results suggest that TGF-β1 and SFN may reduce the Keap1-
directed degradation of Nrf2, therefore allowing its accumulation in the cell. SFN has 
been postulated as activating Nrf2 via an alternative method; Keum and colleagues have 
proposed that it reacts with protein thiols to form thionacyl adducts which affect 
cysteine residues in Keap1, allowing the release of Nrf2, and its translocation to the 
nucleus (Keum et al., 2006). In addition, SFN is thought to affect intracellular kinases to 
phosphorylate Nrf2, thereby affecting its ability to translocate to the nucleus (Keum et 
al., 2011). 
 
However, the nuclear accumulation of a transcription factor is not necessarily an 
indicator of its transcriptional activity. Although Nrf2 nuclear translocation was 
observed in response to TGF-β1 treatment after 2 h, when analysed by 
immunofluorescence, when the TransAM DNA binding ELISA was carried out in order 
to assess Nrf2 transcriptional activity, no change in ARE binding of Nrf2 was observed 
(Fig. 4.19). Baseline levels of nuclear Nrf2 appeared to be higher than levels observed 
in TGF-β1-treated cells, which may indicate that cells were already under some stress 





and that redox pathways, in particular, the Nrf2 pathway, had been activated perhaps 
due to the experimental procedure. 
 
However, similar findings that suggest that TGF-β1 has little or no effect on Nrf2-ARE 
activation have also been reported in airway SMC, where TGF-β1 caused an initial 
increase in HO-1 mRNA levels after 2 h, however there was no increase in Nrf2-ARE 
driven luciferase activity or a change in whole-cell protein levels of Nrf2 (Michaeloudes 
et al., 2011), observations that are consistent with the current study. Interestingly, the 
same study also reported that treatment of airway SMC with SFN resulted in an increase 
in whole cell Nrf2 levels which was accompanied by a concentration-dependent 
increase in ARE-driven luciferase activity (Michaeloudes et al., 2011). Whilst increases 
in whole-cell Nrf2 were not observed in HAoAF in response to SFN, there was a dose-
dependent (2.5 – 5 μM) increase in Nrf2-DNA binding activity.  The modulation of 
Nrf2 by TGF-β1 may be a more complicated process than simple activation and nuclear 
translocation. Michaeloudes and colleagues argue that although initial increases in the 
mRNA of Nrf2-regulated genes are observed in response to TGF-β1 in airway SMC, 
TGF-β1 may inactivate Nrf2 by inducing the expression of the Nrf2 transcriptional 
repressor, ATF-3 which results in the later decrease of HO-1 mRNA levels after 4 h 
(Michaeloudes et al., 2011). They argue that TGF-β1 increases the mRNA of ATF-3, 
thereby blocking Nrf2-mediated transcription; ATF-3 is postulated to do this by 
displacing the Nrf2 co-activator, CREB binding-protein from the ARE complex 
(Michaeloudes et al., 2011). This may also be a mechanism by which HO-1 mRNA 
levels decrease over time in HAoAF, however, in order to determine this, further work 
to investigate other mechanisms, including ATF-3 activity and possibly other 
transcriptional repressors such as Bach1 and DJ-1(Im et al., 2012; Kang et al., 2011; 
Clements et al., 2006; Shan et al., 2006), would need to be carried out.  The evidence in 
the present study regarding SFN-mediated HO-1 induction suggests that SFN may 
activate the Nrf2/ARE pathway in HAoAF as reported previously (Michaeloudes et al., 











4.8.4 Effect of knockdown of Nrf2 on TGF-β1 and SFN induction of antioxidant  
         genes 
To investigate whether Nrf2 regulated HO-1 induction response in HAoAF, knockdown 
of this transcription factor using short interfering RNA transcript was carried out. 
Following transfection, cells were treated with TGF-β1 or SFN. Western blot analyses 
show that HAoAF transfected with Nrf2 siRNA displayed abrogated HO-1 protein 
expression when treated with both TGF-β1 and SFN (Fig 4.20). This further confirms 
that SFN mediated-HO-1 expression in HAoAF is an Nrf2-dependent process. 
However, with regards to TGF-β1, these results do not correlate with those found in the 
Nrf2-DNA binding assay, where it was found that TGF- β1 does not increase Nrf2-ARE 
binding activity, however siRNA studies have demonstrated that in cells transfected 
with Nrf2 siRNA, TGF- β1-induced HO-1 protein expression was abrogated. These data 
suggest that TGF-β1 mediated - HO-1 protein induction may be partly mediated by 
Nrf2. 
 
Previously, Itoh and colleagues reported some of the first evidence that Nrf2 induced 
the expression of phase-II detoxifying enzymes by disrupting the nrf2 gene in vivo. By 
using butylated hydroxyanisole (BHA), a selective phase-II enzyme inducing stress 
agent, in both wild-type (WT) and Nrf2-deficient mice they were able to compare the 
induction of the antioxidant enzymes, HO-1 and NQO1. Findings showed that induction 
of phase-II enzymes in Nrf2-deficient mice was largely eliminated in isolated liver and 
intestinal tissue, whilst WT mice displayed a normal expression pattern of these 
enzymes (Itoh et al., 1997). Similarly another study found a 50-80% reduction in the 
constitutive induction of NQO1 in hepatic and gastric tissue from Nrf2-deficient mice in 
comparison to WT (Ramos-Gomez, 2001).  
 
Interestingly, in the present study, although induction of HO-1 was clearly decreased 
following siRNA knockdown of Nrf2, and Nrf2 protein expression in Nrf2 siRNA-
transfected cells was significantly lower than in non-transfected control cells, some 
Nrf2 protein expression was still detected in transfected cells (Fig. 4.18). This can be 
explained by the ‘Hinge and Latch’ model proposed by Tong and colleagues (see Fig. 
4.17) which postulates that after exposure to electrophillic stress, newly synthesized 
Nrf2 molecules bypass the ‘Keap1 gate’, (which traps Nrf2 and causes its degradation 
via the 26S proteasome) (Tong et al., 2006a; Tong et al., 2006b; Tong et al., 2007; 





Watai et al., 2007). This newly synthesized Nrf2 then translocates to the nucleus where 
it binds to the ARE of antioxidant genes and causes their transcription (Watai et a., 
2007). In this model, instead of causing disruption of the Keap1-Nrf2 association, 
electrophillic stress simply represses Keap1-mediated ubiquitination of Nrf2, so that 
Nrf2 is still associated with Keap1 but not degraded. In the context of the current study, 
it is possible that Nrf2 siRNA caused the knockdown of any newly synthesized Nrf2, 
which would have otherwise bypassed the Keap1 pathway and resulted in transcription 
of antioxidant enzyme(s), whilst affecting Nrf2 already present in the cell. In addition to 
this, only the induction of antioxidant enzymes is abrogated, however their ubiquitous 








































Figure 4.21 The ‘Hinge and Latch’ model of Keap1-Nrf2 degradation.  
Under unstressed conditions, Nrf2 is sequestered in the cytoplasm by Keap1 homodimer and 
rapidly degraded via the ubiquitin-proteasome pathway. Upon exposure to oxidants or 
electrophiles, Keap1 is inactivated and becomes ‘stuck’ with the Nrf2 it is associated with, 
allowing de novo synthesized Nrf2 to bypass the cytoplasmic Keap1-proteasome pathway, 
translocate to the nucleus and bind to the ARE of phase-II and antioxidant genes. Taken from 


















Several studies have reported that activation and transcription of HO-1 can be mediated 
by the NFκB pathway. The TGF-β1 gene promoter contains binding sites for NFκB  
(Lee et al., 2006) as does the gene promoter for HO-1 (Jadhav et al., 2008) and this may 
be an alternative pathway in which TGF-β1 mediates HO-1 induction.  
 
An interaction between HO-1, NFκB and TGF-β1 has been proposed by Jadhav and 
colleagues in a rat model of hypertension where the HO system has been postulated to 
critical for the regulation of fibrotic events mediated by TGF-β1 and the available 
binding sites for NFκB in the TGF-β1 promoter as well as in the HO-1 promoter 
suggest an intricate relationship between both TGF-β1 and HO-1 and their regulation by 
NFκB (Jadhav et al., 2008). Upregulation of HO activity as well as the administration of 
hemin reduced hypertension, suppressed oxidative stress and reduced atherosclerotic 
lesion formation as analysed by immunohistochemistry characteristic of cardiac lesions 
(Jadhav et al., 2008). Furthermore, A459 cells, induction of HO-1 by TGF-β1 was 
thought to be dependent on PI3K/Akt and NFκB signalling as use of both a PI3K 
inhibitor and an NFκB inhibitor inhibited TGF-β1-induced HO-1 expression and HO-1-
ARE luciferase activity (Lin et al., 2007). In human hepatoma HepG2 cells transfected 
with a NFκB reporter plasmid, treatment with TGF-β1 led to a 50% increase in NFκB-
luciferase reporter activity. This was mediated by TRAF-6-induced polyubiquitination 
of TGF-β1-associated kinase 1, thereby activating it and inducing a prosurvival pathway 
via NFκB. This may be a potential mechanism by which HO-1 is induced via the TGF-
β1 signalling pathway (Hamidi et al., 2012). In addition, another study using A459 cells 
demonstrated the importance of NFκB and PI3K in TGF-β1-mediated migration; the 
use of inhibitors for both of these resulted in abrogation of cell migration in response to 
TGF-β1 (Fong et al., 2009). 
 
These studies suggest that other alternative pathways such as NFκB may mediate the 
TGF-β1 mediated HO-1 induction in HAoAF. Although other transcription factors such 
as NFκB were not considered in this present study, it would be important to investigate 
these in any future work to shed light upon the mechanisms behind the lack of Nrf2-
DNA binding activity in HAoAF in response to TGF-β1. The cross-talk between SFN 
and the TGF-β1 signalling pathway was not investigated by the current study, however 
an interaction between the two was first reported by Traka and colleagues in a study 
carried out in NIH-3T3 cells where it was found that SFN can indirectly increase TGF-





β1-mediated activation of the Smad signalling pathway when it is pre-incubated with 
SFN (2 μM) for 30 min. The binding of SFN to TGF-β1 resulted in enhanced Smad-
mediated transcription, inhibiting cell proliferation and the authors went on to propose 
that this was the underlying mechanism by which SFN may act as an anticarcinogenic 
agent (Traka et al., 2008). Similarly, in an adenocarcinoma cell line, pre-incubation of 
cells with SFN (5-50 μM) resulted in an increase in TGF-β1 mRNA levels after 1-3 h 
which was accompanied by an increase in the protein levels of both TGFβ-RI and TGF-
βRII owing to the ability of SFN to suppress ornithine decarboxylase, an enzyme 
required for cell proliferation.  
 
This chapter has provided novel evidence that TGF-β1 causes the induction of HO-1 in 
HAoAF, as well as causing the nuclear translocation of Nrf2, however, it does not 
increase Nrf2-DNA binding activity suggesting that the induction of HO-1 may be via 
an alternative pathway. It has also been demonstrated that SFN also causes the 
induction of HO-1 in HAoAF, GSH depletion and nuclear translocation of Nrf2 as well 
as increasing Nrf2-DNA binding activity, suggesting that SFN is an activator of the 
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Cell migration is a critical process during embryonic development as well as during 
tissue repair and immune function (Valster et al., 2005). Migration is usually triggered 
by a signal, often chemotactic, that results in the polarisation and extension of cellular 
protrusions, such as lamellipodia, in the direction of movement and as the cell moves 
forward, the protrusions, containing focal adhesions (FA) adhere to the substrate and the 
trailing edge of the cell retracts (Hurd et al., 2012). Cell motility is a highly regulated 
process and requires timely assembly, disassembly and reorganisation of the actin 
cytoskeleton, a process that is mediated by members of the Rho family of small 
GTPases (Kole et al., 2005). Membrane protrusions and formation of wide lamellipodia, 
which make up membrane ruffles at the leading edge of the cell, are dependent upon the 
activity of the small GTPases, Rac and Cdc42 (Nobes and Hall, 1999).  There is 
increasing evidence to suggest that reactive oxygen species (ROS) play a role in 
directing changes required for cell motility with one study carried out in zebrafish 
suggesting that hydrogen peroxide (H2O2) produced during injury acts as a 
chemoattractant to attract immune cells to the site of the wound (Niethammer et al., 
2009).  
 
Early studies carried out in vitro have suggested that ROS are important during cell 
migration; this was first demonstrated in human fibroblasts where chemotactic response 
to conditioned medium and platelet-derived growth factor (PDGF) was inhibited in the 
presence of superoxide dismutase (SOD), implicating the superoxide anion (O2
.- ) in 
playing a role during migration in this cell type (Wach et al., 1989). Other studies have 
reported similar findings; in human umbilical vein endothelial cells, exposure to 
Angiotensin-I triggered the production of ROS via NAD(P)H oxidase as well as causing 
a threefold increase in cell migration, however overexpression of SOD and catalase 
significantly inhibited this effect (Harfouch et al., 2005). Furthermore, in mouse 
embryonic fibroblasts, exposure of cells to PDGF increased the production of H2O2 and 
subsequently led to an increase in cell migration and proliferation, both of which were 
abrogated in the presence of antioxidants (Choi et al., 2005). In the same study, mice 
lacking PrxII exhibited enhanced neointimal lesion formation as a result of increased 
vascular smooth muscle cell (VSMC) migration (Choi et al., 2005). It has been 
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postulated that the source of O2
-.  and H2O2 are the NAD(P)H oxidase isoforms, Nox2 
and Nox4 (Haurani and Pagano, 2007). In VSMC, knockdown of Nox4 resulted in a 
marked decrease in ROS production, loss of focal adhesions and inhibition of migration, 
implicating this Nox isoform in all of these processes (Lyle et al., 2009). Furthermore, 
inhibition of Nox4 using diphenyleneidonium (DPI) or knockdown using siRNA in a 
fibroblast cell line abolished the ability of these cells to migrate (Tobar et al., 2010). 
 
TGF-β1 has been widely implicated in mediating increases in ROS production, which 
can cause alterations in actin cytoskeleton organisation and fillipodia formation (Hu et 
al., 2005). Treatment of endothelial cells with TGF-β1 induced an increase in ROS 
production, which was attributed to increased Nox4 activity (Hu et al., 2005). Similar 
findings have been reported in VSMC, where TGF-β1 induced the expression of Nox4 
and consequently increased ROS production, which was reduced when cells were 
treated with the flavoprotein inhibitor, DPI (Sturrock et al., 2006). Furthermore, 
stimulating human lung fibroblasts with TGF-β1 led to a transient but rapid increase in 
H2O2 production.  
 
There is much evidence to suggest that ROS are important in mediating cell migration 
and that TGF-β1 is able to drive this process in various cell types, therefore, in this 
chapter, the effect of TGF-β1 on HAoAF migration was examined. Furthermore, the 
ability of TGF-β1 to mediate ROS generation in HAoAF was also investigated and 
finally, the effect of TGF-β1 on the migration of cells with impaired antioxidant 
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5.2 Effect of TGF-β1 on HAoAF phenotype during migration 
During cell migration, cells undergo various structural changes, such as actin re-
organisation, which enable them to carry out processes such as establishing spatial 
polarity and extension of membrane protrusions in the direction of movement (Kole et 
al., 2005; Ridley et al., 2001). As discussed in Chapter 3, HAoAF had differentiated 
into myofibroblasts and expressed the cytoskeletal proteins, α-smooth muscle actin and 
vimentin, and had acquired a migratory phenotype. In order to determine whether 
cytoskeletal changes had affected the morphology of cells, sub-confluent HAoAF were 
equilibrated in DMEM supplemented with 1% FCS 18 h prior to treatment with TGF-β1 
(2.5 - 5 ng/ml) or DMEM supplemented with 10% FCS and time-lapse video 
microscopy was carried out.  A frame was captured every 10 min over 8 h and 
phenotypic changes were observed. HAoAF incubated with 1 % FCS appeared less 
confluent and were smaller in size displaying an absence of ruffled edges, a hallmark of 
a migrating cell, and therefore were indicative of a less migratory phenotype (Fig. 5.1, 
panel A). HAoAF incubated with TGF-β1 (2.5 ng/ml; Fig. 5.1, panel B) and TGF-β1 (5 
ng/ml; Fig. 5.1, panel C) appeared more confluent and displayed ruffled leading edges 
indicative of cell motility. Cells were elliptical in shape, exhibited cell spreading and a 
flattened morphology. This indicates that TGF-β1 drives HAoAF migration with some 
effect on cell phenotype and behavior. As a positive control, HAoAF were also 
incubated with DMEM supplemented with 10 % FCS (Fig. 5.1, panel D), a known 
inducer of migration. Cells appeared more confluent and exhibited ruffled leading 
edges, indicative of a migratory phenotype and were visibly more motile than cells 
incubated with DMEM supplemented with 1% FCS. These results indicate that TGF-β1 
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5.3 Effect of TGF-β1 on HAoAF migration and velocity 
TGF-β1 is a well known inducer of migration in fibroblasts, with some reports 
suggesting that this process may be driven by enhanced ROS generation, however the 
underlying mechanism by which this occurs has not been fully elucidated (Ren et al., 
2011; Riedy et al., 1999; Shi et al., 1996). In order to determine the effect of TGF-β1 on 
HAoAF migration, sub-confluent HAoAF were equilibrated in DMEM supplemented 
with 1% FCS 18 h prior to treatment with TGF-β1 (5 ng/ml). Some cells were incubated 
with SOD (200 U/ml) 30 min prior to the commencement of imaging in order to 
determine whether ROS mediate TGF-β1-driven migration.  A frame was captured 
every 10 min over an 8 h period and in the presence or absence of SOD (200 U/ml).  
Cells treated with TGF-β1 caused a significant increase in HAoAF migration (p<0.001) 
when compared with untreated control (Fig 5.2A). This increase in migration was 
abrogated when cells were pre-incubated with SOD and subsequently treated with TGF-
β1, indicating that this migration may be driven by ROS. Cells treated with TGF-β1 
alone also migrated with significantly greater velocity when compared to untreated 
control (p<0.01). This was also abrogated in the presence of SOD, which further 
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Figure 5.2 Effects of ROS on TGF-β1-mediated HAoAF migration  
HAoAF were seeded at a density of 2 x 104/well in a 12-well culture plate and allowed to 
adhere overnight. 18 h prior to imaging, cells were adapted in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with TGF-β1 (5 ng/ml). 30 min prior to 
commencement of imaging, some cells were treated with SOD (200 U/ml). Multifield live cell 
imaging was performed with a single frame being taken every 10 min for 8 h. Cell tracking (A) 
was performed using ImageJ. Migration speed (B) was quantified by importing cell-tracking 
data into Excel. Values denote means ± SEM ***p<0.001 TGF-β1 vs. untreated control and 














































Figure 5.3 Effect of TGF-β1 on velocity of HAoAF migration  
HAoAF were seeded at a density of 2 x 104/well in a 12-well culture plate and allowed to 
adhere overnight. 18 h prior to imaging, cells were adapted in phenol red-free DMEM 
supplemented with 1% FCS and subsequently treated with TGF-β1 (5 ng/ml). 30 min prior to 
commencement of imaging, some cells were treated with SOD (200 U/ml). Multifield live cell 
imaging was performed with a single frame being taken every 10 min for 8 h. Cell tracking was 
performed using ImageJ and migration speed was quantified by importing cell-tracking data 
into Excel. Values denote means ± SEM **p<0.01 TGF-β1 vs. untreated control, *p<0.05 
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5.4 Effect of Nrf2 on HAoAF migration and velocity 
To determine whether Nrf2 was involved in TGF-β1-mediated HAoAF migration, sub-
confluent HAoAF were seeded and allowed to adhere overnight. Subsequently cells 
were transfected with scramble or Nrf2 siRNA as validated in Chapter 4 (see Fig 4.20). 
Eight hours following transfection, the transfection mixture was aspirated from wells 
and replaced with DMEM supplemented with 1% FCS for overnight equilibration. Cells 
were treated with TGF-β1 (5 ng/ml) or DMEM supplemented with 10% FCS and live 
imaging was commenced. A frame was captured every 10 min for 8 h. Incubation of 
cells with DMEM supplemented with 10% FCS increased migration, suggesting that 
cells were responsive to a chemotactic stimulus. However, knockdown of Nrf2 had no 
marked effect on migration distance or on the velocity of migration in HAoAF (Fig 
























































Figure 5.4 Effects of Nrf2 siRNA on TGF-β1-mediated HAoAF migration  
HAoAF were seeded at 2 x 104/well in a 12-well culture plate and allowed to adhere overnight 
and were subsequently transfected with scramble or Nrf2 siRNA. Eight hours following 
transfection, the transfection mixture was aspirated from wells and replaced with DMEM 
supplemented with 1% FCS for overnight equilibration. Subsequently cells were treated with 
TGF-β1 (5 ng/ml) or DMEM supplemented with 10% FCS. Multifield live cell imaging was 
performed with a single frame being taken every 10 min for 8 h. Cell tracking (A) was 
performed using ImageJ. Migration speed (B) was quantified by importing cell-tracking data 













































Chapter 5                       Effect of TGF-β1 on HAoAF migration 
 
 228 
5.5 Effect of TGF-β1 on Nox mRNA levels 
As NAD(P)H oxidases have been implicated in mediating the migration of vascular 
smooth muscle cells and adventitial fibroblasts, often in response to TGF-β1 (Hurd et 
al., 2012; Tobar et al., 2010; Lyle et al., 2009; Guzik et al., 2006; Pagano et al., 1998), 
mRNA levels of two Nox isoforms reported to be expressed by adventitial fibroblasts 
(Haurani and Pagano, 2007) were determined. Cells were treated with TGF-β1 (0 – 5 
ng/ml) for 4 and 8 h and levels of Nox2 and Nox4 mRNA were analysed. Treatment 
with TGF-β1 for 4 or 8 h did not alter levels of Nox2 mRNA in HAoAF when 
compared to untreated control (Fig 5.5a). Levels of Nox4 mRNA were also not altered 
in HAoAF in response to treatment with TGF-β1 for 4 or 8 h when compared to 
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Figure 5.5 Nox2 and Nox4 mRNA levels in HAoAF after treatment with TGF-β1 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently treated with TGF-β1 (0 - 5 ng/ml) for 4 or 8 h. Levels of Nox2 and Nox4 mRNA 
in the samples were quantified by qRT-PCR and expressed relative to 3 housekeeping genes 
(RPL13A, SDHA and TATABOX). Values denote means ± SEM. n = Representative of 6 
independent experiments. 
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5.6 Effect of TGF-β1 on ROS generation in HAoAF  
In order to determine the effect of TGF-β1 on ROS generation in HAoAF, cells were 
equilibrated in phenol red-free DMEM supplemented with 1% FCS 18-24 h prior to 
pre-treatment with SOD (200 U/ml) or the NAD(P)H oxidase inhibitor, VAS2870 
(VAS; 10 μM) before co-treatment with TGF-β1 (0 - 5 ng/ml) over 40 minutes of ROS 
measurement. The luminol analogue, LO12 (20 μM) was used as a probe for the 
detection of ROS generation. Treatment with TGF-β1 (2.5 and 5 ng/ml) resulted in 
enhanced ROS generation when compared to untreated control (Fig 5.6). In order to 
determine the type of ROS generated in response to TGF-β1, cells were treated with 
extracellular SOD, which catalyses the dismutation of O2
.-  to H2O2. In the presence of 
SOD, ROS generation was significantly abrogated in cells and comparable to basal 
levels seen in untreated control, suggesting that O2
.-  may be the predominant ROS 
generated in response to TGF-β1 treatment (p<0.01 TGF-β1 (2.5 ng/ml) + SOD vs. 
TGF-β1 alone and p<0.001 TGF-β1 (5 ng/ml)+ SOD vs. TGF-β1 alone). Furthermore, 
use of VAS, a NAD(P)H oxidase inhibitor, also resulted in a significant abrogation of 
ROS levels when compared to cells treated with TGF-β1 (2.5 and 5 ng/ml) alone 
suggesting that O2
.-  generation seen in response to TGF-β1 treatment was NAD(P)H-
dependent (p<0.05 TGF-β1 (2.5 ng/ml) + VAS vs. TGF-β1 alone  and p<0.01 TGF-β1 

























Figure 5.6 Effect of TGF-β1 treatment on ROS generation in HAoAF 
Confluent HAoAF were equilibrated in phenol red-free DMEM supplemented with 1% FCS and 
subsequently pre-treated with SOD (200 U/ml) or the NAD(P)H oxidase inhibitor, VAS2870 
(VAS; 10 μM) for 30 min prior to co-treatment with TGF-β1 (0 - 5 ng/ml). ROS production was 
determined over 40 min using the luminescence probe, LO12 (20 μM) as described in Methods. 
Representative percentage change from control was determined over 40 min. Values denote 
means ± SEM *p<0.05 Untreated control + VAS vs. untreated control alone, **p<0.01 
Untreated control + SOD vs. untreated control alone; # p<0.05 TGF-β1 (2.5 ng/ml) + VAS vs. 
TGF-β1 alone, ## p<0.01 TGF-β1 (2.5 ng/ml)+ SOD vs. TGF-β1 alone;  $$ p<0.01 TGF-β1 (5 
ng/ml) + VAS vs. TGF-β1 alone, $$$ p<0.001 TGF-β1 (5 ng/ml) + SOD vs. TGF-β1 alone. n = 











Inimal thickening and adverse vascular remodelling are key events in advanced vascular 
disease and injury (Pels et al., 1999). Under the autocrine and paracrine actions of TGF-
β1, released in the adventitial layer, adventitial fibroblasts are activated and can migrate 
from the adventitial layer of arteries to the intima, where they subsequently proliferate, 
therefore contributing to this pathology (Zalewski and Shi, 1997). Recent investigation 
into this process has revealed evidence of the pivotal role of adventitia-derived ROS 
with some evidence to suggest that this may be a TGF-β1-mediated event (Csanyi et al., 
2009; Lyle et al., 2009). Understanding the underlying mechanism of this process in 
HAoAF has not been fully elucidated in HAoAF. The following experiments sought to 
explore the mechanisms by which TGF-β1 may cause HAoAF migration in culture.   
 
5.7.1 Effect of TGF-β1 on HAoAF migration  
As discussed in Chapter 3, treatment of HAoAF with TGF-β1 resulted in HAoAF 
proliferation, an event widely reported to occur in vivo in models of vascular injury 
(Ren et al., 2011; Liu et al., 2008; Siow et al., 2003; Shi et al., 1996). As the processes 
of proliferation and migration often occur in parallel in vascular disease (Sivakumar et 
al., 2006), migration of HAoAF in response to TGF-β1 (2.5 - 5 ng/ml, 8 h) treatment 
was analysed using time-lapse video microscopy. Results revealed that the average 
distance of migration was significantly higher in HAoAF treated with TGF-β1 than that 
measured in untreated control (Fig 5.2). These results are in keeping with previous 
studies that have shown that cell migration is a TGF-β1-driven process. It has been 
reported that siRNA against the downstream facilitators of the TGF-β1 signalling 
pathway, phopsho-Smad2 and 3 significantly decrease adventitial fibroblast migration 
in vitro, coupled with a concomitant decrease in proliferation of these cells and a 
decrease in the mRNA levels of the TGF-β1-target genes; α-smooth muscle actin and 
collagens I and II (Ren et al., 2011).  
 
Furthermore, transfection of vessels with an adenovirus coordinating the expression of 
the secreted form of TGF-β type II receptor in order to antagonise TGF-β1 signalling in 
a porcine model of restenosis following angioplasty, revealed a decrease in adventitial 
collagen deposition and decreased constrictive remodelling, suggesting that TGF-β1 
facilitated these pathological events (Kingston et al., 2001). Similarly, TGF-β1 has been 
shown to increase proliferation and migration in the medial layer of the vessel in a rat 
model of carotid balloon injury. Administration of neutralizing anti-TGF-β1 antibodies 
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significantly reduced the size of intimal lesions as well as decreasing cell proliferation 
in the medial layer (Wolf et al 1994). Furthermore, the injection of recombinant soluble 
TGF-β1 type II receptor localised preferentially at the adventitial layer and developing 
neointima in an injured rat carotid artery resulted in a reduction in intimal lesion 
formation of up to 65% and coincided with reduced adventitial fibrosis and collagen 
deposition (Smith et al., 1999). Mallawaarachchi and colleagues reported that gene 
transfer of an adenovirus overexpressing Smad7, an inhibitor of the classical TGF-β1 
signalling pathway, specifically to the adventitial layer, attenuated adventitial cell 
migration to the neointima following balloon injury in rat carotid artery 
(Mallawaarachci et al., 2005). This evidence and results from the current study strongly 
suggest the involvement of TGF-β1 in driving cell migration and in vivo, may be 
implicated in HAoAF-driven migration and consequent vascular remodelling during 
disease. In particular, TGF-β1-mediated adventitial cell migration plays an important 
role in neointima formation and constrictive remodelling, a process, which may be 
attenuated by antagonising TGF-β1 signalling (Kato et al., 2001).  
 
5.7.2 Effect of SOD on TGF-β1–mediated HAoAF migration  
Although it is well established that TGF-β1 causes cell migration during vascular 
disease and injury, the exact mechanisms underlying this process remain to be fully 
elucidated. Redox imbalance is a tenet of the pathogenesis seen during the progression 
of many vascular diseases (Haurani and Pagano, 2007; Rocic and Lucchesi, 2005). This 
imbalance in oxidant-generating vs. oxidant-catalysing systems leads to a build-up of 
ROS, including O2
−. and H2O2. Much of this redox imbalance is first seen in the 
adventitial layer where it has been reported that adventitial NAD(P)H oxidase-derived 
ROS plays a role in neointimal growth and medial hypertrophy by causing cell 
migration (Haurani and Pagano, 2007) and there is mounting evidence to suggest that 
ROS are used to relay signals from activated cell surface receptors to direct changes 
necessary for cell movement (Hurd et al., 2012). Due to existing studies postulating that 
ROS are involved in driving migration of cells from the media and adventitia of injured 
vasculature and that the predominant species implicated is O2
−., the migration of 
HAoAF was investigated in the presence of TGF-β1 with or without the O2
−. 
scavenger, SOD. Findings show that when co-treated with TGF-β1 and SOD, the total 
distance that cells migrated was significantly attenuated and was similar to that 
observed in untreated cells (Fig. 5.2). Furthermore, this was accompanied by a 
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significant attenuation in the velocity of migration, from 2.451 ± 0.366 μm/h in cells 
treated with TGF-β1 to 1.661 ± 0.382 μm/h in cells treated with TGF-β1 in the presence 
of SOD (Table 5.1). These results suggest that ROS may play a role in TGF-β1-
mediated HAoAF migration.  
The first study to suggest that fibroblast migration may be reduced by administration of 
SOD was carried out by Wach and colleagues. Fibroblasts exhibited increased cell 
proliferation and migration in response to phorbol myristate acetate, an inducer of 
superoxide generation, however, addition of SOD abrogated this response suggesting 
that O2
−., in small amounts, is involved in fibroblast migration and possibly 
proliferation (Wach et al., 1987). An earlier study looking at the effects of SOD on 
neutrophil migration in plasma samples from healthy adults was assessed in the absence 
or presence of SOD and it was reported that SOD inhibited the migratory response of 
neutrophils to sites of inflammatory challenge, suggesting that the process was in part, 
O2
−. dependent. In order to rule out the possibility that H2O2 may be partly responsible 
for neutrophil migration, the enzyme that catalyses the breakdown of H2O2 to water and 
oxygen, catalase, was used in place of SOD. Results showed that catalase did not affect 
neutrophil migration, suggesting that this migration was a H2O2-independent event 
(Petrone et al., 1980). Similarly, a recent study in human lung fibroblasts also reported 
that SOD and not catalase was involved in the regulation of TGF-β1 release and 
subsequent activation of fibroblasts (Qi et al., 2009). The study also demonstrated that a 
chloride channel blocker was able to inhibit the increase in intracellular O2
−.  induced 
by exposure to extracellular O2
−. suggesting that this may be a possible mechanism 
whereby extracellular O2
−. may regulate the release of TGF-β1 and cause the 
subsequent activation of fibroblasts (Qi et al., 2009). The findings from the current 
study support existing evidence in the literature and demonstrate for the first time that 
TGF-β1 may drive HAoAF migration and this may be partly through mediating an 
increase in ROS production in this cell type. In particular, this process may be due to 
TGF-β1-driven generation of O2
−.. 
Several studies have shown that extracellular SOD makes up approximately 50% of 
total SOD activity in the human aorta (Luoma et al., 1998; Stralin et al., 1995), whereas 
in other tissues represents only a small proportion of the total SOD activity (Marklund, 
1984), indicating that extracellular SOD is physiologically relevant and plays a 
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significant role in the redox balance of the vascular wall. In the present study, cells were 
treated with exogenous SOD as opposed to the cell permeable form of SOD typically 
linked with polyethylene glycol (PEG-SOD). This ensured that any attenuation of 
migration that was observed in the presence of SOD was likely to be a result of the 
dismutation of O2
−. released into the extracellular space. Results from HAoAF treated 
with TGF-β1 in the presence of SOD show that these cells have markedly reduced 
distance of migration and decreased velocity, suggesting that migration in this cell type 
is driven by O2
−. released into the extracellular space. However, although these results 
demonstrate a significant abrogation in migration distance and speed, it would be 
interesting to observe the effects of administration of PEG-SOD on migration of 
HAoAF as it has been postulated that intracellular O2
−.  may also be important in 
mediating cell motility as has been demonstrated by a study in VSMC in which 
mitochondrial-derived intracellular O2
−. has been shown to activate the PI3K/Akt 
pathway which in turn was able to drive VSMC migration during neointima formation 
(Artaud-Macari et al., 2013; Wang et al., 2012; Lyle et al., 2009).  
Due to the effect of SOD administration on the migratory behaviour of cells, many 
studies have investigated the effect of this antioxidant on pathophysiological cell 
migration. There is a large body of evidence that postulates that the expression of 
extracellular SOD using gene transfer can reduce neointima formation by decreasing the 
migration of cells from the medial and adventitial layers of the blood vessel towards the 
lumen (Wang et al., 2012). This has been observed in a rabbit model where the 
adenoviral gene transfer of extracellular SOD in the aorta after endothelial denudation 
was shown to result in a decrease in VSMC migration and consequently a decrease in 
intimal thickening as well as an accompanied decrease in O2
−. production as 
determined by the dihydroethidium assay was observed (Laukkenen et al., 2002). 
Another study has reported a decrease in restenosis following angioplasty in rabbit 
atherosclerotic iliac arteries after adenovirus-mediated gene transfer of extracellular 
SOD, with a decrease in collagen accumulation, inflammation and improved endothelial 
function when compared to those arteries injected with adenovirus carrying no 
transgene (Durand et al., 2005). Furthermore, Brasen and colleagues have also 
demonstrated the beneficial effects of the gene transfer of extracellular SOD and 
reported a 61% decrease in neointima formation 28 days after endothelial denudation 
and stent insertion in Watanabe heritable hyperlipidemic rabbits as well as a decrease in 
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observed oxidant production following SOD administration (Brasen et al., 2007). These 
studies demonstrate that extracellular SOD may decrease neointima formation by 
abrogating the proliferation of cells in the medial and adventitial layers of the blood 
vessel and their subsequent migration towards the lumen of the vessel. This correlates 
with findings from this study, which have shown that HAoAF migration induced by 
TGF-β1 is abrogated in the presence of extracellular SOD.  
The potential source of superoxide in response to vascular injury has been postulated to 
be the membrane-bound NAD(P)H oxidase system (Csanyi et al., 2009) which is one of 
the major sources of O2
−.  implicated in compounding vascular injury (Kanellakis et al., 
2004; Jacobson et al., 2003; Szocs et al.,  2002). In one study, measurement of Nox 
homologs after carotid injury showed an increase in p22phox, gp91phox and Nox4 
mRNA levels after 3 days. These levels remained elevated for 15 days with an 
accompanied increase in O2
−. , observed in neointimal smooth muscle and adventitial 
fibroblasts (Szocs et al., 2002).  
The presence of growth factors in and around the neointima has led to investigation into 
whether they contribute to the production of ROS during vascular injury. Initial work in 
VSMC led to the observation that TGF-β1 enhanced O2
−.  production in VSMC with an 
accompanied increase in the protein expression of p22phox (Churchman et al., 2009).  
Previously, Thannickal and colleagues proposed a mechanism whereby TGF-β1 may 
induce the expression of membrane bound NAD(P)H oxidase subunits in human lung 
fibroblasts by protein tyrosine phosphorylation  (Thannickal et al., 1998). Blocking the 
TGF-β1-mediated tyrosine phosphorylation using an inhibitor resulted in the abrogation 
of NAD(P)H oxidase activation and H2O2 production,  suggesting that this was the 
primary method by which TGF-β1 induced ROS production in this cell type 
(Thannickal et al., 1998).  In contrast to findings from Thannickal et al., in fibroblasts 
from the human stroma, TGF-β1 is thought to activate Nox4 as opposed to the 
membrane-bound Nox2 (Sampson et al., 2011). TGF-β1 induction of Nox4 and the 
consequent ROS production is required for downstream cytoskeletal remodelling which 
was postulated to accelerate fibroblast-to-myofibroblast differentiation (Sampson et al., 
2011) and may also be an important mechanism during TGF-β1-mediated cell migration 
(Thannickal et al., 2003). TGF-β1 can also activate several MAPK pathways such as 
PKC, independent of Smad signalling, as previously discussed in Chapter 3. 
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A possible mechanism for this enhanced O2
−.  production has been suggested by Lyle 
and colleagues who have demonstrated that Nox4 is involved in cell migration of 
VSMC when in complex with p22phox and an accessory protein known as polymerase 
(DNA-directed) delta-interacting protein (Poldip2). Poldip2 has been shown to associate 
with p22phox, Nox1 and Nox4 and co-localises with p22phox at sites of Nox4 
localisation, increasing its enzymatic activity and positively regulating the basal 
production of ROS in VSMCs (Lyle et al., 2009). Interestingly, overexpressing Poldip2 
results in activation of RhoA, which is known to mediate the process of cell migration 
by regulating actin polymerisation and depolymerisation (Ridley, 2001). Proteins of the 
Rho subfamily are well known to regulate the cytoskeleton, cell growth and migration 
(Meyer et al., 2006; Smith et al., 2006) and Rho-stimulated contractility drives stress 
fibre and focal adhesion formation and up-regulation of α-smooth muscle actin in 
fibroblasts (Hinz et al., 2001) and epithelial cells (Zhong et al., 1997).   
The Poldip2/p22phox/Nox4 complex has been reported to regulate focal adhesion 
turnover in VSMC, a process which is pivotal for cell migration to occur (Lyle et al., 
2009). Moreover the small GTPase Rac1 has been shown to play a key role in vascular 
superoxide generation by NAD(P)H oxidase, regulating myofibroblast migration via 
assembly of adhesion complexes and actin re-organisation alongside ROS-mediated Ras 
activity (Parsons et al. 2008; Alexandrova et al., 2006). These results show that changes 
in ROS production and consequent downstream cytoskeletal re-arrangement may result 
in increased or decreased cell migration and may go some way in explaining the 
underlying molecular processes of migration during neointima formation as a function 
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5.7.3 Effect of TGF-β1 on Nox2 and Nox4 mRNA levels in HAoAF  
Actin cytoskeleton reorganisation is pivotal in promoting cell migration and there is 
much experimental evidence to suggest that during this process both Ras and Rho 
GTPases make an essential contribution (Bar-Sagi and Hall, 2000), possibly in a ROS-
mediated manner (Parsons et al., 2008; Alexandrova et al., 2006). In endothelial cells, 
these ROS-driven changes in migration are thought to be mediated by p21-activated 
kinase-1 (PAK1), the small GTPase Rac1 and NAD(P)H oxidase regulatory subunits 
(Fukai, 2006). In contrast to findings in VSMC where Nox4 is thought to drive 
migration of cells, in endothelial cells, Nox2 is thought to mediate this process by 
colocalising with its regulatory subunit, p47phox at the leading edge of the cells, where it 
associates with actin to promote migration; an effect which is significantly abrogated 
following Nox2 knockdown (Ikeda et al., 2005). Rac1 and PAK1 are equally important 
as dominant negative forms of both of these proteins block ROS production, membrane 
ruffling and as a consequence, cell migration (Wu et al., 2005). 
HAoAF express both Nox2 and Nox4 (Haurani and Pagano, 2007), therefore in order to 
determine which of these NAD(P)H oxidase isoforms were responsible for TGF-β1-
mediated ROS production in HAoAF, levels of Nox2 and Nox4 mRNA in cells treated 
with TGF-β1 were investigated. It was found that cells exhibited no significant changes 
in Nox2 or Nox4 mRNA following treatment with TGF-β1 after 4 or 8 h.  
Assembly of Nox has been reported to occur for up to 24 h after exposure to an oxidant 
(Serrander et al., 2007), however this is largely dependent upon the Nox isoform; Nox4 
is constitutively active isoform and Nox4 mRNA has been reported to increase in the 
absence of a stimulant (Serrander et al., 2007). One study suggests that new protein 
synthesis was not required for TGF-β1 regulated induction of Nox4 in human 
pulmonary SMC (HPSMC) as use of the protein synthesis inhibitor, cycloheximide 
failed to inhibit TGF-β1 induction of Nox4 (Sturrock et al., 2006).  The same study 
reported a significant increase in Nox4 mRNA levels following treatment with TGF-β1 
(2 ng/ml) for 24 h and Nox4 protein levels were also increased after incubation of cells 
with TGF-β1 (1 ng/ml) for 72 h as well as there being a significant increase in O2-. 
production (Sturrock et al., 2006). Similar results have been reported in endothelial cells 
where acute TGF-β1 (10 ng/ml, 5 min) treatment has been observed to increase the 
production of H2O2, an increase which was abrogated in cells transfected with dominant 
negative Nox4 (Hu et al., 2005). ROS produced by Nox4 is still to be fully elucidated - 
although some argue that Nox4 primarily produces H2O2 (Lyle et al., 2009), others 
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suggest that Nox4 may generate O2
-. which dismutates to the membrane-permeant H2O2 
(Serrander et al., 2007). Although the above evidence suggests that TGF-β1 increases 
Nox4 mRNA in other cell types, the current study was not able to demonstrate this in 
HAoAF where TGF-β1 (2.5 – 5 ng/ml) treatment for 4 or 8 h did not affect levels of 
Nox4 mRNA, however further work looking at the effect of TGF-β1 on Nox4 
expression over longer time-points may provide clearer evidence of the underlying 
source of ROS in this cell type.  
The adventitia has also been widely reported as expressing Nox2, and its component 
parts, p22phox, p47phox and p67phox which make up a multiprotein complex required 
for the activation of this Nox isoform (Haurani and Pagano, 2007; Pagano et al., 1998; 
Pagano et al., 1997).  The role of this isoform in cardiovascular disease progression has 
also been widely reported; Wang and colleagues have shown that AngII infusion into 
mice for 6 days resulted in intimal and adventitial NAD(P)H oxidase-derived 
superoxide production and subsequent aortic medial thickening, however upon deletion 
of Nox2, intimal and adventitial superoxide production was attenuated and there was a 
marked reduction in aortic medial thickening (Wang et al., 2001). These findings were 
confirmed in a more recent study where targeted inhibition of Nox2 to the adventitial 
layer resulted in an attenuation of AngII-induced medial hypertrophy (Liu et al., 2004). 
The ROS primarily implicated as being released by Nox2 is O2
-. the production of 
which has been reported as being significantly attenuated in neointima formation 
following targeted delivery of an adenovirus expressing a specific Nox2 inhibitor, 
nox2ds, to the adventitia (Dourron et al., 2005). The observation that Nox2 is also able 
to contribute to ROS production in the adventitial layer and result in the activation and 
migration of fibroblasts from this layer to contribute to restenosis is widely established 
in the literature. However, in the current study, mRNA levels of this Nox isoform were 
relatively low and did not change significantly in response to treatment with TGF-β1 
(2.5 – 5 ng/ml) treatment for 4 or 8 h when compared with untreated control. It should 
be noted that although this data is interesting, mRNA levels of Nox 2 and 4 are not 
entirely reflective of the activity of these isoforms in a cell system when taken alone and 
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5.7.4 Effect of knockdown of Nrf2 on HAoAF migration  
Cellular redox homeostasis is a highly regulated process and is maintained, in part, by 
the Nrf2/ARE signalling pathway; ROS has been shown to increase cell migration and 
interestingly the Nrf2 inhibitor, Keap1 is an actin binding protein which may play a role 
in mechanosensing (Dai et al., 2007; Hosoya et al., 2005) and cell migration via its 
localisation with focal adhesion complexes (Velichkova and Hasson, 2003). 
Therefore in order to determine whether the Nrf2/ARE signalling pathway was acting as 
a mechano-sensor for oxidative stress, cells were transfected with Nrf2 siRNA. 
Subsequently migration studies were carried out, however, knockdown of Nrf2 had no 
effect on HAoAF migration in response to TGF-β1 (Fig 5.4). Previously, others have 
reported that silencing of Nrf2 results in enhanced cell migration; Rachkonda and 
colleagues found that cell migration was increased in A549 cells transfected with Nrf2 
siRNA or in HepG2 cells in which Keap1 had been overexpressed (Rachkonda et al., 
2010). As cell motility is closely related with TGF-β1 signalling, the same study 
investigated the relationship between Nrf2 and TGF-β1 in HepG2 cells; 
immunprecipitation assays demonstrated that Nrf2 forms a nuclear complex with 
phospho-Smad2/3 and Co-Smad4 and that it suppresses CAGA-directed reporter 
activity. RNAi-mediated suppression of Nrf2 enhanced the expression of the Smad 
target genes, plasminogen activator inhibitor-1 (PAI-1) and E-cadherin. In addition, loss 
of Nrf2 in cells was associated with an increase in Smad-mediated motility suggesting 
that loss or suppression of Nrf2 contributes to increased motility as a result of 
dysregulated Smad signalling (Rachkonda et al., 2010). 
Similar results have been observed in a recent study in mouse lung fibroblasts where 
Nrf2 knockdown resulted in fibroblast differentiation and an increase in TGF-β1-
regulated genes such as α-smooth muscle actin when compared to control cells as well 
as an increase in oxidative stress (Artaud-Macari et al., 2013) suggesting that Nrf2/ARE 
and TGF-β1 signalling may be closely related pathways. Further evidence comes from 
the rat renal fibroblast cell line (NRK-49F) in which over-expression of Nrf2 using an 
adenovirus decreased the expression of TGF-β1-target genes, PAI-1, α-smooth muscle 
actin, fibronectin and type I collagen as well as inhibiting TGF-β1-mediated Smad3 
phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 (Oh et al., 
2012). This evidence suggests that Nrf2 negatively regulates the TGF-β1-Smad 
pathway and potential therapeutic intervention may be beneficial during neointima 
formation, restenosis and vascular remodelling seen during disease. 
Chapter 5  Effect of TGF-β1 on HAoAF migration 
 
 242 
The present study provides novel evidence that TGF-β1 may mediate cell migration in 
HAoAF by increasing ROS production. There is much evidence in the literature to 
suggest a close relationship between the TGF-β1 signalling pathway and the Nrf2/ARE 
antioxidant pathway exists and therefore the potential cross-talk between these 
pathways may offer a way of mediating pathophysiological cell migration. Evidence 
from this study did not indicate that Nrf2 knockdown had any effect on cell motility in 
HAoAF, although this is not entirely unexpected since Nrf2 does not lie directly 
downstream of the TGF-β1 signalling pathway established in this cell type.  
Nevertheless, in order to generate more conclusive evidence in this cell type, further 
work would need to be carried out. In particular, it would be interesting to investigate 
the effects of TGF-β1 on migration of fibroblasts from Nrf2 knockout animals. Cells 
from knockout animals have the advantage over Nrf2 siRNA transfected cells as the 
transfection can be inefficient and transient and more importantly, the process of 
transfection itself can be toxic enough to activate stress-response pathways within the 
cell (Seth et al., 2012), a factor which is especially relevant to the current study. In vivo 
studies looking specifically at adventitial cell migration into the neointima of an 
atherosclerotic artery or one that has undergone stenting in Nrf2 knockout animals 
would also provide some clarity about the cross-talk between these two signalling 
pathways and their effects on cell migration.  Elucidating the exact mechanism by 
which TGF-β1 causes HAoAF migration may be an important step towards successful 
therapeutic intervention during vascular injury and disease.  
 
5.7.5 Effect of inhibition of NAD(P)H oxidase on TGF-β1-mediated ROS 
generation in HAoAF  
Generation of ROS in response to TGF-β1 has been widely reported in endothelial cells 
(Hu et al., 2005) and cardiac fibroblasts (Cucoranu et al., 2005), however whether this 
growth factor had a similar effect on HAoAF has not been previously elucidated. In 
order to determine whether TGF-β1 treatment resulted in ROS generation in this cell 
type, cells were treated with TGF-β1 and luminescence was measured using the luminol 
analogue, L-012. In addition, to elucidate the type and potential source of ROS, cells 
were also co-treated with SOD, which catalyses the dismutation of O2
−.  to H2O2 and 
VAS2870, a specific NAD(P)H oxidase inhibitor.  
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Results demonstrated that in response to TGF-β1 (2.5 and 5 ng/ml), there was enhanced 
ROS generation when compared to untreated control and that this increase was 
abrogated in the presence of SOD, suggesting that the primary species of ROS detected 
in HAoAF following TGF-β1 treatment was O2
−.. Similar findings have been reported 
in a study in human umbilical vein endothelial cells (HUVEC) in which treatment of 
cells with TGF-β1 (10 ng/mg) led to ROS production as measured by the probe, 
dichlorodihydrofluorescein (DCF), and which was attributed to a NAD(P)H oxidase 
isoform. The observed ROS generation was attenuated in the presence of the 
flavoprotein inhibitor, diphenyl iodinium (DPI, Hu et al., 2005). Interestingly, the same 
study reported cytoskeletal changes in HUVEC in response to TGF-β1 that were 
blocked following transfection of cells with a dominant- negative Nox4 adenovirus 
which suggests that these changes were mediated by ROS production (Hu et al., 2005). 
Similarly, in cardiac fibroblasts, Cucoranu and colleagues have shown that exposure of 
cells to TGF-β1 (10 ng/ml) resulted in O2
−. release from cardiac fibroblast cell 
membranes and further investigation revealed a significant increase in Nox4 mRNA 
levels after 24 h with a concomitant increase in protein levels of Nox4, suggesting that 
this isoform was the source of ROS in this cell type (Cucoranu et al., 2005). Their 
findings also went on to confirm those from the study by Hu et al., that changes in the 
cytoskeleton of cells in response to TGF-β1, in particular in the upregulation of α-
smooth muscle actin, required ROS; treatment of cells with DPI abrogated this effect 
(Cucoranu et al., 2005).  
 
There is much contention surrounding the species of ROS produced by Nox4 with some 
studies suggesting that this isoform generates predominantly H2O2 at low levels as 
opposed to O2
−., largely determined by its third extracytosolic loop which contains an 
extra 28 amino acids more than Nox1 and Nox2, isoforms which generate O2
−. (Takac 
et al., 2011). Indeed, previous studies have postulated that TGF-β1 exposure results in 
the NAD(P)H-dependent production of H2O2 in lung fibroblasts, although the particular 
isoform responsible for this was not elucidated (Thannickal et al., 1998; Thannickal et 
al., 1995). The probe used to detect ROS generation in the current study was the 
luminol analogue, L-012 which, upon its discovery, was proposed as a specific probe 
for O2
−. (Nishinaka et al., 1993) but has since been discovered as detecting various 
species of ROS, including H2O2 and ONOO
−. (Dikalov et al., 2007). In addition, 
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although initially reported to not undergo redox cycling, investigation of its structure 
revealed that it has the ability to do so (Dikalov et al., 2007). Therefore, specific 
scavengers were used in order to assess the contribution of various species of ROS, 
including SOD as well as the NAD(P)H specific inhibitor, VAS. Alternative methods of 
measuring ROS production are available, in particular and with regards to O2
−., 
production, electron spin resonance (ESR) is the current ‘gold standard’ of measuring 
ROS  (Wang et al., 2012) and future work using ESR to look at TGF-β1-mediated ROS 
production in HAoAF would be important.  
 
VAS compounds work by inhibiting the assembly of NAD(P)H oxidases and differ 
from the conventionally used pharmacological Nox inhibitors, including DPI and 
apocynin, in that they do not exhibit intrinsic antioxidant activity and do not inhibit 
other flavoproteins such as eNOS and xanthine oxidase (Altenhofer et al., 2012). 
Although widely used, DPI and apocynin often have off-target effects which can affect 
other oxidant-generating systems in the cell (Aldieri et al., 2008). Currently, there is the 
lack of an isoform-specific Nox inhibitor, and VAS compounds are the closest 
alternative as specific-NAD(P)H oxidase inhibitors, however, use of a appropriate 
scavengers in conjunction with these compounds would present a more accurate of the 
Nox isoform responsible for ROS generation in a particular model system. Results from 
the current study suggest that the species of ROS generated in HAoAF in response to 
TGF-β1 treatment is O2
−., however the Nox isoform (Nox2 or 4) responsible for this 
was not determined.  
 
The current chapter has presented novel data which suggests that in HAoAF, TGF-β1 
treatment results in the generation of ROS, in particular O2
−., the source of which is 
NAD(P)H oxidase. Furthermore, TGF-β1-mediated HAoAF migration is a ROS-
dependent mechanism and requires the activity of O2
−.. Therefore, targeting the TGF-
β1 signalling pathway in the adventitia may be a potential avenue of therapeutic 
intervention during the progression of cardiovascular disease, as demonstrated by 
Mallawarachichi and colleagues where Smad7 gene transfer attenuated vascular 
remodelling following balloon injury (Mallawaarachichi et al., 2005). Targeting this 
pathway prophylactically may also offer the opportunity as a potential method of 
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CHAPTER 6: General Discussion 
 
As described in Chapter 1, atherosclerosis is a progressive vascular disease, which can 
eventually lead to a plethora of cardiovascular complications, including, angina, myocardial 
infarction and stroke. It has been implicated as being one of the most prevalent causes of 
death in the developed world and despite the development of a number of therapies to 
combat this disease, the number of patients reported to have developed atherosclerosis is on 
the rise (World Health Organisation, 2012). Initial studies into the underlying molecular 
mechanisms of this disease led to the ‘response to injury’ hypothesis (Ross, 1999) which 
postulated that the endothelium plays a central role in mediating the inflammatory response 
by modulating monocyte adhesion and playing a pivotal role in the infiltration of oxidized 
lipids and the consequent formation and progression in development of atherosclerotic 
lesions (Diaz et al., 1997). 
An increasing body of evidence now suggests that this ‘inside-out’ hypothesis of 
atherosclerosis does not take into account the outermost adventitial layer of the blood 
vessel, largely consisting of fibroblasts (Maillaro and Taylor, 2007). Termed the ‘outside-
in’ hypothesis (Zalewski and Shi, 1997), it suggests that early in the development of 
vascular disease, the adventitia plays an important role in the initiation and progression of 
vascular inflammation, characterized by a denser vasa vasorum which is responsible for 
delivering oxygen and nutrients to an increasingly hypoxic and nutrient deficient media as 
well as enhancing the delivery of inflammatory cells  (Csanyi et al., 2009; Kuwuhara et al., 
2002). A key player in the ‘outside-in’ hypothesis is the adventitial fibroblast and its 
phenotypic switch to a myofibroblast cell type which is able to subsequently migrate and 
augments the progression of disease by contributing to the formation of a neointima. This 
phenotypic switch has been reported to be a TGF-β1-dependent event (van den Borne et al., 
2009; Mallawaarachchi et al., 2007; Powell, 2000). In particular, one method by which 
TGF-β1 is thought to elicit phenotypic changes and migration of fibroblasts is from the 
generation of reactive oxygen species (ROS), an effect which is counter-balanced by the 
cell’s innate antioxidant defense pathways, and in particular by the Nrf2/ARE signalling 
pathway. 
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There is increasing emphasis on the activation of endogenous antioxidant defense systems 
in order to counteract pathophysiological disease processes since evidence from clinical 
trials in which exogenous antioxidants such as tocopherol, were administered to patients, 
has provided somewhat inconsistent outcomes (Steinhubl, 2008; Kris-Etherton et al., 2004; 
Steinberg, 2000; Steinberg, 1993). One dietary activator of endogenous antioxidant 
pathways and in particular of the Nrf2/ARE antioxidant pathway is the isothiocyanate, 
sulforaphane (SFN). Found in cruciferous vegetables, its bioavailability and rapid 
absorption and metabolism make it an ideal candidate for use as a therapeutic agent in order 
to activate endogenous phase II enzyme detoxification systems (Petri et al., 2003). Its 
ability to decrease oxidative stress has been demonstrated in spontaneously hypertensive 
rats where it was shown to ameliorate oxidative stress and tissue inflammation (Noyan-
Ashraf et al., 2006). Its potential to prevent neointima formation and inflammation during 
atherosclerosis, to which adventitia-derived cells contribute, is therefore a highly promising 
avenue of research.  
It is important to note that all HAoAF used for the duration of the study came from a total 
number of four human donors. Assurance from the manufacturer stated that all individuals 
had passed away suddenly and without any major disease pathology. Despite this, it is 
important to regard the data gathered in this study with caution. Cells were taken from the 
adventitial layer of the aorta of donors, however the manufacturer was not clear about 
whether the donors suffered from any risk factors that would increase the progression or 
contribute to the development of cardiovascular disease. It is well known that all members 
of the general population exhibit atherosclerotic plaque formation to some extent (Ross, 
1999), and it is likely that the donors from whom these cells were taken also exhibited 
some atherosclerotic plaque development. This variability between donors is likely to have 
affected the behaviour of the fibroblasts isolated from their aortas and ultimately the 
outcomes of the current study. Future work using a larger sample size and perhaps with the 
medical history of the donors would help to reduce this variability and provide more 
accurate data with the potential of less variability.  
 
The present study aimed to elucidate whether TGF-β1 modulates phenotype and motility 
due to enhanced ROS generation or altered antioxidant defense gene expression via the 
Nrf2/ARE pathway. The effect of the isothiocyanate, SFN, an inducer of the Nrf2/ARE 
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pathway, on HAoAF was also investigated in order to determine whether it plays a role in 
the induction of phase II enzymes via the activation of the Nrf2/ARE pathway in this cell 
type and therefore be used as a method of intervention in cardiovascular disease. 
 
6.1 Cellular localisation of the Nrf2/Keap1 complex 
This study has investigated the effect of TGF-β1 and SFN treatment on the expression 
pattern of Nrf2 in HAoAF. Immunofluorescence and Western blot analysis suggests that in 
response to exposure to TGF-β1 or SFN, Nrf2 localises to the nucleus after 2 h and by 4 h 
after exposure, Nrf2 is largely localised in the cytoplasm. These results are consistent with 
findings from a previous study carried out in human aortic smooth muscle cells where 
nuclear accumulation of Nrf2 was seen after 2 h in response to TGF-β1 (Churchman et al., 
2009). Another study in a prostate cancer cell line also confirms results found in the present 
study where exposure of cells to SFN resulted in the translocation of newly synthesized 
Nrf2 to the nucleus, whilst its binding protein, Keap1 remained in the cytoplasm (Xu et al., 
2006). The location of the Nrf2 binding protein, Keap1, was not investigated during the 
present study, however the intracellular localisation of the Nrf2-Keap 1 complex has gained 
much interest in recent years and various studies contend with the initial hypotheses, which 
suggested that under basal conditions, the complex resides mainly in the cytoplasm, bound 
to F-actin, under basal conditions. 
The mechanisms by which Keap1 is thought to regulate Nrf2 levels are controversial as is 
the exact subcellular localisation of the Keap1/Nrf2 complex. The majority of evidence 
suggests that Keap1 sequesters Nrf2 in the cytosol where it mediates the proteasomal 
degradation of this transcription factor via the 26S proteasome (Jain et al., 2005). 
According to this model, upon exposure of Keap1 to oxidants and electrophillic stress 
agents, Nrf2 dissociates from Keap1 and is able to localise to the nucleus owing to a 
nuclear localisation signal (NLS) located in its C-terminus which eventually leads to the 
coordinated activation of a number of antioxidant genes (Jain et al., 2005). The NLS 
domain of Nrf2 is thought to be critical in allowing its nuclear accumulation as deletion of 
this domain has been previously shown to result in a complete inhibition of Nrf2 nuclear 
accumulation and diminished transcriptional activity of genes downstream of Nrf2 (Jain et 
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al., 2005). In addition to this, a similar nuclear export signal (NES), also found on Nrf2 is 
thought to be important in the nuclear export and subsequent degradation of Nrf2 
(Velichkova and Hasson, 2005). 
In contrast to this, emerging evidence suggests that the relationship between Keap1/Nrf2 is 
more complicated than originally proposed. Watai and colleagues postulate that the 
Keap1/Nrf2 complex is localised in different locations in the cell. They suggest that 
although the majority of Keap1 resides in the cytoplasm there is also some localisation of 
this complex in the nucleus and in the endoplasmic reticulum (Watai et al., 2007). 
Interestingly, they also suggest that instead of being an inert protein in the cytoplasm, 
Keap1 is able to shuttle in and out of the nucleus in a NES-dependent manner (Watai et al., 
2007). Velichkova and Hasson further explain this by suggesting that oxidative agents can 
directly oxidatively modify several cysteine residues in immediate proximity to the NES. 
Once oxidised, they can participate in the masking of the NES on Keap1, thereby allowing 
an increase in nuclear Nrf2 in the absence of Keap1–mediated export of Nrf2. Eventually 
this results in the transcription of various target genes via Nrf2/ARE, including HO-1 and 
NQO-1 (Velichkova and Hasson 2005). This is supported by findings in the fibroblast cell 
line, NIH3T3 that show that these cysteine residues are critical for the Keap1-mediated 
ubiquitination of Nrf2 (Zhang et al., 2003). 
Further light was shed on the role of the Keap1/Nrf2 complex on ARE-mediated gene 
expression in HeLa cells. Keap1 was found to contain a NES domain, which allowed it to 
confer the nuclear-cytoplasmic shuttling of the Keap1/Nrf2 complex and mediate gene 
transcription (Karapetian et al., 2005). Perhaps the most controversial suggestion comes 
from Nguyen and colleagues who propose that the Keap1/Nrf2 interaction is a very brief 
one, whereby Keap1 transiently enters the nucleus and targets Nrf2 for ubiquitination in 
this compartment under non-stress conditions. However, they also go a step further by 
suggesting that even under stressed conditions, Keap1 is able to enter the nucleus and target 
Nrf2 for degradation once this transcription factor has activated its target genes (Nguyen et 
al., 2009). This supports findings from Jain et al., who found that treatment of cells with the 
stress agent, t-butylhydroquinone (t-BHQ), caused nuclear Nrf2 localisation but that this 
was abrogated between 1 – 4 h after treatment and gained normal localisation status 8 h 
after treatment (Jain et al., 2005). 
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Questions remain about the mechanism of Nrf2 nuclear localisation and activation by such 
diverse stimulants as TGF-β1 and SFN and it is likely that it involves cross-talk between 
several signalling pathways depending upon the stimulus, the cell and the tissue type. In the 
current study, Western blot analysis revealed several kinase pathways were activated in 
HAoAF in response to TGF-β1 and SFN, including PI3K/Akt, Erk and p38MAPK (see 
Chapter 3). Other studies have proposed the importance of kinases in the regulation of the 
ARE in an Nrf2-dependent manner; Erk has been reported as upregulating the ARE and 
p38MAPK has been shown to suppress this effect (Yu et al., 2000). Others have shown that 
the PI3K pathway results in Nrf2 nuclear translocation upon exposure to tBHQ-induced 
oxidative stress, an effect that is accompanied by actin rearrangement (Kang et al., 2002) 
whilst in HepG2 cells, phosphorylation of Ser40 on Nrf2 by protein kinase C was observed 
as being required for ARE-driven transcription (Huang et al., 2002).  
 
More recently, Xu and colleagues have reported that treatment of a prostate carcinoma cell 
line with phenethyl isothiocyanate (PEITC) activated Erk and Jnk, which phosphorylated 
Nrf2, inducing its translocation to the nucleus and subsequent transcriptional activation of 
the ARE (Xu et al., 2006). In contrast, others have reported that phosphorylation of Nrf2 is 
not a requirement for its activation; Dinkova-Kostova and colleagues have proposed a 
model which suggests that oxidative insults that result in the induction of phase II enzymes 
directly modify cysteine residues on Keap1 allowing Nrf2 nuclear translocation (Dinkova-
Kostova et al., 2002). This is further confirmed by work in mouse embryonic fibroblasts 
that proposed that Cys273 and 288 were the critical residues on Keap1 that were modified 
by electrophiles and required for Nrf2 release from Keap1 and its subsequent nuclear 
translocation (Wakabayashi et al., 2004). Although the current study did not investigate 
phosphorylation of Nrf2 following exposure to TGF-β1 or SFN, it has been shown 
previously that post-translational modification events, including acetylation of several 
lysine residues in the DNA binding domain of Nrf2 (Sun et al., 2009) are important in 
modulating the Nrf2-dependent antioxidant response (Sun et al., 2000) and therefore 
investigating such events would be important for future work in order to elucidate the 
mechanism by which TGF-β1 or SFN cause Nrf2 nuclear translocation, and in the case of 
SFN, its binding to the ARE of target genes in HAoAF.  
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6.2 Mechanisms of TGF-β1-mediated HAoAF migration  
In this study, exposure of HAoAF to TGF-β1 caused changes in the Nrf2/ARE pathway, 
possibly affecting changes in the differentiation, migration and proliferation of these cells 
through altered redox status. These TGF-β1-mediated changes may contribute to adventitial 
activation, atherosclerotic disease progression, neointima formation and restenosis.  
 
The differentiation and migration of adventitial fibroblasts in the setting of cardiovascular 
disease has recently been an area of intensive research. The role of the adventitia has only 
recently been given importance in the context of disease (Ruiz-Ortega et al., 2007) and the 
ability of adventitial fibroblasts to differentiate, proliferate and migrate into the intima and 
contribute to vascular remodelling in response to TGF-β1 can affect the outcome of disease 
progression (Ruiz-Ortega et al., 2007; Birukov, 2009).    
TGF-β1 is a known activator of cell migration, with studies showing that this is due to its 
ability to activate integrins (Asnao et al., 2006). TGF-β1-modulated fibroblast migration 
and differentiation is a critical event during atherosclerotic disease progression and is likely 
to play a large role in the neointima formation and restenosis observed during advanced 
cardiovascular disease (Liu et al., 2010). The current study demonstrated a significant 
increase in migration of HAoAF treated with TGF-β1, an effect that was attenuated in the 
presence of the O2
-. scavenger, superoxide dismutase (SOD; Fig 5.2). However, 
investigation of the levels of Nox2 or Nox4 mRNA in response to treatment with TGF-β1 
revealed that there was no significant increase in the level of these NAD(P)H isoforms, 
though mRNA levels of these Nox isoforms are not indicative of their activity since 
assembly and activity of both Nox2 an Nox4 are subject to post-translational modification 
(Martin-Garrido et al., 2011; Fig. 5.5). The underlying mechanisms of this were not 
investigated here, however, changes in the actin cytoskeleton, to which the Nrf2 inhibitory 
protein, Keap1 is bound may result in the nuclear accumulation of Nrf2 and the consequent 
induction of cytoprotective antioxidant genes that may counteract ROS generation, and 
therefore attenuate migration of these cells. 
Recent evidence from in vitro studies has implicated Nox1 and Nox4-derived ROS in cell 
migration as a reduction in the levels of these NAD(P)H oxidase catalytic subunits resulted 
in the abrogation of TGF-β1-mediated migration of VSMC, with an increase in migration 
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observed when these were overexpressed (Lyle et al., 2009; Schroder et al., 2007) and 
others have shown that ROS produced by Nox1 and Nox4 promotes matrix 
metalloproteinase (MMP) secretion from VSMC (Schroder et al., 2010). In particular, 
Rac1, which regulates cell growth, cellular transformation and especially cell migration, 
has been reported as being essential for the assembly of plasma membrane NAD(P)H 
oxidase (Dikalov et al., 2007). The mechanism by which Rac1 is able to facilitate these 
cellular processes is by controlling the production of ROS, which in turn can increase cell 
migration via the activation of stress-induced responses such as the activation of several 
MAPKs and subsequent downstream activation of several integrins and actin reorganization 
in order to drive the forward movement of the cell (Lassegue et al., 2010; see Fig 6.1). The 
initial  assembly of these NAD(P)H oxidase isoforms may be in response to TGF-β1 
production as a result of its autocrine and paracrine release and may explain the increase in 
the migration of HAoAF in response to this growth factor, an increase which was abrogated 
in the presence of SOD.  
It is thought that the interaction between TGF-β1 receptors and integrins elicits a signalling 
cascade through FAK, subsequent integrin clustering and cellular migration (Margadant 
and Sonnenberg, 2010). Furthermore, TGF-β1 activation and its crosstalk with the integrin 
cluster, αvβ8 has been shown to induce the differentiation of airway fibroblasts into 
myofibroblasts and their subsequent migration (Araya et al., 2007). In the current study, 
TGF-β1 treatment resulted in an acute but significant increased protein expression of pAkt 
(Chapter 3, Fig 3.14) and other studies have purported that this may be a Smad-independent 
pathway by which TGF-β1 can stimulate migration via FAK; FAK has been proposed to 
bind the PI3K p85 regulatory subunit following TGF-β1 treatment in fibroblasts resulting 
in TGF-β1-mediated migration (Hong et al., 2011). Similarly, in monocytes, TGF-β1 has 
been reported as mediating motility in a Smad-independent manner as knockdown of these 
proteins did not affect migration, and it was observed that migration was dependent upon 
PI3K activation (Olieslagers et al., 2011). Results from the current study did not address the 
downstream functional effect of Akt phosphorylation in HAoAF upon treatment with TGF-
β1, but as increased migration was observed in these cells, the phosphorylation of Akt may 
be a mechanism by which TGF-β1 modulates cell motility in HAoAF, however further 
work would need to be carried out to determine this.  
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Given the interactions reported between the Keap1/Nrf2 complex and focal adhesions 
(Velichkova and Hasson, 2005), which contain integrins and the proposed interaction 
between TGF-β1 and integrins as well as between TGF-β1 and Nrf2, further investigation 
of the mechanisms of signalling and activity between these various different pathways 
would need to be carried out in adventitial fibroblasts. One way in which this could be 
investigated in real-time is by using fluorescence resonance energy transfer (FRET) 
microscopy. Fluorescence resonance energy transfer (FRET) allows visualisation of 
individual proteins and allows the quantification of biochemical interactions (Worth and 
Parson, 2008). Based on the evidence that the Keap1/Nrf2 complex localises to the 
cytoskeleton at focal adhesions (Velichkova and Hasson, 2005), the use of FRET to assess 
Nrf2/Keap1 and adhesion complex interactions could clarify the crosstalk of migration 
machinery with this antioxidant pathway. Specific antibody/fluorophore probes would need 
to be generated to facilitate FRET imaging of possible TGF-β1-induced associations 
between Keap1/Nrf2 and focal adhesions.  
A further method of determining cell motility behavior is to measure cell traction force 
(CTF), which is the force generated by actomyosin cross-bridges inside semi-sarcomeres 
containing actin-bundles (Wang and Lin, 2007). Adherent cells generate contractile forces 
by using the cell’s contractile machinery, forces that are transmitted to the extracellular 
matrix (ECM) through focal adhesions which can be in the range of tens of nano-Newtons 
(Wang and Lin, 2007). CTF is essential for cell migration, cell shape maintenance and 
signal transduction and analysis of this force can offer critical understanding of 
physiological and pathophysiological events in cells and tissues. In the case of the current 
study, such information would provide an insight into the mechanisms by which TGF-β1 














    
 
Figure 6.1 Possible mechanisms by which TGF-β1 may drive fibroblast migration in a ROS-
dependent manner. In response to TGF-β1 Nox2/Nox4 produces reactive oxygen species that can 
cause the reorganization of the cytoskeleton and possible activation of integrins. This can lead to  
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6.3 The Nrf2/ARE pathway as a mechanosensor 
The localisation of the Nrf2-Keap1 complex is of particular relevance to the current study 
due to the reported association of Keap1 with the actin cytoskeleton, which may have 
further implications for cell phenotype, proliferation and migration.  
 
It has been shown that Keap1 binds to the actin cytoskeleton and that the interaction 
between the two proteins contributes to its regulatory activity (Kang et al., 2004). In 
particular, the association between Keap1 and the actin cytoskeleton is thought to be 
through focal adhesions (see Fig 6.2). These sites of attachment of the cell membrane to the 
ECM and are formed by groups of cytoskeletal proteins clustered around a transmembrane 
integrin. Integrins consist of an α and a β subunit and constitute a family of transmembrane 
receptors which bind extracellularly to the ECM and intracellularly to the cytoskeleton to 
transduce signals between the extracellular and intracellular environment in order to 
regulate cell adhesion, spreading, proliferation and differentiation (Worth and Parsons, 
2008). Actin remodelling, such as that seen during cell migration, is known to play a 
critical role in transforming a mechanical signal to a biological response (Velichkova and 
Hasson, 2003).  
Previous work by Papaiahgari et al. has demonstrated the importance of the PI3k/Akt 
pathway in mediating ROS-dependent, hyperoxia-induced Nrf2 activation and similar work 
by Kang and colleagues has shown the importance of the PI3K/Akt pathway in regulating 
Nrf2 nuclear translocation via actin rearrangement, suggesting that actin plays a pivotal role 
in, and is closely related to the activation of the Nrf2/ARE pathway (Papaiahgari et al., 
2006; Kang et al., 2002). More recently, immunoprecipitation and immmunocytochemical 
studies have found that disruption of the actin cytoskeleton promotes nuclear entry of Nrf2 
suggesting a role for it in providing a scaffold essential for the function of Keap1 as a 
binding protein for Nrf2 as well as a sensor for oxidative and electrophilic stress (Kang et 
al., 2004). These findings were further confirmed in a study in epithelial and endothelial 
cells where it was found that blocking actin polymerization with the use of a 
pharmacological agent blocked cyclic-stretch induced ARE-mediated gene transcription in 
these cells (Papaiahgari et al., 2007). As a result of these studies, it has been postulated that 
actin plays an important role in enabling the Nrf2/ARE pathway to act as a 
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‘mechanosensor’ for oxidative stress and increased actin-polymerisation may result in a 
higher proportion of Keap1 within the cytoplasm where it also sequesters Nrf2, thereby 
preventing Nrf2 nuclear accumulation and subsequent ARE-mediated gene transcription.  
Studies carried out in endothelial cells have suggested a ‘mechanosensing’ role for the 
Nrf2/ARE pathway, allowing this pathway to differentially regulate the redox status of 
cells. Investigation of the effect of laminar (atheroprotective) shear stress in human 
umbilical vein endothelial cells (HUVEC) dramatically increased intracellular ROS 
generation whilst also activating the Nrf2/ARE pathway and consequently the coordinated 
induction of downstream antioxidant enzymes such as HO-1 and NQO1 (Dai et al., 2007). 
Similarly, a separate study, also in HUVEC, found that laminar shear stress activated the 
Nrf2/ARE pathway and protected cells from external insults, however in cells exposed to 
oscillatory shear stress, Nrf2-regulated atheroprotective gene expression was suppressed, 
predisposing these areas of the blood vessel to the development of atherosclerosis (Hosoya 
et al., 2005). These studies highlight the importance of mechanical stress as a mediator of 
redox signalling in cardiovascular disease where biomechanical forces play a pivotal role 
during disease progression.  
Further investigation of mechanical stress on the activation of Nrf2 in HAoAF is of 
particular relevance as the adventitial layer is exposed to cyclic stretch during normal 
vessel contraction and relaxation, which is enhanced during cardiovascular disease, 
particularly during hypertension (Stenmark et al., 2012; Li et al., 2011). Previous studies 
have reported increases in TGF-β1-dependent activation of NAD(P)H oxidase and 
consequently enhanced generation of ROS during cyclic stretch (Mata-Greenwood et al., 
2005), a possible mechanism by which the Nrf2/ARE pathway may be activated during 
mechanical stress.  
The expression pattern of Nrf2 in HAoAF was investigated in the present study, however 
the cellular localisation of Keap1 was not. Future work pertaining to the cellular 
localisation of Keap1 would help to elucidate the mechanism underlying the possible TGF-
β1 or SFN-induced association between Nrf2/Keap1, focal adhesions and the cytoskeleton 
and may clarify whether this antioxidant pathway is responsible for ‘mechanosensing’ 
during exposure to mechanical stress in the adventitia during hypertension or adverse 
vascular remodelling. 









Figure 6.2 Model for the proposed association of Keap1 with the cytoskeleton and its 
regulation of Nrf2. Under basal conditions, Keap1 is observed in the cytoplasm, at focal adhesions 
and is involved in the targeted, ubiquitin-mediated degradation of Nrf2 via the 26S proteasome. 
Small amounts of the Keap1/Nrf2 complex are shuttled to the nucleus for basal levels of ARE-
regulated gene expression. Chemical/mechanical stress modifies cysteine residues found within 
Keap1, resulting in the release of Keap1 from the cytoskeleton and from the degradation machinery. 
Pools of Keap1/Nrf2 accumulate within the nucleus which results in the Nrf2 mediated activation of 
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The mechanisms of ROS generation and subsequent effect on activating ‘mechanosensing’ 
pathways remains to be fully elucidated, however it is thought that the binding of growth 
factors and chemoattractants to their cell surface receptors causes NAD(P)H oxidases to 
generate ROS (Hurd et al., 2012). The subsequent generation of ROS following ligand 
binding is thought to be mediated by p21-activated kinase-1 (PAK1) and the small GTPase 
Rac1 and an assortment of NAD(P)H regulatory subunits (Hurd et al., 2012). The 
generation of ROS can then direct cellular changes for migration by modifying the activity 
of several proteins, including Keap1 and actin, thereby setting in motion a series of 
signalling cascades, including the activation of cellular defense pathways such as the 
Nrf2/ARE pathway (see Fig 6.1).  
 
6.4 Mechanisms of TGF-β1-mediated ROS generation in the adventitia 
In the current study, the effect of TGF-β1 on ROS generation was investigated in HAoAF 
using the luminescent probe L-O12 and it was observed that TGF-β1 was able to elicit an 
increase in ROS production in HAoAF. Use of a NAD(P)H oxidase inhibitor revealed that 
the ROS was partially NAD(P)H oxidase-derived.  Results from a recent study in rat kidney 
fibroblasts showed that TGF-β1 elicited an increase in ROS generation by increasing the 
activity of NAD(P)H oxidase and the expression of Nox2 and Nox4, whilst also causing an 
increase in the expression of α-smooth muscle actin, a marker of fibroblast differentiation. 
Knockdown of Nox4 was seen to markedly inhibit the TGF-β1-induced stimulation of 
NAD(P)H oxidase activity and reduced α-smooth muscle actin expression (Bondi et al., 
2010). These findings demonstrate that TGF-β1 not only elicits ROS production in 
fibroblasts but in doing so, it also causes activation and differentiation of fibroblasts to 
myofibroblasts. In another study, TGF-β1 caused an increase in the levels of superoxide in 
aortic tissue from ApoE -/- mice, which was produced via NAD(P)H oxidase and which 
was inhibited in the presence of SOD (Buday et al., 2010). TGF-β1-mediated ROS 
production also caused endothelial dysfunction and accelerated atherosclerosis and 
hypertension (Buday et al., 2010). Similarly, TGF-β1 increased cellular ROS levels in 
fibroblasts in an ovarian cancer cell-fibroblast co-culture model, which caused an increase 
in the expression of α-smooth muscle actin and led to fibroblast transdifferentiation to 
myofibroblasts (Yao et al., 2009). Alveolar-epithelial cells also respond to TGF-β1 in a 
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similar way; exposure of these cells to TGF-β1 in the presence of hypoxia led to enhanced 
ROS production which was abrogated by the inhibition of a type I receptor kinase (Zhou et 
al., 2009), suggesting that in this cell type, TGF-β1 plays a pivotal role in ROS generation. 
Interestingly, TGF-β1 has been implicated in eliciting the generation of ROS via various 
sources within the cell, including the mitochondria, where it is thought to generate ROS 
through complex III, ROS, which in-turn, affect TGF-β1-mediated gene expression in lung 
fibroblasts (Jain et al., 2013). It should be noted that during mechanical stress, such as that 
seen during hypertension, TGF-β1 may mediate ROS production, particularly as it is seen 
in high concentration at the site of injury during the pathogenesis of atherosclerosis (Wang 
et al., 2007). Release of TGF-β1 from fibroblasts, SMC and endothelial cells may mediate 
the generation of ROS in the vessel wall, during mechanical stress in a similar way to that 
seen in the current study (see Table 1.1). 
‘Leakage’ of immune cells from the vasa vasorum can also contribute to excessive local 
ROS production in the adventitial and medial layers of a blood vessel (Csanyi et al., 2009). 
One of the hallmarks of the ‘outside-in’ hypothesis is increased vasa vasorum angiogenesis 
and the coupling of this with enhanced ROS production in this outer layer of the blood 
vessel results in an increase in the delivery of inflammatory cells and further ROS 
production (Csanyi et al., 2009). The increased density of the vasa vasorum has been 
postulated as being due to decreased oxygen at the core of the neointima and hyperplastic 
media and consequent increase in the expression of transcription factors including hypoxia-
inducible factor (HIF-1α, Kuwuhara et al., 2002). In addition to the increase in adhesion 
molecule expression along the endothelial lining of the vasa vasorum, this results in a 
positive feed back loop leading to the accumulation of leukocytes in the adventitia and 
consequent inflammatory cell-derived ROS, further compounding local ROS production, 
medial hypertrophy and neointima formation (Csanyi et al., 2009). Enhanced ROS at the 
endothelial layer has been reported to upregulate NFκB, which in turn leads to the release 
of proinflammatory cytokines such as IL-1, IL-6 and TNFα and the increased expression of 
endothelial adhesion molecules (Park et al., 2006). Cross-talk between leukocyte-derived 
and adventitia-derived ROS has also been implicated in further driving NFκB activation 
and increased adhesion molecule expression in the vasa vasorum (Stenmark et al., 2006). 
This positive association between adventitial ROS and adhesion molecule expression in the 
vasa vasorum has been demonstrated in the rat aorta where AngII infusion for 1 week 
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increased NAD(P)H oxidase-derived ROS and was accompanied by enhanced ICAM-1 
expression and adventitial macrophage infiltration (Liu et al., 2003). In addition, the same 
study showed that adventitial ROS served as a direct chemotactic signal for leukocytes 
which were able to penetrate the vessel wall, thereby resulting in increased inflammation in 
the adventitia (Liu et al., 2003).  
Use of an NAD(P)H oxidase inhibitor in the current study revealed that NAD(P)H oxidase 
was a partial source of ROS in HAoAF treated with TGF-β1. However, although the 
inhibitor used is specific for Nox (Altenhofer et al., 2012), there is currently no available 
pharmacological inhibitor that is able to inhibit specific Nox isoforms, and therefore it was 
not determined whether the source of ROS in HAoAF was Nox2 or Nox4-derived, both of 
which have been reported to be expressed by adventitial fibroblasts (Haurani and Pagano, 
2007). Due to the lack of specific, freely available and validated antibodies for Nox4/Nox2, 
the protein expression of these isoforms was not determined in HAoAF. siRNA knockdown 
of either of these isoforms in order to observe differences in ROS production in TGF-β1-
treated cells would also be important for future work, however due to lack of validated 
siRNAs in addition to lack of available antibodies to confirm knock-down, this approach 
would be technically difficult (Altenhofer et al., 2012).  
 
6.5 Future Work  
6.5.1 Investigation of miRNA regulation of TGF-β1 signalling  
Interest in the regulation of gene expression by microRNA (miRNAs) in the context of 
cardiovascular disease (CVD) is currently a highly topical area of research. miRNAs are 
strands of short non-coding  RNAs that regulate gene expression by modulating the 
translation and/or stability of target mRNAs (Boyd, 2008; see Introduction section 1.3.5a).  
Preliminary data from the current study investigated the effect of TGF-β1 and two common 
inflammatory mediators observed in atherosclerosis, the lipid peroxidation product, 4-
Hydroxynonenol (HNE; Abiko et al., 2011), and the H2O2 generator, glucose oxidase 
(GOx; Churchman et al., 2009), on the expression of several miRNAs in HAoAF.  
Studies have found that TGF-β1-mediated expression of contractile smooth muscle genes is 
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in part mediated by miRNAs miR-21, miR-26a, miR-143 and miR-145. As one of the 
objectives of this study was to determine the effect of TGF-β1 on HAoAF differentiation, 
the expression of these mRNAs in response to treatment with this growth factor was 
investigated (Fig 6.3). It is widely known that in VSMC, TGF-β1 induces the expression of 
contractile proteins, however, potential mechanisms by which this occurs have not been 
fully elucidated. Recent studies have reported that several miRNAs, regulated by TGF-β1, 
may be involved in the differentiation process. In one study, miR-21 has been shown to 
mediate the expression of programmed cell death protein-4 (PDCD4) which is rapidly 
induced by TGF-β1 in VSMC and results in the expression of contractile proteins (Hata and 
Davis, 2009). The same study found that TGF-β1 could increase the expression of pre and 
mature miR-21 by facilitating the Drosha step (Hata and Davis, 2009). In addition, miR-21 
has also been implicated in regulating the Erk-MAPK pathway in cardiac fibroblasts and 
the in vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-
induced disease model has been shown to inhibit interstitial fibrosis and attenuate cardiac 
dysfunction (Thum et al., 2008). In the current study, increased activation of the Erk-
MAPK pathway by TGF-β1, though not statistically significant, was observed (see Chapter 
3, Fig. 3.15) and investigation of miR-21 revealed that its expression was decreased in 
TGF-β1-treated cells. These two observations may be linked and it is possible that TGF-β1 
regulation of the Erk-MAPK pathway is via miR-21 in HAoAF, but further work would be 
needed in order to determine this. Interestingly, the pro-inflammatory compounds, HNE 
and GOx were both shown to increase the expression of miR-21 in HAoAF, however this 
increase was non-significant (Fig 6.3, A). This observation may suggest a possible 
regulatory mechanism between miR-21 and HNE and GOx, though a link between these 
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Figure 6.3 The effect of TGF-β1 on microRNA levels in HAoAF. Confluent HAoAF were 
equilibrated in phenol red-free DMEM supplemented with 1% FCS and subsequently treated with 
TGF-β1 (5 ng/ml), HNE (10 μM) or glucose oxidase (GOx; 2.5 U/ml) for 6 h. Micro-RNA levels in 
the samples were quantified by qRT-PCR and expressed relative to 3 housekeeping genes. Data was 
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Similarly, in VSMC and fibroblasts, miR-143 and 145 have been reported as being direct 
transcriptional targets of serum response factor (SRF) and its co-factor myocardin and in 
response to these factors, both miRNAs were downregulated in atherosclerotic vessels 
resulting in a less differentiated cell population (Cordes et al., 2009). Another study in 
mesenchymal stem cells has reported that TGF-β1 led to a rapid and sustained up-
regulation of miR-145, an effect that resulted in a decrease in Disabled-2 (Dab2), a protein 
that has a critical role in stem cell specification. After acute myocardial infarction, Dab2 
levels were rapidly upregulated in cardiac myocytes in the border zone leading to fibrotic 
remodelling with a concomitant decrease in myocardial pri-miR-145 expression (Mayorga 
et al., 2012). These findings are in contrast to preliminary data in the current study that 
suggests that TGF- β1 downregulates the expression of both miR-143 and 145 in HAoAF 
after 6 h and conversely, may decrease the expression of characteristic markers of 
differentiation (Fig 6.3, C and D). Further work looking at the effect of long-term TGF-β1 
treatment on the expression of these miRNAs would provide better insight into their 
regulation by TGF-β1 and the possible effects of this on HAoAF differentiation. 
The role of Smad proteins, which are involved in facilitating TGF-β1 signalling, in the 
Drosha complex has also been studied; study of the nuclear factor Smad nuclear interacting 
protein1 (SNIP1), a nuclear protein partner of Smads, is found in complex with Drosha (Yu 
et al., 2008) suggesting a Smad-dependent regulation of miRNA biosynthesis could be 
modulated independently of TGF-β1 (Hata and Davis, 2009, Fig 6.4) and thereby be 
involved in many signalling pathways and as a result, a number of physiological processes.  
Investigating the possible differential regulation of the Nrf2/ARE pathway by TGF-β1 
would also be an interesting avenue of study. There is emerging evidence that has 
implicated several miRNAs in the regulation of Nrf2, particularly post-
transcriptionally/translationally. One study has identified a miRNA targeting seed sequence 
within Nrf2 3’ UTR in neuronal SH-SY5Y cells which has been postulated as being a 
possible target of miR153/miR27a/miR142-5p/miR144 (Narasimhan et al., 2012). Ectopic 
expression of these miRNAs resulted in diminished transactivation of Nrf2 with diminished 
GCLC and GSR expression, suggesting that alteration in the level of these miRNAs affects 
levels of Nrf2 and could be important in its regulation in disease (Narasimhan et al., 2012). 
As well as the direct regulation of Nrf2, regulation of Keap1 can also influence 
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transcriptional activity of Nrf2 and in breast cancer cells. miR200a has been reported as 
negatively regulating Keap1 via mRNA destabilization, thereby leading to an increase in 
Nrf2 levels and the phase II enzyme, NQO1 (Eades et al., 2011; Loignes et al., 2009). 
Although these miRNAs were not investigated in the current study, investigation into the 
overlap between TGF-β1 or SFN and miRNAs that regulate Nrf2/ARE signalling would be 
of interest, particularly because Nrf2 is known to be post-translationally/transcriptionally 
regulated, at least by SFN, (Negi et al., 2011; Zhang et al., 2003) and the potential 





Figure 6.4 Regulation of miRNA maturation by TGF-β superfamily signalling. TGF-β 
signalling promotes the nuclear localisation of R-Smad proteins which stimulates the Drosha-
mediated production of pre-miRNAs. Thus Smads regulate gene expression in two distinct manners 
(i) transcriptional regulation by DNA binding and (ii) regulation of miRNA maturation by 
associating with the Drosha complex.  Taken from Hata and Davis, 2009. 
 
Chapter 6                                                                                                                                 General Discussion 
 
 265 
6.5.2 The TGF-β1 signalling pathway: A therapeutic target? 
As a result of the increasing evidence demonstrating the role of TGF-β1 in remodelling 
during vascular disease, it is not surprising that this signalling pathway has been a target for 
therapeutic intervention and a number of strategies have been employed in order to 
antagonise TGF-β1 signalling in the hope that it would confer clinical benefit in disease 
progression. Initial studies employed neutralizing anti- TGF-β1 antibodies to inhibit TGF-
β1-mediated signalling. An in vivo study in a rat carotid artery injury model demonstrated 
that administration of neutralizing anti-TGF-β1 antibodies significantly reduced the size of 
the intimal lesions that developed after balloon injury when compared to untreated animals 
as well as an observed decrease in the extracellular matrix components, EDA and 
fibronectin (Wolf et al., 1994). This study not only confirmed that TGF-β1 was upregulated 
in the media of injured arteries, but was also one of the first to suggest that it was causally 
involved in the development of intimal hyperplasia (Wolf et al., 1994).  
Similarly, Smith and colleagues also found that inhibiting the action of TGF-β1 by 
administering a recombinant TβR-II, which competes with cell-surface receptors for the 
binding of active TGF-β1, markedly attenuated adventitial myofibroblast migration and 
adverse remodelling in a rat model of balloon catheter carotid denudation (Smith et al., 
1999). Intimal thickening was also reduced by up to 65% when compared with control 
animals (Smith et al., 1999). Ryan and colleagues showed that inhibition of TGF-β1 by 
antagonizing signalling also using a recombinant TβR-II prevented injury-induced 
reduction in lumen area by promoting vessel enlargement (Ryan et al., 2003). These studies 
demonstrate the potential therapeutic benefits of antagonizing TGF-β1 signalling either 
prophylactically or following vascular injury.  
Use of ribozymes, which catalyse the cleavage of mRNA and therefore inhibit gene 
expression, is a technique that has been used to target TGF-β1 mRNA expression in 
vascular SMC from spontaneously hypertensive rats and have been found to inhibit cellular 
proliferation in this model (Teng et al., 2000). Transfection of FITC-labeled ribozymes in 
vivo to target TGF-β1 signalling has also shown similar results and as a consequence, 
prevented characteristic neointima formation in animals after balloon injury when the 
transfected vessel was examined 2 weeks after transfection (Yamamoto et al., 2000). 
Alternatively, inhibition of downstream TGF-β1 signalling using adenoviral over-
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expression of Smad7, an inhibitor of Smad2 phosphorylation, has been shown to attenuate 
adventitial cell migration and remodelling in a rat model of balloon injury whilst also 
abrogating adventitial fibroblast contribution to neointimal formation (Mallawaarachichi et 
al., 2005). 
Although these methods have proven efficacious in animal models and offer the possibility 
of preventing in-stent restenosis, further work in human studies would be essential in order 
to determine whether inhibiting TGF-β1 locally, perhaps using a drug-eluting stent at sites 
of angioplasty, would be clinically beneficial (Kotsar et al., 2010). One of the major factors 
that may influence the potential beneficial effects of antagonizing TGF-β1 signalling is the 
timepoint of administration. Several studies carried out in mice have reported that 
disruption of TGF-β1 signalling causes the formation of unstable plaques by abrogating the 
profibrogenic ability of TGF-β1 (Gojova et al., 2003; Mallat et al., 2001). In addition, 
inhibiting TGF-β1 has also been shown to result in an increase in the number of pro-
inflammatory T-cells that populate atherosclerotic lesions (Tse and Ley, 2012; 
Ovchinnikova et al., 2009; Robertson et al., 2003; Lutgens et al., 2002). One study in which 
in-stent restenosis was investigated has also reported that adenoviral transfection of TβR-II 
to the coronary arterial segment of a pig, although decreased ECM accumulation, did not 
reduce stent-induced neointima formation and in fact induced vascular inflammation and 
aggravated lesion progression (Chung et al., 2010). Due to the diverse range of 
physiological process in which TGF-β1 is involved, the complete inhibition of this 
signalling pathway may potentially be detrimental in long-term recovery from vascular 
injury. Maximal therapeutic benefit may only be attained if the correct timepoint and 
mechanism of intervention are elucidated, both of which would need further investigation.  
An alternative strategy by which TGF-β1 signalling could be modulated to confer 
protective effects would be via its ability to target and activate the Nrf2 pathway. In the 
current study it was observed that TGF-β1 increases the nuclear translocation of Nrf2 as 
well as causing the induction of HO-1. In human aortic SMC, Churchman and colleagues 
have also reported Nrf2 as being a target of TGF-β1, findings which may explain the 
‘protective cytokine’ hypothesis of TGF-β1 (Churchman et al., 2009). Crosstalk between 
the TGF-β1 and Nrf2/ARE pathways has been demonstrated in the same study, where 
antagonism of TGF-β1 signalling using adenoviral overexpression of Smad7 resulted in a 
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decrease in the protein expression of HO-1 in response to electrophilic stress (Churchman 
et al., 2009). Although the underlying mechanisms of this remain unclear, it has been 
postulated that this interaction may be as a result of crosstalk between Smad and MAPK 
signalling pathways that contribute to Nrf2/ARE activation. Therefore, augmenting the 
activation of the Nrf2 pathway by TGF-β1, may be anti-atherogenic and a possible method 
by which neointima formation and restenosis can be attenuated.  
 
6.5.3 Sulforaphane as a therapeutic agent in cardiovascular disease 
Previous studies investigating the therapeutic potential of antioxidant supplementation have 
delivered inconsistent results in clinical trials (Kris-Etherton et al., 2004; Biondo-Zoccai; 
2002; Steinberg, 2000) and focus has now shifted towards employing methods that activate 
endogenous antioxidant pathways to confer protection against oxidative stress during 
disease, such as the use of novel compounds like SFN that activate the cells own 
antioxidant defense systems against electrophilic stress.  
There has been much interest in the prophylactic capacity of SFN and whether it can indeed 
be considered as a therapeutic option for the prevention of CVD. Pharmacokinetic studies 
have revealed that following the consumption broccoli (200g), volunteers displayed a peak 
plasma concentration of SFN of around 100 nM 1.5 h following ingestion of raw brocolli 
and 6 h following ingestion of cooked broccoli (Hanlon et al., 2009; Vermeulen et al., 
2008). Bioavailabity of SFN based on the processing of glucoraphanin by myrosinase in 
broccoli has been reported as being between 3.4-10% and 32-37% for raw and cooked 
respectively (Vermeulen et al., 2008; Conaway et al., 2000). The absorption of SFN was 
more efficient for raw than cooked broccoli and plasma clearance was also reported as 
being faster for raw than cooked broccoli (Vermeulen et al., 2008; Conaway et al., 2000). 
Concentrations of SFN used in the current study (2.5 – 5 μM) were significantly higher 
than those observed in pharmacokinetic studies and therefore its metabolism, 
bioavailability and excretion would be expected to be different than that reported in those 
studies, especially since it is being used in its pure form as opposed to its precursor, 
glucaphoranin and within a cell culture model. These concentrations were able to activate 
the Nrf2/ARE pathway in HAoAF, however the amount available from the consumption of 
cruciferous vegetables in pharmacokinetic studies would not be sufficient enough to reach 
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plasma levels of 2.5 – 5 μM SFN and therefore further work investigating the effects of 
lower concentrations of SFN in HAoAF would need to be carried out to determine whether 
they would also be sufficient enough to elicit a similar activation of the Nrf2/ARE pathway 
in vivo.        
Epidemiological evidence has highlighted the chemopreventative effectiveness of SFN in 
various cancers. One study has examined the effect of broccoli consumption on gene 
expression in human prostate biopsy tissue before, during and after a 12-month broccoli-
rich diet and a 12-month pea-rich diet (Traka et al., 2008). Individuals with glutathione S-
transferase mu 1 (GSTM1) positive and null genotypes were randomly assigned to either 
the broccoli or pea-rich diet and comparison of biopsies obtained pre- and post-intervention 
revealed more changes in gene expression had occurred in individuals on the broccoli-rich 
diet. The authors of the study suggest that this indicates the interaction of SFN with the 
GSTM1 genotype to result in complex changes in signalling pathways associated with 
inflammation and carcinogenesis in the prostate, including TGF-β1, epidermal growth 
factor and insulin signalling pathways, with direct chemical interaction of isothiocyanates 
with these signalling peptides (Traka et al., 2008). 
The ability of SFN to acts as a tumor suppressor is dependent upon its activity as a histone 
deacetylase (HDAC) inhibitor; in mice a single dose of SFN (10 μM) resulted in a 
significant inhibition of HDAC activity in the colonic mucosa with a concomitant increase 
in acetylated histones and suppression of tumour development in the mucosa of these mice  
(Kaminski et al., 2010; Myazak et al., 2006). Further work in humans revealed that a single 
dose of broccoli (68 g) inhibited HDAC activity significantly in peripheral blood 
mononuclear cells (Myazak et al., 2007). The same study reported suppression of human 
PC-3 prostate cancer cells by 40% in male nude mice with a significant decrease in HDAC 
activity in xenografts (Myazak et al., 2007). These studies demonstrate the potential of SFN 
to be used as a preventative measure for carcinogenesis and as therapy during the disease 
process as a tumour suppressor.  
The therapeutic benefits of SFN have also been highlighted in the context of cardiovascular 
disease models. Spontaneously hypertensive stroke-prone rats were fed dried broccoli 
sprouts (200 mg/day; 5 days/week for 24 weeks), after 14 weeks, animals on the broccoli-
rich diet had significantly decreased oxidative stress levels in cardiovascular and kidney 
Chapter 6                                                                                                                                 General Discussion 
 
 269 
tissues as demonstrated by increased GSH content and reduced oxidized GSH which 
correlated with improved endothelial-dependent relaxation of the aorta and significantly 
lower blood pressure (Wu et al., 2004). In this study, the beneficial effects of SFN were 
attributed to its ability to induce phase II antioxidant enzymes (Wu et al., 2004). Although 
this study did not clarify plasma levels of SFN following consumption of broccoli, they 
proposed that broccoli extracts contained the equivalent of 27.3 μM SFN, a concentration 
that is far above the physiological level of SFN in plasma following broccoli consumption.  
Interestingly local delivery of SFN in a carotid artery injury model has been shown to 
inhibit the mRNA and protein expression of VCAM-1 by blocking the expression of the 
transcription factor GATA6 and preventing its binding to the promoter region of VCAM-1 
whilst significantly reducing neointima formation 14 days after injury (Kwon et al., 2012). 
As well as this, SFN was also able to inhibit the proliferation and migration of VSMC 
highlighting its use as a potential therapeutic agent for the prevention of restenosis after 
vascular injury (Kwon et al., 2012). Currently there is a paucity of evidence about the 
beneficial effects of SFN in the adventitial layer, however results from this study suggest 
that it may be clinically beneficial during atherosclerotic disease progression as it is able to 
activate the Nrf2/ARE antioxidant defense pathway, and thereby induce downstream 
antioxidant gene expression.  
The bioavailability of SFN and the promise it has shown as a beneficial therapeutic agent in 
cardiovascular disease and as a chemopreventative agent offers this dietary isothiocyanate 
as an ideal mode of prevention during these disease processes. However, due to its 
interaction and effect on diverse signalling pathways, the underlying mechanisms of SFN’s 
beneficial effects will need to be fully elucidated in order to harness its true potential and to 
prevent any adverse off target effects.  
 
6.5.4 Interactions between SFN and the TGF-β1/Smad signaling pathway 
Recent evidence suggests that SFN is able to interact with the TGF-β1/Smad signalling 
pathway with varying effects on TGF-β1-mediated gene expression and activity. The first 
study to report an interaction was carried out in a heterogenous human epithelial colorectal 
adenocarcinoma cell line, Caco-2 cells where exposure of cells to different concentrations 
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of SFN (0 – 25.5 μM) resulted in a perturbation of TGF-β1 signalling; analysis of pSmad2 
protein expression revealed that TGF-β1 increased the expression of pSmad2, however 
treatment of cells with broccoli extracts containing SFN resulted in a decrease in pSmad2 
expression (Furniss et al., 2008). Interestingly, the same study found that treatment of cells 
with broccoli extract containing 25.5 μM SFN resulted in enhanced pSmad2 expression, 
although to a lesser extent than in cells treated with TGF-β1 alone (Furniss et al., 2008). 
The perturbation of TGF-β1 signalling, which is known to be involved in cell proliferation 
and cancer metastasis (Padua and Massague, 2009) may go some way in explaining the 
ability of SFN to act as a chemopreventative agent. 
A study in NIH3T3 cells, quantified TGF-β1-induced Smad-mediated transcription by 
using a CAGA-luciferase plasmid in which luciferase activity can be measured upon 
activation of Smad proteins, found that exposure of cells to TGF-β1 that had been pre-
incubated with SFN (2 μM) for 30 min resulted in an increase in Smad-mediated 
transcription compared to exposure of cells to TGF-β1 alone (Traka et al., 2008). The 
authors proposed that SFN is able to directly bind to and modify TGF-β1, thereby altering 
TGF-β1-mediated signalling (Traka et al., 2008). Other studies have reported an increase in 
TGF-β1 levels in response to SFN treatment. In colorectal cancer cells, incubation with 
SFN for 1 and 3 h resulted in an increase in the levels of TGF-β1 mRNA as well as mRNA 
of TβRI and TβRII suggesting a possible transcriptional regulation of the components of 
this signalling pathway by SFN, postulated as being as a result of SFN’s ability to inhibit 
histone deacetylases (HDAC; Kaminski et al., 2010). Histone deacetylase inhibitors have 
been reported as being able to induce the expression of several tumour suppressive genes as 
well as the expression of TGF-β1 and its receptors (Kaminski et al., 2010). 
Recently there has been some evidence to suggest that SFN is able to attenuate TGF-β1-
mediated fibrosis via the Nrf2/ARE pathway. A study examining hepatic fibrosis in a 
HepG2 cell culture model has reported the ability of SFN to suppress TGF- β1-mediated 
fibrosis. Suppression of TGF-β1/Smad signalling by SFN is thought to be indirect and via 
its activation of Nrf2, which itself is thought to physically interact with Smad3 proteins (Oh 
et al., 2012). The authors postulate that this physical interaction may impede 
phosphorylation of Smad proteins either by masking their phosphorylation sites or by 
rendering them resistant to phosphorylation, preventing their nuclear accumulation and the 
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downstream transcription of Smad-regulated genes, which include plasminogen activator 
inhibitor-1 (PAI-1), α-smooth muscle actin and fibronectin, all of which are involved in 
tissue fibrosis (Oh et al., 2012). The ability of SFN to suppress hepatic stellate cell 
activation and fibrogenic gene expression in this model may provide some therapeutic 
benefit to individuals suffering from fibrotic conditions by simply incorporating SFN-rich 
foods into their diet, however further work, including pharamcokinetc studies, would need 
to be carried out in order to determine exact dietary amount required in order to reach a 
therapeutically beneficial concentration of SFN in plasma in these patients.  
In the current study, the expression of fibrogenic proteins expressed by HAoAF in response 
to TGF-β1 was examined however cells were not treated with TGF-β1 and SFN together. It 
would be interesting to assess the effect of SFN pre-treatment on the expression of 
fibrogenic proteins including α-smooth muscle actin and vimentin in the presence of TGF-
β1 and before they have become fully differentiated into myofibroblasts in order to assess 
its ability to attenuate the expression of these proteins in HAoAF. The interaction between 
SFN and TGF-β1/Smad signalling and the Nrf2 pathway is quite likely to be more complex 
than has been reported in the literature. Interaction of SFN with TGF-β1 signalling, which 
is involved in a diverse range of cellular processes is likely to have many targeted effects 
including the activation of other antioxidant pathways, including NFκB and AP-1 (Greco et 
al., 2011). In particular, a very recent study carried out in pulmonary fibroblasts has 
revealed that SFN reduces myofibroblastic dedifferentiation and inhibits the pro-fibrotic 
effects of TGF-β1 in this cell type, an inhibition which is abolished following Nrf2 
knockdown suggesting that SFN mediated these effects via the Nrf2 pathway (Artaud-
Macari et al, 2013).  Therefore further work to fully elucidate the various pathways SFN 
may activate and the mechanism of its interaction with the TGF-β1 signalling pathway is 
important in order to take full advantage of its therapeutic benefit in relation to the disease 
processes that arise during the perturbation of TGF-β1 signalling and during impaired 








Effect in HAoAF TGF-β1 SFN 
Differentiation There was basal expression of α-
smooth muscle actin and vimentin. 
TGF-β1 treatment had no effect on 





No effect. No effect. 








Significant increase in Akt 
phosphorylation at 1, 2 and 4 h. No 
effect on Erk or p38MAPK. 
 
Significant increase in Akt 
phosphorylation at 1, 2 and 4 h. 
No effect on Erk or p38MAPK. 
Nrf2 mRNA and protein No effect on mRNA levels or total 
Nrf2 protein expression. 
No effect on mRNA levels or 
total Nrf2 protein expression. 
 
HO-1 mRNA and protein No effect on mRNA levels. 
Significant increase in HO-1 
protein at 8 h. 
No effect on mRNA levels. 
Significant increase in HO-1 
protein at 8 h. 
 
NQO1 mRNA and 
protein 
No effect on mRNA levels or total 
NQO1 protein expression. 
No effect on mRNA levels or 
total NQO1 protein expression. 
 




Nuclear translocation observed at 2 
h.  





No effect. Significant increase.  
Effect of Nrf2 siRNA on 
HO-1 protein expression 
Significant decrease.  Significant decrease.  
Migration Significant increase in migration 
and velocity of HAoAF.  
 
- 
Nox2 and Nox4 mRNA No effect 
 
- 




Table 6.1 A summary of the results obtained in HAoAF treated with TGF-β1 and SFN. (-) 
indicates that these experiments were not performed with SFN.  
 




Taken together, results from the current study are the first to suggest that TGF-β1 is able to 
induce the expression of HO-1 protein expression in HAoAF, however the underlying 
mechanism of this increase may be independent of the Nrf2/ARE pathway. In addition, this 
study has demonstrated for the first time that TGF-β1-driven migration of HAoAF is a 
ROS-dependent mechanism as abrogation of ROS results in the attenuation of migration in 
this cell type. Investigation into TGF-β1-driven ROS generation found that it was partially 
NAD(P)H oxidase-derived. The current study has also investigated the effect of the 
isothiocyanate, SFN on redox signalling in HAoAF. It has been found that SFN is able to 
activate the Nrf2/ARE pathway and as a consequence, induce HO-1 protein expression in 
this cell type. This study has provided novel data on the effects of TGF-β1 on the 
Nrf2/ARE pathway in HAoAF, its effect on potential modulation of HAoAF phenotype and 
migration and its effects on ROS-generation, all of which may provide an insight into the 
role of this growth factor on the adventitia during the progression of atherosclerotic disease. 
The modulation of endogenous antioxidant defense genes by SFN via the activation of the 
Nrf2/ARE pathway may offer potential therapeutic benefit against the progression of 
atherosclerotic disease. Future work to modulate TGF-β1 signalling and ROS generation 
and the relationship between TGF-β1 and SFN may help to establish clinically beneficial 
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Appendices 
Appendix I – Media composition 
Table AI.1 Dulbecco’s Phosphate Buffered Saline-10 x (D1408) 
Inorganic salts g/L Molecular weight  mM 
CaCl2●2H2O ____   
MgCl●6H20 ____   
KCl 2.0  74.55 26.83 
KH2PO4 2.0 136.07 14.70 
NaCl 80 58.44 368.9 
Na2HPO4 11.5 142 81.4  
 
Other g/L Molecular weight  mM 
D-Glucose ___   
Kanamyein Sulfate  ___   
Penicillin G (sulfate) ___   
Pyruvic Acid●Na ___   
Streptomycin Sulfate  ___   
 
REFERENCE  
1. Dulbecco, R. And Vogt, M, (1957). Plaque Formation and Isolation of Pure Lines with Poliomyelitis 
Viruses. J. Exp.Med 106, 167-169.  
 
Table AI.2 Dulbecco’s Modified Eagle’s Medium – low glucose (D5921) 
Inorganic salts g/L Molecular weight  mM 
CaCl2●2H20 0.265 147 1.803 
Fe(NO3)3●9H2O 0.0001 403.8 0.00025 
MgSO2 0.09767 120.4 0.8112 
KCl 0.4 74.55 5.3655 
NaHCO3 3.7 84 44.048 
NaCl 6.4 58.44 109.51 
NaH2PO4 0.109 120 0.9083 
Succinic Acid  ___   
Sodium Succinate  ___   
 
Amino acids   g/L Molecular weight  mM 
L-Arginine●HCl 0.084 210.7 0.3986 
L-Cystine●2HCl 0.0626 313.2 0.1998 
L-Glutamine  ___   
Glycine 0.030 75.05 0.3997 
L-Histidine●HCl●H20 0.042 209.6 0.2004 
L-Isoleucine  0.105 131.2 0.8003 
L-Leucine  0.105 131.2 0.8003 
L-Lysine ●HCl 0.146 182.6 0.7996 
L-Methionine  0.030 149.2 0.2011 
L-Phenylalamine  0.066 165.2 0.3995 
L-Serine 0.042 105.1 0.3996 
L-Threonine  0.095 119.1 0.7976 
L-Tryptophan  0.016 204.2 0.0784  
L-Tyrosine (free base ___   
L-Tyrosine●2Na●2H20 0.10379 261.2 0.3973 
L-Valine  0.094 117.1 0.8027 
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Vitamins g/L Molecular weight  mM 
Choline Bitartrate  ___   
Choline Chloride  0.004 139.6 0.0287 
Folic Acid  0.004 441.4 0.00907 
myo-Inositol  0.0072 180.2 0.03996 
Niacinamide  0.004 122.1 0.03276 
D-Pantothenic Acid●½ Ca 0.004   
Pyridoxal●HCl ___   
Pyridoxine●HCl 0.004 205.6 0.01946 
Riboflavin 0.0004 376.4 0.00106 
Thiamine●HCl  0.004 337.3 0.01186 
 
Other  g/L Molecular weight mM 
D-Glucose  1.0 180.16 5.5506 
HEPES  ___   
Phenol Red●Na ___   
Pyruvic Acid●Na  ___   
 
Add g/L  Molecular weight  mM 
Glucose  ___   
L-Glutamine  0.584 146.15 3.996 
L-Cystine●2HCl ___   
L-Leucine ___   
L-Lysine●HCl ___   
L-Methionine  ___   
NaHC02 ___   
NaH2P04  ___   
Phenol Red●Na ___   
Pyruvic Acid●Na ___   
 
Appendix II – Composition of SDS lysis buffer 
Components (Sigma Aldrich, UK) Concentration (%) 
Tris base (pH 6.8)  50 mM 
Glycerol  10% 
SDS 2% 
Protease Inhibitor Cocktails  1:1000 dilution  
 
Appendix III – Composition of tank buffer for SDS-PAGE 
Components (Sigma Aldrich, UK) Conconcentration (%) 
Tris base 0.3 
Glycine  1.44 
SDS 0.1 
 
Appendix IV – Composition of transfer buffer for Western blotting 
Components  Concentration 
Tris base 25mM 
Glycine  192mM 
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Appendix V - Composition of Resolving Gel for SDS-PAGE 
Components  Concentration 
4 x Tris-SDS (pH 8.8) 1 X (375 mM Tris-base 0.1% SDS) 
Acrylamide 8, 10 or 12% 
ddH20 ___ 
Ammonium persulfate (APS) 0.04% 
Tetramethylethylenediamine (TEMED) 0.08% 
 
Appendix VI - Composition of Stacking Gel for SDS-PAGE 
Components  Concentration 
4 x Tris-SDS (pH 6.8) 1 x (125mM Tris-base 0.1% SDS) 
Acrylamide  4% 
ddH20 ___ 
Ammonium persulfate (APS) 0.05% 
Tetramethylethylenediamine (TEMED) 0.06% 
 
Appendix VII - Source of antibodies 
Primary Antibody  Origin  Source  
HO-1 Mouse monoclonal Transduction Laboratories  
NQO1 Goat polyclonal Santa Cruz  
CD36 Mouse monoclonal  Santa Cruz 
Nrf2 Rabbit polyclonal Spring Biosciences 
pan-Akt Rabbit polyclonal Cell Signalling 
Phospho-Akt Rabbit polyclonal Cell Signlling 
p38MAPK  Rabbit polyclonal Cell Signalling 
pan-Erk 1/2 Rabbit polyclonal Cell Signalling 
Phospho-Erk Rabbit polyclonal Cell Signalling 
pan-JNK Rabbit polyclonal Cell Signaling 
Phospho-JNK Rabbit polyclonal Cell Signalling 
Phospho-smad2 Rabbit monoclonal Millipore 
α-Tubulin Rat polyclonal Chemicon 
Lamin A/C Goat polyclonal Santa Cruz 
Vimentin Rabbit monoclonal Abcam 
α-Smooth muscle actin  Mouse monoclonal  Santa Cruz 
 
Secondary Antibody  Origin Source 
Goat anti-mouse-HRP Goat  Santa Cruz  
Donkey anti-mouse-HRP Donkey  Santa Cruz 
Goat anti-rabbit-HRP Goat  Santa Cruz 
Goat anti-rat-HRP Goat Santa Cruz 
Alexa Flour 488 anti-rabbit  Goat Molecular Probes  
Alexa Flour 488 anti-mouse Goat Molecular Probes 
Alexa Flour 468 anti-rabbit Goat Molecular Probes 
 
Appendix VIII – Composition of Krebs buffer 
 Components (Sigma Aldrich, UK) Concentration (mM) 












Appendix IX – Addresses of suppliers  
Agar Scientific Ltd 








Amersham Life Sciences  






Biomol International, L.P.  
Palatine House  
Matford Court 
Exeter EX2 8NL 
UK 
Cell Signalling Technology 
Inc. 3 Trask LaneDanvers 
MA 01923 
UK 
Chemicon Europe Ltd 
The Sciences Centre 
Eagle Close 






3 Fountain Drive 





National Diagnostics Ltd 
Unit 4 Fleet Business Park 
Itlings Lane 
Hessle 

















Santa Cruz Biotechnology Inc. 
2145 Delaware Avenue  
Santa Cruz CA, 95060 
USA 
Signal Transduction Laboratories 




UK   
  
   
 
Components (Sigma Aldrich, UK) Concentration (mM) 
Adjust to pH 7.4 
CaCl2 2.5 
MgCl2  1 
L-arginine  0.1 
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